




CPDD 78th Annual Scientific Meeting Program

June 11-16, 2016

**La Quinta Resort and Club
Palm Springs, California**



MEETING FACILITIES



BOARD OF DIRECTORS

Sandra D. Comer, PhD, President
Eric C. Strain, MD, Past-President
Leonard L. Howell, PhD, President-Elect
Linda B. Cottler, PhD, MPH, Treasurer
Patrick M. Beardsley, PhD
Kathleen M. Carroll, PhD
Marilyn E. Carroll, PhD
Howard D. Chilcoat, ScD
Timothy P. Condon, PhD
Linda P. Dwoskin, PhD

Toby K. Eisenstein, PhD
Margaret Haney, PhD
Carl L. Hart, PhD
Sarah H. Heil, PhD
Stephen T. Higgins, PhD
Marc J. Kaufman, PhD
Gregory M. Miller, PhD
Charles O’Keeffe, MBA
Thomas E. Prisinzano, PhD
Jennifer Tidey, PhD

EXECUTIVE OFFICER

Loretta P. Finnegan, MD

DIRECTOR, EXECUTIVE OFFICE

Ellen B. Geller, MA

SCIENTIFIC PROGRAM COMMITTEE

Elise Weerts, PhD, Chair
William W. Stoops, Chair-Elect
Michael Bardo, PhD
Howard Chilcoat, ScD
Ziva Cooper, PhD
Linda Cottler, PhD, MPH
Kelly Dunn, PhD
Linda P. Dwoskin, PhD
Michael Kuhar, PhD
Matthew Johnson, PhD
Kathryn McHugh, PhD
F. Gerald Moeller, MD
Danielle Ramo, PhD
Loretta P. Finnegan, MD, ex officio
Ellen B. Geller, MA, ex officio

PRE-MEETING SATELLITES

*Ninth Annual International Women's and Children's Health
and Gender Group Conference*
Chaired by Wendee Wechsberg

Flores 1-4
June 10

*The 2016 NIDA International Forum: Global
Developments in Drug Trends*
Chaired by Steven Gust

Fiesta 14
June 10
Fiesta 6/8
June 11

*The International Study Group Investigating
Drugs as Reinforcers (ISGIDAR)*
Chaired by Mark Smith

Fiesta 12
June 11

CPDD REGISTRATION **La Cita**

Saturday, June 11

1:30 PM - 5:30 PM

Sunday, June 12 - Wednesday, June 15

7:30 AM - 5:00 PM

Thursday, June 16

7:30 AM - 3:00 PM

OPENING RECEPTION **(Cash Bar)** **CAPRA/LAWN**

Saturday, June 11

7:00 PM - 9:00 PM
*(Pre-registrants can pick up
badges only)*

Plenary Program

Fiesta Ballroom
8:30 - 11:30 AM

- 8:30 *Welcome*
CPDD President Sandra Comer
- 8:40 *Report from the National Institute on Drug Abuse,*
Nora Volkow, Director
- 9:10 *Report from the National Institute on Alcohol Abuse and Alcoholism, Title of Talk:*
The role of stress in addiction: An NIAAA perspective
George Koob, Director
- 9:40 *Presentation of the Stephen G. Holtzman Travel Award for Preclinical Investigators to Jae Kim*
Introduction by Martin W. Adler
- 9:45 *Presentation of the CPDD/Media Award to Bess O'Brien*
Introduction by Bertha Madras
- 10:00 *Presentation of the J. Michael Morrison Award to Minda Lynch*
Introduction by Marilyn Carroll
- 10:10 *Presentation of the Joseph Cochin Young Investigator Award to Jun-Xu Li*
Introduction by Charles France
- 10:20 *Presentation of the Mentorship Award to Kenner Rice*
Introduction by Thomas Prisinzano
- 10:30 *Presentation of the Nathan B. Eddy Award to Warren K. Bickel*
Introduction by Stephen Higgins
- 10:45 *Nathan B. Eddy Lecture: The Addictionomics of Self Control*
Warren Kurt Bickel, Virginia Tech Carilion Research Institute, Roanoke, VA

CPDD Early Career Travel Awards Luncheon (By Invitation Only)

Morgan's
11:45 - 1:00 PM

President's Symposium

Fiesta 6/8
1:30 - 2:30 PM

WHERE THERE'S SMOKE: U.S., AUSTRALASIAN, AND EUROPEAN CANNABIS POLICIES AND USE

President: Sandra Comer, Columbia University and NYSPI
Deborah Hasin, Columbia University; New York State Psychiatric Institute
Alison Ritter, University of New South Wales
Marc Auriacombe, University of Bordeaux (France)

Symposium I

Fiesta 6/8
3:00 - 5:00 PM

DEVELOPING INNOVATIVE BRAIN STIMULATION TREATMENT OPTIONS FOR SUBSTANCE-DEPENDENT INDIVIDUALS: TRANSLATING BASIC SCIENCE KNOWLEDGE OF NEURAL CIRCUITS TO OUR CLINICS

Chairs: Colleen A. Hanlon and Nora Volkow

- 3:00 *Developing innovative brain stimulation treatment options for substance dependent individuals: Translating basic science knowledge of neural circuits to our clinics*
Colleen A Hanlon, Medical University of South Carolina, Charleston, SC
- 3:25 *Theta burst TMS as a tool to change smoking behavior*
Warren Kurt Bickel, Virginia Tech Carilion Research Institute, Roanoke, VA
- 3:50 *10 Hz TMS as a tool to decrease pain and opioid use among prescription opiate-dependent individuals: A single-blind sham controlled MRI & TMS study*
Gregory Sahlem, Medical University of South Carolina, Charleston, SC
- 4:15 *From optogenetics to a potential rTMS treatment against cocaine use disorders*
Nora Volkow, National Institute of Drug Abuse, Baltimore, MD
- 4:40 *DISCUSSANT: Dr. Hanlon and Dr. Volkow will lead an interactive discussion with the panel members and soliciting questions from the audience*
Colleen A Hanlon, Medical University of South Carolina, Charleston, SC

Symposium II

Fiesta 10/14
3:00 - 5:00 PM

INFLUENCE OF METABOLIC HORMONES ON REWARD PROCESSING AND ADDICTION

Chairs: Arbi Nazarian and Minda Lynch

- 3:00 *Insulin signaling and diabetes: What do we know about the rewarding effects of nicotine in the diabetic brain?*
Arbi Nazarian, Western University of Health Sciences, Pomona, CA
- 3:24 *Leptin signaling in the ventral tegmental area regulates food intake and brain reward function*
Adriaan Bruijnzeel, University of Florida, Gainesville, FL
- 3:48 *Ghrelin and GLP-1: Seeking the yin and yang in alcoholism*
Lorenzo Leggio, NIAAA and NIDA, Bethesda, MD
- 4:12 *The role of central glucagon-like peptide-1 receptors in cocaine addiction*
Heath Schmidt, University of Pennsylvania, Philadelphia, PA
- 4:36 *DISCUSSANT: What do metabolic hormones in the brain teach us about reward and addiction?*
Minda Lynch, NIDA, Bethesda, MD

Oral Communications 1

**Fiesta 12
3:00 - 5:00 PM**

RUSH: STIMULANTS-PRECLINICAL STUDIES

Chairs: Wendy J. Lynch and Jae K. Kim

- 3:00 *Effect of a dopamine D3 receptor partial agonist on cocaine-induced locomotion and self-administration*
J. Bonadonna¹, G. Powell¹, A. K. Carlson¹, R. Mendoza¹, R. H. Mach², R. R. Luedtke³, J. L. Neisewander¹, ¹School of Life Sciences, Arizona State University, Tempe, AZ, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Health Science Center, University of North Texas, Fort Worth, TX
- 3:15 *CXCR4 antagonist Plerixafor attenuates cue- and cue/drug-induced relapse to cocaine seeking and expression and development of cocaine-induced conditioned place preference*
J. K. Kim¹, S. Rawls^{1,2}, ¹Pharmacology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ²Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
- 3:30 *Kappa opioid receptor agonist 16-ethynyl salvinorin A attenuates the rewarding effects of cocaine in the progressive ratio model in rats with fewer side-effects*
B. M. Kivell¹, D. Young¹, A. Culverhouse¹, T. Prisinzano², ¹School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand, ²Department of Medicinal Chemistry, University of Kansas, Lawrence, KS
- 3:45 *Effects of chronic amphetamine on abuse-related behavioral and neurochemical effects of cocaine in rats*
A. Johnson, S. S. Negus, Virginia Commonwealth University, Richmond, VA
- 4:00 *Long-term blockade of cocaine use and locomotor activation in rats by an adenoviral vector-delivered cocaine hydrolase*
J. R. Smethells², N. Swalve², S. Brimijoin¹, R. Parks⁴, M. E. Carroll², ¹Molecular Pharmacology, Mayo Clinic, Rochester, MN, ²University of Minnesota, St. Paul, MN, ⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada
- 4:15 *Exercise during early, but not late, abstinence attenuates subsequent relapse vulnerability in a rat model*
W. J. Lynch, R. M. Beiter, A. B. Peterson, J. Abel, Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA
- 4:30 *New generation tamoxifen analogs as potential treatments for amphetamine abuse*
C. A. Carpenter¹, R. Altshuler¹, A. Zestos², R. Sorenson³, E. M. Jutkiewicz¹, R. Kennedy², H. Showalter³, M. Gnegy¹, ¹Pharmacology, University of Michigan, Ann Arbor, MI, ²Chemistry, University of Michigan, Ann Arbor, MI, ³Vahlteich Medicinal Chemistry Core, University of Michigan, Ann Arbor, MI
- 4:45 *Enantiomers of (±)GZ-888 potently and selectively inhibit vesicular monoamine transporter-2 function and methamphetamine-stimulated locomotor activity*
N. Lee¹, G. Zheng³, S. M. Mayfield², E. D. Denehy², J. R. Nickell¹, Z. Cao¹, P. A. Crooks³, M. T. Bardo², L. P. Dwoskin¹, ¹Pharmaceutical Sciences, University of Kentucky, Lexington, KY, ²Psychology, University of Kentucky, Lexington, KY, ³Pharmaceutical Sciences, University of Arkansas for Medical Sciences, Fayetteville, AR

Oral Communications 2

Fiesta 4

3:00 - 5:00 PM

DAZED AND CONFUSED: POLYDRUG ABUSE

Chairs: Kimberly C. Kirby and J. Aaron A. Johnson

- 3:00 *Gender and age bias in drug and alcohol screening*
J. A. Johnson², R. Howell², P. Seale¹, ¹Navicent Health, Macon, GA, ²Augusta University, Augusta, GA
- 3:15 *Addressing unmet addiction need in an urban hospital*
K. Ahamad², S. Nolan³, E. Wood¹, ¹Urban Health Research Initiative, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, BC, Canada, ³Department of Medicine, University of British Columbia, Vancouver, BC, Canada
- 3:30 *Longitudinal health service patterns of patients with alcohol, cannabis, and opioid use disorders*
A. L. Bahorik², D. Satre^{2,1}, A. H. Kline-Simon¹, K. C. Young-Wolff^{1,2}, C. Weisner^{2,1}, C. Campbell^{1,2}, ¹Division of Research, Kaiser Permanente Northern California, Oakland, CA, ²Psychiatry, University of California, San Francisco, San Francisco, CA
- 3:45 *Expanded brief intervention for substance use in primary care*
A. C. Brooks¹, C. M. Carpenedo¹, J. Lauby², D. Metzger^{1,5}, E. Byrne¹, K. Favor³, K. C. Kirby^{1,4}, ¹Treatment Research Institute, Philadelphia, PA, ²Public Health Management Corporation, Philadelphia, PA, ³Lincoln University, Lincoln University, PA, ⁴Rowan University, Glassboro, NJ, ⁵University of Pennsylvania, Philadelphia, PA
- 4:00 *The computer-based drug and alcohol training assessment in Kenya*
V. Clair^{1,2}, V. Mutiso³, A. Musau³, E. Frank¹, D. Ndeti³, ¹University of British Columbia, Vancouver, BC, Canada, ²Urban Health Research Initiative, British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ³Africa Mental Health Foundation, Nairobi, Kenya
- 4:15 *Who says yes?: Sample representativeness in a clinical trial of SBIRT*
S. S. Kelpin², S. J. Ondersma³, D. Svikis¹, ¹Virginia Commonwealth Univ., Richmond, VA, ²Psychology, Virginia Commonwealth University, Richmond, VA, ³Wayne State University, Detroit, MI
- 4:30 *Mortality rates among substance use disorder participants in clinical trials: Pooled analysis of 22 NIDA CTN studies*
P. VanVeldhuisen¹, L. Hu¹, R. Lindblad¹, N. Oden¹, P. Wakim², C. Rosa³, ¹Emmes, Rockville, MD, ²NIH, Bethesda, MD, ³NIDA, Rockville, MD
- 4:45 *A brief substance use screening and assessment for general medical settings: Validation of the tobacco, alcohol, prescription medication, and other substance use tool*
J. McNeely¹, L. T. Wu², G. Subramaniam³, G. Sharma⁴, R. P. Schwartz⁵, ¹NYU School of Med, NYC, NY, ²Duke U School of Med, Durham, NC, ³NIDA, Bethesda, MD, ⁴Emmes Corp, Rockville, MD, ⁵Friends Research Inst, Baltimore, MD

Primm-Singleton Awardees Reception

**The Studios
5:00 - 6:00 PM**

Workshop I

**Fiesta 10/14
6:00 - 8:00 PM**

NAVIGATING KEY STAGES OF A CAREER IN ADDICTION SCIENCE: GRADUATE SCHOOL, POST-DOC AND EARLY-CAREER

Chairs: Teresa Franklin and Denise C. Vidot

Navigating the Pre-doctoral stage: Achieving the impossible!

Qiana Brown, Columbia University Mailman School of Public Health, New York, NY

Navigating the Post-doctoral stage: I made it! Now what?

Teresa Franklin, Perelman School of Medicine at the University of Pennsylvania,
Philadelphia, PA

Navigating the early career stage: How do I obtain NIH funding?

Cristina B Bares, The University of Michigan School of Social Work, Ann Arbor, MI

Workshop II

**Fiesta 6/8
7:00 - 9:00 PM**

THE LANDMARK ADOLESCENT BRAIN COGNITIVE DEVELOPMENT STUDY (ABCD): A DETAILED DISCUSSION OF THE STUDY GOALS, METHODOLOGIES, AND PROJECT START-UP

Chairs: Susan Weiss and Margaret Murray

The NIH Vision for ABCD

Gaya Dowling, National Institute on Drug Abuse, Rockville, MD

Design, sampling strategy, and organization of ABCD

Sandra A Brown, University of California, San Diego, La Jolla, CA

Assessment domains and technologies applied in ABCD

Susan Tapert, University of California, San Diego, La Jolla, CA

ABCD neuroimaging and data sharing

Anders Dale, University of California, San Diego, La Jolla, CA

Current status of the study

Terry Jernigan, University of California, San Diego, La Jolla, CA

Workshop III

**Fiesta 12
7:00 - 9:00 PM**

EMERGING TECHNOLOGY FOR HUMAN SUBJECTS RESEARCH

Chairs: Jonathan J. Stoltman and Edward V. Nunes

Using Amazon's Mechanical Turk (mTurk) to sample substance using populations

Justin C Strickland, Department of Psychology, University of Kentucky, Lexington, KY

HIPAA, quasi-anonymity, and other ethical issues with electronic screening and brief intervention in health care settings

Steven J. Ondersma, Department of Psychiatry & Behavioral Neurosciences, Wayne State University, Detroit, MI

Using Facebook to recruit young adult tobacco users

Danielle Ramo, Department of Psychiatry, University of California, San Francisco, San Francisco, CA

The remote monitoring of smoking among adolescents and emerging adults: Attitudes, acceptability, and feasibility

Erin A McClure, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC

Crossing the bridge between the laboratory and the natural environment in addictions research

Jin H. Yoon, University of Texas Health Science Center at Houston, Houston, TX

DISCUSSANT:

Edward V Nunes, NYS Psychiatric Institute, New York, NY

Workshop IV

Fiesta 4

7:00 - 9:00 PM

INTERNATIONAL EMERGENCE AND ABUSE OF NEW PSYCHOTROPIC SUBSTANCES (NPS), THEIR TOXICITY AND THE CURRENT REGULATORY RESPONSE

Chairs: Patrick Beardsley and Jane C. Maxwell

Introduction to the NPS issues and the status of the International Regulatory Response

Patrick Beardsley, Virginia Commonwealth University, Richmond, VA

Detection, identification, exposure assessment and pharmacological evaluation of new psychotropic substances of abuse

B. F. Thomas, Research Triangle Institute, Research Triangle Park, NC

NPS situation in Europe

Paul Griffiths, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal

NPS situation in Australasia

Raimondo Bruno, University of Tasmania, Hobart Tasmania, TAS, Australia

NPS situation in North America

Jane C. Maxwell, University of Texas Addiction Research Institute, Austin, TX

General Discussion:

Co- Chairs

Workshop V

Fiesta 10/14

8:00 - 10:00 PM

EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS

Chairs: James C. Anthony and Jan Copeland

Introduction to the Workshop

Jan Copeland, National Cannabis Prevention Medicine, University of NSW, New South Wales, NSW, Australia

Sunday, June 12, 2016

Introduction to the Workshop

James C. Anthony, Michigan State University, East Lansing, MI

Overview of NIDA Epidemiology and DESPR Program Announcements and NIDA-supported resources for research

Marsha Lopez, National Institute on Drug Abuse, Bethesda, MD

Estimating causal effects with observational data when there is more than one treatment

Rajeev Ramchand, Rand Corporation, Arlington, VA

Please be advised that no photographing of presentations or data is permitted.
Badges must be worn at all times and are required for admission into all events and sessions.

Town Hall

Fiesta 6/8
8:00 - 10:00 AM

FROM DISCOVERY TO TRANSLATION: NAVIGATING THE ENTREPRENEURSHIP JUNGLE

Chairs: Beatriz Rocha and Marco Pravetoni

Start-ups from an academic view

Andrew Coop, University of Maryland School of Pharmacy, Baltimore, MD

How to spin off small pharmaceutical business

Elena Koustova, National Institute on Drug Abuse, Bethesda, MD

Starting your own spin-off focusing on med development for drug addiction

Paul Kenny, Department of Pharmacology & Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY

Media Forum

Fiesta 10/14
8:00 - 10:00 AM

WHAT'S HOT: PIVOTAL RESEARCH REPORTED AT CPDD 2016

Chairs: Bertha Madras and Anna R. Childress

Introduction to media: How to shape an effective and short presentation

Bertha Madras, Harvard Medical School, Belmont, MD

Introduction to each speaker

Anna Rose Childress, University of Pennsylvania, Philadelphia, PA

Symposium III

Fiesta 10/14
10:15 - 12:15 PM

IDENTIFYING SYSTEM-LEVEL BIOMARKERS OF SUBSTANCE ABUSE USING FUNCTIONAL CONNECTIVITY OF THE BRAIN

Chairs: Yihong Yang and Elliot Stein

10:15 *Imbalanced striatal-frontal functional connectivity predicts compulsive and impulsive behaviors in cocaine addiction*

Yihong Yang, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD

10:40 *Graph-theoretical modeling of brain connectivity in long-term, heavy cannabis users*

Francesca Filbey, University of Texas at Dallas, Dallas, TX

11:05 *Alcohol and brain connectivity: Neuroimaging of humans and animal models*

Adolf Pfefferbaum, Center for Health Sciences, SRI International, Menlo Park, CA

11:30 *Towards a biomarker of nicotine dependence*

Elliot Stein, National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD

11:55 *DISCUSSANT: Addiction: Unbalanced neurocircuitry*

Susan Weiss, National Institute on Drug Abuse, Rockville, MD

Symposium IV

Fiesta 6/8
10:15 - 12:15 PM

COGNITIVE FUNCTION AS A NOVEL TREATMENT TARGET FOR DRUG ADDICTION

Chairs: Mehmet Sofuoglu and Kathleen Carroll

- 10:15 *Psychostimulants as cognitive enhancers in cocaine addiction*
Muhammad A. Parvaz, Icahn School of Medicine at Mount Sinai, New York, NY
- 10:40 *Use of compensatory strategies in technological enhancement treatment for substance abusers*
Efrat Aharonovich, Columbia University, New York, NY
- 11:05 *Smart phones for smoking cessation: Cognitive bias modification for addiction*
Andrew Waters, Uniformed Services University of the Health Sciences, Bethesda, MD
- 11:30 *A placebo controlled trial of galantamine and CBT4CBT as a cognitive enhancement strategy*
Kathleen Carroll, Yale University, West Haven, CT
- 11:55 *DISCUSSANT: The promise of cognitive enhancement as a treatment for addictions*
Mehmet Sofuoglu, Yale University School of Medicine, West Haven, CT

Oral Communications 3

Fiesta 12
10:15 - 12:15 PM

THE MAN WITH THE GOLDEN ARM: OPIOID TREATMENT

Chairs: Charles Gorodetzky and Kelly E. Dunn

- 10:15 *Pain severity and subsequent opioid use during buprenorphine-naloxone treatment of prescription opioid-dependent patients with chronic pain*
R. Weiss¹, M. L. Griffin³, K. McDermott², K. McHugh⁴, S. L. Karakula², G. Fitzmaurice⁴,
¹Harvard Medical School, Belmont, MA, ²Alcohol and Drug Abuse Clinical Research Program, McLean Hospital, Brookline, MA, ³McLean Hospital/HMS, Belmont, MA, ⁴McLean Hospital/Harvard Medical School, Belmont, MA
- 10:30 *The role of genetic polymorphisms on patient response to opioid use disorder therapy with naltrexone and guanfacine*
E. Blokhina¹, E. Krupitsky^{1,4}, A. Kibitov³, E. Verbitskaya¹, T. Kosten², D. A. Nielsen²,
E. Zvartau¹, ¹First Pavlov State Medical University, St. Petersburg, Russian Federation,
²Baylor College of Medicine, Houston, TX, ³Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Moscow, Russian Federation, ⁴Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation
- 10:45 *Optimal minimum length of treatment in opioid-dependence with buprenorphine*
V. Zah¹, N. Matveev¹, C. Chen², J. Ruby³, ¹Health Economics, ZRx Outcomes Research Inc., Mississauga, ON, Canada, ²College of Pharmacy, University of New Mexico, Albuquerque, NM, ³Medical Affairs / HEOR, Indivior, Inc., Richmond, VA
- 11:00 *Optimal prevention of relapse among opioid users: A 12-week randomized controlled trial of extended-release naltrexone injections versus daily buprenorphine-naloxone*
L. H. Tanum^{1,3}, A. Opheim², K. Solli³, K. Sharma-Haase³, Z. Latif¹, N. Kunoe³, ¹R&D mental health, Akershus University Hospital, Lorenskog (Oslo), Norway, ²Department of addiction medicine, Haukeland University Hospital, Bergen, Norway, ³University of Oslo, Norwegian Centre for Addiction Research, Oslo, Norway

- 11:15 *Randomized controlled evaluation of tramadol for opioid detoxification*
K. E. Dunn, D. A. Tompkins, G. Bigelow, E. C. Strain, Johns Hopkins University, Baltimore, MD
- 11:30 *A phase III, randomized, double-blind, placebo-controlled study of the safety and efficacy of lofexidine for relief of symptoms in adults undergoing inpatient opioid detoxification*
C. Gorodetzky¹, S. L. Walsh², K. Gullo³, ¹USWM (Cons.), Kansas City, MO, ²Univ. KY, Lexington, KY, ³USWM, Louisville, KY
- 11:45 *Interim buprenorphine treatment for reducing illicit opioid use during treatment delays*
S. C. Sigmon¹, T. A. Ochalek², B. Hruska¹, S. H. Heil¹, S. Higgins¹, G. Rose¹, B. A. Moore³, ¹Psychiatry, The University of Vermont, Burlington, VT, ²Psychology, University of Vermont, Burlington, VT, ³Psychiatry, Yale University School of Medicine, New Haven, CT
- 12:00 *Unobserved home induction onto buprenorphine: Outcomes at year 7*
J. D. Lee², E. Patterson Bhatraju², B. Tofighi², M. Flannery², A. Kermack², M. Gourevitch², A. Garment³, K. Goldfeld², J. McNeely¹, E. Grossman³, ¹Population Health, NYU School of Medicine, New York, NY, ²Population Health, New York University, New York, NY, ³Medicine, New York University, New York, NY

Oral Communications 4

Fiesta 4

10:15 - 12:15 PM

MRS. DOUBTFIRE: SEX/GENDER

Chairs: Eduardo Butelman and Logan Dowdle

- 10:15 *Oxytocin reduced motivation to take cocaine in female rats and reduced reinstated drug seeking in male and females*
K. Leong, A. Hand, S. M. Ghee, C. M. Reichel, Neuroscience, Medical University of South Carolina, Charleston, SC
- 10:30 *Methamphetamine addiction vulnerability, the marked sex differences in the propensity to select methamphetamine over food reinforcement*
M. Purpura, P. Viera, Psychological and Brain Sciences, University of California Santa Barbara, Santa Barbara, CA
- 10:45 *Sex differences in a mood-based impulsivity model as a predictor for amphetamine CPP in rats*
D. B. Vazquez Sanroman², M. T. Bardo^{1,2}, ¹Psychology, University of Kentucky, Lexington, KY, ²Psychology, Center for Drug Abuse Research Translation, Lexington, KY
- 11:00 *Taurine's effects on cocaine-induced behavioral sensitization in male and female rats*
K. Y. Salas-Ramirez, M. Muritala, S. Singh, S. Ayo, R. Liang, T. Adebawale, K. Chauhan, A. Elzanie, CUNY School of Medicine, New York, NY
- 11:15 *Examining frontal-striatal circuit integrity in male and female cocaine users with TMS*
L. T. Dowdle, W. DeVries, M. Canterberry, C. A. Hanlon, Medical University of South Carolina, Charleston, SC
- 11:30 *Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse outcomes for women*
B. J. Sherman¹, N. Baker², A. McRae-Clark¹, ¹Psychiatry, Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, SC

- 11:45 *Sex differences in smoking withdrawal, urge, and cessation after stroke-induced insular cortex damage*
A. Abdolahi^{1,2}, G. Williams², C. Benesch², H. Wang², E. Spitzer³, B. Scott³, R. Block², E. van Wijngaarden², ¹Acute Care Solutions, Philips Research, Cambridge, MA, ²University of Rochester, Rochester, NY, ³Rochester General Hospital, Rochester, NY
- 12:00 *Addictive diseases and depression comorbidity: Age trajectory and gender comparison*
E. Butelman¹, S. Bacciardi², A. G. Maremmani², M. Darst-Campbell¹, B. M. Ray¹, E. Ducat¹, M. Kreek¹, ¹Laboratory on the Biology of Addictive Diseases, The Rockefeller University, New York, NY, ²“VP Dole” Dual Diagnosis Unit, Santa Chiara University Hospital of Pisa, Pisa, Italy

Poster Session I

(Lunch)

Odd-numbered posters manned first hour;

Even-numbered, second hour

Flores

12:15 - 2:15 PM

Set-up time begins Sunday, 1 PM

Must be removed by Monday 2:30 PM

IMMUNE/HIV

- 1 *Preliminary findings: HIV/STD risk among crack cocaine-dependent patients in treatment in Brazil's 'Crackland'*
S. McPherson², C. S. Madruga¹, A. Q. Miguel¹, M. G. McDonell², A. Ribeiro¹, ¹Psychiatry, UNIFESP, Sao Paulo, Brazil, ²Washington State University, Spokane, WA
- 2 *Rates and correlates of syphilis reinfection among men who have sex with men in San Francisco*
J. P. Jain¹, G. Santos², S. Scheer³, S. Gibson⁴, P. Crouch⁴, R. Kohn³, W. Chang¹, A. Carrico¹, ¹CHS, UCSF, San Francisco, CA, ²Community Health Systems, University of California San Francisco, San Francisco, CA, ³SFDPH, San Francisco, CA, ⁴SFAF, San Francisco, CA
- 3 *HIV, overdose mortality and the impact of anti-retroviral therapy adherence*
A. Caudarella², H. Dong¹, K. Hayashi¹, T. Kerr¹, E. Wood¹, M. Milloy¹, ¹Urban Health Research Initiative, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ²University of British Columbia, Toronto, ON, Canada
- 4 *Food insecurity and HIV progression among Russians with heavy alcohol consumption*
B. Idrisov², K. Lunze², D. M. Cheng², E. Blokhina¹, N. Gnatienko², G. Patts², C. Bridden², C. Chaisson², S. D. Weiser⁴, E. Krupitsky¹, J. H. Samet², ¹First St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation, ²Boston University, Boston, MA, ⁴UCSF School of Medicine, San Francisco, CA
- 5 *Predictors of skin infections among hospitalized injection drug users in Boston*
K. T. Phillips², B. J. Anderson^{3,4}, J. M. Liebschutz¹, M. Stein^{3,4}, ¹Medicine, Boston University School of Medicine, Boston, MA, ²University of Northern Colorado, Greeley, CO, ³General Internal Medicine, Butler Hospital, Providence, RI, ⁴Brown University, Providence, RI
- 6 *CD8⁺ lymphocytes and CD14_{high} CD16_{low} monocytes in chronic marijuana-using HIV patients*
J. Panee, L. Chang, University of Hawaii, Honolulu, HI

- 7 *Marijuana use frequency is associated with viral load suppression and biobehavioral outcomes in HIV+ patients*
L. H. Lundahl¹, C. L. Arfken¹, J. A. Cohn², M. Greenwald¹, ¹Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, MI, ²Internal Med, Wayne State University, Detroit, MI
- 8 *Effects of HIV infection and cocaine dependence on laboratory-based decision making task performance*
S. L. Towe, A. L. Hobkirk, C. S. Meade, Psychiatry & Behavioral Sciences, Duke University, Durham, NC
- 9 *The interaction between cocaine dependence and HIV infection on risky decision making and its neural substrates*
M. Addicott, A. L. Hobkirk, D. Cordero, C. S. Meade, Psychiatry & Behavioral Sciences, Duke University, Durham, NC
- 10 *Is TAAR1 a potential therapeutic target for immune dysregulation in drug addiction?*
L. M. Fleischer, N. Tamashunas, G. M. Miller, Pharmaceutical Sciences, Northeastern University, Boston, MA
- 11 *Development of a combination heroin-HIV vaccine*
G. R. Matyas¹, O. Torres², R. Jalah², J. Antoline^{3,4}, K. K. Peachman², M. Rao¹, A. Jacobson^{3,4}, C. Alving¹, K. Rice^{3,4}, ¹US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, ²US Military HIV Research Program, Henry M. Jackson Foundation, Silver Spring, MD, ³NIDA, NIH, Bethesda, MD, ⁴NIAAA, NIH, Bethesda, MD
- 12 *HIV-1 Tat-protein elevates forebrain glutathione levels and increases morphine drug-seeking and depression-like behaviors in mice*
J. P. McLaughlin², S. Eans², J. Medina², K. Hymel², A. Rock³, D. Mintzopoulos³, M. J. Kaufman¹, ¹Brain Imaging Center, McLean Hospital, Belmont, MA, ²Pharmacodynamics, University of Florida, Gainesville, FL, ³McLean Imaging Center, McLean Hospital, Belmont, MA

PRECLINICAL STUDIES

- 13 *Search for novel TLR4 antagonists for the treatment of neuropathic pain and drug abuse*
M. Wang, A. E. Jacobson, Molecular Targets and Medications Discovery Branch, National Institute of Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD
- 14 *Morphine-induced analgesia in the sensory and affective components of inflammatory pain*
A. Armendariz, A. Nazarian, Pharmaceutical Sciences, Western University of Health Sciences, Pomona, CA
- 15 *Partial kappa opioid receptor agonist effects in vivo in mice: Biased versus unbiased*
C. Guariglia, A. Dunn, K. Windisch, E. Butelman, B. Reed, M. Kreek, The Rockefeller University, New York, NY
- 16 *Abuse-related effects of the biased mu opioid receptor agonist TRV130 on intracranial self-stimulation in rats*
A. Altarifi¹, B. Blough³, S. S. Negus², ¹Pharmacology, Jordan University of Science & Technology, Irbid, Jordan, ²Virginia Commonwealth University, Richmond, VA, ³Research Triangle Institute, Research Triangle Park, NC

- 17 *Chronic administration of nandrolone increases the liability to morphine dependence with no correlation with LVV-hemorphin 7 in rats*
E. Huang¹, Y. Chen³, T. Huang¹, L. Chow², ¹Pharmacology, National Defense Medical Center, Taiwan, Taipei, Taiwan, ²Anesthesiology Department, Taipei Veterans General Hospital, Taipei, Taiwan, ³Department of Neurological Surgery, Tri-Service General Hospital, Taipei, Taiwan
- 18 *Anxiolytic-like and discriminative stimulus effects of benzodiazepine+neuroactive steroid combinations in rats*
B. W. Gunter^{2,1}, S. A. Jones¹, D. Platt¹, J. K. Rowlett¹, ¹University of Mississippi Medical Center, Jackson, MS, ²Vanderbilt University, Pegram, TN
- 19 *Novel environment response as a predictor of midazolam self-administration in rats*
J. E. Cook¹, S. L. Huskinson¹, B. W. Gunter², K. Freeman¹, J. K. Rowlett¹, ¹University of Mississippi Medical Center, Jackson, MS, ²Vanderbilt University, Pegram, TN
- 20 *Emerging role of microRNAs in regulation of nicotine dependence: A Caenorhabditis elegans model*
X. Pan, J. R. Polli, Biology, East Carolina University, Greenville, NC
- 21 *The role of the $\alpha 7$ and $\alpha 4\beta 2$ nicotinic receptors in nicotine sensitization and neural plasticity of adolescent rats neonatally treated with quinpirole: Effects on mTOR and nicotinic receptor density*
D. J. Peterson^{1,2}, J. Wherry², E. D. Cummins³, D. Hoover², R. W. Brown², ¹Psychology, East Tennessee State University, Johnson City, TN, ²Biomedical Sciences, East Tennessee State University, Johnson City Tennessee, TN, ³Psychology, University of Nebraska, Lincoln, NE
- 22 *Silencing giant cholinergic interneurons in the nucleus accumbens with DREADDs reduces nicotine self-administration in rats*
E. A. Williams, C. A. Bradley, M. I. Palmatier, Psychology, East Tennessee State University, Johnson City, TN
- 23 *Role of accumbens nicotinic acetylcholine receptors in cue-induced nicotine seeking and synaptic plasticity*
A. del Franco^{1,2}, G. Powell^{1,2}, B. Pagni¹, J. Goenaga¹, M. Scofield³, C. Gipson-Reichardt¹, ¹Psychology, Arizona State University, Tempe, AZ, ²School of Life Sciences, Arizona State University, Tempe, AZ, ³Neurosciences, Medical University of South Carolina, Charleston, SC
- 24 *Vulnerability to glutamate excitotoxicity is sexually dimorphic in rats exposed to chronic social defeat stress: Relevance to astrocytic glutamate-glutamine cycle*
V. Rappeneau¹, A. BLAKER², J. PETRO¹, B. Yamamoto², A. Shimamoto¹, ¹Neuroscience and Pharmacology, Meharry Medical College, Nashville, TN, ²Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN
- 25 *Expression of the cannabinoid CB1 receptor in Chinese hamster ovary cells: A specific cellular model to investigate the acute and chronic effects of synthetic cannabinoids*
M. Funada, K. Tomiyama, Drug Dependence Research, NIMH, NCNP, Kodaira, Japan
- 26 *In vivo and in vitro cannabinoid effects of three synthetic compounds*
M. J. Forster, M. B. Gatch, Center for Neuroscience Discovery, UNT Health Science Center, Fort Worth, TX

- 27 *Physiological and pharmacokinetic effects of e-cigarette-type exposure to delta9-tetrahydrocannabinol in rats*
J. D. Nguyen¹, S. M. Aarde¹, S. Vandewater¹, Y. Grant¹, D. G. Stouffer¹, M. Cole², L. Parsons¹, M. A. Taffe¹, ¹CNAD, The Scripps Research Institute, San Diego, CA, ²La Jolla Alcohol Research, Inc., La Jolla, CA
- 28 *Real-time, continuous electrochemical monitoring of drugs in vivo*
P. Vieira¹, N. Arroyo Currás², J. Somerson², K. Ploense¹, K. Plaxco², T. E. Kippin¹, ¹Psychological & Brain Sciences, University of California Santa Barbara, Goleta, CA, ²Chemistry, University of California Santa Barbara, Santa Barbara, CA

IMAGING

- 29 *Fractional anisotropy increase in long-term anabolic-androgenic steroid users*
M. J. Kaufman², J. Seitz¹, A. E. Lyall¹, G. Kanayama², N. Makris^{1,2}, J. I. Hudson², M. Kubicki¹, H. G. Pope, Jr.², ¹Brigham & Women's Hospital, Boston, MA, ²McLean Hospital, Belmont, MA
- 30 *Alexithymia and addiction: A review and preliminary data suggesting neurobiological links to reward/loss processing*
K. P. Morie¹, S. W. Yip², C. Nich³, K. Hunkele³, K. Carroll², M. N. Potenza², ¹Diagnostic Radiology, Yale University, New Haven, CT, ²Psychiatry, Yale University, New Haven, CT, ³Connecticut Mental Health Center, New Haven, CT
- 31 *A brain imaging study of dopamine receptor D₂ availability in cannabis-dependent users after recovery from cannabis-induced psychosis using [¹²³I] IBZM in Single Photon Emission Tomography*
A. M. Weinstein^{1,2}, H. Lerman², M. Gremland², O. Frisch³, E. Even-Sapir², ¹Behavioral Sciences, University of Ariel, Ariel, Israel, ²Nuclear Medicine, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Kfar Izun Treatment Center, Ceasaria, Israel
- 32 *Psilocybin in long-term meditators: Effects on default mode network functional connectivity and retrospective ratings of qualitative experience*
F. S. Barrett¹, M. W. Johnson¹, R. R. Griffiths^{1,2}, ¹Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, ²Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD
- 33 *Altered resting state fMRI response in young adult marijuana users and heavy drinkers*
A. D. Dager¹, S. Meda², H. Tennen³, S. Raskin⁴, C. Austad⁵, R. Wood⁵, C. Fallahi⁵, G. Pearlson^{1,2}, ¹Yale, New Haven, CT, ²Olin Neuropsych Res Ctr, Hartford, CT, ³Univ of CT Health Ctr, Farmington, CT, ⁴Trinity College, Hartford, CT, ⁵Central CT State Univ, New Britain, CT
- 34 *Striatal responses to d-amphetamine differentiates young adults at "high-risk" of drug abuse*
M. J. Wesley¹, J. A. Lile¹, C. E. Emurian¹, C. Martin², J. Joseph³, T. H. Kelly¹, ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Psychiatry, University of Kentucky College of Medicine, Lexington, KY, ³Neurosciences, Medical University of South Carolina, Charleston, SC
- 35 *Psychological intervention with working memory training increases basal ganglia volume: A VBM study of inpatient treatment for methamphetamine dependence*
S. J. Brooks, D. J. Stein, L. Van Nunen, Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa

- 36 *Methamphetamine dependence linked to interoceptive processing deficits during aversive breathing load*
A. C. May¹, J. L. Stewart⁴, P. Davenport², S. Tapert¹, M. P. Paulus³, ¹UC San Diego, San Diego, CA, ²Physiological Sciences, University of Florida, Gainesville, FL, ³Laureate Institute for Brain Research, Tulsa, OK, ⁴Queens College, City University of New York, Flushing, NY
- 37 *The effects of naltrexone on neural responses to methamphetamine cues*
K. E. Courtney¹, D. Ghahremani², L. Ray³, ¹Psychology, University of California, Los Angeles, San Diego, CA, ²Psychiatry and Biobehavioral Science, University of California, Los Angeles, Los Angeles, CA, ³Psychology, University of California, Los Angeles, Los Angeles, CA
- 38 *Structural analysis of the limbic system in substance dependence*
M. F. Regner, R. Rosello, J. Honce, D. Yamamoto, M. Dalwani, J. Sakai, J. Tanabe, UCD, Aurora, CO
- 39 *Effective connectivity of attentional bias in cocaine dependence*
F. Moeller^{7,8,3}, L. Ma^{7,9}, J. Steinberg^{7,3}, J. Bjork^{7,3}, S. D. Lane², P. A. Narayana¹⁰, T. Kosten¹, A. Bechara¹¹, J. Schmitz⁴, A. E. Price⁶, K. A. Cunningham⁵, ¹Psychiatry, Baylor, Houston, TX, ²Psychiatry & Behavioral Sciences, UT Health Science Center, Houston, TX, ³Psychiatry and Pharmacology, VCU, Richmond, VA, ⁴UT, Houston, TX, ⁵Center for Addiction Research, UT Medical Branch, Galveston, TX, ⁶Neuroscience Graduate Program, UT Medical Branch, League City, TX, ⁷Institute for Drug and Alcohol Studies, VCU, Richmond, VA, ⁸Center for Clinical and Translational Research, Richmond, VA, ⁹Radiology, VCU, Richmond, VA, ¹⁰Radiology, UT Houston Medical School, Houston, TX, ¹¹Psychology, USC Brain and Creativity Institute, Los Angeles, CA
- 40 *When bigger isn't better: Widespread brain activation during attempted inhibition of the response to 6-sec cocaine video cues predicts poor drug use outcome*
A. R. Childress, K. Jagannathan, P. Regier, J. Suh, Z. Monge, T. Franklin, R. Wetherill, K. A. Young, S. Darnley, M. Gawrysiak, D. Langleben, K. M. Kampman, C. P. O'Brien, University of Pennsylvania, Philadelphia, PA
- 41 *Transition to problem stimulant use marked by amplified insular responding to pleasant interoceptive stimuli*
E. Ramirez-Coombs¹, A. C. May³, J. L. Stewart^{1,4}, S. Tapert^{5,3}, M. P. Paulus^{6,3}, ¹Psychology, CUNY Graduate Center, New York, NY, ³Psychiatry, UC San Diego, San Diego, CA, ⁴Psychology, CUNY Queens College, Flushing, NY, ⁵Psychiatry Service, Veterans Affairs San Diego Healthcare System, San Diego, CA, ⁶Laureate Institute of Brain Research, Tulsa, OK
- 42 *Resting state functional connectivity among cocaine users*
A. L. Hobkirk¹, R. P. Bell², A. V. Utevsy³, C. S. Meade¹, ¹Psychiatry & Behavioral Sciences, Duke University, Durham, NC, ²Psychology, University of North Carolina, Chapel Hill, NC, ³Psychology and Neuroscience, Duke University, Durham, NC
- 43 *Hemispheric associations of behavioral inhibition and approach in substance dependence*
D. Yamamoto¹, M. T. Banich⁵, M. F. Regner³, J. Sakai¹, J. Tanabe¹, ¹Department of Psychiatry and Radiology, University of Colorado Denver, Aurora, CO, ³Departments of Radiology and Bioengineering, University of Colorado Denver, Denver, CO, ⁵Institute of Cognitive Science, University of Colorado Boulder, Boulder, CO

- 44 *Neural effects of treatment in a trial of behavioral therapies and disulfiram for cocaine dependence*
E. E. DeVito¹, G. Dong^{2,1}, H. Kober¹, J. Xu¹, K. Carroll¹, M. N. Potenza¹, ¹Psychiatry, Yale University School of Medicine, New Haven, CT, ²Psychology, Zhejiang Normal University, Jinhua, China
- 45 *Poorer working memory performance among cocaine users accounted for by increased activation in the middle frontal gyrus*
J. Y. Yi¹, R. P. Bell¹, T. Ross², E. Stein², S. B. Daughters¹, ¹Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Neuroimaging Research Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD
- 46 *Distress tolerance among substance users associated with connectivity between the MFG and vmPFC/sgACC during a distress tolerance task*
E. D. Reese¹, R. P. Bell¹, J. Y. Yi¹, T. Ross², E. Stein², S. B. Daughters¹, ¹Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Neuroimaging Research Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD
- 47 *The “little brain” steps up: Cerebellar activity during successful inhibition predicts treatment outcome in cocaine patients*
P. S. Regier, K. Jagannathan, J. Suh, M. Goldman, K. M. Kampman, T. Franklin, C. P. O’Brien, A. R. Childress, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 48 *Switching gears: Shifts in reward function associated with age of onset of MJ use*
N. Hager¹, K. Jagannathan¹, R. Wetherill¹, P. Regier¹, Y. Mashhoon², H. Pater¹, C. P. O’Brien¹, A. R. Childress¹, T. Franklin¹, ¹Psychiatry, University of Pennsylvania, Philadelphia, PA, ²Psychiatry, Harvard, Belmont, MA
- 49 *Losing balance: Time course of smoking cue-elicited neural activity*
T. Franklin, K. Jagannathan, N. Hager, R. Wetherill, H. Rao, H. Pater, A. R. Childress, Psychiatry, University of Pennsylvania, Philadelphia, PA
- 50 *Right inferior frontal gyrus structure and function predict smoking (re)lapse in real-world and laboratory contexts*
B. Froeliger^{1,2}, P. McConnell¹, S. Bell¹, C. Eichberg¹, M. Sweitzer³, K. M. Gray², J. McClernon³, ¹Neuroscience, MUSC, Charleston, SC, ²Psychiatry, MUSC, Charleston, SC, ³Psychiatry, Duke, Durham, NC
- 51 *Insula reactivity to negative stimuli is associated with daily cigarette use: A preliminary investigation using the human connectome database*
A. L. Peechatka^{1,2}, N. Dias³, A. Janes³, ¹McLean Imaging Center, McLean Hospital, Belmont, MA, ²Psychology, Suffolk University, Boston, MA, ³McLean Imaging Center, McLean Hospital/ Harvard Medical School, Belmont, MA

ABUSE LIABILITY

- 52 *Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: Results from a multi-site clinical trial*
E. Donny¹, T. T. Smith¹, R. Cassidy², J. W. Tidey², X. Luo³, C. Le³, D. Hatsukami⁴, ¹Psychology, University of Pittsburgh, Pittsburgh, PA, ²Brown University, Providence, RI, ³University of Minnesota, Minneapolis, MN, ⁴University of Minnesota Medical School, Minneapolis, MN

- 53 *Interactions between alcohol and mephedrone in humans*
M. Farré^{1,2,3}, E. Papaseit^{2,1,3}, C. Pérez-Mañá^{2,3}, E. de Souza Fernandes⁴,
J. F. Mateus², E. Olesti^{2,6}, K. Kuypers⁴, E. Theunissen⁴, F. Fonseca^{5,3}, M. Torrens^{5,3},
J. Ramaekers⁴, R. F. de la Torre^{2,6}, ¹Clinical Pharmacology, Hospital Universitari Germans
Trias i Pujol-IGTP, Badalona, Spain, ²Pharmacology, Hospital del Mar Medical Research
Institute-IMIM, Barcelona, Spain, ³Universitat Autònoma de Barcelona-UAB, Barcelona,
Spain, ⁴Faculty of Psychology and Neuroscience, Maastricht University, Maastricht,
Netherlands, ⁵Institut de Neuropsiquiatria i Addiccions, Hospital del Mar-IMIM-PSMAR,
Barcelona, Spain, ⁶Universitat Pompeu Fabra, Barcelona, Spain
- 54 *Select characteristics of recreational of opioid users undergoing a human abuse potential study*
M. D. Smith, L. R. Webster, PRA Health Sciences, Salt Lake City, UT
- 55 *Abuse liability of buprenorphine vs. buprenorphine/naloxone: Importance of absolute amount*
J. D. Jones⁴, J. M. Manubay³, S. Mogali⁴, V. Metz¹, S. Comer⁴, ¹Columbia University NYSPI,
New York, NY, ³Family Medicine/Psychiatry, NYSPI/Columbia University, New York, NY,
⁴Division on Substance Abuse, New York State Psychiatric Institute/ Columbia University
College of Physicians and Surgeons, New York, NY
- 56 *Monitoring Internet postings for mentions of an extended-release hydrocodone formulation with
abuse-deterrent properties*
A. DeVeugh-Geiss¹, H. Chilcoat¹, P. Coplan¹, V. Harikrishnan¹, A. C. Besharat², J. L. Green²,
¹Purdue Pharma LP, Stamford, CT, ²Denver Health RADARS System, Denver, CO
- 57 *Correlating viscosity and in vitro dissolution to in vivo pharmacokinetic profiles of proprietary
injected-molded tablet formulations with abuse-deterrent characteristics*
T. Elhauge, N. Skak, M. J. Øvergård, K. Lindhardt, Egalet Corporation, Værløse, Denmark
- 58 *Moderate TBI increases susceptibility to rewarding effects of a subthreshold dose of cocaine in
mice*
L. Cannella¹, S. Merkel^{1,2}, R. Razmpour¹, C. S. Tallarida^{2,3}, S. Rawls^{2,3}, S. Ramirez^{1,2,4},
¹Pathology, TUSM, Philadelphia, PA, ²CSAR, TUSM, Philadelphia, PA, ³Pharmacology,
TUSM, Philadelphia, PA, ⁴Shriner's, Philadelphia, PA
- 59 *Evaluation of human abuse liability of JZP-110*
L. P. Carter^{1,5}, E. Sellers², J. Henningfield^{3,6}, G. Wang¹, Y. Lu¹, D. Kelsh⁴, B. Vince⁴, ¹Jazz
Pharmaceuticals, Palo Alto, CA, ²University of Toronto, Toronto, ON, Canada, ³Pinney
Associates, Bethesda, MD, ⁴Vince & Associates Clinical Research, Overland Park, KS,
⁵University of Arkansas for Medical Sciences, Little Rock, AR, ⁶Johns Hopkins School of
Medicine, Baltimore, MD

ETHIC DIFFERENCES/HEALTH DISPARITIES

60 **WITHDRAWN**

- 61 *A multi-component brief intervention for risky drug use among Latino patients of a federally
qualified health center in East Los Angeles: A randomized controlled trial of the QUIT Using
Drugs Intervention Trial (QUIT) brief intervention*
L. Gelberg¹, R. Andersen¹, M. Vahidi¹, M. Rico¹, S. Baumeister², B. Leake¹, ¹UCLA,
Los Angeles, CA, ²University of Regensburg, Regensburg, Germany

- 62 *Subjective happiness moderates the effects of nicotine dependence on acute tobacco withdrawal in African-American smokers*
M. M. Liautaud¹, R. Pang¹, A. Leventhal^{1,2}, ¹Preventive Medicine, University of Southern California, Los Angeles, CA, ²Psychology, University of Southern California, Los Angeles, CA
- 63 *Smoking and trauma in Syrian refugees*
H. Jefee-Bahloul^{1,2}, M. Jaafar³, ¹Psychiatry- Division of Substance Use, University of Massachusetts Medical School, Boston, MA, ²Psychiatry, Yale School of Medicine, New Haven, CT, ³Union of Syrian Medical Relief Organizations, Reyhanli, Turkey
- 64 *Sport involvement and marijuana use during adolescence: The significance of level of contact and race/ethnicity*
K. Rigg², J. A. Ford¹, ¹Sociology, University of Central Florida, Orlando, FL, ²Mental Health Law & Policy, University of South Florida, Tampa, FL
- 65 *Perceived racial discrimination and motivations for illicit substance use among Black college student drug users*
D. Lanaway, Psychology, University of Cincinnati, Cincinnati, OH
- 66 *The gap in marijuana prevalence between Black and White adolescents has disappeared since 2011: The role of perceived risk of marijuana use*
R. Miech¹, P. O'Malley¹, L. A. Johnston¹, J. Wallace⁴, ¹University of Michigan, Ann Arbor, MI, ⁴University of Pittsburgh, Pittsburgh, PA
- 67 *US trends in past-year marijuana use and perceived risk of regular use, 2002-2013, by race/ethnicity*
D. Shmulewitz, Q. Brown, R. Rahim-Juwel, S. S. Martins, M. M. Wall, P. M. Mauro, H. Carliner, A. L. Sarvet, D. Hasin, Columbia University, New York, NY
- 68 *The interactive effects of race, community support, and neighborhood environment in predicting adolescent marijuana use trajectories*
A. Rowe³, C. M. Risco³, J. W. Felton², C. W. Lejuez³, L. MacPherson³, ²University of Maryland, College Park, MD, ³Psychology, University of Maryland, College Park, MD
- 69 *Racial discrimination and risk taking propensity among African American young adults*
C. M. Risco², D. Iwamoto¹, A. Rowe¹, F. Fonseca¹, M. Benner¹, T. Mbonu¹, I. Espinoza¹, C. W. Lejuez², ¹University of Maryland, College Park, MD, ²Psychology, University of Maryland, College Park, College Park, MD
- 70 *Interpersonal predictors of short-term treatment outcomes among African-American women in MMT*
J. J. Lister¹, S. Xuan¹, M. Greenwald², D. M. Ledgerwood², ¹Social Work, Wayne State University, Detroit, MI, ²Psychiatry, Wayne State University, Detroit, MI
- 71 *Does perceived racial discrimination and degree of ethnic identity predict changes in substance use over time? An examination of Black emerging adults*
A. Saint-Fleur, D. M. Anglin, City College of New York, Hempstead, NY

EPIDEMIOLOGY

- 72 *Perceived harmfulness of marijuana and risk for adolescent use: Individual and collective beliefs*
A. L. Sarvet¹, M. Wall¹, K. Keyes¹, M. Cerda², J. Schulenberg³, D. Hasin¹, ¹Columbia University, New York, NY, ²University of California, Davis, CA, ³University of Michigan, Ann Arbor, MI

- 73 *Age differences in adult past-year marijuana use and risk perceptions in the U.S., 2002-2013*
P. M. Mauro, D. Shmulewitz, D. Hasin, A. L. Sarvet, R. Rahim-Juwel, Q. Brown, H. Carliner, M. Wall, S. S. Martins, Columbia University, New York, NY
- 74 *Male-female differences in cannabis use onset among U.S. adolescents and young adults in the 21st century*
C. Lopez-Quintero¹, J. C. Anthony², ¹Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, ²Michigan State University, East Lansing, MI
- 75 *Toward a patient registry for cannabis use: An exploratory study*
K. Hoffman^{2,3}, J. Ponce-Terashima³, D. McCarty¹, J. Muench⁴, ¹CB 669 PHPM, Oregon Health & Science University, Portland, OR, ²School of Public Health, Oregon Health & Science University, Portland, OR, ³INCAAS, Lima, Peru, ⁴Family Medicine, Oregon Health & Science University, Portland, OR
- 76 *Characterizing therapeutic users of cannabis in Ontario, Canada*
B. Brands^{1,2,4}, H. Hamilton^{2,3}, A. Ialomiteanu², R. Mann^{2,3}, ¹Health Canada, Toronto, ON, Canada, ²Centre for Addiction and Mental Health, Toronto, ON, Canada, ³DLSPH, University of Toronto, Toronto, ON, Canada, ⁴Pharmacology, University of Toronto, Toronto, ON, Canada
- 77 *Is cannabis use associated with an increased risk of onset and persistence of alcohol use disorders? A three-year prospective study among adults in the United States*
A. H. Weinberger², J. Platt³, R. Goodwin^{1,3}, ¹Queens College, City University of New York, Flushing, NY, ²Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, ³Department of Epidemiology, Columbia University, New York, NY
- 78 *Using MyChart® to assess patient attitudes toward cannabis use*
D. McCarty¹, R. Leed¹, M. Payment¹, L. Kunkel¹, T. Korthuis⁵, T. Burdick³, ¹School of Public Health, Oregon Health & Science University, Portland, OR, ³Family Medicine, OHSU, Portland, OR, ⁵Internal Medicine, OHSU, Portland, OR
- 79 *Monetary payment for research participation: What do marijuana users think?*
K. Vaddiparti, C. W. Striley, E. Kwiatkowski, L. Cottler, Epidemiology, University of Florida, Gainesville, FL
- 80 *Cannabis use data collected via social media: A methodological comparison*
J. Borodovsky, D. C. Lee, B. S. Crosier, A. J. Budney, Geisel School of Medicine at Dartmouth, Lebanon, NH
- 81 *Physical activity and marijuana use among United States adults: Results from the national health and nutrition examination surveys 2007-2012*
D. C. Vidot¹, W. Hlaing¹, G. Prado¹, A. Acheampong², S. Messiah¹, ¹University of Miami, Miami, FL, ²University of Florida, Gainesville, FL
- 82 *Hypertension medication use among past 30-day marijuana users in a community sample from Northeast Florida*
H. R. Crooke, L. Cottler, E. Kwiatkowski, C. W. Striley, Epidemiology, University of Florida, Gainesville, FL
- 83 *DSM-5 cannabis use disorders in the United States, 2012-2013*
D. S. Hasin^{1,2}, B. F. Grant³, ¹Columbia University, New York, NY, ²New York State Psychiatric Institute, New York, NY, ³National Institute on Alcohol Abuse and Alcoholism, Rockville, MD

- 84 *Marijuana use problems predict post-college employment outcomes*
K. M. Caldeira¹, K. E. O'Grady², B. A. Bugbee¹, K. B. Vincent¹, A. M. Arria¹, ¹School of Public Health, University of Maryland, College Park, MD, ²Psychology, University of Maryland, College Park, MD
- 85 *Is risk of cannabis dependence lower for 'cannabis only' users?*
K. Alcover, C. Lopez-Quintero, J. C. Anthony, Epidemiology & Biostatistics, Michigan State University, East Lansing, MI
- 86 *Elevated cotinine levels in recently active cannabis users absent recent cigarette or other tobacco exposure: Unmeasured blunt or environmental sources?*
B. J. Fairman¹, O. Alshaarawy², ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
- 87 *Perceived nicotine content and its association with perceived disease risks of Spectrum research cigarettes*
L. Pacek³, F. J. McClernon³, R. Denlinger¹, M. Mercincavage⁵, A. Strasser⁵, R. Vandrey⁴, N. Nardone⁸, D. Hatsukami⁷, E. Donny⁶, ¹Brown University, Providence, RI, ³Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, ⁴Johns Hopkins University, Baltimore, MD, ⁵Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁶Psychology, University of Pittsburgh, Pittsburgh, PA, ⁷University of Minnesota Medical School, Minneapolis, MN, ⁸University of California San Francisco, San Francisco, CA
- 88 *Has nicotine dependence increased among smokers in the United States? A new test of the hardening hypothesis*
R. Goodwin^{1,2}, M. Wall³, S. Galea⁵, M. J. Zvolensky⁴, M. Gbedemah¹, M. Hu⁶, D. S. Hasin², ¹Psychology, City University of New York, Queens, NY, ²Epidemiology, Columbia University, New York, NY, ³Biostatistics, Columbia University, New York, NY, ⁴Psychology, University of Houston, Houston, TX, ⁵Epidemiology, Boston University, Boston, MA, ⁶Sociomedical Sciences, Columbia University, New York, NY
- 89 *Some context for understanding the place of the GED in the relationship between educational attainment and smoking prevalence*
A. N. Kurti^{2,1}, E. Klemperer^{1,2,3}, I. A. Zvorsky^{1,2,3}, R. Redner^{1,2}, J. Priest^{5,2}, S. Higgins^{1,2,3}, ¹Vermont Center on Behavior and Health, Burlington, VT, ²Psychiatry, University of Vermont, South Burlington, VT, ³Psychological Science, University of Vermont, Burlington, VT, ⁵Biostatistics, University of Vermont, Burlington, VT
- 90 *Energy drink use trajectories predict substance use outcomes*
A. M. Arria¹, K. M. Caldeira¹, B. A. Bugbee¹, K. B. Vincent¹, K. E. O'Grady², ¹School of Public Health, University of Maryland, College Park, MD, ²Psychology, University of Maryland, College Park, MD
- 91 *The transition to recovery: Key predictors and how they relate to aging*
M. L. Dennis¹, C. K. Scott¹, J. G. Csernansky², H. C. Breiter², ¹Lighthouse Inst., Chestnut Health Systems, Normal & Chicago, IL, ²Department of Psychology and Behavioral Science, Northwestern University School of Medicine, Chicago, IL
- 92 *Life chaos among drug users and non-drug users*
S. O. Lasopa, K. Vaddiparti, C. W. Striley, L. Cottler, Epidemiology, University of Florida, Gainesville, FL

- 93 *Executive functioning and DSM-5 criteria for substance use disorder among addicted inpatients*
D. R. Lima, P. D. Goncalves, M. Ometto, A. Malbergier, R. Amaral, S. Nicastri, A. Andrade,
P. J. Cunha, Interdisciplinary Group of Studies on Alcohol and Drugs, Institute of Psychiatry,
São Paulo, Brazil

POLICY

- 94 *Does perceived availability of marijuana explain changes in marijuana use after medical marijuana law implementation among U.S. adults?*
C. Mauro¹, J. Santaella², J. H. Kim², M. M. Wall¹, S. S. Martins², ¹Biostatistics, Columbia University, NY, NY, ²Epidemiology, Columbia University, NY, NY
- 95 *Medical marijuana dispensaries in Los Angeles: Access and service among young adults*
A. Kioumars, M. Reed, S. Lankenau, Drexel University, Philadelphia, PA
- 96 *Attitudes and practices of cannabis dispensary staff*
N. A. Haug¹, D. Kieschnick¹, J. E. Sottile¹, R. Vandrey², K. Babson³, M. O. Bonn-Miller³,
¹Palo Alto University, Palo Alto, CA, ²Johns Hopkins University, Baltimore, MD, ³VA Palo Alto Health Care System, Menlo Park, CA
- 97 *Nonmedical use of prescription opioids and medical marijuana laws in the U.S. from 2004-2013*
J. H. Kim, J. Santaella, P. M. Mauro, J. A. Cisewski, C. Mauro, M. M. Wall, S. S. Martins,
Columbia University, New York, NY
- 98 *Smoking cessation assistance pre- and post-implementation of stage 1 meaningful use*
S. R. Bailey², M. J. Hoopes³, J. Puro³, J. E. DeVoe^{2,3}, T. Burdick⁴, D. J. Cohen⁴, J. Heintzman²,
M. Marino⁴, J. Irvine³, D. McCarty¹, S. P. Fortmann⁵, ¹CB 669 PHPM, Oregon Health & Science Univ, Portland, OR, ²Family Medicine, Oregon Health & Science University, Portland, OR, ³Research, OCHIN, Portland, OR, ⁴Family Medicine, OHSU, Portland, OR, ⁵Center for Health Research, Kaiser Permanente Northwest, Portland, OR
- 99 *Impact of recovery interventions on opioid users. A simulation study*
G. Bobashev¹, B. Eggleston¹, R. J. Morris¹, C. Barbosa¹, W. Dowd¹, M. L. Dennis²,
C. K. Scott², ¹RTI International, Durham, NC, ²Chestnut, Chicago, IL
- 100 *Benzodiazepine dependence among young adults in the club scene: Data from a second cohort*
S. P. Kurtz¹, M. E. Buttram¹, M. Pagano³, ¹ARSH: Center for Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, ³Department of Psychiatry, Division of Child Psychiatry, Case Western Reserve University, Cleveland, OH
- 101 *Potential opioid misuse in the social security healthcare system of Peru*
J. Ponce Terashima¹, K. Hoffman¹, F. Fiestas³, V. Dongo³, D. McCarty², ¹International Center for Advanced Research and Applied Science, Lima, Peru, ²Oregon Health & Science Univ, Portland, OR, ³EsSalud, Lima, Peru
- 102 *Impact of the opioid safety initiative on opioid prescribing practices in the Veterans Healthcare Administration*
L. A. Lin¹, A. S. Bohnert^{1,2}, M. Ilgen^{1,2}, ¹Department of Psychiatry, University of Michigan, Ann Arbor, MI, ²Department of Veterans Affairs Healthcare System, Serious Mental Illness Treatment Resource and Evaluation Center, Ann Arbor, MI
- 103 *Naloxone access laws and implementation of overdose prevention programs at Veteran Affairs hospitals*
M. E. Niculete^{2,1}, A. Peckham³, D. Boggs^{3,1}, H. Steinberg^{2,1}, ¹Psychiatry, Yale University, New Haven, CT, ²Psychology, VA Connecticut Healthcare System, West Haven, CT, ³Pharmacy, VA Connecticut Healthcare System, West Haven, CT

- 104 *State-level opioid antagonist access laws: The emergence of three distinct strategies, 2001–2015*
S. Burris¹, S. K. Johnson³, J. Ibrahim², E. Platt³, L. Allen³, ¹Temple University Beasley School of Law, Philadelphia, PA, ²College of Public Health, Temple University, Philadelphia, PA, ³Legal Science, LLC, Philadelphia, PA
- 105 *Naloxone uptake and use among people who inject drugs in the Seattle area, 2009-2015*
S. N. Glick¹, J. Tsui¹, M. Hanrahan², C. J. Banta-Green¹, H. Thiede², ¹University of Washington, Seattle, WA, ²Public Health-Seattle & King County, Seattle, WA
- 106 *Change in abuse diagnoses in patients prescribed oxycontin after its reformulation with abuse-deterrent properties*
A. Kadakia², P. Coplan¹, R. Singh², A. DeVeauh-Geiss¹, ¹Risk Management and Epidemiology, Purdue Pharma, Stamford, CT, ²Purdue, Stamford, CT
- 107 *Diversion of controlled substances at the pharmacy level: Findings from RxPATROL since introduction of opioids with abuse-deterrent properties*
J. G. Erensen, J. D. Haddox, L. N. Bauza, Purdue Pharma L.P., Stamford, CT
- 108 *Drug users' advice on enrollment and retention in health research*
A. Zulich, A. Elliott, C. W. Striley, L. Cottler, Epidemiology, University of Florida, Gainesville, FL
- 109 *Drug users and non-drug users both favor uncommon informed consent practices*
A. Elliott, A. Zulich, L. Cottler, C. W. Striley, Epidemiology, University of Florida, Gainesville, FL
- 110 *Increased drug use and the timing of social assistance receipt among people who use illicit drugs*
L. Wang, E. Krebs, M. Olding, K. DeBeck, K. Hayashi, M. Milloy, L. Richardson, B. Nosyk, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- 111 *Meta-analysis as a form of evidence: An examination of the Cochrane reviews for behavioral health*
S. Magura, M. J. Lee, S. Means, Western Michigan University, Kalamazoo, MI
- 112 *A summary of addiction services in a Canadian city: Preliminary results from an Internet-based scoping study*
E. Knight, St. Paul's Hospital Goldcorp Addiction Medicine Fellowship, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- 113 *Using residential in-patient detoxification units to facilitate effectiveness of therapeutic community rehabilitation: A comparative follow-up pilot study*
S. Rabinovitz, School of Criminology, University of Haifa, Haifa, Israel

Marian W. Fischman Memorial Award Lecture

**Fiesta 6/8
2:15 - 3:15 PM**

Presentation of the Marian W. Fishman Award to Marilyn Huestis

Introduction by *Jack Henningfield*

*Lecture: The Great US Cannabis Experiment: Research & Education
to Enable Informed Public Decisions*
Marilyn Huestis

Symposium V

**Fiesta 10/14
3:30 - 5:30 PM**

INTRACELLULAR SIGNALING MOLECULES AS TARGETS FOR STIMULANT ABUSE TREATMENT

Chairs: Margaret Gnegy and John Traynor

- 3:30 *A tonic-phasic model explains the effect of deltaFosB on addiction-related behaviors*
Thomas Green, University of Texas Medical Branch, Galveston, TX
- 3:55 *RGS2 signaling and implication for drug addiction*
Rong Chen, Wake Forest School of Medicine, Winston Salem, SC
- 4:20 *Trace amine-associated receptor 1 as a target for stimulant abuse treatment*
Jun-Xu Li, University at Buffalo, New York, NY
- 4:40 *PKCbeta as a target for amphetamine abuse*
Margaret Gnegy, University of Michigan School of Medicine, Ann Arbor, MI
- 5:10 *DISCUSSANT:*
John Traynor, University of Michigan Medical School, Ann Arbor, MI

Symposium VI

**Fiesta 6/8
3:30 - 5:30 PM**

IS TWO BETTER THAN ONE? NEW INSIGHTS ON POLYSUBSTANCE USE FROM EPIDEMIOLOGICAL, CLINICAL, AND BASIC RESEARCH

Chairs: Heather Kimmel and Paul W. Czoty

- 3:30 *Epidemiology of polysubstance use in the United States: Findings from national cross-sectional and longitudinal studies*
Sean McCabe, University of Michigan, Ann Arbor, MI
- 3:55 *Early adolescent polysubstance use and young adult substance use disorders*
Howard Moss, University of California at Riverside School of Medicine, La Jolla, CA
- 4:20 *Polysubstance users versus alcohol users: Do different cognitive and neurobiological deficits ask for different treatment?*
Dieter Meyerhoff, School of Medicine UCSF, San Francisco, CA
- 4:45 *The toxic effects of serial exposure to alcohol and methamphetamine*
Bryan K Yamamoto, Indiana University School of Medicine, Indianapolis, IN
- 5:10 *DISCUSSANT: Translational studies of polysubstance abuse: Enhancing translation*
Paul W. Czoty, Wake Forest School of Medicine, Winston-Salem, NC

Oral Communications 5

Fiesta 4
3:30 - 5:30 PM

STUDIO 54: CLUB DRUGS

Chairs: Leonard Howell and Matthew W. Johnson

- 3:30 *Ketamine-induced changes in resting state functional connectivity in conscious nonhuman primates: Implications for drug abuse*
E. A. Maltbie¹, K. Gopinath², L. Howell¹, ¹Yerkes National Primate Research Center, Emory University, Atlanta, GA, ²Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA
- 3:45 *Juvenile ketamine exposure alters sensitivity to reward-related stimuli in adulthood*
S. D. Iniguez^{1,2}, L. M. Riggs², A. R. Zavala³, ¹Psychology, University of Texas at El Paso, El Paso, TX, ²Psychology, California State University, San Bernardino, San Bernardino, CA, ³Psychology, California State University, Long Beach, Long Beach, CA
- 4:00 *Alterations in brain neurotransmitter levels after single and repeated inhalation of toluene in rats*
A. A. Elkoussi, Pharmacology, Assiut College of Medicine, Assiut, Egypt
- 4:15 *MDMA increases affiliative behaviors and vocalizations in nonhuman primates in a 5-HT_{2A} receptor-dependent manner*
E. G. Pitts, A. R. Minerva, E. B. Oliver, L. Howell, Yerkes National Primate Research Center, Emory University, Atlanta, GA
- 4:30 *S-Mephedrone: Preclinical investigation against behavioral effects of the synthetic cathinone MDPV*
H. Philogene¹, S. Rawls¹, A. Reitz², ¹Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ²Fox Chase Chemical Diversity Center, Doylestown, PA
- 4:45 *3,4-Methylenedioxy-N-ethylcathinone and its analogs differentially affect dopamine and 5-HT systems in rat brain*
H. M. Walters¹, O. Dillon-Carter¹, J. S. Partilla¹, F. Sakloth², R. A. Glennon², C. W. Schindler³, M. H. Baumann¹, ¹Designer Drug Research Unit, IRP, NIDA, NIH, Baltimore, MD, ²Department of Medicinal Chemistry, VCU School of Pharmacy, Richmond, VA, ³Preclinical Pharmacology Section, IRP, NIDA, NIH, Baltimore, MD
- 5:00 *Pharmacological mechanisms underlying cardiovascular effects of 3,4-methylenedioxypyrovalerone*
C. W. Schindler¹, E. Thorndike¹, M. Suzuki⁴, K. Rice⁴, M. Baumann⁵, ¹Preclinical Pharmacology Section, NIH/NIDA Intramural Research, Baltimore, MD, ⁴Drug Design and Synthesis Section, NIH/NIDA Intramural Research, Baltimore, MD, ⁵Designer Drug Unit, NIH/NIDA Intramural Research, Baltimore, MD
- 5:15 *Commuting distance to Miami's club scene and binge substance use and related problems among young adults*
M. E. Buttram¹, M. Pagano², S. P. Kurtz¹, ¹Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, ²Department of Psychiatry, Division of Child Psychiatry, Case Western Reserve University, Cleveland, OH

Oral Communications 6

Fiesta 12
3:30 - 5:30 PM

A STREET CAR NAMED DESIRE: REWARD/ REINFORCEMENT

Chairs: Adam Leventhal and Sally L. Huskinson

- 3:30 *Caffeine self-administration in rats*
C. A. Bradley, E. M. Sanders, E. A. Williams, M. I. Palmatier, Psychology, East Tennessee State University, Johnson City, TN
- 3:45 *Variable availability as a determinant of cocaine choice in rhesus monkeys*
S. L. Huskinson¹, K. Freeman¹, N. Petry², J. K. Rowlett^{1,3}, ¹University of Mississippi Medical Center, Jackson, MS, ²University of Connecticut School of Medicine, Farmington, CT, ³Tulane National Primate Research Center, Covington, LA
- 4:00 *Increasing nicotine cost and decreasing nicotine dose are not equivalent manipulations: A behavioral economics analysis*
T. T. Smith², L. E. Rupprecht¹, A. F. Sved^{1,2}, E. Donny², ¹Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA, ²Psychology, University of Pittsburgh, Pittsburgh, PA
- 4:15 *Influence of cocaine cues on monetary choice in cocaine users*
J. C. Strickland¹, C. R. Rush^{1,2,3}, W. W. Stoops^{1,2,3}, ¹Psychology, University of Kentucky, Lexington, KY, ²Behavioral Science, University of Kentucky, Lexington, KY, ³Psychiatry, University of Kentucky, Lexington, KY
- 4:30 *Physical activity enjoyment predicts sensitivity to the acute subjective effects of amphetamine in healthy volunteers*
M. Pester, M. Kirkpatrick, A. Leventhal, Preventive Medicine, University of Southern California, Los Angeles, CA
- 4:45 *Neural responses to risk and reward predict transition to problem stimulant use*
J. L. Stewart^{2,3}, A. C. May¹, M. Reske⁴, S. Tapert^{1,5}, M. P. Paulus^{6,1}, ¹Psychiatry, UC San Diego, La Jolla, CA, ²Psychology, CUNY Graduate Center, New York, NY, ³Psychology, CUNY Queens College, Flushing, NY, ⁴Institute of Neuroscience and Medicine-4, Medical Imaging Physics, Forschungszentrum Jülich GmbH, Jülich, Germany, ⁵Psychiatry Service, Veterans Affairs San Diego Healthcare System, San Diego, CA, ⁶Laureate Institute of Brain Research, Tulsa, OK
- 5:00 *Activity based reward processing among opiate users: Validation of the behavioral incentive delay task*
R. P. Bell, J. Y. Yi, Y. Chen, A. Petruzzella, I. Jiang, K. A. Johnson, E. D. Reese, S. B. Daughters, Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 5:15 *Differences in delay discounting between heroin and prescription opioid users*
S. L. Karakula¹, M. L. Griffin², R. Weiss², K. McHugh², ¹McLean Hospital, Belmont, MA, ²McLean Hospital/Harvard Medical School, Belmont, MA

Pre- and Post-Doctoral Trainees Networking Event

**CAPRA
5:45 - 7:00 PM**

Workshop VI

**Fiesta 10/14
7:00 - 9:00 PM**

22ND ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP

Chairs: Diann Gaalema and Kelly E. Dunn

Workshop VII

**Fiesta 4
7:00 - 9:00 PM**

INTRODUCING THE NATIONAL DRUG EARLY WARNING SYSTEM (NDEWS)

Chairs: Eric Wish and Moira O'Brien

Building a national drug early warning system: Introducing the NDEWS model and new drug use trends and patterns from 12 sentinel community sites

Erin Artigiani, University of Maryland, Center for Substance Abuse Research (CESAR), College Park, MD

Emerging patterns and trends in the use of heroin, prescription opioids, and other drugs in San Francisco

Phillip Coffin, San Francisco Department of Public Health, San Francisco, CA

Screening and reporting synthetic cannabinoid use in an urban emergency department

J Richardson, University of Maryland, African-American Studies Department, College Park, MD

Analyzing drug trends on social media

Jennifer Golbeck, University of Maryland, College of Information Studies, College Park, MD

Discussant: NIDA's new epidemiology

Linda Cottler, University of Florida, Department of Epidemiology, Gainesville, FL

Workshop VIII

**Fiesta 12
7:00 - 9:00 PM**

A GENDER LENS TO ADDRESSING ADOLESCENT SUBSTANCE USE DISORDERS AND TRAUMA WITH SYSTEMS LEVEL APPROACH / SASATE BUSINESS MEETING

Chairs: Michael L. Dennis and Sally Stevens

Substance use disorders and trauma symptoms in national data from adolescents entering substance abuse treatment by sex and sexual identity

Michael L Dennis, Chestnut Health Systems, Normal, IL

The impact of a system of care approach in treating substance use disorders among adolescent girls

Sally Stevens, University of Arizona – Southwest Institute for Research on Women, Tucson, AZ

Outcomes of a trauma responsive system of care for LGBT youth

Claudia Powell, University of Arizona – Southwest Institute for Research on Women,
Tucson, AZ

Empowering female adolescent drug users in Cape Town: A government response

Felicia Browne, RTI International, Durham, NC

Workshop IX

Fiesta 6/8

7:00 - 9:00 PM

MARIJUANA LAWS: THE CHANGING LEGAL LANDSCAPE AND ITS CONSEQUENCES

Chairs: Marsha Lopez and Andrew Freedman

Do patterns of medical marijuana use correspond to overall health levels?

Bridget Freisthler, Luskin School of Public Affairs, University of California, Los Angeles, CA

Tracking emerging cannabis use trends with social media

Raminta Daniulaityte, Boonshoft School of Medicine, Wright State University, Kettering, OH

*Adolescent marijuana-related attitudes and behaviors in the context of non-medical marijuana
legalization in Washington State: Implications for prevention*

Walter Mason, Boys Town National Research Institute for Child and Family Studies, Boys
Town, NE

Public health effects of medical marijuana legalization in Colorado

Karen F Corsi, Univ. of Colorado School of Medicine, Denver, CO

DISCUSSANT:

Andrew Freedman, Governor's Office of Marijuana Coordination, Denver, CO

Please be advised that no photographing of presentations or data is permitted.
Badges must be worn at all times and are required for admission into all events and sessions.

2016 NIDA International Forum Abstracts

Flores

7:00 to 9:00 PM

Basic Science

- 100 *The impact of lifestyle on mental health in the Gilgel Gibe Field Research Center, Ethiopia: Khat abuse as a risk factor for the development of psychotic symptoms*
K. Adorjan¹, M. Tesfaye², M. Widmann³, F. Tessema⁴, M. Odenwald³, S. Toennes⁵, S. Papiol¹, E. Susser⁶, M. Soboka², Z. Mekonnen⁷, M. Rietschel⁸, S. Suleman⁷, T.G. Schulze¹.
¹Institute of Psychiatric Phenomics and Genomics, Germany; ²Department of Psychiatry, Jimma University, Ethiopia; ³Department of Psychology, University of Konstanz, Germany; ⁴Department of Epidemiology, Jimma University, Ethiopia; ⁵Toxicology, University of Frankfurt, Germany; ⁶Department of Epidemiology, Columbia University, United States; ⁷Drug Laboratory, Jimma University, Ethiopia; ⁸Department of Genetic Epidemiology in Psychiatry, Germany
- 101 *Haemodynamic responses to tobacco smoke inhalation in male adolescents in Lusaka, Zambia*
T. Chikopela¹, F.M. Goma². ¹Lusaka Apex Medical University, Zambia; ² School of Medicine, The University of Zambia, Zambia
- 102 *Alterations in brain neurotransmitter levels after single and repeated inhalation of toluene in rats*
A. Elkoussi, Department of Pharmacology, College of Medicine, University of Assiut, Egypt
- 103 *Cognitive dysfunction and altered cerebral functional connectivity in chronic ketamine users*
C. Hung^{1,2,3}, C-S.R. Li^{4,5}, S. Zhang⁴, S. Hu⁴, J.R. Duann⁶, T. S-H. Lee⁷. ¹Bali Psychiatric Center, Ministry of Health and Welfare, Taiwan; ²Institute of Brain Science, National Yang-Ming University, Taiwan; ³Brain Connectivity Laboratory, Institute of Neuroscience, National Yang-Ming University, Taiwan; ⁴Department of Psychiatry, Yale School of Medicine, United States; ⁵Department of Neuroscience, Yale School of Medicine, United States; ⁶Biomedical Engineering Research and Development Center, China Medical University, China; ⁷Department of Health Promotion and Education, National Taiwan Normal University, Taiwan
- 104 *Attenuation of morphine withdrawal by kappa agonist nalbuphine: Involvement of adenosine 3':5'-cyclic monophosphate system*
R. Jain¹, R. Raghav¹, T.S. Roy², A. Dhawan¹, P. Kumar¹. ¹Department of Psychiatry, National Drug Dependence Treatment Centre, India; ²Department of Anatomy, All India Institute of Medical Sciences, India
- 105 *The effects of recreational marijuana and ecstasy use on brain activation during visual-motor associative learning*
A. Kustubayeva^{1,2}, B. Lewis¹, M. Smith¹, M. Smith¹, J. Eliassen¹. ¹University of Cincinnati, United States; ²Kazakh National University, Kazakhstan
- 106 *Effects of short periods of maternal separation on social behavior and drug reward on the adolescent rat*
A. Magalhães^{1,2}, M. Nogueira³, J. Bravo¹, C.J. Alves¹, A. Mesquita³, T. Summavielle¹, L. De Sousa². ¹Instituto de Investigação e Inovação em Saúde, Portugal; ²Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Portugal; ³Centro de investigação em Psicologia, Universidade do Minho, Portugal

- 107 *Survival meta-analysis of age at onset of cannabis use based on the International Cannabis Consortium sample of 24,222 individuals*
C.C. Minica¹, K.J.H. Verweij¹, P. van der Moost², H. Mbarek¹, International Cannabis Consortium, D.I. Boomsma¹, J.M. Vink³, N.A. Gillespie⁴, E.M. Derks⁵. ¹Department of Biological Psychology, Vrije Universiteit Amsterdam, The Netherlands; ²Department of Epidemiology, University of Groningen, University Medical Center, The Netherlands; ³Behavioural Science Institute, Radboud University, The Netherlands; ⁴Department of Psychiatry, Virginia Institute for Psychiatric and Behavior Genetics, Virginia Commonwealth University, United States; ⁵Department of Psychiatry, Academic Medical Centre, The Netherlands
- 108 *Reduced insula and prefrontal cortex volumes in chronic methamphetamine users with psychosis*
C. Qi, Y.H. Liao, Q.X. Wu, T.Q. Liu, W. Hao. Mental Health Institute, The Second Xiangya Hospital, Central South University, China
- 109 *Effect of nalbuphine on opiate withdrawal and changes in dopaminergic and serotonergic expressions in rat brain*
R. Raghav¹, R. Jain¹, T.S. Roy², A. Dhawan¹, P. Kumar². ¹National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, India; ²Department of Anatomy, All India Institute of Medical Sciences, India
- 110 *Abused drugs regulate dopamine release in the striatum throughout presynaptic nicotinic receptors*
F.R. Rizzo, M. Federici, N.B. Mercuri. IRCCS Fondazione Santa Lucia and Università Tor Vergata, Italy
- 111 *No association between crack cocaine addiction and COMT Val/Met polymorphism*
T. Roman^{1,2}, A.R. Stolf³, J.B. Schuch^{1,2}, D. Müller^{1,2}, G.C. Akutagava-Martins^{1,2}, C.M. Szobot^{3,4}, F. Pechansky³, F.H.P. Kessler³. ¹Post Graduate Program in Genetics and Molecular Biology, Federal University of Rio Grande do Sul (UFRGS), Brazil; ²Department of Genetics, UFRGS, Brazil; ³Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre (HCPA), UFRGS, Brazil; ⁴Child and Adolescent Psychiatric Service, HCPA, UFRGS, Brazil
- 112 *Accumbens volumes are reduced among crack cocaine users*
S.B. Schuch-Goi¹, P.D. Goi², R. Massuda², M. Bermudez¹, L.S. Fara¹, F.P. Kessler¹, L. von Diemen¹, C.S. Gama², F. Pechansky¹. ¹Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS); ²Laboratory of Molecular Psychiatry, HCPA, UFRGS, Brazil
- 113 *Role of the dopaminergic system on crack cocaine addiction: DRD2 and DRD4 genes, individual and interaction effects*
A.R. Stolf¹, J.B. Schuch^{2,3}, D. Müller^{2,3}, G.C. Akutagava-Martins^{2,3}, C.M. Szobot^{1,4}, F. Pechansky¹, F.H.P. Kessler¹, T. Roman^{2,3}. ¹Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre (HCPA), Federal University of Rio Grande do Sul (UFRGS), Brazil; ²Post Graduate Program in Genetics and Molecular Biology, UFRGS, Brazil; ³Department of Genetics, UFRGS, Brazil; ⁴Child and Adolescent Psychiatric Service, HCPA, UFRGS, Brazil

- 114 *TAAR1 modulates context-dependent Pavlovian conditioning to amphetamine*
I.M. Sukhanov^{1,2}, L. Caffino³, E.V. Efimova^{4,5}, S. Espinoza², T.D. Sotnikova^{2,5}, L. Cervo⁶, F. Fumagalli³, R.R. Gainetdinov^{2,4,5}, E.E. Zvartau¹. ¹First Pavlov State Medical University, Russia; ²Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia, Italy; ³Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Italy; ⁴Skolkovo Institute of Science and Technology, Russia; ⁵Institute of Translational Biomedicine, Faculty of Biology, St. Petersburg State University, Russia; ⁶IRCCS–Istituto di Ricerche Farmacologiche Mario Negri, Experimental Psychopharmacology, Italy
- 115 *TBARS and BDNF changes in newborns exposed to crack cocaine during pregnancy—a comparative study*
C. Szobot^{1,2,3}, L.A. Rohde^{1,2,4,5}, K.M. Mendes Ceresér^{2,6}, C. de Moura Gubert⁶, E. Galvão da Silva⁶, F. Xavier⁷, R. Porcianello², L.M. Röhsig⁸, F. Pechansky^{2,3,8}, V. Mardini¹. ¹Child and Adolescent Psychiatry Service, Hospital de Clínicas de Porto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Brazil; ²Graduate Program in Medicine–Psychiatry, UFRGS, Brazil; ³Center for Drug and Alcohol Research, HCPA, UFRGS, Brazil; ⁴Instituto Nacional de Psiquiatria do Desenvolvimento, Brazil; ⁵Department of Psychiatry, UFRGS, Brazil; ⁶Laboratory of Molecular Psychiatry and Instituto Nacional de Ciência e Tecnologia Translacional em Medicina, HCPA, UFRGS, Brazil; ⁷Undergraduate Program in Biomedical Sciences, Centro Universitário Metodista–IPA, Brazil; ⁸Cord Blood Bank and Cryobiology Unit, HCPA, UFRGS, Brazil
- 116 *Case control association β -arrestin 2 gene (ARRB2) with opioid and cocaine dependence*
M. Vaswani^{1,2}, L. Ambrose¹, T. Clarke¹, W. Berrettini¹. ¹University of Pennsylvania, United States; ²All India Institute of Medical Sciences, India
- 117 *Evaluation of oxidative stress markers among adolescent inhalant users seeking treatment at a tertiary care center in North India*
A. Verma¹, R. Jain¹, A. Dhawan¹, R. Lakshmy². ¹National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, India; ²Department of Cardiac Biochemistry, All India Institute of Medical Sciences, India
- 118 *Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as toll-like receptor 4 antagonists*
X. Wang. Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, China

Epidemiology

- 200 *Nonproblematic and problematic Internet use among undergraduate students of medical colleges in Zagazig, Egypt*
M. Abdelghani^{1,2}, G.S. El-Deen¹. ¹Department of Psychiatry, Zagazig University, Egypt; ²Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
- 201 *Cannabis use among road transport workers: The roles of life orientation and resilience*
G.E. Abikoye^{1,2}, E.B. Edet¹. ¹Department of Psychology, University of Uyo, Nigeria; ²Center for Research and Information on Substance Abuse, Nigeria
- 202 *Reasons for the change in drug use patterns toward psychoactive drugs in Gaza Strip and the level of satisfaction*
M. AlAfifi¹, M. Sakka², R. Afifi¹. ¹Substance Abuse Research Center, Palestine; ²Al-Azhar University, Palestine

- 203 *Perceived community-level violence and prevalence of sexually transmitted infections among Mexican female sex workers who inject drugs*
N.A. Alamillo¹, S.M. Kiene², G. Rangel³, G. Martinez⁴, A. Vera⁵, S. Manian⁶, S.A. Strathdee⁵. ¹Joint Doctoral Program in Public Health, San Diego State University/University of California, San Diego, United States; ²Division of Epidemiology and Biostatistics, Graduate School of Public Health, San Diego State University, United States; ³El Colegio de la Frontera del Norte, Mexico; ⁴Community Health and Development of Ciudad Juarez and the Mexican Federation of Private Associations, Mexico; ⁵Division of Global Health, University of California, San Diego (UCSD), United States; ⁶Department of Economics, UCSD, United States
- 204 *Introducing a new research method for evaluating alcohol and other drug use among fatally injured victims in Latin America*
G. Andreuccetti^{1,2}, V. Leyton¹, I.D. Miziara^{1,3}, N.P. Lemos⁴, D.R. Munoz¹, C.J. Cherpitel², H.B. Carvalho¹. ¹University of São Paulo Medical School, Brazil; ²Alcohol Research Group, United States; ³Technical-Scientific Police Superintendency of the State of São Paulo, Brazil; ⁴Office of Chief Medical Examiner-San Francisco, United States
- 205 *Examining the impact of the government's attempt to regulate the novel psychoactive substance market*
M. Beltgens. Department of Criminology, University of Leicester, United Kingdom
- 206 *Understanding the increase in prescription opioids in Peru: Protocol for an exploration of practitioner knowledge*
J. Beltran¹, K. Hoffman^{2,3}, J. Ponce-Terashima^{2,4}, F. Fiestas⁵, D. McCarty³, V. Dongo⁵. ¹Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; ²International Center for Advanced Research and Applied Science, Peru; ³Oregon Health & Science University, United States; ⁴George Washington University, United States; ⁵Peruvian Social Security System, Peru
- 207 *Composition of party drugs in Belgium: Not what you might expect*
P. Blanckaert¹, K. Maudens², E. Deconinck³, P. Calle⁴. ¹Belgian Early Warning System Drugs, Scientific Institute of Public Health, Belgium; ²Toxicological Centre, University of Antwerp, Belgium; ³Section of Medicines, Scientific Institute of Public Health, Belgium; ⁴Department of Internal Medicine, Ghent University, Belgium
- 208 *Challenges and limitations in the implementation of research findings: The case of the "largest open drug scene" in Israel*
H. Bonny-Noach^{1,2,3}, S. Toys¹. ¹Department of Criminology, Ariel University and Beit Berl College, Israel; ²Prevention and Education Division, Israel Anti-Drug Authority, Israel; ³Israeli Society of Addiction Medicine, Israel
- 209 *Incarceration patterns and risk of HIV infection among people who inject drugs in Tijuana, Mexico*
A. Borquez¹, D. Abramovitz¹, G. Rangel², L. Beletsky¹, N. Martin¹, S. Strathdee¹. ¹Division of Global Public Health, University of California, San Diego, United States; ²Comisión de Salud Fronteriza, Mexican Ministry of Health, Mexico
- 210 *The prevalence of adult attention deficit/hyperactivity disorder among treatment-seeking problem gamblers*
L. Brandt¹, G. Fischer^{1,2}. ¹Center for Public Health, Medical University of Vienna, Austria; ²Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria

- 211 *Drug consumption, knowledge of the consequences of consumption, and the relationship with academic performance among undergraduate students in St. Joseph, Trinidad*
N. Brathwaite. Department of Research and Graduate Studies, University of the Southern Caribbean, Trinidad and Tobago
- 212 *Development and validation of a scale for amotivational syndrome in chronic cannabis users*
G.A. Castaño Pérez¹, E. Becoña Iglesias², S.M. Restrepo Escobar³, O.S. Diaz-Granados⁴, L.A. Rojas-Bernal¹. ¹Mental Health Research Group, CES University, Colombia; ²University of Santiago de Compostela, Spain; ³FUNLAM University, Colombia; ⁴Drug Abuse Project, the Ministry of Health and Social Protection, Colombia
- 213 *HIV, overdose mortality, and the impact of antiretroviral therapy*
A. Caudarella¹, K. Hayashi¹, H. Dong¹, M.J. Milloy^{1,2}, T. Kerr^{1,2}, E. Wood^{1,2}. ¹British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Canada; ²Department of Medicine, University of British Columbia, Canada
- 214 *Gender and the role of alcohol on HIV risk behavior among drug users in Costa Rica*
M. Chacón-Ortiz¹, R. Achí¹, M. Comerford², K. Barrantes¹, C. McCoy². ¹Instituto de Investigaciones en Salud, Universidad de Costa Rica, Costa Rica; ²Comprehensive Drug Research Center, University of Miami, United States
- 215 *Chronic pain not associated with occupational status among a predominantly dextropropoxyphene-abusing population: Cross-sectional study from Sikkim, North East India*
A. Chakrabarti¹, D. Datta², S. Pandey², Y. Verma³, S. Dutta⁴. ¹Regional Occupational Health Centre-Eastern, National Institute of Occupational Health, Indian Council of Medical Research, India; ²Department of Pharmacology, Sikkim Manipal Institute of Medical Sciences (SMIMS), India; ³Department of Pathology, SMIMS, India; ⁴Department of Psychiatry, SMIMS, India
- 216 *High prevalence of major depression among treatment-seeking ketamine-dependent patients*
L-Y. Chen¹, X. Ke², C-K. Chen³, M-C. Huang^{1,4}. ¹Department of Psychiatry, Taipei City Hospital and Psychiatric Center, Taiwan; ²Department of Psychiatry, Yale School of Medicine, United States; ³Department of Psychiatry, Chang Gung Memorial Hospital, Taiwan; ⁴Department of Psychiatry, School of Medicine, Taipei Medical University, Taiwan
- 217 *Substance abuse and HIV risks among the youth of urban Nepal*
M.B.P. Chhetri. Nepal Center for Disaster Management, Nepal
- 218 *Patients in mental health crisis admitted to hospital and use of combined drugs*
J. Da Silva¹, E. Ferreira². ¹Anna Nery School of Nursing, Federal University of Rio de Janeiro, Brazil; ²Institute of Psychiatry, Federal University of Rio de Janeiro, Brazil
- 219 *Drug use in relation to tobacco and alcohol use in Iraqi men*
R.M. Dabbagh¹, N.J. Al-Hemairy², J.J. Al-Diwan³, A.L. Hasson⁴, R.R. Rawson⁴. ¹Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles (UCLA), United States; ²Unit of Psychiatry, Department of Medicine, College of Medicine, Baghdad University, Iraq; ³Unit of Mental Health, Department of Community Medicine, College of Medicine, Baghdad University, Iraq; ⁴Integrated Substance Abuse Programs, Semel Institute for Neuroscience and Human Behavior, UCLA, United States

- 220 *Attitudes toward people with problematic drug use in the city of Loja, Ecuador*
A. Delgado¹, R. Mann², H. Hamilton², B. Brands^{2,3}, F. Cumsille⁴, M. Wright⁴, A. Khenti².
¹National Council for Control of Narcotic and Psychotropic Substances, Ecuador; ²Center for Addiction and Mental Health, University of Toronto, Canada; ³Office of Research and Surveillance, Controlled Substance and Tobacco Directorate, Health Canada, Canada; ⁴Inter-American Drug Abuse Control Commission, Organization of American States, United States
- 221 *Impact of harm reduction and medically assisted treatment on HIV incidence among people who inject drugs in Ukraine: Results of a prospective cohort study*
K. Dumchev¹, M. Samko², J. Barska². ¹Ukrainian Institute on Public Health Policy, Ukraine; ²Alliance for Public Health, Ukraine
- 222 *Is khat use disorder a valid diagnostic entity?*
S. Duresso, A. Matthews, S. Ferguson, R. Bruno. School of Medicine, University of Tasmania, Australia
- 223 *A national survey of U.S. primary care physicians' knowledge and practices regarding e-cigarettes*
O. El-Shahawy¹, J.E. Lafata², S. Sherman¹. ¹Section on Tobacco, Alcohol, and Drug Use, Department of Population Health, School of Medicine, New York University, United States; ²Department of Health Behavior and Policy, School of Medicine, Virginia Commonwealth University, United States
- 224 *Family-related factors and concurrent heroin use in methadone maintenance treatment: Report from China*
N. Feng¹, C. Lin¹, K. Rou², L. Li¹. ¹Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, United States; ²National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, China
- 225 *Patterns of prescription drug use and misuse in Spain: The European Opioid Treatment Patient Survey*
F. Fonseca^{1,2,3}, M. Torrens^{1,2,3}, M. Farré^{2,3,4}, K.E. McBride⁵, I. Maremmani^{6,7}, M. Guareschi⁷, D. Touzeau⁸, P. Villeger⁹, A. Benyamina¹⁰, O. D'Agnone¹¹, L. Somaini¹², R.C. Dart^{5,13}. ¹Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Spain; ²Institut Hospital del Mar d'Investigacions Mèdiques, Spain; ³Universitat Autònoma de Barcelona, Spain; ⁴Hospital Universitari Germans Trias i Pujol-IGTP, Spain; ⁵Denver Health Rocky Mountain Poison and Drug Center, United States; ⁶Department of Neurosciences, Santa Chiara University Hospital, Italy; ⁷Associazione per l'Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali, Italy; ⁸Clinique Liberté, France; ⁹Laboratoire de Toxicologie, Centre Hospitalier Universitaire, France; ¹⁰Centre d'Enseignement, de Recherche et de Traitement des Addictions, Hôpital Paul Brousse, France; ¹¹Crime Reduction Initiative, United Kingdom; ¹²Addiction Treatment Centre, Local Health Unit, Italy; ¹³School of Medicine, University of Colorado-Denver, United States
- 226 *Khat use prevalence and causes, and its effect on mental health among Bahir-Dar University students, North West Ethiopia*
A.G. Gebiresilus. Addis Ababa University, Ethiopia

- 227 *Gender differences among people who inject drugs with regard to HIV transmission risk in St. Petersburg, Russia*
N. Gnatienco¹, J.I. Tsui², J.A. Wagman³, D.M. Cheng⁴, A. Raj³, E. Blokhina⁵, O. Toussova⁵, L. Forman⁴, D. Lioznov⁵, J.H. Samet^{1,4}. ¹Boston Medical Center, United States; ²University of Washington, United States; ³University of California, San Diego, United States; ⁴Boston University, United States; ⁵First St. Petersburg Pavlov State Medical University, Russia
- 228 *An evaluation of opioid substitution treatment (OST) in prison on risk of mortality in period immediately after prison: Does leaving prison on OST reduce the risk of death?*
M. Hickman¹, G. Stillwell², H. Jones¹, J. Shaw³, M. Farrell⁴, J. Marsden². ¹School of Social and Community Medicine, University of Bristol, United Kingdom; ²National Addiction Centre, Institute of Psychiatry, Kings College London, United Kingdom; ³Institute of Brain, Behaviour and Mental Health, University of Manchester, United Kingdom; ⁴National Drug and Alcohol Research Centre, University of New South Wales, Australia
- 229 *Prevalence of marijuana use among university students in Bolivia, Colombia, Ecuador, and Peru*
M. Hynes¹, M. Demarco¹, J.C. Araneda², F. Cumsille¹. ¹Inter-American Observatory on Drugs, Inter-American Drug Abuse Control Commission, Organization of American States, United States; ²Global SMART Programme-Latin America, United Nations Office on Drugs and Crime, United States
- 230 *Abstinence from injecting drugs associated with decline in inflammatory markers but not with monocyte activation markers*
S. Islam^{1,2}, J. Astemborski², H. Li³, S.X. Leng³, D. Piggott², S.H. Mehta², G.D. Kirk². ¹Department of Microbiology, Jahangirnagar University, Bangladesh; ²Department of Epidemiology, School of Public Health, Johns Hopkins University, United States; ³Department of Medicine, School of Medicine, Johns Hopkins University, United States
- 231 *Psychosocial factors associated with relapse to drug addiction among women in Bangladesh*
S.M.S. Islam, M.M. Rahman. International Center for Diarrheal Disease Research, Bangladesh
- 232 *Hepatitis C virus subtype distribution and evolution characteristic among drug users, men who have sex with men, and the general population in Beijing*
Y. Jiao^{1,2}, C. Wang², S. Li², L. Li², J. Liu², K.J. Bar³, H. Wei¹, Y. Hu², P. Huang², Z. Zeng², S. Jiang², J. Du⁴, D. Metzger^{3,5}, Y. Shao¹, X. Zhang², L. Ma^{*1}. ¹State Key Laboratory for Infection Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Chinese Center for Disease Control and Prevention, China; ²Beijing Chaoyang District Centre for Disease Control and Prevention, China; ³Perelman School of Medicine, University of Pennsylvania, United States; ⁴National Institutes for Food and Drug Control, China; ⁵The Treatment Research Center, United States
- 233 *Trends and patterns of emerging drugs in Mombasa and Nairobi counties, Kenya*
R. Kahuthia-Gathu¹, R. Gakunju², J. Thungu³, P. Okwarah². ¹Kenyatta University, Kenya; ²Movement Against Substance Abuse in Africa, Kenya; ³Thogoto Teachers Training College, Kenya
- 234 *Prevalence of smoking behavior in a tobacco-growing Southeastern Province in Turkey*
I. Kayi^{1,2}, S. Abes³, G. Yakan³, M. Teke³, O.B. Akici³, A. Bozlak³, M. Kutlu³. ¹Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; ²School of Medicine, Koc University, Turkey; ³Adiyaman Public Health Directorate, Turkey

- 235 *Preliminary results of the first nationwide general population survey on drugs in the Republic of Georgia*
I. Kirtadze¹, D. Otiashvili¹, M. Tabatadze¹, G. Kamkamidze², L. Sturua³, T. Zabransky⁴, B. Sopko^{5,6}, M-S. Martens⁷, J.C. Anthony⁸. ¹Addiction Research Center, Alternative Georgia, Georgia; ²Health Research Union, Georgia; ³National Center of Disease Control and Public Health, Georgia; ⁴ResAd, Czech Republic; ⁵National Monitoring Centre for Drugs and Drug Addiction, Czech Republic; ⁶Department of Medical Chemistry and Clinical Biochemistry, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Czech Republic; ⁷Center of Interdisciplinary Addiction Research, University of Hamburg, Germany; ⁸Michigan State University, United States
- 236 *The impact of enrollment in methadone maintenance therapy on initiation of heavy drinking among people who use heroin*
J. Klimas^{1,2}, E. Wood^{1,3}, P. Nguyen¹, H. Dong¹, M-J. Milloy^{1,3}, T. Kerr^{1,3}, K. Hayashi^{1,3}. ¹British Columbia Centre for Excellence in HIV/AIDS, Canada; ²University College Dublin, Coombe Healthcare Centre, Ireland; ³University of British Columbia, Canada
- 237 *Electronic cigarette use among youth in the Russian Federation*
G. Kong¹, B. Idrisov^{2,3}, A. Galimov³, R. Masagutov³, S. Sussman⁴. ¹Yale School of Medicine, United States; ²Boston University, United States; ³Bashkir State Medical University, Russia; ⁴University of Southern California, United States
- 238 *Systematic review and meta-analysis of injecting-related injury and disease in people who inject drugs*
S. Larney¹, A. Peacock², B.M. Mathers³, L. Degenhardt¹. ¹National Drug and Alcohol Research Centre, University of New South Wales (UNSW), Australia; ²School of Medicine, University of Tasmania, Australia; ³The Kirby Institute for Infection and Immunity in Society, UNSW, Australia
- 239 *The prevalence of ketamine abuse among vocational school adolescents in Taiwan*
T.S.H. Lee¹, S-F. Tang¹, C-C. Hung². ¹Department of Health Promotion and Health Education, National Taiwan Normal University, Taiwan; ²Bali Psychiatric Hospital, Taiwan
- 240 *Risks of other substance use among kratom users: Findings from a 2011 Thailand national household survey*
S. Likhitsathian¹, A. Aramrattana^{2,3,4}, S. Assanangkornchai⁵, C. Angkurawaranon², K. Thaikla³, M. Srisurapanont¹. ¹Department of Psychiatry, Chiang Mai University, Thailand; ²Department of Family Medicine, Chiang Mai University, Thailand; ³Research Institute for Health Sciences, Chiang Mai University, Thailand; ⁴Northern Substance Abuse Center, Chiang Mai University, Thailand; ⁵Epidemiology Unit, Prince of Songkla University, Thailand
- 241 *Psychoactive substance use and sexual risk among methadone maintenance therapy clients in China*
S. Luo¹, C. Lin¹, X. Cao², L. Li¹. ¹Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, United States; ²National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, China
- 242 *The roles of depression and binge drinking in the association between crack cocaine use and urban violence in Brazil*
C.S. Madruga^{1,2}, C.A. Miguel^{1,2}, S. McPherson³, M.G. McDonell³, R. Caetano^{1,2}, R. Laranjeira^{1,2}. ¹National Institute of Alcohol and Drug Policies, Brazil; ²Federal University of São Paulo, Brazil; ³Washington State University, United States

- 243 *What works and what does not work in measures against new psychoactive substances (NPS)? Similarities and differences in changing NPS market brought by new regulatory approaches in Eastern and Central European states*
A. Malczewski¹, A. Zile-Veisberga². ¹Reitox National Focal Point, National Bureau for Drug Prevention, Poland; ²Ministry of the Interior, Latvia
- 244 *Drug abuse among street children in Dhaka City*
J.H.B. Masud. Center for Telehealth Services, Bangladesh
- 245 *Risky sexual behavior formation in the context of drug abuse: A study with Iranian women*
E. Merghati-Khoei¹, M. Jamshidimanesh², S.A. Mousavi³, A. Keramat², M.H. Emamian⁴, K. Dolan⁵. ¹Iranian National Center of Addiction Studies, Tehran University of Medical Sciences, Iran; ²Department of Reproductive Health, Shahroud University of Medical Sciences, Iran; ³Psychiatry Center for Health-Related Social and Behavioral Sciences Research, Shahroud University of Medical Sciences, Iran; ⁴Shahroud University of Medical Sciences, Iran; ⁵Program of International Research and Training, National Drug and Alcohol Research Centre, University of New South Wales, Australia
- 246 *Global positioning system technology to survey injecting drug users' movements and social interactions*
A. Mirzazadeh^{1,2}, M. Grasso¹, K. Johnson¹, A. Briceno¹, S. Navadeh^{2,3}, W. McFarland¹, K. Page⁴. ¹Department of Epidemiology and Biostatistics, University of California, San Francisco, United States; ²Regional Knowledge Hub and World Health Organization Collaborating Centre for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Iran; ³Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Iran; ⁴Department of Internal Medicine; Division of Epidemiology, Biostatistics and Preventive Medicine, University of New Mexico Health Sciences Center, United States
- 247 *Ambivalent attitudes toward drug users in Guyana: A preliminary study*
P.M. Mohamed¹, D. Renville². ¹Faculties of Social Science and Health Sciences, University of Guyana-Turkeyen Campus, Guyana; ²Faculty of Natural Sciences, Department of Mathematics, University of Guyana-Turkeyen Campus, Guyana
- 248 *Impact of HIV/HCV co-infection in middle-aged/older patients with substance use disorder*
R. Muga^{1,2}, A. Sanvisens¹, F. Bolao^{3,4}, F. Fonseca^{2,5}, P. Zuluaga^{1,2}, M. Torrens^{2,5}, D. Fuster^{1,2}, J. Tor^{1,2}. ¹Hospital Universitari Germans Trias i Pujol, Spain; ²Universitat Autònoma de Barcelona, Spain; ³Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain; ⁴Universitat de Barcelona, Spain; ⁵Parc de Salut Mar, Spain
- 249 *Are energy drinks associated with increased frequency of antisocial behaviors among those with alcohol use disorders?*
E. Ngjelina¹, K. Polak¹, A. Edwards², K. Kendler², D. Sviki¹. ¹Department of Psychology, Virginia Commonwealth University (VCU), United States; ²Psychiatry Department, VCU, United States
- 250 *Influence of awareness of HIV status on risky behavior among people who inject drugs in Ukraine*
Y. Novak, I. Sazonova. International Alliance for Public Health, Ukraine

- 251 *Psychological factors and risk perception as predictors of tobacco smoking behavior among undergraduates of University of Calabar*
U.C. Onukogu¹, U. Owoidoho², J.B. Okegbe¹, C.A. Anya³, E.E. Ekpe¹, B. Edet¹. ¹Federal Neuro Psychiatric Hospital-Calabar, Nigeria; ²University of Calabar, Nigeria; ³Federal University Guso, Nigeria
- 252 *High prevalence of physical and sexual abuse among socially vulnerable women crack users in Brazil*
F. Ornell, J.N. Scherer, S. Halpern, J. Narvaez, V.S. Roglio, F. Pechansky, F.H.P. Kessler, L. von Diemen. Collaborating Center on Alcohol and Drugs, Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil
- 253 *Crack cocaine users with high family/social problems show more psychiatric symptoms and violent behavior*
M.P. Pachado^{1,2}, J.N. Scherer¹, N. Marchi¹, R.M.M. De Almeida², F. Pechansky¹, F.H.P. Kessler¹. ¹Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul (UFRGS), Brazil. ²Psychology Institute, UFRGS, Brazil
- 254 *Cocaine use in trauma patients admitted to intensive care medicine: Clinical and epidemiological characterization.*
A. Pascale¹, F. Verga², J. Gil³, A França², I. Alvez², E. Echavarría², H. Bagnulo². ¹Red Latinoamericana de Investigadores en Drogas Network (REDLA), Uruguay; ²Intensive Care Unit, Hospital Maciel, Montevideo, Uruguay; ³Statistics Department, Hospital de Clínicas, Montevideo, Uruguay
- 255 *Gender differences in drug dependence, anxiety, and depressive symptoms among residents of therapeutic communities in Peru*
M. Piazza^{1,2}, D. Blitchtein-Winicki^{1,2}, C. Gómez Restrepo³. ¹Universidad Peruana Cayetano Heredia, Peru; ²National Institute of Health, Peru; ³Pontificia Universidad Javeriana, Colombia
- 256 *Potential opioid misuse in the social security health care system of Peru, January 2014 to March 2015*
J. Ponce¹, F. Fiestas², V. Dongo², K. Hoffman¹, D. McCarty³. ¹International Center for Advanced Research and Applied Science, Perú; ²Seguro Social de Salud, Perú; ³Oregon Health & Science University, United States
- 257 *First experience of medication-assisted therapy provision by family physicians in Ukraine*
I. Pykalo¹, O. Morozova², S. Dvoryak¹. ¹Ukrainian Institute on Public Health Policy, Ukraine; ²Yale School of Public Health, United States
- 258 *Methamphetamine use among Iranian patients in methadone maintenance treatment: Is this a threat?*
S.R. Radfar¹, U.S. Warda², R. Rawson². ¹Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Iran; ²Integrated Substance Abuse Programs, University of California, Los Angeles, United States
- 259 *Drug use, economic vulnerability, and experiences of sexual violence among female sex workers in Tijuana, Mexico*
E. Reed¹, J.G. Silverman¹, B.S. West¹, M. Salazar¹, M.G.R. Gómez^{2,3}, K.C. Brouwer¹. ¹University of California, San Diego; United States; ²U.S.–Mexico Border Health Commission, Mexico; ³El Colegio de la Frontera Norte, Mexico

- 260 *Characteristics and pharmacological treatment of patients with severe cannabis use disorder in Badalona, Spain*
I. Rivas¹, A. Sanvisens², M. Rodriguez³, D. Fuster², P. Caballería³, R. Muga². ¹Municipal Center for Substance Abuse Treatment, Institut Municipal De Serveis Personals, Spain; ²Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Spain; ³Management of Pharmacy, Metropolitan Areas of Health Regions Barcelona, Catalan Health Service, Spain
- 261 *Health impacts of kratom (*Mitragyna speciosa* Korth) use in Thailand*
D. Saingam, S. Assanangkornchai, A.F. Geater. Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Thailand
- 262 *Factors associated with hepatitis C among people who inject drugs in Ukraine*
T. Saliuk, Y. Sazonova. Alliance for Public Health, Ukraine
- 263 *High prevalence of driving under the influence, and legal and psychiatric problems, among crack cocaine drivers*
J.N. Scherer, R. Silvestrin, F. Ornell, T.R.V. Sousa, L. Von Diemen, F.H.P. Kessler, F. Pechansky. Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil
- 264 *High prevalence of suicide risk and brain-derived neurotrophic factor serum levels in crack cocaine users during early abstinence*
L. Schwanck, J. Scherer, F. Ornell, R. Silvestrin, J. Narvaez, F. Kessler, F. Pechansky, L. Von Diemen. Center for Drug and Alcohol Research, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil
- 265 *Correlates of needle sharing in Iranian drug-injecting dyads: The results of cross-classified modeling of personal networks*
A. Shahesmaeili^{1,2}, A.A. Haghdoust², H. Soori³. ¹Regional Knowledge Hub and World Health Organization Collaborating Centre for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Iran; ²Epidemiology Department, School of Public Health, Shahid Beheshti University of Medical Sciences, Iran; ³Safety Promotion and Injury Prevention, School of Public Health, Shahid Beheshti University of Medical Sciences, Iran
- 266 *Pattern of uterus bleeding in methamphetamine users differs from heroin users during long-term abstinence*
W. Shen, Y. Zhang, L. Li, W. Zhou. Ningbo Addiction Research and Treatment Center, China
- 267 *Smokeless tobacco used as traditional medicine during pregnancy contributes to habituation in Southeast Asia*
P.N. Singh¹, D. Yel², T. Rathavy³, S. Vong³, K. Somsamouth⁴, R. Paulino¹, S. Tonstad¹, J.S. Job¹. ¹Center for Health Research, Loma Linda University, United States; ²World Health Organization, Cambodia; ³National Center for Maternal and Child Health, Ministry of Health, Cambodia; ⁴Ministry of Health, Laos
- 268 *Predictors of hepatitis C virus/human immunodeficiency virus/sexually transmitted diseases among drug users in Rio de Janeiro, Brazil*
P. Telles-Dias. Nucleus of Study and Research on Drug Use, State University of Rio de Janeiro, Brazil; Epidemiology Department, Federal Fluminense University, Brazil

- 269 *Relationship of determinants for risk behavior and the use of new psychoactive substances*
A. Vreeker¹, B.G. van der Burg¹, M. van Laar¹, T.M. Brunt^{1,2}. ¹Netherlands Institute of Mental Health and Addiction (Trimbos Institute), Drug Information and Monitoring System, Department of Drug Monitoring, The Netherlands; ²Department of Psychiatry, Academic Medical Centre, University of Amsterdam, The Netherlands
- 270 *Characteristics of community heroin users in Taiwan: A social network approach*
S-C. Wang^{1,2}, N.Y. Wang¹, T-T. Ting³. ¹Center for Neuropsychiatric Research, National Health Research Institutes, Taiwan; ²Department of Psychiatry, Far Eastern Memorial Hospital, Taiwan; ³Institute of Sociology, Academia Sinica, Taiwan
- 271 *Delay discounting among smokers, e-cigarette users, and nondependent controls*
S. Weidberg, A. González-Roz, V. Martínez-Loredo, C. López-Núñez, I. Pericot-Valverde, R. Secades-Villa. Department of Psychology, University of Oviedo, Spain
- 272 *Effects of synthetic cannabinoids on executive function in regular users in Israel and Hungary*
A. Weinstein¹, K. Cohen^{1,2}, P. Rosca³, Z. Demetrovics². ¹Department of Behavioral Science, Ariel University, Israel; ²Institute of Psychology, Eötvös Loránd University, Hungary; ³Department for the Treatment of Substance Abuse, Ministry of Health, Israel
- 273 *Systematic literature review on synthetic cathinone ("bath salts") use and HIV risk and transmission*
A.V. Williams¹, F. Hariga². ¹King's College London, Addictions Department, Institute of Psychiatry, Psychology and Neuroscience, United Kingdom; ²United Nations Office on Drugs and Crime, Austria
- 274 *What is the relationship between selected sociodemographic variables, knowledge of consequences, and drug consumption at a faith-based university in Jamaica?*
F. Williams. Interdisciplinary Department, Lakehead University-Orillia Campus, Canada
- 275 *Implementing a large multisite experimental study in Ukraine*
O. Zeziulin¹, K. Dumchev¹, O. Denisyuk², S. Dvoriak¹, T. Kiryazova¹, Y. Sereda¹, P. Smyrnov². ¹Ukrainian Institute on Public Health Policy, Ukraine; ²Alliance for Public Health, Ukraine
- 276 *Gender differences and correlated factors of heroin use among heroin users in China*
X. Zhou¹, Z. Yi¹, X. Yang¹, Z. Wang¹, X. Lyu², J. Li¹. ¹Department of Psychiatry, West China Hospital, Sichuan University, China; ²National Surveillance Center on Drug Abuse, China

Other

- 300 *The Khat Research Program (KRP): Progress and achievements*
M. al'Absi. University of Minnesota Medical School, United States
- 301 *Global developments in professional development: Engagement with free online course, "Management of Addiction," by University of Adelaide*
F. Buisman-Pijlman¹, L. Gowing^{1,2}, A. Salem¹, R. Ali^{1,2}. ¹Discipline of Pharmacology, School of Medicine, University of Adelaide, Australia; ²Drug and Alcohol Services South Australia, World Health Organization Collaborative Centre, Australia
- 302 *Review of the evaluation processes for the International Programme in Addiction Studies*
A. Coetzer-Liversage¹, M. Loos², L. Cathers², F. Buisman-Pijlman³, A. Williams⁴. ¹Hubert H. Humphrey Fellowship, Virginia Commonwealth University, United States; ²Virginia Commonwealth University, United States; ³University of Adelaide, Australia; ⁴Kings College London, United Kingdom

- 303 *The Hubert H. Humphrey Fellowship Program at Virginia Commonwealth University*
J.R. Koch, R.L. Balster, A. Breland, L.D. Hedges. Virginia Commonwealth University, United States
- 304 *Enhancing forensic investigations of narcotic drugs and suspected murder cases in Sierra Leone*
J. Lahai. Criminal Investigations Department, Sierra Leone Police Force, Sierra Leone; Hubert H. Humphrey Fellowship, Virginia Commonwealth University, United States
- 305 *The Virginia Commonwealth University Hubert H. Humphrey Fellowship in Substance Abuse Prevention, Treatment, and Policy: One-year follow-up*
O. Leonchuk¹, J.R. Koch², R.L. Balster², A. Breland². ¹North Carolina State University, United States; ²Virginia Commonwealth University, United States
- 306 *Quarter century of drug decriminalization in the Czech Republic: Tremendous success, pathetic failure?*
T. Zabransky^{1,2}, J. Radimecky^{2,3}. ¹ResAD Institute, Czech Republic; ²Charles University in Prague, First Medical Faculty, Clinic of Addictology, Czech Republic; ³White Light Non-Governmental Organization, Czech Republic

Prevention

- 400 *Impact of "class smoke-free" pledge on nicotine dependence in male adolescents: A cluster randomized controlled trial*
N.A. Al-sheyab¹, M.A. Alomari¹, S. Shah², R. Gallagher². ¹Jordan University of Science and Technology, Jordan; ²The University of Sydney, Australia
- 401 *Knowledge of smoking in university to prevent students' tobacco consumption*
F. Bautista-Pérez. Universidad Evangélica de El Salvador, El Salvador
- 402 *Hepatitis C and HIV in injecting drug users in Armenia, Colombia*
D. Berbesi-Fernández, Á. Segura-Cardona, L. Montoya-Vélez, G. Castaño. CES University, Colombia
- 403 *Influence of cannabis perceptions on consumption behaviors among users in Togo*
M. Bohm^{1,2}, N. Djassoa³, K. Gbati³, K. Dassa⁴. ¹Comité National Anti-Drogue, Togo; ²Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; ³Institut National des Sciences de l'Éducation, Filière de Psychologie Appliquée, Université de Lomé, Togo; ⁴Université de Lomé, Togo
- 404 *The specific needs of female heroin users in Taiwan: Using quantitative and qualitative approaches*
Y-L. Chien^{1,2}, W-L. Huang^{1,3}, S-T. Lee³. ¹Department of Psychiatry, National Taiwan University Hospital, Taiwan; ²Department of Psychiatry, University of California, San Francisco, United States; ³Department of Psychiatry, National Taiwan University Hospital Yunlin Branch, Taiwan
- 405 *Outreach case management and community support for improved treatment uptake in HIV-positive people who are injectable drug users in Ukraine*
O. Denisiuk, P. Smyrnov, A. Tyshkevych. ICF Alliance for Public Health, Ukraine
- 406 *Substance use and sexual risk for HIV among women in Russia*
D. Diakonova-Curtis¹, A. Shaboltas¹, T. Balachova². ¹Department of Psychology, St. Petersburg State University, Russia; ²Department of Pediatrics, University of Oklahoma Health Sciences Center, United States

- 407 *A novel family-based motivational interviewing approach in reducing/eliminating drug abuse: A focus on individuals from Mexican descent*
A. Diallo. University of Texas-Rio Grande Valley, United States
- 408 *Egyptian Humphrey Fellows' initiative to train dentistry students on screening, brief intervention, and referral to treatment model*
W. Hassan^{1,2}, A.H. Elrasheed^{1,2}, M. Elhamshary^{2,3}. ¹Institute of Psychiatry, Ain Shams University, Egypt; ²Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States; ³Psychological Medicine Hospital, Egypt
- 409 *Food insecurity and HIV progression among Russians with heavy alcohol consumption*
B. Idrisov^{1,2}, K. Lunze², D.M. Cheng², E. Blokhina³, N. Gnatenko², G. Patts², C. Briden², C.E. Chaisson², S.D. Weiser⁴, E. Krupitsky³, J.H. Samet². ¹Bashkir State Medical University, Russia; ²Boston University, United States; ³First St. Petersburg Pavlov State Medical University, Russia; ⁴School of Medicine, University of California, San Francisco, United States
- 410 *Feasibility of a multimedia family-based intervention for prevention of drug use among at-risk adolescents in Central Asia*
L. Ismayilova¹, A. Terlikbayeva², Y. Rozental², E. Gaveras¹. ¹University of Chicago, United States; ²Global Health Research Center of Central Asia, Kazakhstan
- 411 *Immediate trauma response as a tool to prevent substance abuse among traumatized children*
L. Juríčková. Four Leaf NGO, Slovakia; Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
- 412 *Social connections among women who use drugs in the aftermath of child loss to Child Protective Services*
K.S. Kenny¹, C. Barrington². ¹Department of Maternal and Child Health, The Gillings School of Global Public Health, University of North Carolina (UNC) at Chapel Hill, United States; ²Department of Health Behavior, The Gillings School of Global Public Health, UNC at Chapel Hill, United States
- 413 *History of injecting drugs mediates effect of project START intervention on sex behavior of males released from prison in Ukraine*
T. Kiriazova¹, Y. Sereda², O. Neduzhko¹, O. Postnov¹, S. Dvoriak¹. ¹Ukrainian Institute on Public Health Policy, Ukraine; ²Institute for Social Research After Olexander Yaremenko, Ukraine
- 414 *HIV antiretroviral drugs for recreational substance use and implications for HIV pre-exposure prophylaxis in South Africa*
C. Kuo^{1,2,3}, D. Operario^{1,2}, J. Hoare³, K. Underhill⁴, D. Giovenco¹, L. Brown^{2,5}. ¹Department of Behavioral and Social Sciences, Center for Alcohol and Addiction Studies, School of Public Health, Brown University, United States; ²Lifespan/Tufts/Brown Center for AIDS Research, United States; ³Department of Psychiatry and Mental Health, University of Cape Town, South Africa; ⁴Center for Interdisciplinary Research on AIDS, Yale University, and Yale Law School, United States; ⁵Department of Psychiatry and Mental Health, Alpert Medical School, Brown University, United States
- 415 *Assessing commune health workers' knowledge of methadone maintenance therapy in Vietnam*
C. Lin¹, N.A. Tuan², L. Li¹. ¹Semel Institute for Neuroscience and Human Behavior, Center for Community Health, University of California, Los Angeles, United States; ²National Institute of Hygiene and Epidemiology, Vietnam

- 416 *Intimate violence partner, alcohol, and drugs in Uruguay*
R. Magri. Hospital Pereira Rossell, Uruguay
- 417 *Playing with fire: Nonmedical pharmaceutical opioid use among young people in Sydney, Australia*
L. Maher, G. Dertadian. The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Australia
- 418 *Translating and adapting efficacious prevention interventions in partnership with Latin American collaborators*
F.F. Marsiglia, S. Kulis. Arizona State University, United States
- 420 *Evaluation of a brief intervention based on motivational interviewing in Colombia*
J. Mejia-Trujillo. Corporacion Nuevos Rumbos, Colombia
- 421 *Index of HIV policy environments regarding people who inject drugs across the European region*
P. Meylakhs. Laboratory for Comparative Social Research, National Research University Higher School of Economics, Russia
- 422 *HPTN 074: Density-based analysis to identify spatial aggregation of eligible people who inject drugs in Jakarta*
M. Muslim^{1,2}, H. Susami^{1,3}, Z. Djoerban^{1,3}, S. Djauzi^{1,3}, R. Sarasvita^{1,3}, D. Imran¹, S. Suyitno¹, S. Rose⁴, D. Metzger^{5,6}. ¹HPTN 074 Indonesia Site, Cipto Mangunkusumo Hospital, Indonesia; ²Climate Change Research Center, University of Technology-Sumbawa, Indonesia; ³Abhipraya Foundation, Indonesia; ⁴FHI 360 International, United States; ⁵University of Pennsylvania, United States; ⁶The Treatment Research Institute, United States
- 423 *A geospatial approach for participant recruitment of HPTN 074 study in Jakarta, Indonesia*
M. Muslim¹, H. Susami^{*1}, Z. Djoerban¹, S. Djauzi¹, R. Sarasvita¹, D. Imran¹, T. Hadi¹, S. Rose², D. Metzger^{3,4}. ¹HPTN 074 Indonesia Site, Cipto Mangunkusumo Hospital, Indonesia; ²FHI 360 International, United States; ³University of Pennsylvania, United States; ⁴The Treatment Research Institute, United States
- 424 *Alcohol marketing and early alcohol use among young people: An exploratory study in Uganda*
R. Mutaawe. Uganda Youth Development Link, Uganda; Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
- 425 *Mobile society and drug use associated with transmission of HIV/AIDS among women and girls in Burma (Myanmar)*
R. Myint¹, L.A. Swe². ¹Myanmar Anti-Narcotics Association, Burma (Myanmar); ²Community-Based Self-Help Group, Burma (Myanmar)
- 426 *Prevalence of substance use and psychological problems among adolescents: A community survey*
F. Naveed. Drug Free Pakistan Foundation, Pakistan
- 427 *Motivations and reasons for drug use in Armenia*
S.R. Nazinyan¹, A.A. Bazarchyan¹, A.I. Hovhanisyan², A.H. Karamyan¹, M.R. Kostandyan¹. ¹National Institute of Health After S. Avdalbekyan, Ministry of Health, Armenia; ²Ministry of Justice, Armenia
- 428 *Training of village health teams in community-based integration of prevention measures of substance use among youth and women in West Nile region of Uganda*
R. Nerima. WellShare International, Uganda

- 429 *Community pharmacists' knowledge, attitudes, and confidence regarding naloxone for overdose reversal*
S. Nielsen^{1,2}, N. Menon¹, S. Larney¹, M. Farrell¹, L. Degenhardt¹. ¹National Drug and Alcohol Research Centre, University of New South Wales, Australia; ²South Eastern Sydney Local Health District Drug and Alcohol Services, Australia
- 430 *Policing, massive street drug testing, and polysubstance use chaos in Georgia: A policy case study*
D. Otiashvili¹, M. Tabatadze^{1,2}, N. Balanchivadze³, I. Kirtadze^{1,2}. ¹Addiction Research Centre–Alternative Georgia, Georgia; ²Business School, Ilia State University, Georgia; ³National Centre for Commercial Law, Free University, Georgia
- 431 *Personality profile of adolescents with substance use disorders*
R. Racheva. Department of Psychology, Bulgarian Academy of Sciences, Bulgaria
- 432 *Risk and protective factors for recreational and hard drug use among adolescents and emerging adults in Malaysia*
M. Razali¹, W. Kliewer². ¹Sultan Idris Education University, Malaysia; ²Virginia Commonwealth University, United States
- 433 *Quit Using Drugs Intervention Trial: A brief intervention for risky drug use among federally qualified health centers in East Los Angeles*
M. Rico¹, L. Gelberg¹, R.M. Andersen¹, M. Vahidi¹, S. Baumeister², B. Leake¹. ¹Department of Family Medicine, University of California, Los Angeles, United States; ²University of Regensburg, Germany
- 434 *Evaluation of CHOICE-8 effect on girls and boys, who took part in the substance abuse prevention program*
V. Ryabukha. Prevention Center “Choice,” Ukraine
- 435 *Family members affected by a relative's substance misuse looking for social support: Who are they?*
H.M.T. Sakiyama^{1,2}, M. de Fatima Rato Padin^{1,2}, M. Canfield³, R. Laranjeira^{1,2}, S.S. Mitsuhiro^{1,2}. ¹National Institute of Public Policy for Alcohol and Other Drugs, Brazil; ²Federal University of São Paulo, Brazil; ³University of Roehampton, United Kingdom
- 436 *Substance use among female sex workers in two U.S.–Mexico border cities: Associations with age of entry*
M. Salazar, K. Brouwer, S. Boyce, J. Silverman. Division of Global Public Health, University of California, San Diego, United States
- 437 *HIV trends among people who inject drugs in the biggest cities of Ukraine*
I. Sazonova, Y. Novak, T. Saluik. ICF Alliance for Public Health, Ukraine
- 438 *Motherhood, substance abuse, and HIV risk among sex workers in the U.S.–Mexico border region: Implications for interventions*
A.E. Servin-Aguirre^{1,2}, E. Reed², J.G. Silverman², C. Magis-Rodriguez³, S. Boyce², S.A. Strathdee², K.C. Brouwer². ¹School of Medicine, Universidad Xochicalco, Campus Tijuana, Mexico; ²Division of Global Public Health, School of Medicine, University of California, San Diego, United States; ³Centro Nacional para la Prevención y el Control del VIH/SIDA, Mexico

- 439 *A critical analysis of the falling age of initiation among adolescent injecting drug users and the programmatic response in Manipur, India*
K. Shimray¹, P. Batsen². ¹National Health Mission, India; ²Royal Tropical Institute (KIT), The Netherlands
- 440 *Cigarette gifting between Chinese smokers and nonsmokers*
J. Tang^{1,2}, Y. Liao^{1,2}. ¹Mental Health Institute, the Second Xiangya Hospital of Central South University, China; ²Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, United States

Treatment

- 500 *Use of marijuana among former opioid substitution treatment clients in Nepal*
S.L. Acharya¹, J. Howard^{2,3}, R. Shrestha⁴, K. Lama⁴, S. Paudel⁵. ¹Master's Program, Tribhuvan University, Nepal; ²National Cannabis Prevention and Information Centre, University of New South Wales (UNSW), Australia; ³National Drugs and Alcohol Research Centre, UNSW, Australia; ⁴Saarathi Nepal Non-Governmental Organization, Nepal; ⁵HIV and Human Rights Consultant, Nepal
- 501 *Improvements in general health and methamphetamine use treatment: A study of the efficacy of cognitive-behavioral therapy*
Z. Alam-Mehrjerdi¹, P. Clare², N. Ezard³, K. Dolan¹. ¹Program of International Research and Training, Faculty of Public Health and Community Medicine, National Drug and Alcohol Research Centre (NDARC), University of New South Wales (UNSW), Australia; ²Faculty of Public Health and Community Medicine, NDARC, UNSW, Australia; ³Alcohol and Drug Service, St. Vincent's Hospital, Australia
- 502 *The creation of a female-friendly women's drug treatment and rehabilitation center in Pakistan*
A. Ashraf. Sunny Trust International, Addiction Treatment and Rehabilitation Center, Pakistan; Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
- 503 *Accessibility of harm reduction services at drop-in centers in Burma (Myanmar)*
T.M. Aung, Z.N. Soe. John Snow Inc., Burma (Myanmar)
- 504 *Addiction medicine course for medical residents at the National Institute of Neurology and Neurosurgery in Mexico City*
M. Azcarraga. National Institute of Neurology and Neurosurgery, Mexico; Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
- 505 *Emerging substance use patterns among children in India*
S. Bhattacharjee¹, R. Kumar¹, A. Agrawal², K.E. O'Grady³, H.E. Jones⁴. ¹Society for Promotion of Youth and Masses, India; ²National Drug Dependency Treatment Centre, All India Institute of Medical Sciences, India; ³University of Maryland-College Park, United States; ⁴University of North Carolina, United States
- 506 *Feasibility and acceptability of a Short Message Service (SMS) smoking cessation program for young adults in Lima: Pilot study results*
D. Blitchtein-Winicki¹, K. Zevallos¹, R. Samolski, D. Requena¹, Ch. Velarde¹, M. Ybarra³, J.C. Anthony². ¹Universidad Peruana Cayetano Heredia, Peru; ²Department of Epidemiology, Michigan State University, United States; ³Center for Innovative Public Health Research, United States

- 507 *The role of genetic polymorphisms on patient response to opioid use disorder therapy with naltrexone and guanfacine*
E. Blokhina¹, E. Krupitsky^{1,2}, A. Kibitov³, E. Verbitskaya¹, V. Brodyansky³, V. Palatkin¹, T. Kosten⁴, D. Nielsen⁴, E. Zvartau¹. ¹First Pavlov State Medical University of St. Petersburg, Russia; ²Bekhterev Research Psychoneurological Institute, Russia; ³Serbsky Federal Medical Research Centre of Psychiatry and Narcology, Russia; ⁴Baylor College of Medicine, United States
- 508 *In-house outreach: Strategies to promote and advertise a smoking cessation program in a Mexican university hospital*
O. Campollo^{1,2}, O.P. Torres¹. ¹Center of Alcoholism and Addictions, University of Guadalajara, Mexico; ²Molecular Biology Department, Hospital Civil de Guadalajara "Fray Antonio Alcalde," Mexico
- 509 *Effects of eye movement desensitization and reprocessing on reducing craving and anxiety: A randomized trial*
J. Chen¹, L. Yang¹, D. Yan^{1,2}, S. Teng¹, J. Cao^{1,2}, Y. Zhao¹, Z. Wang^{1,2}. ¹Department of Epidemiology and Health Statistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, China; ²Mental Health Center, Tongji Medical College, Huazhong University of Science and Technology, China
- 510 *Screening, brief intervention, and referral to treatment implementation in primary care centers in Brazil: Successful initiative beyond drug issues*
F. de Conto, R. de Cerqueira Campos. Florianopolis Department of Mental Health and Primary Care, Brazil
- 511 *Treatment retention and adherence in an integrated treatment program for opiate addiction and HIV in Ho Chi Minh City, Vietnam*
C. Denis¹, D. Metzger¹, L. Huang², V. Trias², M. Auriacombe^{1,3}, A. Voisin⁴, T. Doan², H. Tran², L. Nguyen², G. Raguin², S. Mai Thi Hoai⁵, G. Le Truong⁵, J-P. Daulouède^{2,3,4}, C. O'Brien¹. ¹Center for Studies of Addiction, University of Pennsylvania, United States; ²Expertise France, France; ³CNRS USR 3413 SANPsy, University of Bordeaux, France; ⁴Bizia Addiction Clinic, France; ⁵HCMC AIDS Committee, Vietnam
- 512 *Addiction treatment human resources and training needs during Vietnam's rapid scale-up of methadone treatment*
N.B. Diep¹, N.T. Trang¹, N.T.M. Tam², P.Q. Loc¹, S. Larkins³, L.M. Giang¹. ¹Hanoi Medical University, Vietnam; ²Vietnam Administration of HIV/AIDS Control, Vietnam; ³University of Los Angeles, California, United States
- 513 *Time variant dynamic top-down regulation in fronto-amygdalar network during drug cue exposure in heroin dependents*
H. Ekhtiari^{1,2,3}, A.Z. Sadeghi², A. Shahbabei^{1,3}, M.A. Oghabian². ¹Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Iran; ²Neuroimaging and Analysis Group, Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Iran; ³Translational Neuroscience Program, Institute for Cognitive Science Studies, Iran

- 514 *Methylphenidate substitution for methamphetamine addiction and implications for future randomized clinical trials: A case series*
R. Gabrhelík¹, J. Minařík¹, R. Malcolm², A. Pavlovská¹, P. Miller². ¹Department of Addictology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Czech Republic; ²Department of Psychiatry and Behavioral Sciences, Addiction Sciences Division, Medical University of South Carolina, United States
- 515 *Histopathological alterations in liver structures of cocaine-addicted rats fed a nutritionally supplemented rat diet*
N. Gardner¹, A. Wheatley¹, B. Hanchard², T. Gibson², W. De La Haye³, K. Luke⁴, P. Bahadosingh⁴, L. Dilworth², A. Salako⁵, H. Lowe⁶, H. Asemota^{1,4}. ¹Biotechnology Centre, University of the West Indies-Mona Campus, Jamaica; ²Department of Pathology, University of the West Indies-Mona Campus, Jamaica; ³Department of Community Health and Psychiatry, University of the West Indies-Mona Campus, Jamaica; ⁴Department of Basic Medical Sciences, University of the West Indies-Mona Campus, Jamaica; ⁵Awele Foundation International, United States; ⁶Environmental Health Foundation, Jamaica
- 516 *Informing drug treatment development through science: International standards on the treatment of drug use disorders*
G. Gerra¹, V. Poznyak², E. Sáenz¹, A. Busse¹, N. Clark². ¹United Nations Office on Drugs and Crime, Italy; ²World Health Organization, Switzerland
- 517 *Executive functioning and outpatient treatment adherence after intensive inpatient care for cocaine dependence: A 6-month follow-up study*
P.D. Gonçalves^{1,2}, M. Ometto¹, A. Malbergier¹, P.A. Martins¹, L. Beraldo¹, B. dos Santos¹, S. Nicastri¹, A.G. Andrade¹, P.J. Cunha¹. ¹Institute of Psychiatry, School of Medicine, University of São Paulo, Brazil; ²University of California, San Diego, United States
- 518 *Assessment of cognitive functions in tramadol-dependent patients: A case control study*
S. Hassaan, A. Darwish, H. Khalifa, S. Mostafa. Department of Psychiatry, Assiut University, Egypt
- 519 *A summary of addiction services in a Canadian city: Results from an Internet-based scoping study*
E. Knight. St. Paul's Hospital Goldcorp Addiction Medicine Fellowship, BC Centre for Excellence in HIV/AIDS, Canada
- 520 *Pregabalin for opioid detoxification: Interim results*
E.M. Krupitsky¹, R.D. Ilyuk¹, A.D. Mikhailov¹, K.A. Kazankov², K.V. Rybakova¹, O.G. Grishina¹, I.A. Zaplatkin¹, D.D. Langleben³, G. Woody³. ¹St. Petersburg Bekhterev Psychoneurological Institute, Russia; ²Murmansk Regional Addiction Hospital, Russia; ³School of Medicine, University of Pennsylvania, United States
- 521 *Extended-release Naltrexone for discontinuation of opioid maintenance treatment: A randomized prospective study*
N. Kunøe¹, K.K. Solli^{1,2}, A. Opheim³, L. Tanum^{1,2}. ¹Norwegian Centre for Addiction Research, University of Oslo, Norway; ²Vestfold Hospital Trust, Norway; ³Haukeland University Hospital, Norway; ³Akershus University Hospital, Norway
- 522 *Relationship between anger and psychoactive substance use: A systematic review*
H.V. Laitano, F.H.P. Kessler, T.C. Hartmann, P.T. Souza Filho, A. Ely. Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil

- 523 *Adherence to methadone maintenance treatment protocol among service providers in China*
C-W. Lan¹, C. Lin¹, X. Cao², L. Li¹. ¹Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, United States; ²National Center for AIDS/STD Control and Prevention, Chinese Centers for Disease Control and Prevention, China
- 524 *Comparing psychiatric symptoms in subjects with chronic ketamine use and methamphetamine use*
Y. Liao^{1,2}, J. Tang^{1,2}, C. Qi¹, Q. Wu¹. ¹Mental Health Institute, the Second Xiangya Hospital of Central South University, China; ²Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, United States
- 525 *How synthetic cannabinoid users differ from intravenous drug users in their attitudes toward Narcotics Anonymous in Russia*
B. Lobodov¹, L. Rod², E. Chernyckii², P. Strogonov². ¹Medical Center "Semya," Russia; ²Voronezh State Regional Narcological Dispensary, Russia
- 526 *Impulsivity, sensation seeking, and substance use among adolescents: A longitudinal research study*
C. López-Núñez, V. Martínez Loredó, S. Fernández-Artamendi, J.R. Fernández-Hermida, I. Pericot-Valverde, S. Weidberg, R. Secades-Villa. University of Oviedo, Spain
- 527 *Child protection experts' initiatives in Tehran for treatment of street children with substance use disorder*
M. Maarefvand¹, R. Daneshmand¹, S. Shariati-Rad^{1,2}, A. Noroozi¹, O. Massah¹, E. Salari¹, H. Bahari¹, N. Habibi¹, N. Dodangi¹, M. Sadeghi¹, M. Firoozhoohi¹, R. Radfar¹, L. Lundgren³, A. Farhoudian¹. ¹Substance Abuse and Dependence Research Center, University of Social Welfare and Rehabilitation Sciences, Iran; ²Students Research Center of International Campus, Tehran University of Medical Sciences, Iran; ³Center for Addictions Research and Services, School of Social Work, Boston University, United States
- 528 *Correlates of lifetime addiction treatment experience among people who inject drugs in four Ukrainian cities*
A. Mazhnaya¹, S.D. Phillips², O. Filippova³, R. Aleksanyan⁴, T. Zub³, P. Alpatova³, J. Owczarzak⁵. ¹ICF Alliance for Public Health, Ukraine; ²Department of Anthropology, Indiana University, United States; ³Department of Sociology, V.N. Karazin Kharkiv National University, Ukraine; ⁴Center for AIDS Intervention Research, Medical College of Wisconsin, United States; ⁵Department of Health, Behavior, and Society, School of Public Health, Johns Hopkins University, United States
- 529 *Publications related to methadone maintenance treatment in China, 2005–2014: A bibliometric analysis*
X. Mei¹, W. Zhou², X. Tan¹, P. Liu², L. Luo², C. Liu², M. Chawarski³. ¹School of Public Health, Wuhan University, China; ²Wuhan Centers for Disease Prevention and Control, China; ³Yale School of Medicine, United States
- 530 *Demographic, temporal, and geographical features of suspected opiate overdoses attended by the London Ambulance Service, 2005–2007*
I. Miftari. Insight Advantage Inc., Canada

- 531 *Improving the lives of children who use drugs in Afghanistan*
A.S. Momand¹, E. Mattfeld², G. Gerra², B. Moralis³, T. Brown³, K. O'Grady⁴, H.E. Jones⁵.
¹United Nations Office on Drugs and Crime (UNODC), Afghanistan; ²UNODC, Austria;
³Bureau of International Narcotics and Law Enforcement, U.S. Department of State, United States; ⁴Department of Psychology, University of Maryland-College Park, United States;
⁵University of North Carolina (UNC) Horizons, Department of Obstetrics and Gynecology, UNC at Chapel Hill, United States
- 532 *Nicotine dependence as a mediator of Project EX's effects to reduce tobacco use in high-risk youth*
A. Morales, M.T. González, M. Orgilés, J.P. Espada. Miguel Hernández University, Spain
- 533 *"Not on the agenda": A qualitative study of health services' use among poor young women who use drugs in Cape Town, South Africa*
B. Myers¹, T. Carney¹, W.M. Wechsberg². ¹Alcohol, Tobacco and Other Research Unit, South African Medical Research Council, South Africa; ²RTI International, United States
- 534 *Retraumatization: Sexual abuse, post-traumatic stress disorder, and sexual risk behavior among club drug users*
J.C.M. Narvaez¹, L. Remy¹, J. Scherer¹, F. Ornell¹, R. Silvestrin¹, H. Surratt², S. Kurtz², F. Pechansky¹. ¹Collaborating Center on Alcohol and Drugs, Center for Drug and Alcohol Research, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Brazil; ²Center for Drug and Alcohol Research, Nova Southeastern University, United States
- 535 *A stepped-wedge cluster randomized trial of behavioral interventions targeting amphetamine-type stimulant use and sexual risk among female entertainment and sex workers in Cambodia: Design of implementation science protocol*
K. Page¹, E.S. Stein², A.W. Carrico³, J.L. Evans², M. Sokunny⁴, E. Nil⁴, S. Ngak⁴, C. Sophal⁵, C. McCulloch², L. Maher⁶. ¹Division of Epidemiology, Biostatistics and Preventive Medicine, Department of Internal Medicine, University of New Mexico Health Sciences Center, United States; ²Department of Epidemiology and Biostatistics, University of California, San Francisco, United States; ³Department of Community Health Systems, School of Nursing, University of California, San Francisco, United States; ⁴FHI360 Cambodia, Cambodia; ⁵Department of Mental Health and Substance Abuse, Ministry of Health, Cambodia; ⁶The Kirby Institute for Infection and Immunity, University of New South Wales, Australia
- 536 *Codeine misuse/dependence: Best practice and future innovations in addressing risk, harm, and successful treatment*
C.D.H. Parry¹, M.C. van Hout², I. Norman³. ¹Alcohol, Tobacco, and Other Drug Research Unit, Medical Research Council, South Africa; ²School of Health Sciences, Waterford Institute of Technology, Ireland; ³Florence Nightingale Faculty of Nursing and Midwifery, Kings College London, United Kingdom
- 537 *Validation of a purchase task for assessing the relative reinforcing efficacy of e-cigarettes*
I. Pericot-Valverde, S. Fernández-Artamendi, A. González-Roz, C. López-Núñez, S. Weidberg, R. Secades-Villa. University of Oviedo, Spain
- 538 *What does addiction mean? A qualitative study to assess patients' understanding about addiction and its treatment*
S. Prakash, R. Rao, P. Ramshankar, V. Krishnan, A. Ambekar, A. Dhawan. National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, India

- 539 *Retention and drop out of opioid substitution therapy program due to drug diversion in Ukraine*
T. Prokhorova, V.P. Kolomiets. ICF Alliance for Public Health, Ukraine
- 540 *Detoxification unit within a residential substance abuse treatment facility: A gateway to better outcomes?*
S. Rabinovitz. School of Criminology, Unit for Excellence in Research & Study of Addiction, University of Haifa, Israel
- 541 *Quality of life in patients attending substance abuse treatment: A study in Songkhla Province, Thailand*
P. Rattanakornpreeda, S. Paileeklee. Khon Kaen University, Thailand
- 542 *Preliminary findings: Suicidal ideation among crack cocaine-dependent patients receiving treatment in São Paulo, Brazil's "Crackland" and its association with HIV/STD*
A. Ribeiro^{1,2}, C. Madruga^{2,3}, A. Miguel^{2,3}, S. McPherson⁴, M. Ribeiro^{1,2}. ¹Reference Centre of Drug Addiction Treatment, Brazil; ²Federal University of São Paulo, Brazil; ³National Institute of Alcohol and Drug Policies, Brazil; ⁴Washington State University, United States
- 543 *Substance use: Recruitment and control tools for forced entry into sex work in two U.S.–Mexico border cities*
T. Rocha-Jimenez, K. Brouwer, S. Boyce, M. Salazar, J. Silverman. University of California, San Diego, United States
- 544 *Linking infectious and narcology care: A strengths-based case management intervention to link HIV-infected people who inject drugs in Russia to HIV care: Randomized controlled trial results*
J.H. Samet^{1,2}, E. Blokhina³, D.M. Cheng¹, A.Y. Walley^{1,2}, D. Lioznov³, C.E. Chaisson¹, C. Bridden², E. Quinn¹, N. Gnatienco², O. Toussova³, A. Gifford¹, E. Krupitsky³, A. Raj⁴. ¹Boston University, United States; ²Boston Medical Center, United States; ³First St. Petersburg Pavlov State Medical University, Russia; ⁴University of California, San Diego, United States
- 545 *A retrospective chart review of treatment completers versus noncompleters among those seeking in-patient treatment at a tertiary care drug dependence treatment center*
S. Sarkar, Y.P.S. Balhara, N. Gautam, J. Singh. Department of Psychiatry, National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, India
- 546 *Improvement in the treatment of substance use disorders through adopting evidence-based practices in Pakistan*
U. Shamim. Hubert H. Humphrey Fellowship Program, Virginia Commonwealth University, United States
- 547 *Gender differences among Russian addicts in their attitude toward long-term nonmedical treatment*
E. Smirnova¹, B. Lobodov¹, L. Rod². ¹Medical Center "Semya," Russia; ²Voronezh State Regional Narcological Dispensary, Russia
- 548 *The percentage of patients on high methadone doses in Ho Chi Minh City and related factors*
M.T.H. Son, T.T.T. Van. Ho Chi Minh City AIDS Preventive Center, Vietnam
- 549 *Acute tryptophan depletion response in cocaine-dependent subjects with comorbid depression*
M. Torrens^{1,2,3}, J.I. Mestre-Pintó¹, C. Pérez-Mañá^{1,3}, E. Papaseit^{1,3}, F. Fonseca^{1,2,3}, M. Farré^{1,3,4}. ¹Institut Hospital del Mar d'Investigacions Mèdiques, Spain; ²Institut de Neuropsiquiatria i Addiccions, Spain; ³Universitat Autònoma de Barcelona, Spain; ⁴Hospital Universitari Germans Trias i Pujol-IGTP, Spain

- 550 *Antiretroviral therapy initiation and adherence in people who inject drugs: Community-based approach*
A. Tyshkevych, O. Denisiuk, P. Smyrnov. ICF Alliance for Public Health, Ukraine
- 551 *Initial results of integrated antiretroviral and methadone treatment in District Preventive Medicine Centers in Ho Chi Minh City, 2013–2015*
T.T.T. Van, N.T.T. Nga, D.Q. Thong, L.T.N. Diep, M.T.H. Son, N.T.T. Thao, V. Hung, N.T. Hoa. Ho Chi Minh City Provincial AIDS Committee, Vietnam
- 552 *Fatal overdose in recently detoxified HIV-infected individuals who inject drugs in St. Petersburg, Russia: Role of Naltrexone*
T. Yaroslavtseva¹, E. Blokhina¹, E. Krupitsky^{1,2}, D.M. Cheng³, N. Gnatienko⁴, A.Y. Walley³, E. Verbitskaya¹, E. Zvartau¹, S. Poole⁵, R. Gross⁵, G. Woody⁵, J.H. Samet^{3,4}. ¹First Pavlov State Medical University of St. Petersburg, Russia; ²Bekhterev Research Psychoneurological Institute, Russia; ³Boston University, United States; ⁴Boston Medical Center, United States; ⁵University of Pennsylvania, United States

Please be advised that no photographing of presentations or data is permitted.
Badges must be worn at all times and are required for admission into all events and sessions.

Policy Forum

Fiesta 6/8
8:00 - 10:00 AM

Chairs: Martin Y. Iguchi

- 8:00 *Friends of NIDA*
Martin Y. Iguchi
- 8:10 *Update from Capitol Hill: Implications for NIH/NIDA funding*
Ed Long, Van Scoyoc Associates, Washington, DC
- 8:40 *Integrated care: Is 42 CFR Part 2 a barrier or a necessity?*
Westley Clark, Santa Clara University Public Health Program, Santa Clara, CA
- 9:06 *Integrated care: Is 42 CFR Part 2 a barrier or a necessity?*
Gavin Bart, Division of Addiction Medicine Hennepin County Medical Center, Minneapolis, MN
- 9:32 *Integrated care: Is 42 CFR Part 2 a barrier or a necessity?*
Dennis McCarty, OHSU/PSU School of Public Health, Oregon Health & Science University, Portland, OR

Symposium VII

Fiesta 10/14
10:15 - 12:15 PM

5HT_{2A} AND 5HT_{2C} LIGANDS AS POTENTIAL THERAPEUTICS FOR SUBSTANCE USE DISORDERS

Chairs: Jane B. Acri and Leonard Howell

- 10:15 *Behavioral effects of lorcaserin in rhesus monkeys: Interactions with stimulant drugs*
C. P. France, Dept. of Pharmacology, University of Texas Health Science Center, San Antonio, TX
- 10:40 *Effects of pimavanserin and lorcaserin on drug vs. food choice in rhesus monkeys*
Matt Banks, Dept. of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA
- 11:05 *Effects of 5-HT_{2C} receptor agonist lorcaserin on THC self-administration and reinstatement of THC-seeking in squirrel monkeys*
Zuzana Justinova, Preclinical Pharmacology Section, National Institute on Drug Abuse, IRP, NIH, Baltimore, MD
- 11:25 *Modification of the abuse-related effects of cocaine by serotonergic ligands*
Jack Bergman, McLean Hospital, Harvard Medical School, Belmont, MA
- 11:50 *DISCUSSANT: Targeted 5HT_{2A/C} pharmacotherapy for drug addiction*
Leonard Howell, Yerkes National Primate Research Center, Emory University, Atlanta, GA

Symposium VIII

**Fiesta 6/8
10:15 - 12:15 PM**

**NEONATAL ABSTINENCE SYNDROME: CONTEXT
AND CONSEQUENCES IN 2016**

Chairs: Karol Kaltenbach and Hendree E. Jones

- 10:15 *Neonatal abstinence syndrome: How it has been used to drive policies against women using substances during pregnancy*
Hendree E Jones, University of North Carolina School of Medicine, Chapel Hill, NC
- 10:45 *Understanding factors that exacerbate or mitigate severity and duration of neonatal abstinence syndrome*
Karol Kaltenbach, Emeritus Professor of Pediatrics, Sidney Kimmel Medical College at Thomas Jefferson University, Moorestown, NJ
- 11:15 *The assessment and treatment of neonatal abstinence syndrome: What do we know?*
Sarah Hughes Heil, University of Vermont, Burlington, VT
- 11:45 *DISCUSSANT: Neonatal abstinence syndrome in context: Science, family, and society*
Mishka Terplan, Behavioral Health System, Baltimore, MD

Oral Communications 7

**Fiesta 4
10:15 - 12:15 PM**

GATTACA: GENOTYPE/PHENOTYPE

Chairs: Mehdi Farokhnia and Mark Greenwald

- 10:15 *Extinction and reinstatement of cocaine-reinforced behavior in rat lines selected for low and high levels of intravenous drug self-administration*
K. Grasing, H. Xu, Kansas City VA Medical Center, Kansas City, MO
- 10:30 *Adrenoceptor variants moderate treatment response of doxazosin for cocaine use disorder*
D. A. Nielsen², D. Shorter², C. Domingo², M. H. Harding², E. M. Nielsen², T. Kosten¹,
¹Psychiatry, Baylor, Houston, TX, ²Psychiatry and Behavioral Science, Baylor College of Medicine, Houston, TX
- 10:45 *Composition of the N-methyl-D-aspartate receptor protein complex in the medial prefrontal cortex associates with individual differences in motor impulsivity*
C. A. Krebs, N. C. Anastasio, UTMB Galveston, Galveston, TX
- 11:00 *Recent cocaine use behavior differs by GLT1 genotype: A pilot study*
M. Greenwald¹, E. A. Woodcock¹, L. H. Lundahl¹, M. Burmeister³, ¹Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, ³Psychiatry and Human Genetics, University of Michigan, Ann Arbor, MI
- 11:15 *Targeted over-expression of brain-derived neurotrophic factor in the nucleus accumbens increases goal tracking and nicotine locomotor sensitization, but reduces nicotine self-administration in rats*
R. W. Brown², L. A. Beuttel¹, S. A. Dean¹, C. A. Bradley¹, J. Wherry², S. Kirby¹,
M. I. Palmatier¹, M. Zhu², ¹Psychology, East Tennessee State University, Johnson City, TN,
²Biomedical Sciences, East Tennessee State University, Johnson City, TN

- 11:30 *GABBR2 gene variants affect cigarette smoking pattern in alcohol-dependent individuals: A genetic association study*
M. Farokhnia¹, M. Schwandt², C. Hodgkinson³, L. Leggio¹, ¹Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, NIAAA and NIDA, NIH, Bethesda, MD, ²Laboratory of Clinical and Translational Studies, NIAAA, NIH, Bethesda, MD, ³Laboratory of Neurogenetics, NIAAA, NIH, Rockville, MD
- 11:45 *Cannabinoid receptor gene polymorphism (rs2023239) associated with demand for marijuana*
E. R. Aston¹, V. Knopik^{3,4}, J. McGue^{2,3,4}, J. MacKillop^{5,1}, J. Metrik^{2,1}, ¹Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, RI, ²Providence Veterans Affairs Medical Center, Providence, RI, ³Division of Behavioral Genetics, Department of Psychiatry, Rhode Island Hospital, Providence, RI, ⁴Department of Psychiatry and Human Behavior, Alpert Medical School, Brown University, Providence, RI, ⁵Peter Boris Centre for Addictions Research, McMaster University, Hamilton, ON, Canada

Oral Communications 8

Fiesta 12

10:15 - 12:15 PM

ALTERED STATES: ABUSE LIABILITY

Chairs: Ziva D. Cooper and Michelle Baladi

- 10:15 *The experimental tobacco marketplace II: Substitutability in dual e-cigarette and cigarette users*
A. Quisenberry, M. N. Koffarnus, A. Bianco, E. Perry, W. K. Bickel, Addiction Recovery Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA
- 10:30 *Validity of the modified cigarette evaluation questionnaire in predicting the reinforcing effects of cigarettes that vary in nicotine content under double-blind conditions*
C. A. Arger⁴, S. H. Heil⁴, S. C. Sigmon⁴, J. W. Tidey³, M. Stitzer⁴, D. Gaalema¹, M. Desarno¹, H. Durand⁴, E. Ruggieri⁴, S. T. Higgins⁴, ¹University of Vermont, Burlington, VT, ³Psychiatry, Brown, Providence, RI, ⁴Psychiatry, University of Vermont, Burlington, VT
- 10:45 *3,4-Methylenedioxypyrovalerone maintains differential patterns of responding in male Sprague-Dawley rats*
G. T. Collins^{1,2}, B. M. Gannon¹, K. Rice³, ¹Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²South Texas Veterans Health Care System, San Antonio, TX, ³Chemical Biology Research Branch, NIDA/NIAAA, Bethesda, MD
- 11:00 *Evaluation of the effects of JZP-110 in nonclinical models of abuse liability*
M. Baladi², L. P. Carter^{2,3}, J. Black², J. Bergman¹, ¹McLean Hospital/Harvard Medical School, Belmont, MA, ²Jazz Pharmaceuticals, Palo Alto, CA, ³University of Arkansas for Medical Sciences, Little Rock, AR
- 11:15 *Assessment of the abuse potential of ABT-126, an $\alpha 7$ -selective nicotinic agonist*
T. J. Hudzik, Preclinical Safety, AbbVie, North Chicago, IL
- 11:30 *Opioid modulation of cannabis-induced analgesia and subjective effects in cannabis smokers*
Z. D. Cooper, S. D. Comer, M. Haney, Psychiatry, Columbia University and NYSPI, New York, NY

- 11:45 *Analgesia and abuse liability of high-dose intravenous opioids in patients on methadone or buprenorphine*
D. A. Tompkins¹, M. T. Smith¹, R. R. Edwards², G. Bigelow¹, E. C. Strain¹, ¹Johns Hopkins University, Baltimore, MD, ²Harvard Medical School, Boston, MA
- 12:00 *No evidence of increased abuse potential of CL-108, a bilayered tablet containing hydrocodone/acetaminophen/promethazine, in recreational opioid users*
N. Levy-Cooperman¹, M. Shram¹, L. R. Webster², ¹Altros Research Partners, Toronto, ON, Canada, ²PRA, Salt Lake City, UT

Poster Session II

(Lunch)

Odd-numbered posters manned first hour;

Even-numbered, second hour

Flores

12:15 - 2:15 PM

Set-up time begins Monday, 3 PM

Must be removed by Tuesday 2:30 PM

MARIJUANA & CANNABINOIDS: HUMAN STUDIES

- 1 *Timing of sexual abuse, sexual risk behaviors and substance use among U.S. women*
M. Cook. "Moved to Poster Session IV, #04 on Thursday"
- 2 *Ethical issues in using text message assessments for sensitive behaviors: A prospective study of young adults' drug use and risky sexual behaviors*
E. E. Bonar³, G. P. Koocher⁴, R. Cunningham², R. L. Collins⁵, J. A. Cranford³, M. Walton²,
²University of Michigan, Ann Arbor, MI, ³Psychiatry, University of Michigan, Ann Arbor, MI,
⁴DePaul University, Chicago, IL, ⁵University at Buffalo, State University of New York, Buffalo, NY
- 3 *Examining problematic marijuana use among marijuana-using young adults*
C. F. Wong¹, E. Iverson¹, S. E. Lankenau², ¹Children's Hospital Los Angeles/USC, Los Angeles, CA, ²Community Health and Prevention, Drexel University, Philadelphia, PA
- 4 *Properties of the marijuana motives questionnaire among medical cannabis patients*
K. Bohnert^{2,1}, M. Ilgen^{2,1}, ¹Psychiatry, University of Michigan, Ann Arbor, MI, ²VA Center for Clinical Management Research, Ann Arbor, MI
- 5 *Linking animal models to human self-administration practices among medical cannabis patients: A daily diary study*
S. P. Novak, N. Peiper, J. Wiley, Behavioral Epidemiology, RTI International, Research Triangle Park, NC
- 6 *High impulsivity correlates with cannabis cue-induced craving in a non-treatment seeking cohort of heavy cannabis users*
G. Sahlem¹, N. Baker³, R. J. Malcolm², A. McRae-Clark¹, ¹Psychiatry, Medical University of South Carolina, Charleston, SC, ²Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, ³Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC
- 7 *Craving and anxiety responses to laboratory stress for individuals seeking treatment for cannabis use disorder: A pilot study*
M. Olonoff², M. Pavlicova³, S. Evans², J. J. Mariani², J. Choi³, D. J. Brooks¹, A. Mahony³, F. R. Levin², ¹Substance Abuse, NYSPI, New York, NY, ²Columbia University, New York State Psychiatric Institute, New York, NY, ³Columbia University, New York, NY

- 8 *Responses to social stress in regular cannabis smokers*
J. Xia, D. N. Patel, G. Bedi, Psychiatry, Columbia University and NYSPI, New York, NY
- 9 *Single administration of oxytocin attenuates craving to smoke cannabis*
K. J. Hartwell^{1,2}, N. Baker¹, J. R. Walker¹, A. McRae-Clark¹, ¹MUSC, Charleston, SC,
²Ralph H Johnson VAMC, Charleston, SC
- 10 *A dynamic causal modeling study of the reward system in marijuana users*
L. Ma^{1,2}, J. Steinberg^{1,3}, J. Bjork^{1,3}, L. Keyser-Marcus^{1,3}, J. Vassileva^{1,3}, S. Ferré⁴, F. Moeller^{1,3},
¹Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA,
²Department of Radiology, Virginia Commonwealth University, Richmond, VA, ³Department
of Psychiatry, Virginia Commonwealth University, Richmond, VA, ⁴Integrative Neurobiology
Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes
of Health, Baltimore, MD
- 11 *Chronic cannabis use is associated with impaired discrimination of threat and safety cues in
Pavlovian conditioning*
S. Papini⁴, L. Ruglass², T. Lopez-Castro², J. Smits⁴, A. Campbell³, D. Hien¹, ¹Psychology,
Adelphi University, NY, NY, ²Psychology, The City College of New York, New York, NY,
³Psychiatry, Columbia University Medical Center, New York, NY, ⁴Psychology,
The University of Texas at Austin, Austin, TX
- 12 *Efforts to diversity research populations can pay dividends*
C. W. Striley, E. Kwiatkowski, L. Cottler, Epidemiology, University of Florida,
Gainesville, FL

SEX/GENDER DIFFERENCES

- 13 *Sex differences on cortical brain morphometry and behaviors in adolescent marijuana users*
V. Douet, L. Chang, B. Stoytcheva, T. Ernst, T. PING Consortium, Department of Medicine,
University of Hawaii, John A. Burns School of Medicine, Honolulu, HI
- 14 *Are gender differences in the prevalence of past-year marijuana use and risk perception in the
U.S. narrowing from 2002-2013?*
R. Rahim-Juwel, H. Carliner, D. Shmulewitz, A. L. Sarvet, M. Wall, S. S. Martins, Q. Brown,
P. M. Mauro, D. Hasin, Columbia University, New York, NY
- 15 *Gender differences in the effect of childhood adversity on alcohol, drug, and poly-substance use
disorders*
E. Evans^{1,2}, D. Upchurch¹, C. E. Grella², ¹Fielding School of Public Health, UCLA,
Los Angeles, CA, ²UCLA Integrated Substance Abuse Programs, University of California,
Los Angeles, CA
- 16 *Gender differences in the effects of concurrent drug use on the risk of heroin relapse*
A. L. Moskowitz^{1,2}, C. E. Grella², ¹Psychology, UCLA, Los Angeles, CA, ²Integrated
Substance Abuse Programs, UCLA, Los Angeles, CA
- 17 *Gender differences in remission from alcohol and marijuana dependence in college students*
B. A. Bugbee¹, K. M. Caldeira¹, K. E. O'Grady², K. B. Vincent¹, A. M. Arria¹, ¹University of
Maryland School of Public Health, College Park, MD, ²Psychology, University of Maryland,
College Park, MD
- 18 *Heavy episodic drinking and weight control behavior among college students: Does gender
matter?*
R. L. Peralta¹, P. B. Barr², ¹Department of Sociology, The University of Akron, Akron, OH,
²Department of Psychology and African American Studies, Virginia Commonwealth
University, Richmond, VA

- 19 *Barriers to long-acting reversible contraceptive use among opioid-maintained women*
A. K. Matusiewicz, H. S. Melbostad, S. H. Heil, Department of Psychiatry, University of Vermont, Burlington, VT
- 20 *Health characteristics and sexual risk behaviors among young adult prescription opioid misusers in the club scene: Examining the role of gender*
M. A. Levi Minzi, M. E. Buttram, S. P. Kurtz, ARSH: Center for Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL
- 21 *What's in Your medicine cabinet?: Gender differences*
L. Cottler, E. Kwiatkowski, C. W. Striley, Epidemiology, University of Florida, Gainesville, FL
- 22 *Male-female differences in making a rapid transition from first heroin use to onset of heroin dependence: United States, 2005-2013*
O. J. Santiago Rivera, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
- 23 *Gender differences among PWID with regard to HIV transmission risk in St. Petersburg, Russia*
N. Gnatenko⁵, J. Tsui², J. A. Wagman³, D. M. Cheng⁴, A. Raj³, E. Blokhina¹, O. Toussova¹, L. Forman⁴, D. Lioznov¹, J. H. Samet^{4,5}, ¹First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation, ²University of Washington, Seattle, WA, ³University of California, San Diego, CA, ⁴Boston University, Boston, MA, ⁵Boston Medical Center, Boston, MA
- 24 *Working memory is impaired for both male and female HIV+ substance users*
E. Martin², R. Gonzalez¹, J. Vassileva⁴, P. Maki³, L. Rubin³, D. Hardy⁵, ¹Psychology, Florida International University, Miami, FL, ²Psychiatry, Rush University Medical Center, Chicago, IL, ³Psychiatry, University of Illinois, Chicago, IL, ⁴Psychiatry, Virginia Commonwealth University, Richmond, VA, ⁵Psychology, Loyola Marymount University, Los Angeles, CA
- 25 *Sexual violence among patients with substance use disorders in FQHCs*
C. W. Bone², R. Andersen³, M. Vahidi¹, L. Gelberg^{1,3}, ¹Family Medicine, UCLA, Woodland Hills, CA, ²Internal Medicine, Yale, New Haven, CT, ³UCLA School of Public Health, Los Angeles, CA
- 26 *Predictors of Internet-delivered drug treatment outcomes and acceptability among women*
T. Saraiya¹, A. Campbell², M. Hu², ¹Adelphi University, New York, NY, ²Dept of Psychiatry, Columbia University, New York, NY
- 27 *Gender and racial/ethnic differences in referral sources for SUD treatment among adolescents and young adults in California (2009-2014)*
J. Lim, D. Urada, UCLA Integrated Substance Abuse Programs, Los Angeles, CA
- 28 **WITHDRAWN**
- 29 *"Sex and the new Kandel-Kandel nicotine gateway evidence": Initial stepping-stones*
F. A. Wagner^{1,3}, K. C. Alcover³, O. A. Vsevolozhskaya², J. C. Anthony³, ¹PSRC, Morgan State University, Baltimore, MD, ²Biostatistics, University of Kentucky, Lexington, KY, ³Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI

- 30 *Mentholated cigarette use among African American women and men: What's blunt smoking got to do with it?*
L. Montgomery, Counseling/Substance Abuse Counseling, University of Cincinnati, Cincinnati, OH
- 31 *Gender discrimination, educational attainment, and illicit drug use among U.S. women*
H. Carliner¹, A. Sarvet², A. R. Gordon³, D. S. Hasin^{1,2}, ¹Epidemiology, Columbia University, New York, NY, ²New York State Psychiatric Institute, New York, NY, ³Pediatrics, Harvard Medical School, Boston, MA
- 32 *Social ties and substance use among reserve soldiers in single and dual military households*
E. M. Anderson Goodell¹, S. Cercone Heavey², D. Homish², G. G. Homish², ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Community Health and Health Behavior, State University of New York at Buffalo, Buffalo, NY

HIV/HCV

- 33 *Borderline personality disorder and brief intervention for drug use in HIV primary care*
J. Derri², A. Le², D. S. Hasin^{1,2}, E. Aharonovich^{1,2}, ¹Psychiatry, Columbia University Medical Center, New York, NY, ²New York State Psychiatric Institute, New York, NY
- 34 *Modeling a theory-based approach to examine the influence of neurocognitive impairment on HIV risk reduction behaviors among drug users in treatment*
R. Shrestha^{1,2}, T. B. Huedo-Medina^{2,3}, M. Copenhaver^{2,3}, ¹Department of Community Medicine & Health Care, University of Connecticut Health Center, Farmington, CT, ²Center for Health, Intervention, and Prevention, University of Connecticut, Storrs, CT, ³Department of Allied Health Sciences, University of Connecticut, Storrs, CT
- 35 *Feasibility, acceptability, tolerability of targeted naltrexone for non-dependent methamphetamine-using and binge-drinking men who have sex with men*
G. Santos^{1,1}, P. Coffin¹, D. Santos¹, S. Huffaker¹, T. Matheson¹, J. Euren¹, A. DeMartini¹, C. Rowe¹, J. Hahn³, D. Vlahov³, E. Vittinghoff³, S. L. Batki¹, ¹Community Health Systems, University of California San Francisco, San Francisco, CA, ³University of California San Francisco, San Francisco, CA
- 36 *Health knowledge and sociodemographic predictors of risky behaviors*
B. Peteet¹, M. Staton-Tindall², ¹Psychology, University of Cincinnati, Cincinnati, OH, ²Social Work, University of Kentucky, Lexington, KY
- 37 *Gender disparities in HIV prevalence and risk behaviors among people who inject drugs in Tajikistan*
W. Zule¹, D. Otiashvili², A. Latypov³, S. Bangel¹, W. Wechsberg¹, ¹RTI International, Durham, NC, ²Addiction Research Center, Alternative Georgia, Tbilisi, Georgia, ³Management Sciences for Health, Leadership, Management and Governance, Kiev, Ukraine
- 38 *Condom barriers among African American substance users: Age and gender differences*
C. L. McCuistian, K. Burlew, Psychology, University of Cincinnati, Cincinnati, OH
- 39 *Current drug users and women have higher rates of risky sexual behaviors*
K. A. Phillips, L. Moran, S. K. Hertz, D. H. Epstein, K. L. Preston, Treatment Section, NIDA IRP, Baltimore, MD
- 40 *Racial and ethnic differences in substance use diagnoses, comorbid psychiatric disorders and treatment initiation among HIV-positive and HIV-negative women*
E. D. Storholm^{1,3,2}, M. Silverberg², D. Satre^{2,3}, ¹Rand Corporation, Santa Monica, CA, ²Kaiser Permanente, Oakland, CA, ³Psychiatry, UCSF, San Francisco, CA

- 41 *Latent classes of polydrug use and associations with HIV risk behaviors and overdose among people who inject drugs in Tijuana, Mexico*
M. C. Meacham^{1,2,3}, S. Roesch², S. Strathdee¹, P. Gonzalez-Zuniga¹, T. Gaines¹, ¹University of California San Diego, La Jolla, CA, ²San Diego State University, San Diego, CA, ³University of California San Francisco, San Francisco, CA
- 42 *Used syringes analysis: A new approach to better-know what is injected*
T. Nefau^{2,1}, S. Karolak², Y. Levi², V. Thibault³, C. Duplessy-Garcon¹, J. Bara¹, ¹SAFE association, Paris, France, ²Univ Paris Sud, Châtenay-Malabry, France, ³Virology Laboratory, Hôpital Pitié-Salpêtrière, Paris, France
- 43 *Syringe-sharing among a prospective cohort of street-involved youth in Vancouver, Canada: Implications for structural interventions*
N. Bozinoff¹, E. Wood^{1,2}, L. Richardson^{1,3}, H. Dong¹, T. Kerr^{1,3}, K. DeBeck^{1,4}, ¹BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ²Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Department of Sociology, University of British Columbia, Vancouver, BC, Canada, ⁴School of Public Policy, Simon Fraser University, Vancouver, BC, Canada
- 44 *Access to and retention in harm reduction services among persons who inject drugs in Washington, DC*
S. T. Allen¹, M. Ruiz², S. Sherman¹, ¹Epidemiology, Johns Hopkins University, Baltimore, MD, ²Prevention and Community Health, George Washington University, Washington, DC
- 45 *Provider perspectives on care coordination for people living with HIV who use drugs*
K. Claborn^{1,2}, ¹Psychiatry & Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, ²Medicine, Rhode Island Hospital, Providence, RI
- 46 *Domestic prevalence of substance use disorders in HIV care settings*
B. Hartzler¹, D. Donovan¹, B. Beadnell⁹, H. M. Crane¹, J. J. Eron², E. H. Geng³, W. C. Matthews⁵, K. H. Mayer⁴, R. D. Moore⁶, M. Mugavero⁷, S. Napravnik², B. Rodriguez⁸, J. C. Dombrowski¹, ¹University of Washington, Seattle, WA, ²University of North Carolina-Chapel Hill, Chapel Hill, NC, ³University of California-San Francisco, San Francisco, CA, ⁴Harvard University, Boston, MA, ⁵University of California-San Diego, San Diego, CA, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Alabama-Birmingham, Birmingham, AL, ⁸Case Western Reserve University, Cleveland, OH, ⁹Prevention Research Institute, Louisville, KY
- 47 *Impact of a strengths-based case management intervention on HIV viral load among people who use drugs in Oakland, California*
A. Kral, M. L. Comfort, C. Powers, H. Cheng, A. Lopez, B. Lambdin, J. Lorvick, RTI International, San Francisco, CA
- 48 *Sexual risk and substance use behaviors among partnered and non-partnered HIV-infected adults with substance dependence*
A. R. Bazzi³, M. Sullivan⁶, M. Drainoni⁴, A. S. Ventura², G. J. Patts², A. Y. Walley¹, R. Saitz⁵, ¹General Internal Medicine, Boston Univ, Boston, MA, ²Boston University, Boston, MA, ³Community Health Sciences, Boston University School of Public Health, Boston, MA, ⁴Health Policy and Management, Boston University School of Public Health, Boston, MA, ⁵Community Health Sciences, Boston University and Boston Medical Center, Boston, MA, ⁶Boston Medical Center, Boston, MA

- 49 *LINC - A strengths-based case management intervention to link HIV-infected PWID in Russia to HIV care – RCT Results*
J. H. Samet¹, E. Blokhina², D. M. Cheng¹, A. Y. Walley¹, D. Lioznov², C. Chaisson¹, C. Bridden³, E. Quinn¹, N. Gnatienco³, O. Toussova², A. Gifford¹, E. Krupitsky², A. Raj⁴,
¹Boston University, Boston, MA, ²First Pavlov State Medical University, St. Petersburg, Russian Federation, ³Boston Medical Center, Boston, MA, ⁴University of California, San Diego, CA
- 50 *Daily alcohol use as an independent risk factor for HIV seroconversion among people who inject drugs*
S. Young¹, E. Wood^{1,2}, H. Dong², T. Kerr^{1,2}, K. Hayashi², ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Urban Health Research Initiative, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- 51 *Extended-release naltrexone feasibility in HIV clinics: A pilot study*
T. Korthuis³, P. J. Lum⁵, P. Vergara-Rodriguez⁶, K. Ahamad⁴, E. Wood⁴, R. Lindblad¹, R. Mandler², J. Sorensen⁵, D. Ha³, N. Oden¹, L. Kunkel³, D. McCarty³, ¹EMMES, Rockville, MD, ²NIDA, Bethesda, MD, ³OHSU, Portland, OR, ⁴UBC, Vancouver, BC, Canada, ⁵UCSF, San Francisco, CA, ⁶CORE Center, Chicago, IL
- 52 *Technology-based intervention preferences to enhance self-management of substance use disorders, HIV, and hepatitis C among patients in inpatient detoxification*
B. Tofighi², F. Grazioli¹, A. Thomas³, A. Desai², A. Coelho Pinguello², P. Greco², J. D. Lee²,
¹School of Social Work, New York University, New York, NY, ²Population Health, New York University School of Medicine, New York City, NY, ³Psychiatry, New York University, New York, NY
- 53 *Sexual and drug use risk behaviors and HIV- and Hepatitis-C transmission knowledge among non-treatment-seeking individuals with opioid use disorders in NYC*
V. Metz^{1,2}, M. Sullivan^{1,2,3}, J. D. Jones^{1,2}, E. Evans^{1,2}, R. Luba^{1,2}, J. Vogelmann^{1,2}, S. Comer^{1,2},
¹New York State Psychiatric Institute, New York, NY, ²Columbia University Medical Center, New York, NY, ³Alkermes, Inc, Waltham, MA
- 54 *HCV incidence and treatment in aging Latino injectors*
M. R. Klawans, Y. Villarreal, T. Northrup, A. Stotts, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX
- 55 *Hepatitis C virus core antigen reliably diagnoses HCV infection in injection and non-injection drug users*
M. Zeremski², Y. Chen³, R. Zavala⁴, Y. de Jong², C. Sylvester¹, G. Cloherty⁶, A. Talal⁵,
¹Research & Evaluation, START: Treatment & Recovery Centers, Brooklyn, NY, ²Weill Cornell Medical College, New York, NY, ³Biostatistics, University at Buffalo (SUNY), Buffalo, NY, ⁴START: Treatment & Recovery Centers, Brooklyn, NY, ⁵Medicine, University at Buffalo (SUNY), Buffalo, NY, ⁶Abbott Diagnostics, Des Plaines, IL

ADOLESCENT DRUG ABUSE

- 56 *Alcohol use during an N-acetylcysteine cannabis cessation trial in adolescents*
L. M. Squeglia, N. Baker, E. A. McClure, K. M. Gray, Medical University of South Carolina, Charleston, SC
- 57 *Adolescent cannabis use disorder: Adaptive treatment for poor responders to initial treatment*
Y. Kaminer, Psychiatry, University of CT School of Medicine, Farmington, CT

- 58 *Male-female differences of antecedent cannabis use among newly incident young alcohol drinkers: Does age matter?*
H. G. Cheng¹, C. Lopez-Quintero¹, J. C. Anthony², ¹Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, ²Michigan State University, East Lansing, MI
- 59 *A longitudinal examination of the impact of childhood emotional abuse on cannabis use trajectories among community youth*
A. N. Banducci^{1,2}, J. W. Felton², M. O. Bonn-Miller¹, C. W. Lejuez², L. MacPherson², ¹VA Palo Alto Health Care System, The National Center for PTSD, Palo Alto, CA, ²University Of Maryland, College Park, College Park, MD
- 60 *The romantic relationship context of adolescent marijuana use*
P. A. Matson², N. Ialongo¹, S. Chung², G. Bobashev³, J. M. Ellen⁴, ¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Johns Hopkins School of Medicine, Baltimore, MD, ³RTI International, Durham, NC, ⁴All Children's Hospital Johns Hopkins Medicine, St. Petersburg, FL
- 61 *Psychometric assessment of the marijuana adolescent problem inventory*
S. F. Babbin, C. Stanger, A. J. Budney, Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH
- 62 *Predictors of cannabis uptake in an adolescent cohort: Associations with tobacco use, drinking, and child, peer, and familial factors*
R. P. Mattick¹, P. Clare¹, A. Aiken¹, M. Wadolowski^{1,4}, R. Bruno², K. Kypri⁴, J. Najman⁵, D. Hutchinson¹, N. McBride⁵, ¹National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia, ²School of Medicine, University of Tasmania, Hobart, TAS, Australia, ⁴School of Medicine and Public Health, University of New Castle, New Lambton Heights, NSW, Australia, ⁵School of Public Health, University of Queensland, Brisbane, QLD, Australia
- 63 *Attitudes towards tobacco use among parents of adolescents*
S. E. Gomez Luna¹, D. A. Cavallo², S. Krishnan-Sarin³, ¹School of Medicine, RAMS/YALE, Stamford, CT, ²Psychiatry, Yale University, New Haven, CT, ³Psychiatry, Yale School of Medicine, New Haven, CT
- 64 *Cigarillo use patterns among adolescents*
G. Kong¹, D. A. Cavallo⁴, D. R. Camenga³, M. E. Morean⁴, P. Simon², K. M. Gutierrez⁴, S. Krishnan-Sarin⁴, ¹Yale School of Medicine, New Haven, CT, ²Department of Psychiatry, Division of Prevention and Community Research, Yale School of Medicine, New Haven, CT, ³Emergency Medicine, Yale School of Medicine, New Haven, CT, ⁴Department of Psychiatry, Yale University, School of Medicine, New Haven, CT
- 65 *Greater curiosity about smoking cigarettes among 6th and 12th grade students using alternative tobacco-smoking products*
L. E. Segura¹, A. Maldonado¹, J. Santaella¹, C. Storr², S. S. Martins¹, ¹Epidemiology, Columbia University, New York, NY, ²University of Maryland School of Nursing, Baltimore, MD
- 66 *Longitudinal patterns of e-cigarette and cigarette dual use in adolescents*
D. R. Camenga, K. Bold, G. Kong, D. A. Cavallo, K. M. Gutierrez, P. Simon, S. Krishnan-Sarin, Yale School of Medicine, New Haven, CT
- 67 *Low socioeconomic status is associated with e-cigarette and tobacco product use latent class membership among adolescents*
P. Simon², D. R. Camenga¹, G. Kong², D. A. Cavallo², M. E. Morean², K. M. Gutierrez², S. Krishnan-Sarin², ¹Emergency Medicine, Yale University, New Haven, CT, ²Psychiatry, Yale University, New Haven, CT

- 68 *Associations between non-traditional tobacco product use and ADHD symptoms in adolescents*
N. Goldenson¹, R. Khoddam², A. Leventhal^{1,2}, ¹Preventive Medicine, University of Southern California, Los Angeles, CA, ²Psychology, University of Southern California, Los Angeles, CA
- 69 *Polydrug use among a cohort of adolescent light smokers*
K. McKelvey, D. Ramo, K. Delucchi, M. Rubinstein, UCSF, San Francisco, CA
- 70 *Intra-individual changes in Stroop-related neural activations linked to cigarette abstinence in adolescent smokers*
S. W. Yip, S. Krishnan-Sarin, I. Balodis, K. Carroll, M. N. Potenza, Psychiatry, Yale University, New Haven, CT
- 71 *Classifying youth substance use with non-invasive questions*
A. Mellis¹, C. Eddy³, C. Franck³, A. G. Wilson², M. N. Koffarnus¹, W. K. Bickel¹, ¹Addiction Recovery Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA, ²Department of Psychology, University of Kentucky, Lexington, KY, ³Department of Statistics, Virginia Tech, Blacksburg, VA
- 72 *Persistence of extra-medical prescription pain reliever use among United States adolescents: A latent class analysis*
M. A. Parker, J. C. Anthony, Epidemiology & Biostatistics, Michigan State University, East Lansing, MI
- 73 *Parental permission for adolescent alcohol use at home with friends: Associations with demographic factors and risky drinking in Ontario, Canada*
H. Hamilton^{1,2}, A. Boak¹, R. Mann^{1,2}, ¹Centre for Addiction and Mental Health, Toronto, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada

CRIMINAL JUSTICE

- 74 *Illegal drug use and criminal behavior among Kentucky juvenile offenders*
C. Leukefeld^{2,1}, M. F. Dickson¹, M. Staton-Tindall¹, M. Webster^{1,2}, C. B. Oser^{1,3}, H. K. Knudsen^{2,1}, K. R. Marks², J. R. Havens^{1,2}, ¹Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY, ²Behavioral Science, University of Kentucky, Lexington, KY, ³Sociology, University of Kentucky, Lexington, KY
- 75 *Delivering HIV-prevention services to criminally-involved adolescents in substance abuse treatment*
K. L. Dugosh, D. S. Festinger, Law and Ethics, Treatment Research Institute, Philadelphia, PA
- 76 *Patterns of substance use and arrest among hospitalized people living with HIV: A latent class analysis*
K. Shiu¹, A. M. Brincks⁷, D. J. Feaster⁷, J. A. Frimpong¹, L. Gooden¹, A. Nijhawan⁸, R. P. Schwartz², L. Haynes³, S. Tross¹, J. Sorensen⁴, M. Drainoni⁹, R. Mandler⁵, C. del Rio⁶, L. R. Metsch¹, ¹Columbia University, New York, NY, ²Friends Research Institute, Baltimore, MD, ³MUSC, Charleston, SC, ⁴University of California, San Francisco, San Francisco, CA, ⁵NIDA, Bethesda, MD, ⁶Emory University, Atlanta, GA, ⁷University of Miami, Miami, FL, ⁸UT Southwestern Medical Center, Dallas, TX, ⁹Boston University, Boston, MA
- 77 *Substance use and HIV care among Puerto Ricans living with HIV on Rikers Island*
T. Pugh¹, J. Wiersema², P. Teixeira³, ¹SMS, Mailman School of Public Health, NYC, NY, ²NYC Correctional Health Services, NYC, NY, ³Weill Cornell Medicine, NYC, NY

- 78 *Preliminary outcomes of a brief intervention to reduce HIV and HCV risk among rural women*
M. Staton-Tindall³, G. Ciciurkaite¹, J. R. Havens², B. Peteet⁴, M. Webster², C. B. Oser¹,
¹Sociology, University of Kentucky, Lexington, KY, ²Behavioral Science, University of
Kentucky, Lexington, KY, ³Social Work, University of Kentucky, Lexington, KY, ⁴University
of Cincinnati, Cincinnati, OH
- 79 *Drugged driving and other high-risk behavior among rural drug-involved female offenders*
M. Webster, M. F. Dickson, M. Staton-Tindall, C. B. Oser, C. Leukefeld, Center on Drug and
Alcohol Research, University of Kentucky, Lexington, KY
- 80 *The association between religion/spirituality and 30-day crack/cocaine and marijuana use
among female offenders*
A. Acheampong¹, D. C. Vidot³, C. W. Striley², L. Cottler², ¹University of Florida,
Gainesville, FL, ²Epidemiology, University of Florida, Gainesville, FL, ³University of Miami
Miller School of Medicine, Miami, FL
- 81 *Hallucinogen use is associated with a decreased likelihood of positive urine drug screen
following entry into community corrections supervision*
P. Hendricks¹, S. Lappan¹, K. L. Cropsey², ¹Health Behavior, University of Alabama
at Birmingham, Birmingham, AL, ²Psychiatry, University of Alabama at Birmingham,
Birmingham, AL
- 82 *History of injection drug use mediates the effect of Project START intervention in men who were
released from prison in Ukraine*
T. Kiriazova², Y. Sereda¹, ¹Sociology, Institute for Social Research after Olexander
Yaremenko, Kyiv, Ukraine, ²Ukrainian Institute on Public Health Policy, Kyiv, Ukraine
- 83 *Criminal justice involvement and violence in civilians with substance use disorders and
posttraumatic stress disorder*
T. Lopez-Castro², D. Hien¹, S. Papini³, ¹Psychology, Adelphi University, NY, NY, ²Dept.
of Psychology, The City College of New York, New York, NY, ³Psychology, University of
Texas, Austin, TX
- 84 *Substance use disorders, trauma and victimization in a representative sample of Latino prison
inmates*
M. Vélez Pastrana^{3,1}, R. A. Gonzalez^{2,1}, A. Alicea-Rodríguez^{1,3}, C. Albizu¹, ¹Center for
Evaluation and Sociomedical Research, University of Puerto Rico, San Juan, PR, ²Centre
for Mental Health, Imperial College London, London, United Kingdom, ³Carlos Albizu
University, San Juan, PR
- 85 *The pathway to substance misuse for young people with ADHD and conduct disorder*
R. A. Gonzalez^{1,2}, G. Gudjonsson³, K. Wolff³, K. Xenitidis³, L. Mutch³, I. Mallet-Lambert³,
F. R. Levin⁴, S. Young¹, ¹Centre for Mental Health, Imperial College London, London,
United Kingdom, ²Center for Evaluation and Sociomedical Research, University of Puerto
Rico Medical Sciences Campus, San Juan, PR, ³IoP, King's College London, London,
United Kingdom, ⁴Division on Substance Abuse, New York State Psychiatric Institute,
New York, NY
- 86 *The effect of treatment for opioid use disorders on the costs of crime*
E. Krebs¹, D. Y. Huang⁴, E. Evans², D. Urada⁴, Y. Hser³, B. Nosyk¹, ¹BC Centre for
Excellence in HIV/AIDS, Vancouver, BC, Canada, ²UCLA, Los Angeles, CA, ³Department
of Psychiatry & Behavioral Sciences, UCLA, Los Angeles, CA, ⁴Integrated Substance Abuse
Programs, UCLA, Los Angeles, Los Angeles, CA

- 87 *Methadone patients in patient-centered treatment: One-year arrest data*
S. M. Kelly¹, K. E. O'Grady², J. Gryczynski¹, S. G. Mitchell¹, J. H. Jaffe^{1,3}, R. P. Schwartz¹,
¹Friends Research Institute, Baltimore, MD, ²Univ. of MD, College Park, MD, ³Univ. of MD,
School of Medicine, Baltimore, MD
- 88 *Addictive behaviors and psychiatric comorbidities of incarcerated women in a French overseas territory*
L. Techer³, J. Alexandre², D. Mété³, M. Auriacombe², M. Fatseas², ²Addiction Psychiatry
(CNRS USR 3413), Université Bordeaux, Bordeaux, France, ³Addiction Treatment Center,
CHU Ile de la Réunion, Saint Denis, France

THEORETICAL

- 89 *The quest to extend health services to vulnerable substance users in Rio de Janeiro, Brazil, in the context of an unfolding economic crisis*
N. Krawczyk³, D. Kerrigan², F. I. Bastos¹, ¹ICICT, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, ²Health Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 90 *Parallel growth modeling to better understand co-addiction: A randomized clinical trial of tobacco smoking and stimulant use*
M. Mamey¹, L. Burns¹, C. Barbosa-Leiker², C. Parks¹, S. McPherson², ¹Psychology, Washington State University, Pullman, WA, ²College of Nursing, Washington State University, Spokane, WA
- 91 *Dealing with zero-numerators in estimating drug-dependence chances: A Bayesian approach*
O. A. Vsevolozhskaya³, F. A. Wagner², J. C. Anthony¹, ¹Michigan State University, East Lansing, MI, ²PSRC, Morgan State University, Baltimore, MD, ³Biostatistics, University of Kentucky, Lexington, KY
- 92 *Statistical assessment of abuse-deterrent opioids*
L. Chen, FDA/CDER, Silver Spring, MD
- 93 *A theory of social roles in addiction and recovery suitable for dynamic simulation modeling*
E. Stringfellow, Brown School of Social Work, Washington University in St. Louis, St. Louis, MO
- 94 *Driving impairment of CNS prescription and non-prescription drugs*
T. Hopyan², R. Mann^{1,3}, C. Wickens^{1,3}, ¹Center for Addiction & Mental Health, Toronto, ON, Canada, ²INC Research, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
- 95 *Assessing the abuse potential of botanical substances*
K. Bonson, A. Trachtenberg, M. Klein, Controlled Substance Staff, Food and Drug Administration, Silver Spring, MD
- 96 *Pre-clinical abuse testing applications in drug development*
J. Randall-Thompson, M. Klein, Controlled Substance Staff, Food and Drug Administration, Silver Spring, MD
- 97 *FDA role in the drug scheduling process of a drug under development*
S. N. Calderon, D. Chiapperino, M. Klein, CDER/CSS, Food and Drug Administration, Silver Spring, MD
- 98 *Assessment of the abuse potential and benefits of kratom and its mitragynine alkaloids: Implications for regulation*
R. K. Lanier¹, R. V. Fant², E. Cone², J. Henningfield², ¹US Naturals, Washington, DC, ²Pinney Associates, Bethesda, MD

- 99 *Readiness to change is a predictor of reduced substance use involvement: Findings from a randomized controlled trial of patients attending South African emergency departments*
B. Myers¹, D. J. Stein², K. Sorsdahl², ¹Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Tygerberg, South Africa, ²University of Cape Town, Cape Town, South Africa

CLUB/DESIGNER DRUGS

- 100 *Dopaminergic mediation of the discriminative stimulus effects of three cathinone analogs of MDMA*
S. Dolan², M. B. Gatch¹, ¹Pharmacology & Neuroscience, UNT Health Science Center, Fort Worth, TX, ²Institute for Healthy Aging, Center for Neuroscience Discovery, University of North Texas Health Science Center, Fort Worth, TX
- 101 *Entactogenic effects of synthetic cathinones*
M. B. Gatch, M. J. Forster, Center for Neuroscience Discovery, UNT Health Science Center, Fort Worth, TX
- 102 *Comparison of anomalous experiences after ingesting psilocybin mushrooms in research and non-research settings*
T. M. Carbonaro, M. W. Johnson, R. R. Griffiths, Johns Hopkins University, Baltimore, MD
- 103 *Reliability and validity of the Japanese version of the DAST-2*
T. Shimane, T. Matsumoto, Department of Drug Dependence Research, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan

STIMULANTS: ANIMAL STUDIES

- 104 *Participation of CC-Chemokine ligands in reward system on methamphetamine-induced psychological dependence in mice*
S. Kishioka¹, F. Saika¹, S. Matsuzaki¹, M. Ko², N. Kiguchi^{1,2}, ¹Pharmacology, Wakayama Medical University, Wakayama, Japan, ²Physiology and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC
- 105 *Pharmacological effects of injected or vaporized methamphetamine and alpha-PVP in mice*
J. A. Marusich, T. Lefever, B. Blough, B. F. Thomas, J. Wiley, RTI International, Research Triangle Park, NC
- 106 *Combined effects of a serotonin 5HT_{2C} receptor agonist and a serotonin 5HT_{2A} receptor antagonist on methamphetamine-induced sleep disruption evaluated with actigraphy in rhesus monkeys*
L. F. Berro, M. Peres Diaz, M. L. Andersen, L. Howell, Emory University, Atlanta, GA
- 107 *Effects of lorcaserin on cocaine and methamphetamine self-administration and on reinstatement of extinguished responding in rhesus monkeys*
L. R. Gerak¹, G. T. Collins^{1,2}, C. P. France^{1,3}, ¹Pharmacology, University of Texas Health Science Center, San Antonio, TX, ²South Texas Veterans Health Care System, San Antonio, TX, ³Psychiatry, University of Texas Health Science Center, San Antonio, TX
- 108 *Cocaine-cue memory extinction is associated with depotentiation at amygdala synapses*
M. T. Rich, T. Cahanap, Y. Huang, M. M. Torregrossa, University of Pittsburgh, Pittsburgh, PA
- 109 *Regulation of gene expression of the delta opioid receptor, corticotropin-releasing hormone, and CRH-1 receptor during withdrawal from chronic cocaine*
K. L. Connelly, E. M. Unterwald, Center for Substance Abuse Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA
- 110 *Crabp2 and Fabp5 mediated retinoic acid signaling is a novel mechanism controlling depression- and addiction-related behavior*
Y. Zhang, E. Crofton, S. Koshy, T. Green, University of Texas Medical Branch, Galveston, TX

- 111 *Hyperactivity, but not anxiety-like, behavior is observed in rats receiving chronic cocaine followed by exposure to single prolonged stress*
S. A. Perrine, M. J. Lisieski, Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI
- 112 *Disruption of the serotonin 5-HT_{2C} receptor interaction with protein phosphatase and tensin homologue regulates the behavioral effects of the selective 5-HT_{2C}R agonist WAY163909*
C. Soto³, R. G. Fox³, N. C. Anastasio^{3,1}, H. C. Du², S. Gilbertson², K. A. Cunningham^{3,1},
¹Department of Pharmacy & Toxicology, UTMB, Galveston, TX, ²Department of Chemistry, University of Houston, Houston, TX, ³Center for Addiction Research, UTMB, Galveston, TX
- 113 *Crack cocaine users with high family/social problems show more psychiatric symptoms and violent behaviors*
M. P. Pachado^{1,3}, J. N. Scherer^{1,3}, L. S. Guimaraes^{1,3}, N. Marchi^{1,3}, R. Almeida³,
F. P. Pechansky^{2,3}, F. H. Kessler^{2,3}, ¹Psychiatric Dept, Center for Drug and Alcohol Research, Porto Alegre, Brazil, ²Psychiatry, Center for Drug and Alcohol Studies at HCPA/UFRGS, Porto Alegre, Brazil, ³Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- 114 *Mediational pathways among trait impulsivity, use consequences, and quit attempts in cocaine users*
E. A. Woodcock¹, J. J. Lister², L. H. Lundahl¹, M. Greenwald¹, ¹Psychiatry, Wayne State University, Detroit, MI, ²Social Work, Wayne State University, Detroit, MI

Symposium IX

Fiesta 6/8
2:15 - 3:15 PM

TRANSLATIONAL MARKERS OF SUBSTANCE USE VULNERABILITY: RECEPTORS, RISK-PROCESSING, AND PSYCHOPATHOLOGY

Chairs: Noelle C. Anastasio and Thomas J. Crowley

- 2:15 *Interrogations into the neuromolecular underpinnings of inherent impulsivity in rodents*
Noelle C Anastasio, University of Texas Medical Branch at Galveston, Galveston, TX
- 2:35 *Brain-driven vulnerability to substance use disorders: Do brains make drug abusers?*
Thomas J Crowley, University of Colorado School of Medicine, Aurora, CO
- 2:55 *Interventions targeting endophenotypes of risk for addiction*
Patricia Conrod, University of Montreal, Catherine Montreal, QC, Canada

Symposium X

Fiesta 10/14
2:15 - 3:15 PM

IMAGING THE MALE & FEMALE ADDICTED BRAIN: STRUCTURAL AND FUNCTIONAL DIFFERENCES AND IMPLICATIONS FOR PRECISION MEDICINE

Chairs: Cora Lee Wetherington and Will Aklin

- 2:15 *Brain structure and function in female compared to male stimulant users with long-term abstinence*
Jody Tanabe, University of Colorado Denver School of Medicine, Aurora, CO
- 2:35 *Imaging the dopamine signature in tobacco smokers*
Kelly Cosgrove, Yale University, New Haven, CT
- 2:55 *Functional brain connectivity in addictions: The impact of sex and early trauma*
Kathleen T. Brady, Medical University of South Carolina, Charleston, SC

Oral Communications 9

**Fiesta 4
2:15 - 3:15 PM**

SON OF FLUBBER: CHEMISTRY

Chairs: Jun Zhu and Linda Dwoskin

- 2:15 *Tyrosine470 and 88 of human dopamine transporter are responsible for the allosteric modulatory effect of SRI-30827, SRI-20041 and HIV-1 Tat protein on dopamine transporter*
J. Zhu¹, W. Sun², S. Ananthan⁴, C. Zhan⁵, ¹Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, ²Drug Discovery and Biomedical Sciences, University of South Carolina, Columbia, SC, ⁴Organic Chemistry, Southern Research Institute, Birmingham, AL
- 2:30 *Oral JPC-077, a vesicular monoamine transporter-2 inhibitor, reduces methamphetamine self-administration across repeated treatments*
A. Wilson³, N. Lee², J. R. Nickell², J. P. Culver², V. Janganati⁴, G. Zheng⁴, P. A. Crooks⁴, L. P. Dwoskin², M. T. Bardo³, ²Pharmaceutical Sciences, University of Kentucky, Lexington, KY, ³Psychology, University of Kentucky, Lexington, KY, ⁴University of Arkansas for Medical Sciences, Little Rock, AR
- 2:45 *Stereoselective differences in the reinforcing effects of "bath salts" constituent 3,4-methylenedioxypyrovalerone under a progressive ratio schedule of reinforcement in rats*
B. M. Gannon¹, K. Galindo¹, K. Rice², G. T. Collins^{1,3}, ¹Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Chemical Biology Research Branch, NIDA and NIAAA, Bethesda, MD, ³South Texas Veterans Health Care System, San Antonio, TX
- 3:00 *Investigation of the κ -opioid receptor agonist CR845 and reference comparator, butorphanol, in rats trained to discriminate (-) pentazocine from saline*
D. J. Heal², J. Gosden², N. Slater², R. H. Spencer¹, F. Menzaghi¹, ¹Cara Therapeutics, Shelton, CT, ²RenaSci Ltd, Nottingham, United Kingdom

Oral Communications 10

**Fiesta 12
2:15 - 3:15 PM**

SHAWSHANK REDEMPTION: CRIMINAL JUSTICE

Chairs: Carlos C. Mahaffey and David S. Festinger

- 2:15 *Attitudes and practices on the use of extended-release naltrexone in criminal justice settings*
D. S. Festinger¹, K. L. Dugosh¹, D. R. Gastfriend³, C. Sierka¹, ¹Law and Ethics, Treatment Research Institute, Philadelphia, PA, ³Treatment Research Institute, Philadelphia, PA
- 2:30 *An evaluation of opioid substitution treatment in prison on risk of mortality in period immediately after prison: Does leaving prison on OST reduce the risk of death?*
G. Stillwell¹, H. Jones², J. Shaw³, M. Farrell⁴, J. Marsden¹, ¹National Addiction Centre, Institute of Psychiatry, Kings College London, London, United Kingdom, ²School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom, ³Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, United Kingdom, ⁴National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW, Australia
- 2:45 *Alcohol and cocaine use and drug distribution among formerly incarcerated black men*
C. C. Mahaffey², D. Stevens-Watkins¹, C. Leukefeld³, ¹Spalding University, Louisville, KY, ²University of Kentucky, Lexington, KY, ³Behavioral Science, University of Kentucky, Lexington, KY

- 3:00 *The Silk Road Health Project: The intersection between criminal justice involvement, substance use and HIV risks among migrant and non-migrant workers in Almaty, Kazakhstan*
P. Marotta, N. El-Bassel, Columbia University, New York, NY

Symposium XI

Fiesta 6/8
3:30 - 5:30 PM

NOT YOUR AVERAGE JOINT: ALTERNATIVE METHODS OF CANNABIS ADMINISTRATION

Chairs: Adam Leventhal and Marcel Bonn-Miller

- 3:30 *Dose effects of oral cannabis administration*
Ryan Vandrey, Johns Hopkins University School of Medicine, Baltimore, MD
- 3:55 *Patterns of vaping cannabis among adolescent and adult cannabis users*
Dustin C. Lee, Geisel School of Medicine at Dartmouth, Lebanon, NH
- 4:20 *Routes of cannabis consumption as a function of clinical status*
Marcel O. Bonn-Miller, VA Palo Alto Health Care System & University of Pennsylvania, Menlo Park, CA
- 4:45 *Prevalence and correlates of cannabis vaping, smoking, and edible use among adolescents*
Adam Leventhal, University of Southern California Keck School of Medicine, Los Angeles, CA
- 5:10 *DISCUSSANT: Leveraging alternative methods of cannabis administration research to inform science, practice, and policy*
Alan J. Budney, Geisel School of Medicine at Dartmouth, Lebanon, NH

Oral Communications 11

Fiesta 4
3:30 - 5:30 PM

DAYS OF WINE AND ROSES: ALCOHOL

Chairs: Elise M. Weerts and Erica McGrath

- 3:30 *Regional- and sex-dependent effects of chronic ethanol and cocaine co-administration on adult neural stem cell survival and differentiation*
E. McGrath^{1,3,4}, P. Wu³, K. A. Cunningham¹, T. Dunn³, J. Gao³, A. C. Grant³, K. Dineley², J. Allende-Labastida⁶, B. Kaphalia⁷, ¹Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, ²Neurology, University of Texas Medical Branch, Galveston, TX, ³Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX, ⁴Institute for Translational Science, University of Texas Medical Branch, Galveston, TX, ⁶Cell Biology, University of Texas Medical Branch, Galveston, TX, ⁷Toxicology, University of Texas Medical Branch, Galveston, TX
- 3:45 *Comparison of the reinforcing efficacy of midazolam, ethanol, and mixtures of the two in male rats*
D. Townsend¹, J. K. Rowlett^{1,2}, D. Platt¹, K. Freeman¹, ¹University of Mississippi Medical Center, Jackson, MS, ²Comparative Pathology, Tulane National Primate Research Center, Covington, LA
- 4:00 *Naltrexone reduces appetitive and consummatory responses to alcohol in a sex-dependent manner in rats*
S. J. Nieto, K. J. Winoske, T. A. Kosten, Psychology, University of Houston, Houston, TX

- 4:15 *The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats*
C. N. Haile^{1,2,3}, T. A. Kosten^{1,2,3}, ¹Psychiatry, Baylor College of Medicine, Houston, TX, ²Psychology & TIMES, University of Houston, Houston, TX, ³Michael E. DeBakey VA Medical Center, Houston, TX
- 4:30 *Reduction of alcohol self-administration by 3-ISO-PBC*
E. M. Weerts¹, V.V.N.P.B. Tiruveedhulaand², J. M. Cook², ¹Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, ²Department of Chemistry & Biochemistry, University of Wisconsin Milwaukee, Milwaukee, WI
- 4:45 *Inhibitory processing predicts increases in binge-drinking behavior: A six-month longitudinal design*
A. L. Paz², J. Conniff¹, D. Ferrato¹, R. Gonzalez³, M. Rosselli¹, ¹Florida Atlantic University, Davie, FL, ²Neuropsychology, Florida Atlantic University, Miami, FL, ³Florida International University, Miami, FL
- 5:00 *Rates of homelessness and factors that predict them among homeless, alcohol-dependent adults in a therapeutic workplace clinical trial*
A. Holtyn¹, E. Carlson¹, B. Jarvis², M. Fingerhood¹, K. Silverman², ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD
- 5:15 *Treatment for alcohol use disorders in seriously mentally ill adults using the ethyl glucuronide biomarker*
M. G. McDonell¹, E. Leickly¹, S. McPherson¹, D. Srebnik², J. M. Roll¹, R. Ries², J. Skalsky¹, ¹Washington State University, Spokane, WA, ²University of Washington, Seattle, WA

Oral Communications 12

Fiesta 12

3:30 - 5:30 PM

DUE DATE: PERINATAL DRUG ABUSE

Chairs: Loretta Finnegan and Qiana Brown

- 3:30 *Cannabis use during pregnancy for the United States, 2005-2013*
O. Alshaarawy^{1,2}, J. C. Anthony¹, ¹Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, ²Epidemiology and Biostatistics, Indiana University, Bloomington, IN
- 3:45 *Trends in marijuana use among reproductive age women: 2002-2013*
Q. Brown¹, D. Shmulewitz^{1,2}, S. S. Martins¹, D. Hasin^{1,2}, ¹Columbia University, New York, NY, ²New York State Psychiatric Institute, New York, NY
- 4:00 *Marijuana doesn't count: Is objective screening in obstetrics clinics needed to identify and assist pregnant marijuana users?*
T. Northrup¹, M. R. Klawans¹, Y. Villarreal¹, P. Berens², A. Stotts¹, ¹Family and Community Medicine, University of Texas Health Science Center at Houston, Houston, TX, ²OB/GYN, University of Texas Health Science Center at Houston, Houston, TX
- 4:15 *Prevalence of prenatal cigarette smoking and marijuana use in North Delaware State*
Y. Washio, R. Butler, N. D. Goldstein, M. K. Hoffman, Christiana Care Health Services, Newark, DE

- 4:30 *Microstructural brain development in infants with prenatal stimulant exposure during first three months of age*
L. Chang¹, K. Oishi², J. Skranes³, S. Buchthal¹, E. Cunningham¹, C. Jiang¹, D. Alicata¹, R. Yamakawa¹, S. Hayama¹, T. Ernst¹, ¹University of Hawaii, John A. Burns School of Medicine, Honolulu, HI, ²Johns Hopkins Medicine, Baltimore, MD, ³Norwegian University Science and Technology, Trondheim, Norway
- 4:45 *Bupropion therapy during pregnancy: Concentrations of the drug and its major metabolites in umbilical cord plasma and amniotic fluid*
V. M. Fokina¹, H. West¹, C. Oncken², S. Clark¹, M. S. Ahmed¹, G. Hankins¹, T. Nanovskaya¹, ¹OB/GYN Maternal Fetal Medicine, University of Texas Medical Branch, Galveston, TX, ²University of Connecticut Health Center, Farmington, CT
- 5:00 *Benzodiazepine and other illicit drug use during methadone-maintained pregnancies: 2002-2011*
D. J. Hand, K. Kaltenbach, V. Short, D. J. Abatemarco, Pediatrics, Thomas Jefferson University, Philadelphia, PA
- 5:15 **WITHDRAWN** - *Factors associated with cocaine use in pregnancy*
R. M. Nagarajan, X. Cai, C. Hine, B. Merry, K. A. Yonkers, Psychiatry, Yale University, New Haven, CT

Oral Communications 13

Fiesta 10/14
3:30 - 4:30 PM

MISERY: PAIN

Chairs: Launette M. Rieb and Caroline A. Arout

- 3:30 *Pain as a predictor and consequence of tobacco withdrawal among African-American smokers*
J. F. McBeth¹, J. Ditre², M. Kirkpatrick¹, L. Ray³, A. Leventhal⁴, ¹Preventive Medicine, University of Southern California, Camarillo, CA, ²Psychology, Syracuse University, Syracuse, NY, ³Psychology, University of California Los Angeles, Los Angeles, CA, ⁴Preventive Medicine, University of Southern California, Los Angeles, CA
- 3:45 *Marijuana use in adults with sickle cell disease*
A. Forray², J. Bozzo³, J. Cole³, J. Spodick³, J. D. Roberts¹, ¹Yale School of Medicine, New Haven, CT, ²Psychiatry, Yale School of Medicine, New Haven, CT, ³Yale-New Haven Hospital, New Haven, CT
- 4:00 *Healed injury sites can hurt again during opioid withdrawal: A descriptive case series*
L. M. Rieb^{2,1}, W. Norman², R. Martin³, J. Berkowitz^{2,4}, E. Wood^{1,5}, M. Miloy^{1,5}, ¹BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada, ²Family Practice, University of British Columbia, Vancouver, BC, Canada, ³School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ⁴Sauder School of Business, UBC, Vancouver, BC, Canada, ⁵Medicine, UBC, Vancouver, BC, Canada
- 4:15 *Rates and correlates of specialized pain clinic use nationally in the Veterans Health Administration*
C. A. Arout², M. Sofuoglu^{1,3}, R. A. Rosenheck^{2,3}, ¹Psychiatry, Yale University, West Haven, CT, ²Psychiatry, Yale University School of Medicine, New Rochelle, NY, ³Mental Illness Research, Education, and Clinical Center, Veterans Health Administration, West Haven, CT

Oral Communications 14

**Fiesta 10/14
4:45 - 5:45 PM**

CLEAN AND SOBER: WITHDRAWAL

Chairs: Scott E. Lukas and Meg Haney

- 4:45 *Parallel changes in brain GABA levels, sleep and mood state during acute cocaine withdrawal: Predictors of “readiness for treatment”?*
S. E. Lukas², C. Zuo², N. Dias¹, A. Janes², J. Betts¹, W. Tartarini¹, M. L. Copersino², D. Penetar², ¹McLean Hospital/Harvard Medical School, Belmont, MA, ²Psychiatry, McLean Hospital/Harvard Medical School, Belmont, MA
- 5:00 *Nicotine withdrawal induces negative correlation in resting connectivity between insula and executive control networks in smokers*
A. L. Matous, J. Fedota, K. Slater, B. Salmeron, H. Gu, T. Ross, E. Stein, NIDA-IRP, Baltimore, MD
- 5:15 *Premenstrual symptom severity and tobacco withdrawal, craving, and mood after overnight tobacco abstinence*
R. Pang¹, A. Leventhal², ¹University of Southern California, Los Angeles, CA, ²Preventive Medicine, University of Southern California, Los Angeles, CA
- 5:30 *Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and relapse among non-treatment-seeking cannabis users*
E. S. Herrmann, Z. Cooper, G. Bedi, D. Ramesh, S. C. Reed, S. D. Comer, R. Foltin, M. Haney, New York State Psychiatric Institute, New York, NY

Film Night

**CAPRA
7:00 - 9:00 PM**

THE HUNGRY HEART

A documentary about prescription drug abuse
Produced and directed by Bess O'Brien

MIT- Town Hall

**Fiesta 4
5:45 - 6:45 PM**

Workshop X

**Fiesta 12
7:00 - 9:00 PM**

**RESEARCH AND EMERGING STRATEGIES FOR PARENTS
OF SUBSTANCE INVOLVED ADOLESCENTS AND YOUTH:
RESULTS FROM NIDA'S PARENTS' TRANSLATIONAL
RESEARCH CENTER**

Chairs: Kimberly C. Kirby and Elena Bresani

- Addressing adolescent substance use: Parental perspectives*
Brenda L Curtis, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA
- Quality indicators for adolescent SAT: The consumer guide to adolescent treatment*
Kathleen Meyers, Treatment Research Institute, Philadelphia, PA

Adolescent treatment for substance abuse: What goes on outside of specialty treatment?

Mary Tabit, Treatment Research Institute, Philadelphia, PA

Community reinforcement and family training (CRAFT) for parents: Efficacy and online training program

Kimberly C Kirby, Departments of Psychology and Biomedical Sciences, Rowan University, Glassboro, NJ

Discussant: Making sense of needs and quality treatment

David R Gastfriend, American Society of Addiction Medicine, Newtown Center, ME

Workshop XI

Fiesta 10/14

7:00 - 9:00 PM

ANNUAL CPDD DESIGN AND ANALYSIS WORKSHOP

Chairs: Sterling M. McPherson and Susan K. Mikulich-Gilbertson

Potential peril lurking in substance variables that are ratios

Susan Kay Mikulich-Gilbertson, University of Colorado Anschutz Medical Center, Aurora, CO

Testing invariance of growth models to examine gender differences in substance use outcomes from clinical trials

Celestina Barbosa-Leiker, Washington State University, College of Nursing, Spokane, WA

Issues in the measurement and analysis of health-related quality of life in populations with substance use disorders

Bohdan Nosyk, BC Centre for Excellence in HIV/AIDS, Vancouver BC, BC, Canada

An introduction to machine learning and potential uses in substance use research

Daniel J. Feaster, University of Miami Miller School of Medicine, Miami, FL

Toward precision addiction medicine: Applying machine learning techniques to predict and model treatment response on an individual level

Sean Luo, Columbia University, New York, NY

Workshop XII

Fiesta 4

7:00 - 9:00 PM

EDUCATION IN DRUG ABUSE

Chairs: Michael Kuhar and Jack Stein

Online degree programs

Robert Balster, Virginia Commonwealth University, Richmond, VA

Those amazing MOOCs

Michael Kuhar, Emory University, Atlanta, GA

Available knowledge: What should a physician/scientist in the 21st century know?

Bertha Madras, Harvard University, Belmont, ME

Discussant: Discovering NIDA's research portfolio

Jack Stein, National Institute on Drug Abuse, Bethesda, MD

Workshop XIII

**Fiesta 6/8
7:00 - 9:00 PM**

REGULATORY AND METHODOLOGICAL CONSIDERATIONS IN THE EVALUATION OF DRUG DEPENDENCE IN THE PRECLINICAL AND CLINICAL SETTING

Chairs: Beatrice Setnik and Michael Klein

Regulatory and methodological considerations in the assessment of drug dependence and withdrawal in humans

Alicja Lerner, Controlled Substances Staff, FDA, Silver Spring, MD

Untangling dependence, tolerance, and addiction – An examination of definitions and diagnostic criteria

Jack Henningfield, Pinney Associates, The Johns Hopkins School of Medicine, Bethesda, MD

An overview of preclinical models to assess physical and psychological dependence and their translation to the clinic

David John Heal, RenaSci, Ltd, BioCity, Nottingham, United Kingdom

Analyzing and interpreting adverse events related to withdrawal and dependence

Sian Ratcliffe, Pfizer Inc., Groton, CT

DISCUSSANT: Practical considerations for the assessment of drug dependence in animal, patient and healthy volunteer populations

Beatrice Setnik, INC Research, Raleigh, NC

Population Neuroscience

Fiesta 6/8
8:00 - 10:00 AM

TOWARDS POPULATION NEUROSCIENCE

Chairs: Carlos Blanco and A. Roger Little

- Priorities within the division of neuroscience and behavior: Overview and opportunities*
A. Roger Little, NIDA, Bethesda, MD
- Research priorities for epidemiology, services and prevention*
Carlos Blanco, NIDA, Bethesda, MD

Animal Forum

Fiesta 4
8:00 - 10:00 AM

STUDYING ADDICTION IN MALE AND FEMALE ANIMALS: TRANSLATION TO HUMANS

Chairs: Marilyn E. Carroll and Mark S. Todtenkopf

- 8:00 *Sex influences on brain and body: An issue whose time has come*
Larry Cahill, UC Irvine, Irvine, CA
- 9:00 *Sex differences in behavioral dyscontrol, addiction and treatment: Translation from animals to humans*
John R. Smethells, University of Minnesota
- 9:30 *Power analysis for animal studies of sex differences in addiction*
Mark S Todtenkopf, Alkermes, Inc., Waltham, MA

Symposium XII

Fiesta 4
10:15 - 12:15 PM

MEDICINAL CHEMISTRY OF NOVEL KAPPA OPIOID RECEPTOR LIGANDS

Chairs: F. I. Carroll and Thomas Prisinzano

- 10:15 *Small changes in macrocyclic tetrapeptide structure have significant impact on opioid activity in vivo*
Jane Aldrich, University of Florida, Gainesville, FL
- 10:40 *Development of neoclerodane-based drug abuse medication*
Thomas Prisinzano, University of Kansas, Lawrence, KS
- 11:05 *Biased kappa opioid receptor ligands: Chemistry, pharmacology, and physiology*
Jeff Aubé, University of North Carolina, Chapel Hill, NC
- 11:30 *New JDTic analogs as potential pharmacotherapies for treating substance abuse*
Ivy Carroll, Research Triangle Institute, Research Triangle Park, NC
- 11:55 *DISCUSSANT:*
Linda P Dwoskin, University of Kentucky, Lexington, KY

Symposium XIII

Fiesta 6/8
10:15 - 12:15 PM

BIO-BEHAVIORAL RESEARCH ON HIV AMONG PEOPLE WHO USE DRUGS

Chairs: Christina S. Meade and Adam Carrico

- 10:15 *Bio-behavioral outcomes from the women's health CoOp: The seek, test, treat and retain model in Pretoria, South Africa*
Wendee Wechsberg, RTI International, Research Triangle Park, NC
- 10:40 *Prospects of ending the HIV epidemic among people who inject drugs in Haiphong, Vietnam*
Don Des Jarlais, Icahn School of Medicine at Mount Sinai, New York, NY
- 11:05 *Impact of HIV infection and cocaine dependence on decision-making processes: Results from a functional neuroimaging study*
Christina S Meade, Duke University, Durham, NC
- 11:30 *Optimizing biomedical approaches to HIV prevention with substance-using men who have sex with men*
Adam Carrico, University of California San Francisco, San Francisco, CA
- 11:55 *DISCUSSANT: NIH and NIDA priorities for HIV/AIDS research*
Shoshana Kahana, National Institute on Drug Abuse, Bethesda, MD

Oral Communications 15

Fiesta 10/14
10:15 - 12:15 PM

A BEAUTIFUL MIND: CO-MORBIDITIES

Chairs: Marc Auriacombe and Cathryn Glanton Holzhauer

- 10:15 *How psychiatric comorbidity and mood states influence craving and substance use in daily life? An ecological momentary assessment study in patients with alcohol, tobacco, cannabis and heroin use disorders*
F. Serre², M. Fatseas², J. Swendsen³, M. Auriacombe², ²Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, ³CNRS UMR 5287 - INCIA, Univ. Bordeaux, Bordeaux, France
- 10:30 *Are greater consequences in polysubstance-using women related to anxiety?*
C. Glanton Holzhauer¹, E. Wulfert², ¹Psychiatry, University of Massachusetts Medical School, Worcester, MA, ²Psychology, University at Albany, SUNY, Albany, NY
- 10:45 *Prevalence and correlates of hazardous alcohol use and co-occurring mental health problems in Nepal following the 2015 earthquakes*
J. C. Kane¹, N. Luitel², M. J. Jordans^{3,4}, B. A. Kohrt⁵, M. Greene¹, W. A. Tol^{1,6}, ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Transcultural Psychosocial Organization, Kathmandu, Nepal, ³Research and Development, Healthnet TPO, Amsterdam, Netherlands, ⁴Centre for Global Mental Health, Institute of Psychiatry, Psychology and Neuroscience, Kings College, London, United Kingdom, ⁵Duke Global Health Institute, Duke University, Durham, NC, ⁶Peter C. Alderman Foundation, Bedford, NY

- 11:00 *1-Year post-treatment outcomes from a RCT of a behavioral activation treatment for substance use and depression*
K. A. Johnson, C. Seitz-Brown, K. Anderson, D. DeGeorge, E. Blevins, S. B. Daughters, Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 11:15 *Neuropharmacological investigation of withdrawal-induced inhibitory control deficits among smokers with ADHD*
F. J. McClernon, S. H. Kollins, R. Kozink, M. Hallyburton, M. Sweitzer, J. Oliver, Psychiatry and Behavioral Sciences, Duke Univ. Medical Center, Durham, NC
- 11:30 *The prevalence of adult attention deficit/hyperactivity disorder among treatment-seeking problem gamblers*
L. Brandt¹, G. Fischer^{1,2}, ¹Center for Public Health, Medical University of Vienna, Vienna, Austria, ²Department for Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
- 11:45 *Internalizing symptoms and conduct problems: Redundant, incremental, or interactive risk factors for substance use during the first year of high school?*
R. Khoddam¹, N. Jackson¹, A. Leventhal², ¹Psychology, University of Southern California, Los Angeles, CA, ²Preventive Medicine, University of Southern California, Los Angeles, CA
- 12:00 *Anxiety and depression as predictors of long-term abstinence among stimulant-dependent outpatients in a clinical trial of concurrent smoking cessation and substance abuse treatment*
K. Sanchez^{1,2}, ¹School of Social Work, University of Texas at Arlington, Arlington, TX, ²Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX

Oral Communications 16

Fiesta 12

10:15 - 12:15 PM

THE SOCIAL NETWORK

Chairs: Warren K. Bickel and Deena Peyser

- 10:15 *The effects of social contact on “binge” cocaine self-administration*
A. M. Robinson³, R. Lacy¹, J. C. Strickland², C. P. Magee³, M. A. Smith³, ¹Psychology, Franklin and Marshall, Lancaster, PA, ²University of Kentucky, Lexington, KY, ³Psychology, Davidson College, Davidson, NC
- 10:30 *Prosocial effects and neurotoxicity of (–)-3,4-methylenedioxymethamphetamine in mice*
D. Curry, A. Belkoff, L. Howell, Yerkes National Primate Research Center, Emory University, Atlanta, GA
- 10:45 *Social reinstatement: A rat model of peer-induced relapse*
V. G. Weiss², J. R. Yates¹, M. T. Bardo³, ¹Experimental Psychology, University of Kentucky, Lexington, KY, ²Psychology, University of Kentucky, Lexington, KY, ³University of Kentucky, Lexington, KY
- 11:00 *Social facilitation of alcohol effects predicts self-reported progression of use in adolescents*
M. Kirkpatrick, R. Pang, M. Stone, A. Leventhal, Preventive Medicine, University of Southern California, Los Angeles, CA
- 11:15 *Social networks, support, and alcohol use among late middle-aged and older adults*
S. Kim¹, S. Spilman², D. Liao², P. Sacco³, A. Moore², ¹UCLA Integrated Substance Abuse Programs, Los Angeles, CA, ²University of California, Los Angeles, Los Angeles, CA, ³University of Maryland, Baltimore, MD

- 11:30 *Age- and gender-specific impacts of social influences on last 30-day marijuana use*
J. E. Goldstick, Q. Epstein-Ngo, J. Heinze, H. Hsieh, M. Walton, R. Cunningham,
M. Zimmerman, University of Michigan, Ann Arbor, MI
- 11:45 *Do as I say, not as I do: A unique social support network among women, but not men, seeking treatment for alcohol and drug use disorders*
D. Peyser, J. Buckman, L. Banu, M. Bates, Psychology, Rutgers University, Piscataway, NJ
- 12:00 *The social interactome of recovery: Network topology influences social media engagement*
W. K. Bickel¹, A. Quisenberry¹, P. Chandrasekar², M. N. Koffarnus¹, E. A. Fox², C. Franck²,
¹Addiction Recovery Research Center, Virginia Tech Carilion Research Institute,
Roanoke, VA, ²Virginia Tech, Blacksburg, VA

Poster Session III

(Lunch)

Odd-numbered posters manned first hour;

Even-numbered, second hour

Set-up time begins Tuesday, 3 PM

Must be removed by Wednesday 2:30 PM

OPIOID TREATMENT

- 1 *Gender differences in timing of reminder messages for automated, CBT-based treatment for methadone*
D. M. Printz¹, F. D. Buono¹, D. P. Lloyd², S. Reichin², B. A. Moore¹, ¹Psychiatry, Yale University, New Haven, CT, ²APT Foundation, New Haven, CT
- 2 *Predicting craving and mood 90 minute into the future using GPS data*
W. J. Kowalczyk¹, M. Tyburski¹, M. Vahabzadeh¹, J. Lin¹, K. A. Phillips¹, A. J. Milam²,
D. M. Furr-Holden², M. Mezghanni¹, D. H. Epstein¹, K. L. Preston¹, ¹NIDA, IRP,
Baltimore, MD, ²Johns Hopkins, Baltimore, MD
- 3 *Evaluation of tailored therapeutic recommendations to improve use of an automated telephone-based treatment for methadone*
D. P. Lloyd¹, D. M. Printz³, F. D. Buono³, S. Reichin¹, B. A. Moore², ¹APT Foundation,
New Haven, CT, ²Psychiatry, Yale University School of Medicine, New Haven, CT,
³Psychiatry, Yale University, New Haven, CT
- 4 *Finding a needle in the haystack: Using machine learning to predict overdose in opioid users*
B. S. Crosier¹, J. Borodovsky², P. Mateu-Gelabert³, H. Guarino⁴, ¹Center for Technology and
Behavioral Health, Dartmouth College, West Windsor, VT, ²Psychiatry, Dartmouth College,
Hanover, NH, ³NDRI, Inc., New York, NY, ⁴National Development & Research Institutes,
New York, NY
- 5 *Gender differences in methadone dose patterns and length of treatment in outpatient methadone maintenance treatment programs*
J. A. Frimpong¹, K. Shiu², T. D'Aunno³, H. Pollack⁴, P. Friedmann⁵, ¹Columbia University,
New York, NY, ²Sociomedical Sciences, Columbia University, New York, NY,
³New York University, New York, NY, ⁴University of Chicago, Chicago, IL,
⁵Baystate Health, Springfield, MA
- 6 *Measuring circadian entrainment during outpatient opioid agonist maintenance*
J. W. Bertz¹, D. H. Epstein¹, M. Rea², M. G. Figueiro², G. Ward², K. L. Preston¹, ¹Clinical
Pharmacology and Therapeutics Research Branch, NIDA Intramural Research Program,
Baltimore, MD, ²Lighting Research Center, Rensselaer Polytechnic Institute, Troy, NY

- 7 *A randomized trial of patient-centered methadone treatment with optional counseling*
R. P. Schwartz¹, S. M. Kelly¹, J. Gryczynski¹, K. O'Grady², D. Gandhi⁴, Y. Olsen³, J. H. Jaffe¹, S. G. Mitchell¹, ¹Friends Research Institute, Baltimore, MD, ²Univ. of Maryland, College Park, MD, ³IRB REACH, Baltimore, MD, ⁴Psychiatry, Univ. of Maryland, Baltimore, MD
- 8 *Fair hearing outcomes for patients recommended discharge from methadone maintenance*
J. S. Chang, J. Chiu, V. Gruber, J. Sorensen, U.C. San Francisco, San Francisco, CA
- 9 *A systematic review of opioid agonist treatments for pharmaceutical opioid dependence*
S. Nielsen^{3,2}, B. Larance³, L. Degenhardt³, L. Gowing¹, N. Lintzeris^{2,4}, ¹University of Adelaide, Adelaide, SA, Australia, ²South Eastern Sydney Local Health District, Sydney, NSW, Australia, ³UNSW Australia, Sydney, NSW, Australia, ⁴University of Sydney, Sydney, NSW, Australia
- 10 *The impact of psychopharmacotherapy on disenrollment from office-based opioid treatment with buprenorphine*
Z. M. Weinstein^{1,2}, D. M. Cheng¹, E. Quinn¹, D. Hui¹, H. Kim¹, G. Gryczynski^{1,2}, C. Labelle^{1,2}, J. H. Samet^{1,2}, ¹Boston University, Boston, MA, ²Boston Medical Center, Boston, MA
- 11 *Urine drug testing for patients on buprenorphine: Informative beyond self-reported cocaine and opioid use?*
S. M. Bagley², D. M. Cheng⁴, M. R. Winter⁴, D. Alford³, C. Labelle³, A. Y. Walley¹, J. H. Samet³, ¹General Internal Medicine, Boston Univ, Boston, MA, ²Medicine, Boston University School of Medicine, Boston, MA, ³Boston University Medical Center/Boston Medical Center, Boston, MA, ⁴Boston University School of Public Health, Boston, MA
- 12 *Within-subject evaluation of interim buprenorphine vs. waitlist on illicit opioid use*
T. A. Ochalek⁵, J. D. Pusey⁵, B. Hruska¹, S. H. Heil¹, S. Higgins¹, G. Rose¹, B. A. Moore⁴, S. C. Sigmon¹, ¹Psychiatry, The University of Vermont, Burlington, VT, ⁴Psychiatry, Yale University School of Medicine, New Haven, CT, ⁵Psychology, University of Vermont, Burlington, VT
- 13 *Safety of combination buprenorphine/naloxone and extended-release naltrexone*
R. Lindblad¹, A. Saxon³, P. VanVeldhuisen¹, L. Lu¹, L. Hu¹, A. Hasson², C. Thomas², S. Sparenborg⁴, L. Mooney², W. Ling², ¹EMMES, Rockville, MD, ²UCLA, Los Angeles, CA, ³VA, Seattle, WA, ⁴NIDA, Rockville, MD
- 14 *"The devil I know is better than the devil I don't know": Enrollment in a pilot trial of opioid dose escalation vs. buprenorphine/naloxone for pain*
A. Manhapra, D. A. Fiellin, W. Becker, Yale University, New Haven, CT
- 15 *Improving buprenorphine treatment outcomes with the L-type calcium channel blocker isradipine*
A. Oliveto¹, J. McGaugh¹, J. B. Guise¹, J. D. Thostenson², M. J. Mancino¹, ¹Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, ²Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR
- 16 *Sensitivity analysis of a comparative trial of 6-month buprenorphine implants (Probuphine) and sublingual buprenorphine in stable opioid-dependent patients*
R. Rosenthal², M. R. Lofwall¹, S. Kim³, M. Chen⁴, K. Beebe⁵, F. Vocci⁶, ¹University of Kentucky, Lexington, KY, ²Psychiatry, Icahn School of Medicine, New York, NY, ³Braeburn Pharmaceuticals, Princeton, NJ, ⁴TCM Groups, Berkeley Heights, NJ, ⁵Titan Pharmaceuticals, South San Francisco, CA, ⁶Friends Research Institute, Baltimore, MD

- 17 *Pregabalin for opioid detoxification: Interim results*
E. Krupitsky¹, R. Ilyuk¹, A. Mikhailov¹, K. Kazankov¹, K. Rybakova¹, O. Grishina¹, I. Zaplatkin⁴, D. Langelben³, G. E. Woody³, ¹St. Petersburg VM Bekhterev Research Psychoneurological Institute, St. Petersburg, Russian Federation, ³Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴Murmansk Regional Addiction Hospital, Murmansk, Russian Federation
- 18 *The effect of substance use disorders on the association between guideline-concordant long-term opioid therapy and all-cause mortality*
J. R. Gaither^{1,2}, J. Goulet^{1,2}, W. Becker^{1,2}, S. Crystal³, E. J. Edelman¹, K. S. Gordon², R. Kerns^{1,2}, D. Rimland⁴, M. Skanderson², A. Justice^{1,2}, D. A. Fiellin¹, ¹Yale, New Haven, CT, ²VA, West Haven, CT, ³Rutgers, New Brunswick, NJ, ⁴Emory, Atlanta, GA
- 19 *Increasing medication use for alcohol and opioid disorders through organizational change*
J. H. Ford², A. Abraham⁴, N. Lupulescu-Mann⁵, R. Croff³, K. Johnson², M. Chalk⁶, L. Schmidt⁷, D. McCarty¹, ¹CB 669 PHPM, Oregon Health & Science Univ, Portland, OR, ²University of Wisconsin-Madison, Madison, WI, ³Public Health & Preventive Medicine, Oregon Health & Science University, Portland, OR, ⁴University of Georgia, Athens, GA, ⁵OHSU, Portland, OR, ⁶TRI, Philadelphia, PA, ⁷UCSF, San Francisco, CA
- 20 *Pay for performance and treatment outcome in medication-assisted treatment*
E. Loscalzo, A. Levit, R. Sterling, S. Weinstein, Psychiatry and Human Behavior, Thomas Jefferson University, Philadelphia, PA
- 21 *Injection heroin use and methadone maintenance treatment outcomes*
D. M. Ledgerwood¹, J. J. Lister², B. V. LaLiberte¹, M. Greenwald¹, ¹Psychiatry, Wayne State School of Medicine, Detroit, MI, ²Wayne State University, Detroit, MI
- 22 *Comparison of risk behavior, addiction severity, and history of overdose between active and agonist-maintained heroin users*
B. Todhunter^{1,3}, K. Wehmeyer¹, J. D. Jones³, S. D. Comer², ¹Psychology, Columbia University, Teachers College, New York, NY, ²Psychiatry, Columbia University and NYSP, New York, NY, ³Division of Substance Abuse, New York Psychiatric Institute, Columbia Medical School, New York, NY
- 23 *Modeling heroin careers over 40 years: Social costs*
A. Ritter¹, V. Hoang¹, V. Cao³, M. Shanahan¹, N. Shukla³, P. Perez³, M. Farrell², ¹Drug Policy Modelling Program, University of New South Wales, Sydney, NSW, Australia, ²NDARC, UNSW, Sydney, NSW, Australia, ³SMART Infrastructure Facility, University of Wollongong, Wollongong, NSW, Australia
- 24 *Baseline predictors of outpatient induction onto extended-release naltrexone*
V. A. Barbieri², K. Mishlen¹, M. Sullivan^{4,3}, A. Bisaga², ¹Substance Abuse, Columbia University, New York, NY, ²Substance Abuse, Columbia University/ New York State Psychiatric Institute, New York, NY, ³Columbia University, New York, NY, ⁴Alkermes, Inc., Waltham, MA
- 25 *Opioid use following an outpatient detoxification and induction onto XR-NTX: Testing the blockade as a predictor of retention in treatment*
K. Mishlen¹, V. A. Barbieri¹, M. A. Sullivan^{2,3}, A. Bisaga¹, ¹Substance Abuse, Columbia University/ New York State Psychiatric Institute, New York, NY, ²Alkermes, Inc., Waltham, MA, ³Columbia University, New York, NY
- 26 *Employment-based reinforcement of naltrexone adherence in unemployed heroin users: Effects on opiate use*
B. Jarvis, A. Holtyn, A. DeFulio, A. Umbricht, M. Fingerhood, G. Bigelow, K. Silverman, Johns Hopkins University School of Medicine, Baltimore, MD

- 27 *Developing home-based continuing care: Exploring feasibility and acceptance with parents and young adults*
K. Zentgraf¹, D. Zaslav¹, E. Bresani¹, K. Meyers¹, M. Tabit¹, K. C. Kirby^{1,2,3}, ¹Treatment Research Institute, Philadelphia, PA, ²Psychology, Rowan University, Glassboro, NJ, ³Psychiatry, University of Pennsylvania, Philadelphia, PA
- 28 *A pilot trial of two models of clinical supervision of integrated cognitive behavioral therapy for PTSD and substance use disorders*
A. Meier¹, M. P. McGovern², C. Lambert-Harris¹, B. McLeman⁴, E. Saunders⁴, ¹Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Psychiatry and Community & Family Medicine, Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁴Psychiatric Research Center, Geisel School of Medicine at Dartmouth, Lebanon, NH

GENETICS

- 29 *Gene variants of the dopaminergic system are associated with non-dependent heroin use and heroin dependence*
M. Randesi¹, O. Levran¹, J. Ott¹, P. Blanken², W. van den Brink², J. M. van Ree², M. Kreek¹, ¹The Rockefeller University, New York, NY, ²Central Committee on the Treatment of Heroin Addicts, Utrecht, Netherlands
- 30 *RNA-seq analysis: Differential transcriptome in the dorsal and ventral striatum in male C57BL/6J mice after chronic oxycodone self-administration*
Y. Zhang¹, Y. Liang², M. Randesi¹, O. Levran¹, V. Yuferov¹, M. Kreek¹, ¹The Laboratory of the Biology of the Addictive Diseases, The Rockefeller University, New York, NY, ²Hospital Informatics, The Rockefeller University, New York, NY
- 31 *Unbiased gene profiling of the rhesus macaque mesolimbic system following long-term cocaine self-administration*
E. J. Vallender^{1,2,3}, D. Goswami³, N. M. Shinday³, S. Westmoreland³, W. D. Yao³, J. K. Rowlett^{1,2,3}, ¹University of Mississippi Medical Center, Jackson, MS, ²Tulane National Primate Research Center, Covington, LA, ³Harvard Medical School, Southborough, MA
- 32 *The role of dopaminergic system on crack-cocaine addiction: DRD2 and DRD4 genes and their individual and interaction effects*
A. R. Stolf², J. B. Schuch¹, D. Muller¹, G. C. Akutagava-Martins¹, C. Szobot³, F. P. Pechansky², F. P. Kessler², T. Roman¹, ¹Post Graduate Program in Genetics and Molecular Biology / Department of Genetics, Federal University of Rio Grande do Sul, Porto Alegre, Brazil, ²Center for Drug and Alcohol Research, HCPA/UFRGS, Porto Alegre, Brazil, ³Child and Adolescent Psychiatric Service / Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
- 33 *No association between crack-cocaine addiction and COMT Val/Met polymorphism*
T. Roman³, A. R. Stolf², J. B. Schuch³, D. Muller³, G. C. Akutagava-Martins³, C. Szobot¹, F. P. Pechansky², F. P. Kessler², ¹Child and Adolescent Psychiatric Service / Hospital de Clínicas de Porto Alegre, UFRGS, Porto Alegre, Brazil, ²Center for Drug and Alcohol Research / HCPA, UFRGS, Porto Alegre, Brazil, ³Post Graduate Program in Genetics and Molecular Biology / Department of Genetics, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

REWARD & PUNISHMENT

- 34 *Cocaine increases permeability of blood-brain-barrier in the hippocampus and striatum: Implications for drug use and abuse*
A. L. Riley¹, D. Kearns², S. Hargrave¹, T. Davidson¹, ¹Psychology, American University, Washington, DC, ²Psychology, American University, Washington, MD

- 35 *Measuring sign-tracking in humans: The promise and pitfalls of translation*
M. Wardle¹, S. Fligel², P. Lopez-Gamundi¹, C. Amador¹, ¹Psychiatry and Behavioral Science, University of Texas Health Science Center at Houston, Houston, TX, ²Psychiatry, University of Michigan, Ann Arbor, MI
- 36 *Age-related differences in licking microstructural indices of incentive motivation and hedonic impact in rats*
I. A. Mendez¹, N. Murphy¹, S. Ostlund³, N. Maidment¹, ¹Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA, ³Anesthesiology and Perioperative Care, UCI, Irvine, CA
- 37 *Extended vs. brief intermittent access to palatable food differently promote binge-like intake and rejection of less preferred food in female rats*
A. Kreisler, E. Zorrilla, Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, San Diego, CA
- 38 *The highly selective 5-HT_{2C} receptor agonist WAY163909 reduces compulsive behavior and food intake in female rhesus monkeys*
M. Perez Diaz², L. Howell^{2,1}, M. Wilson^{2,3}, ¹Neuropharmacology and Neurologic Diseases, Emory University, Atlanta, GA, ²Yerkes National Primate Research Center, Emory University, Atlanta, GA, ³Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA
- 39 *Comparison of the effects of psychostimulant drugs of abuse on brain endothelial barrier integrity and extracellular microvesicle production*
A. M. Andrews^{1,2}, S. Merkel^{1,2}, E. Lutton¹, C. Hicks², S. Rawls², S. Ramirez^{1,2,3}, ¹Pathology and Laboratory Medicine, Temple University, Philadelphia, PA, ²Center for Substance Abuse Research, Temple University, Philadelphia, PA, ³The Shriners Hospitals Pediatric Research Center, Philadelphia, PA
- 40 *PPAR γ agonism to treat white matter damage in cocaine use disorder*
A. Dimet^{1,3}, L. Denner¹, R. Miller^{1,3}, K. A. Cunningham^{1,3}, M. Huentelman⁴, S. D. Lane², K. Dineley^{1,3}, ¹UTMB, Galveston, TX, ²Psychiatry & Behavioral Sciences, University of Texas Health Science Center - Houston, Houston, TX, ³Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, ⁴Translational Genomics Research Institute, Phoenix, AZ
- 41 *The effects of repeated cocaine administration on the surface expression of glutamate receptor subunits in the medial prefrontal cortex*
J. D. Steketee, K. C. Summers, Pharmacology, University of Tennessee Health Science Center, Memphis, TN
- 42 *Combining multiple schedules of reinforcement with glutamate biosensors to examine the effects of cocaine and food on prelimbic glutamatergic signaling in freely moving rats*
S. R. Batten, J. S. Beckmann, Psychology, University of Kentucky, Lexington, KY
- 43 *DREADD-induced activation of agranular insular cortex decreases cue reactivity associated with self-administration of high fat pellets*
A. E. Price¹, S. J. Stutz¹, H. Neelakantan¹, N. C. Anastasio^{1,2}, K. A. Cunningham^{1,2}, ¹Center for Addiction Research, UTMB, Galveston, TX, ²Department of Pharmacology & Toxicology, UTMB, Galveston, TX
- 44 *Estradiol increases choice of cocaine over food in male rats: The effect of estradiol on cocaine choice generalizes to both sexes*
J. R. Bagley, T. E. Kippin, Psychological and Brain Sciences, University of California at Santa Barbara, Santa Barbara, CA

- 45 *Comparative analysis of transcriptomics and proteomics of environmental enrichment and cocaine*
E. Crofton, Y. Zhang, F. Kong, B. Luxon, H. Spratt, C. F. Lichti, T. Green, University of Texas Medical Branch, Galveston, TX
- 46 *Preexposure attenuates methylphenidate-induced taste avoidance, but enhances BDNF/TrkB activity in the insular cortex of the rat*
B. B. Wetzell², M. Muller³, S. M. Flax³, H. E. King³, K. DeCicco-Skinner⁴, A. L. Riley,
²Psychopharmacology Laboratory, American University, Washington, DC, ³Psychology Department, American University in Washington DC, Washington, DC, ⁴Biology, American University, Washington, DC
- 47 *Across time and space: Independent component analysis reveals spatial and temporal differences in functional brain networks between cocaine and alcohol users*
T. Kearney-Ramos, L. T. Dowdle, O. Mithoefer, C. Mullins, W. DeVries, M. George, C. A. Hanlon, Medical University of South Carolina, Charleston, SC
- 48 *An analysis of the rewarding and aversive associative effects of nicotine in the neonatal quinpirole model of schizophrenia: Underlying mechanisms and the effects of antipsychotics*
S. Kirby¹, A. R. Denton¹, D. J. Peterson¹, E. D. Cummins¹, J. M. Dose³, R. W. Brown²,
¹Psychology, East Tennessee State University, Johnson City, TN, ²Biomedical Sciences, East Tennessee State University, Johnson City, TN, ³Psychology, St. Norbert College, De Pere, WI

ALCOHOL

- 49 *Evaluation of CERC-501, a selective kappa opioid antagonist in preclinical models of alcoholism*
D. R. Gehlert^{2,1}, L. Rorick-Kehn³, A. Thorsell⁴, B. Paterson¹, M. Heilig⁴, ¹Cerecor, Baltimore, MD, ²Matrix Pharma Consulting, Boulder, CO, ³Lilly Research Laboratories, Indianapolis, IN, ⁴Linkoping University, Linkoping, Sweden
- 50 *Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care*
J. Chen¹, R. D. McDonald¹, R. Obi¹, S. Wong¹, M. Flannery¹, B. Tofighi¹, A. Kermack¹, J. Rotrosen², M. Gourevitch¹, J. D. Lee¹, ¹Population Health, New York University, New York, NY, ²Psychiatry, New York University, New York, NY
- 51 *Alexithymia in alcohol-dependent patients is mediated by stress, anxiety and loss of self-control over drinking*
F. A. Thorberg^{1,6,2}, R. M. Young², M. Lyvers⁴, J. Connor⁵, R. Tyssen⁶, E. London³, G. Feeney⁷,
¹Natnl Cntr Dual Diagnosis, Innlandet Hosp Trust, Ottestad, Norway, ²Qld Univ Technol, Brisbane, QLD, Australia, ³Univ Calif Los Angeles, Los Angeles, CA, ⁴Bond Univ, Gold Coast, QLD, Australia, ⁵Univ Qld, Brisbane, QLD, Australia, ⁶Behav Sciences in Medicine, Univ Oslo, Oslo, Norway, ⁷Princess Alex Hosp, Brisbane, QLD, Australia
- 52 *Similarities across addictive processes: Cross-commodity discounting of alcohol, food, and money*
L. Moody¹, W. K. Bickel², ¹Virginia Tech, Roanoke, VA, ²Addiction Recovery and Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA
- 53 *The worse get better: Instruction following improves among the alcohol dependent rate dependently*
S. E. Snider, S. M. LaConte, W. K. Bickel, Addiction Recovery Research Center, Virginia Tech Carilion Research Institute, Roanoke, VA
- 54 *Prevalence and predictors of alcohol withdrawal delirium in a Thai university hospital*
R. Kalayasiri, P. Sareedenchai, Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

- 55 *Husband/partner intoxication and intimate partner violence against women in the Philippines*
B. T. Kerridge, Epidemiology, Columbia University, Gaithersburg, MD
- 56 *Alcohol use and intimate partner violence among women and their partners in sub-Saharan Africa*
M. Greene¹, D. M. Furr-Holden², W. A. Tol¹, ¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Washington, DC, ²Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 57 *WITHDRAWN*
- 58 *Using a lifetime relationships calendar with veterans to model the effects of military deployment on sexual partnering*
M. I. Rosen^{1,2}, A. C. Black^{1,2}, T. McMahon^{1,2}, L. Brecht³, M. N. Potenza^{1,2}, ¹Psychiatry, Yale University, West Haven, CT, ²VA Connecticut Healthcare System, West Haven, CT, ³School of Nursing, UCLA, Los Angeles, CA
- 59 *Associations between intervention intensity and underage drinking outcomes: A methodological approach from the Kansas SPF-SIG*
K. D. Anderson-Carpenter¹, J. Watson-Thompson², M. Jones³, L. Chaney⁴, ¹Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA, ²The University of Kansas, Lawrence, KS, ³Centers for Disease Control and Prevention, Atlanta, GA, ⁴Learning Tree Institute, Greenbush, Girard, KS
- 60 *New epidemiological research on 'school bonding' and drug involvement*
M. Chandra, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
- 61 *WITHDRAWN EPIDEMIOLOGY*
- 62 *Concordance between urine drug screen and self-reported cocaine use*
G. Sharma, N. Oden, P. VanVeldhuisen, The Emmes Corporation, Rockville, MD
- 63 *Intravenous and smoked methamphetamine produce different subjective and physiological effects in women*
N. E. Goeders, LSU Health Sciences Center, Shreveport, LA
- 64 *Comparative hazards of acute myocardial infarction among hospitalized patients with methamphetamine- or cocaine-use disorders: A retrospective cohort study*
J. Gatley¹, M. Osiowy¹, J. Sykes², S. J. Kish³, R. Callaghan¹, ¹Northern Medical Program, UNBC, Prince George, BC, Canada, ²Princes Margaret Cancer Centre, Toronto, ON, Canada, ³Human Brain Lab, CAMH, Toronto, ON, Canada
- 65 *Crack/Cocaine consumption and urban violence in Brazil: Data from the Brazilian National Alcohol and Drugs Survey*
C. S. Madruga¹, A. Q. Miguel¹, S. McPherson³, M. G. McDonell², R. Laranjeira¹, ¹Psychiatry, Federal University of São Paulo, Sao Paulo, Brazil, ²College of Medical Sciences, Elson S. Floyd College of Medicine, Washington, WA, ³Program of Excellence in Addictions Research, Washington State University, Washington, WA

- 66 *Factors predicting methamphetamine use among homeless people in Bangkok, Thailand*
C. Areesantichai¹, U. Perngparn¹, L. Cottler², ¹Drug Dependence Research Center
WHO Collaborating Center for Research and Training in Drug Dependence (WHOCC),
Chulalongkorn University, Bangkok, Thailand, ²Epidemiology, University of Florida,
Gainesville, FL
- 67 *Release from drinking-age restrictions is associated with increases in alcohol-related motor
vehicle collisions among young drivers in Canada*
R. Callaghan², J. Gatley², M. Sanches³, C. Benny⁴, ²Northern Medical Program, University of
Northern British Columbia, Prince George, BC, Canada, ³Biostatistical Consulting, CAMH,
Toronto, ON, Canada, ⁴Community Health Sciences, UNBC, Prince George, BC, Canada
- 68 *Ultrasound correlates of liver disease in patients seeking treatment for alcohol use disorder*
D. Fuster³, A. Sanvisens³, P. Zuluaga³, E. Barluenga⁴, I. Rivas², J. Tor¹, R. Muga¹, ¹Internal
Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Municipal Center
for Substance Abuse Treatment, Badalona, Spain, ³Medicine, Hospital Germans Trias i Pujol,
Badalona, Spain, ⁴Radiology, Hospital Germans Trias i Pujol, Badalona, Spain
- 69 *Gender differences in patterns of prescription opioid use and binge drinking among middle-
aged Floridians*
M. Serdarevic, L. Cottler, Epidemiology, University of Florida, Gainesville, FL
- 70 *Changes in nonmedical use of OxyContin after reformulation with abuse deterrent properties*
H. Chilcoat, P. Coplan, N. Sessler, R. Singh, Risk Management and Epidemiology, Purdue
Pharma, Stamford, CT
- 71 *Evaluating prescription drug abuse survey questions*
B. Sproule^{2,1}, M. Zhang^{2,1}, ¹University of Toronto, Toronto, ON, Canada, ²Centre for
Addiction and Mental Health, Toronto, ON, Canada
- 72 *Association between prescription opioid use and frequent emergency department use*
S. A. Milani, H. R. Crooke, L. Cottler, C. W. Striley, Epidemiology, University of Florida,
Gainesville, FL
- 73 *Peer networks, marital satisfaction and nonmedical use of prescription drugs among reserve
soldiers and partners*
S. Cercone Heavey², D. Homish², J. Devonish², E. M. Anderson Goodell¹, G. G. Homish²,
¹Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD,
²Community Health & Health Behavior, State University of New York at Buffalo,
Buffalo, NY
- 74 *Characteristics of pain patients related to risk of aberrant opioid medication behaviors*
S. F. Butler, R. A. Black, T. A. Cassidy, K. L. Zacharoff, S. H. Budman, Inflexxion, Inc.,
Newton, MA
- 75 *Multiple sources of payment and risky opioid therapy among military/VA*
W. Becker¹, E. Doyle⁴, B. Fenton³, J. Francis⁵, C. Brandt³, B. A. Moore², R. Kerns³,
P. Kreiner⁴, ¹Internal Medicine, VA Connecticut Healthcare System, West Haven, CT,
²Psychiatry, Yale University School of Medicine, New Haven, CT, ³VA Connecticut
Healthcare System, West Haven, CT, ⁴Brandeis University, Waltham, MA, ⁵VA Central
Office, Washington, DC
- 76 *Insurance is not enough: Significant increases in insurance coverage do not increase substance
abuse treatment entry among rural Appalachian drug users*
J. R. Havens, H. K. Knudsen, M. R. Lofwall, S. L. Walsh, Center on Drug and Alcohol
Research, University of Kentucky, Lexington, KY

- 77 *The role of adverse childhood experiences in initiation of substance use and sexual behaviors among opioid-using young adults*
H. Guarino¹, P. Mateu-Gelabert¹, S. Sirikantraporn², K. Ruggles³, C. Syckes¹, E. Goodbody¹, S. R. Friedman¹, ¹NDRI, New York, NY, ²Alliant International U, San Diego, CA, ³NYU, New York, NY
- 78 *Associations between integration and drug use among deported migrants in Tijuana, Mexico*
D. Horyniak^{1,2}, M. Pinedo³, J. Burgos¹, V. Ojeda¹, ¹Division of Global Public Health, University of California, San Diego, La Jolla, CA, ²Centre for Population Health, Burnet Institute, Melbourne, VIC, Australia, ³Alcohol Research Group, University of California, Berkeley, Berkeley, CA
- 79 *Utilization of opioid agonist therapy among persons who inject drugs in the Seattle area*
J. I. Tsui¹, S. N. Glick¹, H. Thiede², ¹School of Medicine, University of Washington, Seattle, WA, ²Public Health–Seattle & King County, Seattle, WA
- 80 *Systematic review and meta-analysis of injecting related injury and disease in people who inject drugs*
S. Larney², A. Peacock¹, B. M. Mathers³, L. Degenhardt², ¹School of Medicine, University of Tasmania, Hobart, TAS, Australia, ²NDARC, UNSW Australia, Sydney, NSW, Australia, ³Kirby Institute, UNSW Australia, Sydney, NSW, Australia
- 81 *Risk factors for prescription opioid misuse by duration of misuse*
V. Osborne, S. O. Lasopa, C. W. Striley, L. Cottler, Epidemiology, University of Florida, Gainesville, FL
- 82 *Self-compassion and substance use*
S. M. Paniagua¹, C. L. Phelps², K. D. Rosen¹, J. S. Potter¹, ¹Psychiatry, UT Health Science Center, San Antonio, TX, ²InnerAlly, San Antonio, TX
- 83 *Causes of death and expected years of life lost among opioid-dependent individuals using agonist therapy in the U.S. and Taiwan*
K. Chang¹, A. Saxon⁴, G. E. Woody³, J. Wang⁵, Y. Hser², ¹General Psychiatry, Jianan Psychiatric Center, Ministry of Health & Welfare, Tainan, Taiwan, ²Department of Psychiatry & Behavioral Sciences, UCLA, Los Angeles, CA, ³Psychiatry, University of Pennsylvania, Philadelphia, PA, ⁴Veterans Affairs Puget Sound Health Care System, USA, Seattle, WA, ⁵Public Health, National Cheng Kung University, Tainan, Taiwan
- 84 *Increasing abuse of gabapentin and pregabalin as reported to U.S. poison centers 2006 through 2014*
R. C. Dart², B. Bucher Bartelson⁴, S. G. Severtson³, G. Bau³, J. L. Green¹, ¹RADARS System, Denver Health, Denver, CO, ²RMPDC, Denver, CO, ³Rocky Mountain Poison and Drug Center, Denver, CO, ⁴Research, Rocky Mountain Poison and Drug Center, Denver, CO
- 85 *Introducing a new research method for evaluating alcohol and other drug use among fatally injured victims in Latin America*
G. Andreuccetti¹, V. Leyton¹, I. D. Miziara^{1,4}, N. P. Lemos², D. R. Munoz¹, C. J. Cherpitel³, H. B. Carvalho¹, ¹University of Sao Paulo Medical School, Sao Paulo, Brazil, ²Office of Chief Medical Examiner, San Francisco, CA, ³Alcohol Research Group, Emeryville, CA, ⁴Technical-Scientific Police Superintendency of the State of Sao Paulo, Sao Paulo, Brazil
- 86 *The impact of enrollment in methadone maintenance therapy on initiation of heavy drinking among people who use heroin*
J. Klimas, E. Wood, P. Nguyen, H. Dong, M. Milloy, T. Kerr, K. Hayashi, B.C. Centre for Excellence in HIV/AIDS, Urban Health Research Initiative, Vancouver, BC, Canada

PERINATAL DRUG ABUSE

- 87 *Pregnancy incidence and contraceptive use among young women who inject drugs in Sydney, Australia*
L. Maher^{1,2}, B. White³, C. Day³, K. Black⁴, ¹Centre for Immunology, Kirby Institute, Sydney, NSW, Australia, ²UNSW Australia, Faculty of Medicine, Sydney, NSW, Australia, ³Sydney University, Discipline of Addiction Medicine, Sydney, NSW, Australia, ⁴Central Clinical School, Sydney University, Sydney, NSW, Australia
- 88 *Trends in receipt of medication-assisted treatment for pregnant women with opioid use disorder in the United States*
L. MacAfee³, A. Sawyer², M. Terplan^{1,3}, ¹Behavioral Health System Baltimore, Baltimore, MD, ²Baltimore City Health Department, Baltimore, MD, ³Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI
- 89 *Reduction in alcohol, tobacco, and illicit drug use during childbearing years in the USA: A comparison of pregnant and non-pregnant women*
S. M. Watchko², Q. Brown¹, S. S. Martins¹, ¹Epidemiology, Columbia University, New York City, NY, ²Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
- 90 *Buprenorphine during pregnancy: Clearance and fetal exposure*
J. L. Coker¹, C. McLeod¹, S. L. Narayanan³, T. David³, J. Ritchie⁴, M. J. Mancino¹, Z. Stowe¹, ¹Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, ³Castle Medical, Smyrna, GA, ⁴Emory University, Atlanta, GA
- 91 *Where there's smoke: Psychosocial and mental health correlates of prenatal marijuana use*
J. S. Sadicario², S. S. Kelpin², D. Svikis¹, ¹Virginia Commonwealth Univ., Richmond, VA, ²Psychology, Virginia Commonwealth University, Richmond, VA
- 92 *Are stressful life events associated with smoking cigarettes and marijuana during pregnancy?*
A. M. Allen¹, J. Hughes², A. Alexander³, A. Lemieux⁴, S. Allen¹, K. Ward³, M. al'Absi⁴, ¹Family Medicine & Community Health, University of Minnesota, Minneapolis, MN, ²Biostatistics, University of Minnesota, Minneapolis, MN, ³Public Health, The University of Memphis, Memphis, TN, ⁴Biobehavior, University of Minnesota, Duluth, Duluth, MN
- 93 *Cigarette purchase task: Identifying quit success in pregnant cigarette smokers*
I. A. Zvorsky^{3,1}, R. Redner^{3,2}, A. N. Kurti^{3,2}, J. Priest¹, S. T. Higgins^{3,1}, ¹University of Vermont, Winooski, VT, ²Psychiatry, University of Vermont, Burlington, VT, ³Vermont Center on Behavior and Health, Burlington, VT
- 94 *Household smoking rules among pregnant and newly postpartum smokers*
D. R. Keith¹, A. N. Kurti¹, J. M. Skelly², S. Higgins¹, ¹Psychiatry, University of Vermont, South Burlington, VT, ²Medical Biostatistics, University of Vermont, Burlington, VT
- 95 *Comparing smoking topography of usual brand cigarettes in pregnant and non-pregnant women*
C. L. Bergeria^{2,3}, S. H. Heil^{1,2,3}, S. C. Sigmon^{1,2,3}, H. Durand³, S. Higgins^{1,2,3}, ¹Psychiatry, University of Vermont, Burlington, VT, ²Psychology, University of Vermont, Burlington, VT, ³Vermont Center on Behavior and Health, Burlington, VT
- 96 *Initial assessment of smoking status of pregnant women enrolled in a clinical trial for smoking cessation*
T. Nanovskaya¹, V. M. Fokina², H. West², C. Oncken³, M. S. Ahmed¹, G. Hankins¹, ¹OB/GYN Maternal Fetal Medicine, University of Texas Medical Branch, Galveston, TX, ²UTMB, Galveston, TX, ³University of Connecticut Health Center, Farmington, CT

- 97 *Trajectory of mental health among low-income smokers across pregnancy and postpartum*
V. H. Coleman-Cowger¹, B. Koszowski¹, M. Terplan², ¹Health & Analytics, Battelle, Baltimore, MD, ²Behavioral Health System, Baltimore, MD

NICOTINE: HUMAN STUDIES

- 98 *Validation of a purchase task for assessing the relative reinforcing efficacy of e-cigarettes*
I. Pericot-Valverde¹, S. Fernández-Artamendi¹, A. González-Roz², C. López-Núñez¹, S. E. Weidberg¹, R. Secades-Villa¹, ¹Department of Psychology, University of Oviedo, Oviedo, Spain, ²University of Oviedo, Oviedo, Spain
- 99 *Delay Discounting among smokers, e-cigarette users and non-dependent controls*
S. E. Weidberg, A. González-Roz, V. Martínez-Loredo, C. López-Núñez, I. Pericot-Valverde, R. Secades-Villa, Department of Psychology, University of Oviedo, Oviedo, Spain
- 100 *Development of a conceptual framework regarding consumer perception, health, and use patterns of electronic cigarettes*
T. M. Dailey, E. C. McNaughton, K. Manser, M. Behling, S. F. Butler, Inflexxion, Inc, Newton, MA
- 101 *Fear-eliciting antismoking ads unintentionally motivate smokers to consider an e-cigarette: The boomerang effect*
S. J. Kim, L. A. Marsch, Dartmouth College, Lebanon, NH
- 102 *Associations between educational attainment, smoking history, quit attempts and interest in quitting*
R. Denlinger², J. W. Tidey², D. Hatsukami³, E. Donny¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Brown University, Providence, RI, ³University of Minnesota, Minneapolis, MN
- 103 *Ongoing survey of alternative nicotine and tobacco use among cardiac patients*
Z. H. Morford¹, D. Gaalema¹, R. Elliott¹, P. Ades¹, S. Higgins², ¹University of Vermont, South Burlington, VT, ²University of Vermont, Burlington, VT
- 104 *Contraceptive use among female smokers*
H. S. Melbostad², G. J. Badger⁴, A. K. Matusiewicz¹, S. H. Heil¹, ¹Psychiatry, University of Vermont, Burlington, VT, ²Psychology, University of Vermont, Burlington, VT, ⁴Medical BioStatistics, University of Vermont, Burlington, VT
- 105 *A computerized adaptive testing version of the ASI*
R. A. Black^{1,2}, S. McCaffrey¹, S. F. Butler¹, ¹Inflexxion, Inc, Newton, MA, ²Psychology, Nova University, Ft. Lauderdale, FL

106 WITHDRAWN

- 107 *Initial subjective favorability moderates the relationship between false harm beliefs and daily consumption of reduced nicotine content cigarettes*
M. Mercincavage, M. L. Saddleson, A. Strasser, Center for Interdisciplinary Research on Nicotine Addiction and Tobacco Center of Regulatory Science, University of Pennsylvania, Philadelphia, PA
- 108 *Anxiety sensitivity as a predictor of acute subjective effects of smoking in African Americans*
C. Guillot, R. Pang, M. Kirkpatrick, A. Leventhal, University of Southern California, Los Angeles, CA

- 109 *Impact of lifetime depression and anxiety on effectiveness of mass distribution of nicotine patches: Secondary analysis of a randomized controlled trial*
V. Kushnir¹, B. Sproule¹, L. Zawertailo¹, P. Selby¹, R. Tyndale¹, S. Leatherdale², J. Cunningham¹, ¹Centre for Addiction and Mental Health, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada
- 110 *Different trajectories of smoking behaviors across racial groups*
L. Johnson, S. Hartz, L. Bierut, Psychiatry, Washington University in St. Louis, Saint Louis, MO
- 111 *Effects of electronic vs. combustible cigarette administration on smoking withdrawal suppression*
C. G. Aguirre, A. Leventhal, M. Kirkpatrick, N. Goldenson, J. Huh, Preventive Medicine, University of Southern California, Los Angeles, CA
- 112 *The tobacco status project: Three month outcomes for a randomized controlled trial of a Facebook smoking cessation intervention for young adults*
D. Ramo¹, J. Thrul¹, K. Delucchi¹, S. m. Hall¹, P. Ling¹, A. Belohlavek¹, S. Zhao¹, B. Han¹, J. Prochaska², ¹UCSF, San Francisco, CA, ²Stanford University, Stanford, CA
- 113 *Tobacco cessation among poor and underserved: Expanding alternatives through community-based participatory research*
P. Sheikhattari^{1,2}, C. Schutzman^{1,2}, T. Addison^{1,2}, J. Apata^{1,2}, J. Bucceri², M. Gunning², F. A. Wagner^{1,2}, ¹PSRC, Morgan State University, Baltimore, MD, ²CEASE, Baltimore, MD
- 114 *Impact of group motivational interviewing on enhancing treatment engagement for homeless veterans with nicotine dependence and other substance use disorders*
E. J. Santa Ana, S. LaRowe, K. J. Hartwell, K. Lamb, Charleston VAMC and MUSC, Charleston, SC

Late-Breaking Research

Fiesta 6/8
2:15 - 3:15 PM

Symposium XIV

Fiesta 6/8
3:30 - 5:30 PM

REDUCING THE HARMS OF OPIOID ANALGESIC USE IN HEALTH SYSTEMS

Chairs: Amy S. Bohnert and Tae Woo Park

- 3:30 *Treatment patterns associated with overdose among patients with comorbid pain and substance use disorders*
Tae Woo Park, Alpert Medical School of Brown University, Providence, RI
- 3:55 *Opioid risk mitigation in the military health system: Results from a mixed-methods study*
Jennifer Sharpe Potter, University of Texas Health Science Center San Antonio, San Antonio, TX
- 4:20 *Investigating clinicians' opioid prescribing and dispensing practices: A qualitative study*
Mark Edlund, RTI International, Research Triangle Park, NC
- 4:45 *Use of non-pharmacological strategies for pain relief in addiction treatment patients with chronic pain*
Lewei Allison Lin, University of Michigan Medical School, Ann Arbor, MI
- 5:10 *DISCUSSANT: Future directions in reducing opioid misuse and overdose*
David A Fiellin, Yale University School of Medicine, New Haven, CT

Oral Communications 17

Fiesta 10/14
3:30 - 5:30 PM

THE BREAKFAST CLUB: ADOLESCENTS

Chairs: Katherine M. Serafine and Kaliris Y. Salas-Ramirez

- 3:30 *Taurine's effects on cocaine reward in adolescent male and female rats*
U. Akpara, R. Liang, A. Villa-Gonzalez, D. Harris, A. Elzanie, K. Chauhan, C. Vasquez, T. Irving, A. Cole, K. Y. Salas-Ramirez, Department of Physiology, Pharmacology and Neuroscience, CUNY School of Medicine, New York, NY, Brooklyn, NY
- 3:45 *Addiction-like and cognitive effects of adolescent cannabinoid self-administration in rats*
E. Kirschmann, M. Pollock, V. Nagarajan, M. M. Torregrossa, Psychiatry, University of Pittsburgh, Pittsburgh, PA
- 4:00 *Sex differences in high fat diet-induced enhancement of sensitivity to the behavioral effects of the dopamine D2/D3 receptor agonist quinpirole in adolescent rats*
K. M. Serafine, C. Hernandez-Casner, J. Ramos, Psychology, University of Texas at El Paso, El Paso, TX
- 4:15 *Altered intrinsic brain connectivity in prenatally cocaine-exposed adolescents*
Y. Zakariaeiz, S. W. Yip, I. Balodis, C. Lacadie, L. C. Mayes, R. Sinha, M. N. Potenza, Psychiatry, Yale University, New Haven, CT
- 4:30 *Age and working memory predict delay discounting in adolescents in treatment for cannabis use disorders*
M. M. Sweeney, M. W. Johnson, Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD
- 4:45 *Neural activity in childhood predicts adolescent substance use initiation*
L. M. Cope, J. Heffernan, C. S. Sripada, J. E. Hardee, R. A. Zucker, M. Heitzeg, University of Michigan, Ann Arbor, MI
- 5:00 *Predicting contingency management treatment efficacy among adolescents by using measures of impulsivity*
A. Harvanko, J. C. Strickland, B. Reynolds, University of Kentucky, Lexington, KY
- 5:15 *A novel paradigm associated with callous unemotional traits among adolescents with substance and conduct problems: Behavioral and fMRI findings*
J. Sakai¹, M. Dalwani¹, S. K. Mikulich-Gilbertson¹, S. K. McWilliams¹, K. Raymond¹, J. Tanabe¹, M. T. Banich², T. J. Crowley¹, ¹University of Colorado, Aurora, CO, ²University of Colorado Boulder, Boulder, CO

Oral Communications 18

Fiesta 4
3:30 - 5:30 PM

SUPER SIZE ME: ALTERNATE ADDICTIONS

Chairs: Elizabeth C. Katz and Cecile M. Denis

- 3:30 *Naloxone-precipitated withdrawal following sucrose self-administration in C57BL/6 mice*
C. Kroll, B. D. Fischer, Cooper Medical School of Rowan University, Camden, NJ
- 3:45 *Chronic fructose consumption enhances cue-triggered cocaine- and food-seeking*
A. Koshelev¹, L. Tsan¹, Y. Zhuang¹, F. Gomez-Pinilla¹, S. Ostlund², N. Murphy¹, N. Maidment¹, ¹University of California Los Angeles, Encino, CA, ²University of California Irvine, Irvine, CA

- 4:00 *Eating disorder, food addiction and associated factors in obese patients*
M. Fatseas³, M. Henry⁴, M. C. Rosa¹, J. Collombat³, A. Gregoire³, C. Kervran³, B. Cherifi⁴,
M. Auriacombe³, ¹Center for Drug and Alcohol Research, Federal University of Rio Grande
do Sul, Porto Alegre, Brazil, ³Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux,
Bordeaux, France, ⁴Obesity Clinic, CHU de Bordeaux, Bordeaux, France
- 4:15 *Are DSM-5 criteria for SUD transferable to food addiction? IRT analysis for alcohol, tobacco,
cannabis, opiate and food addiction in a clinical sample*
C. M. Denis^{1,3}, M. C. Rosa^{5,3}, F. Serre³, C. Kervran³, M. Henry⁴, B. Cherifi⁴, M. Auriacombe^{1,3},
M. Fatseas³, ¹Univ. Pennsylvania, Philadelphia, PA, ³Addiction Psychiatry, Univ. Bordeaux /
CNRS USR 3413, Bordeaux, France, ⁴Obesity Clinic, CHU de Bordeaux, Bordeaux, France,
⁵Univ. Rio Grande, Porto Allegre, Brazil
- 4:30 *Video game addiction: Duration of play and impulsivity*
F. D. Buono², B. A. Moore³, D. M. Printz³, D. P. Lloyd³, C. J. Cutter¹, M. E. Sprong⁴,
¹Internal Medicine, Yale School of Medicine, New Haven, CT, ²Psychiatry, Yale University,
New Haven, CT, ³Psychiatry, Yale University School of Medicine, New Haven, CT,
⁴Rehabilitation Counseling, Northern Illinois University, DeKalb, IL
- 4:45 *Association between working memory, impulsivity and problematic technology use*
C. Lewis, E. C. Katz, Psychology, Towson University, Towson, MD
- 5:00 *Game type as a moderator of the relationship between pathological video game use, impulsivity,
aggression, and general psychopathology*
M. S. Sferra¹, S. Fields¹, D. Gentile², ¹Psychology, Texas A&M University, College
Station, TX, ²Psychology, Iowa State University, Ames, IA
- 5:15 *Reduced precuneus activation in adolescents at risk for food addiction*
J. Hardee, A. Gearhardt, L. M. Cope, R. Zucker, M. Heitzeg, Psychiatry, University of
Michigan, Ann Arbor, MI

Oral Communications 19

Fiesta 12
3:30 - 5:30 PM

WHAT'S LOVE GOT TO DO WITH IT?: TRAUMA/PTSD

Chairs: Shane A. Perrine and Jacquelyn L. Meyers

- 3:30 *Cocaine self-administration and single prolonged stress produce hyperarousal-like, but not
anxiety-like, behavior in rats*
M. J. Lisieski, S. A. Perrine, Psychiatry and Behavioral Neurosciences, Wayne State
University School of Medicine, Detroit, MI
- 3:45 *A modified single prolonged stress episode delays acquisition of cocaine self-administration*
R. S. Hofford, M. A. Prendergast, M. T. Bardo, Psychology, University of Kentucky,
Lexington, KY
- 4:00 *Pharmacological mechanisms of MDMA's facilitative effect on fear extinction*
M. Young¹, L. F. Berro², L. Howell¹, ¹Emory University, Atlanta, GA, ²Yerkes National
Primate Research Center, Emory University, Atlanta, GA
- 4:15 *Early life trauma, neurocognitive functioning, and substance use*
J. L. Meyers^{1,2}, V. V. McCutcheon³, J. Salvatore⁴, D. Chorlian¹, A. Pandey¹, *. Collaborative
Study on the Genetics of Alcoholism Collaborators¹, K. K. Bucholz³, B. Porjesz¹, ¹Psychiatry,
The State University of New York, Brooklyn, NY, ²Columbia University, New York, NY,
³Washington University School of Medicine, St. Louis, MO, ⁴Virginia Commonwealth
University, Richmond, VA

Wednesday, June 15, 2016

- 4:30 *Oxytocin decreases methamphetamine-seeking and gene expression changes in rats after traumatic stress*
J. F. McGinty, Neuroscience, Medical University of South Carolina, Charleston, SC
- 4:45 *Concurrent treatment with prolonged exposure for co-occurring PTSD and substance use disorders: A randomized clinical trial*
D. Hien^{1,2}, L. Ruglass³, S. Back⁴, ¹Psychology, Adelphi University, NY, NY, ²Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, ³Psychology, City College of New York, New York, NY, ⁴Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
- 5:00 *Nonmedical and illicit drug use: Associations with PTSD severity & symptom clusters among a sample of U.S. Army Reserve/National Guard Soldiers*
D. Homish¹, S. Cercone Heavey¹, J. Devonish¹, J. Cornelius², G. G. Homish¹, ¹Community Health & Health Behavior, State University of New York at Buffalo, Buffalo, NY, ²Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA

Business Meeting
(MEMBERS ONLY)

CAPRA
5:30 - 6:30 PM

DINNER AND DANCING
BADGES MUST BE WORN FOR ADMISSION

Fiesta Ballroom
7:30 - 10:30 PM

Please be advised that no photographing of presentations or data is permitted.
Badges must be worn at all times and are required for admission into all events and sessions.

Poster Session IV

(Breakfast)

Odd-numbered posters manned first hour;

Even-numbered, second hour

Set-up time begins Wednesday, 3PM

Must be removed by Thursday 12 Noon

PROGRAM DESCRIPTION

- 1 *Forging a new path: Urban Indian approaches to service improvement in Ramsey County, Minnesota*
A. H. Skinstad, J. Gringer Richards, L. E. Thompson, S. A. Bear, Dept of Community and Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA
- 2 *Mother and child: Improving the health of opiate-dependent mothers and their babies using a community-based peer counselor*
T. L. Horton, L. Bechler, B. L. Wilson, M. Lanyon, c. Jurkovitz, Y. Washio, Christiana Care Health System, Newark, DE
- 3 *“Group Prenatal Care” – Providing obstetric care in a community-based substance abuse treatment center*
E. Zadzielski, S. Rogers, S. Gargano, Y. Washio, Christiana Care Health Services, Newark, DE
- 4 *Integrated telemedicine-based treatment for hepatitis C at an opioid agonist treatment program*
L. S. Brown^{6,8}, A. Talal^{2,3,4}, P. Andrews⁴, A. Mcleod¹, M. Zeremski⁵, Y. Chen⁷, C. Sylvester¹,
¹Research & Evaluation, START: Treatment & Recovery Centers, Brooklyn, NY, ²Medicine, University at Buffalo, Buffalo, NY, ³Gastroenterology, Hepatology, and Nutrition, Cornell University, New York, NY, ⁴Medicine, START: Treatment & Recovery Centers, New York, NY, ⁵Gastroenterology, Hepatology, and Nutrition, Cornell University, New York, NY, ⁶CEO, START: Treatment & Recovery Centers, Brooklyn, NY, ⁷Biostatistics, University at Buffalo, Buffalo, NY, ⁸Medicine, Weill Cornell Medical College, New York, NY
- 5 *OverdoseFreePA.org: A resource for overdose prevention in Pennsylvania*
M. D. Reynolds, J. L. Pringle, S. Rickard-Aasen, J. Oblak, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA
- 6 *Images for science communications pertinent to drug dependence research and to the general public*
D. Barondess, J. C. Anthony, Epidemiology and Biostatistics, Michigan State University, East Lansing, MI
- 7 *Contribution of e-learning to addiction teaching: A successful experience at the University of Bordeaux, France*
M. Auriacombe¹, J. Alexandre¹, J. Dubernet¹, J. Tanguy², M. Fatseas¹, ¹Addiction Psychiatry (CNRS USR 3413), Universite Bordeaux, Bordeaux, France, ²MAPI, Univ. Bordeaux, Bordeaux, France
- 8 *The research in addiction medicine scholars program – Developing researchers in addiction fellowships*
P. O'Connor³, J. I. Tsui², D. Gobel¹, B. Brett⁵, C. Briden¹, J. H. Samet^{4,1}, ¹Boston Medical Center, Boston, MA, ²Internal Medicine, University of Washington School of Medicine, Seattle, WA, ³Yale University, New Haven, CT, ⁴Boston University, Boston, MA, ⁵Brett Consulting Group, Somerville, MA

- 9 *Specialized community disease management to reduce substance use and hospital readmissions*
J. E. Chambers¹, A. C. Brooks¹, M. F. Morrison², J. R. McKay³, D. R. Gastfriend¹, ¹Treatment Research Institute, Philadelphia, PA, ²Lewis Katz School of Medicine at Temple University, Philadelphia, PA, ³Department of Psychiatry, University of Pennsylvania, Philadelphia, PA
- 10 *Research to practice: Fidelity monitoring and lessons learned with patient navigation and HIV*
K. Gilmore², D. Svikis¹, A. Rhodes², T. Moore¹, L. Yerkes², ¹Virginia Commonwealth Univ., Richmond, VA, ²Virginia Department of Health, Richmond, VA
- 11 *Theoretical implications of gender, power, and sexual scripts for HIV prevention programs aimed at young, substance-using African American women*
M. Hill¹, A. Stotts², ¹Emergency Medicine, University of Texas Health Science Center, McGovern Medical School, Houston, TX, ²University of Texas Medical School at Houston, Houston, TX
- 12 *RICH Recovery: Integrating primary and behavioral healthcare for individuals with substance use disorders*
J. May^{2,1}, D. Farrell-Moore^{2,1}, D. N. Masri^{2,1}, B. Cox^{2,1}, ¹Grants, Research, Evaluation and Planning, RBHA, Richmond, VA, ²Richmond Behavioral Health Authority, Richmond, VA
- 13 *The Baltimore reproductive health initiative: Bringing family planning to women in treatment*
M. Terplan¹, J. Kirschner², S. Muqueeth², R. Dineen², ¹Behavioral Health System Baltimore, Baltimore, MD, ²Baltimore City Health Department, Baltimore, MD
- 14 *Using electronic health records data for clinical research*
L. T. Wu², S. Spratt², B. Heidenfelder², B. Tai⁴, U. Ghitza⁴, ²Duke University, Durham, NC, ⁴NIDA, Bethesda, MD
- 15 *Foundational development of a post-market surveillance program for e-vapor products using Internet forum data*
E. C. McNaughton, T. M. Dailey, M. Behling, S. F. Butler, Inflexxion, Inc., Newton, MA
- 16 *In-house outreach: Strategies to promote and advertise a smoking cessation program in a Mexican university hospital*
O. Campollo^{1,2}, O. Torres¹, ¹Center of Alcoholism and Addictions, University of Guadalajara, Guadalajara, Mexico, ²Molecular Biology, Hospital Civil de Guadalajara FAA, Guadalajara, Mexico

LITERATURE REVIEW

- 17 *Prenatal cannabis exposure and cognitive functioning: A critical review*
C. A. Torres², C. L. Hart^{1,3}, ¹Psychology, Columbia University, New York, NY, ²School of Social Work, Columbia University, New York, NY, ³Psychiatry, Columbia University, New York, NY
- 18 *A review of recent developments (2012-15) on the use of financial incentives with pregnant smokers*
D. R. Davis^{1,2}, L. J. Solomon², S. Higgins^{2,1}, ¹Psychology, University of Vermont, Burlington, VT, ²Psychiatry, University of Vermont, Burlington, VT
- 19 *WITHDRAWN*
- 20 *Community-based drug treatment in Thailand*
U. Perngparn, C. Areesantichai, Drug Dependence Research Center WHO Collaborating Center for Research and Training in Drug Dependence (WHOCC), Chulalongkorn University, Bangkok, Thailand

- 21 *Systematic review: Do take-home naloxone programs effectively reduce opioid overdose deaths? A Bradford Hill analysis*
R. McDonald, J. Strang, Addictions Department, King's College London, London, United Kingdom
- 22 *Prescription stimulant non-medical use: Literature review*
S. Vosburg, M. Sokolowska, Grunenthal, Morristown, NJ
- 23 *A systematic review of barriers and facilitators to implementing a prescription drug monitoring program*
A. A. Garcia¹, K. D. Rosen², E. Finley³, J. S. Potter¹, ¹Psychiatry, University of Texas Health Science Center San Antonio, San Antonio, TX, ²University of Texas Health Science Center, San Antonio, TX, ³South Texas Veterans Healthcare System, San Antonio, TX
- 24 *Opioid therapy misuse factors: A systematic review*
K. Song^{1,3}, D. McGeary², M. Pugh^{4,5}, W. Kazanis², S. M. Paniagua², E. Finley^{4,6}, A. A. Garcia², V. Bebart⁷, D. Carnahan^{8,9}, J. S. Potter², ¹Pharmacotherapy Education & Research Center, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, ²Psychiatry, UT Health Science Center, San Antonio, TX, ³Pharmacy, South Texas Veterans Healthcare System, San Antonio, TX, ⁴South Texas Veterans Healthcare System, San Antonio, TX, ⁵Epidemiology & Biostatistics, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, ⁶Division of Clinical Epidemiology, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, ⁷San Antonio Military Medical Center, San Antonio, TX, ⁸Defense Health Agency, San Antonio, TX, ⁹United States Air Force Medical Support Agency, San Antonio, TX

PREVENTION

- 25 *Child-parent attachment mediates but not moderates parent and child substance involvement*
Z. Zhai², T. Ridenour¹, R. E. Tarter³, ¹Research Triangle Institute, Allison Park, PA, ²Psychiatry, Yale University School of Medicine, New Haven, CT, ³University of Pittsburgh School of Pharmacy, Pittsburgh, PA
- 26 *Are distinct parenting practices all equally protective against adolescent substance use?*
L. A. Ghandour, N. J. El Salibi, N. Yassin, R. Afifi, American University of Beirut, Beirut, Lebanon
- 27 *Conflicts between youths and their parents in relation to future NIDA prevention research*
J. R. Parra-Cardona¹, H. H. Yeh², J. C. Anthony², ¹Michigan State University, East Lansing, MI, ²Epidemiology, Michigan State University, East Lansing, MI
- 28 *Is parenting really that stressful? Daily behavioral stress in drug-using parents compared to non-parents*
A. Moreland¹, D. Brown³, N. Baker², A. McRae-Clark¹, ¹Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, SC, ³Howard University, Washington, DC
- 29 *Codeine misuse/dependence: Best practice and future innovations in addressing risk, harm and successful treatment*
C. D. Parry¹, M. van Hout², I. Norman³, ¹Alcohol, Tobacco & Other Drug Research Unit, South African Medical Research Council, Cape Town, South Africa, ²School of Health Sciences, Waterford Institute of Technology, Waterford, Ireland, ³Florence Nightingale Faculty of Nursing & Midwifery, King's College London, London, United Kingdom

- 30 *An exploratory factor analysis of a brief self-report scale to detect neurocognitive impairment among MMT patients*
M. Copenhaver^{1,2}, R. Shrestha^{2,3}, F. L. Altice⁴, ¹Allied Health Sciences, University of Connecticut, Storrs, CT, ²Center for Health, Intervention, and Prevention, University of Connecticut, Storrs, CT, ³Community Medicine & Health Care, University of Connecticut Health Center, Farmington, CT, ⁴Department of Medicine, Yale University, New Haven, CT
- 31 *The Affordable Care Act and HIV/HCV testing in substance use disorder treatment programs*
C. N. Behrends⁵, J. A. Frimpong¹, T. D'Aunno², H. Pollack⁴, B. Schackman⁵, P. Friedmann³, ¹Columbia University, New York, NY, ²New York University, New York, NY, ³Baystate Health, Springfield, MA, ⁴University of Chicago, Chicago, IL, ⁵Weill Cornell Medical College, New York, NY
- 32 *Harm reduction service utilization and HIV incidence among people who inject drugs in Ukraine*
D. C. Ompad¹, J. Wang¹, K. Dumchev³, J. Barska⁴, M. Samko⁴, O. Zeziulin³, T. Salyuk⁴, O. Varetska⁴, J. DeHovitz⁵, ¹New York University, New York, NY, ³Ukrainian Institute on Public Health Policy, Kiev, Ukraine, ⁴Alliance for Public Health Ukraine, Kiev, Ukraine, ⁵SUNY Downstate Medical Center, Brooklyn, NY
- 33 *HIV pre-exposure prophylaxis for people who inject drugs: Willingness to prescribe among general internists*
E. J. Edelman¹, B. A. Moore¹, G. Berkenblit², S. Calabrese¹, C. Cunningham⁴, D. A. Fiellin¹, V. Patel⁴, K. A. Phillips³, J. Tetrault¹, M. Shah⁵, O. Blackstock⁴, ¹Yale, New Haven, CT, ²Johns Hopkins, Baltimore, MD, ³NIDA-IRP, NIH, Baltimore, MD, ⁴Montefiore, Bronx, NY, ⁵UIC, Chicago, IL
- 34 *High-risk behaviors among Iranian female drug users inspiring health belief model*
E. Merghati-khoei¹, M. Jamshidimanesh¹, I. Ilika¹, M. Hosseini², ¹Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of), ²Epidemiology, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of)
- 35 *Screening for oral cancer in tobacco and/or alcohol addicts: A comparison of different organizations*
S. Rollier, Public Health, Centre Hospitalier Régional Universitaire de TOURS, Tours, France
- 36 *The interaction of masculine gender norm conformity and depression predict alcohol use in African American young adult men*
F. Fonseca, C. M. Risco, M. L. Boyd, T. S. Chaudhry, G. M. Munayco, C. I. Burt, C. W. Lejuez, R. Yi, Psychology, University of Maryland, College Park, MD
- 37 *Marijuana use in young adult women & men attending primary care: Results from a pilot study integrating behavioral health care into primary care*
G. Lapham, M. Addis, A. K. Lee, C. Achtmeyer, J. Richards, E. Ludman, T. Gildred, R. Caldeiro, L. Marx, P. Lozano, K. A. Bradley, Group Health Research Institute, Seattle, WA
- 38 *Application of system dynamics to inform a model of adolescent SBIRT implementation in primary care settings*
S. G. Mitchell¹, D. Lounsbury², Z. Li⁵, R. P. Schwartz¹, J. Gryczynski¹, A. Kirk³, M. Oros⁴, C. Hosler⁴, K. Dusek¹, B. Brown¹, ¹Friends Research Institute, Baltimore, MD, ²Albert Einstein College of Medicine, Yeshiva University, Bronx, NY, ³Total Health Care, Baltimore, MD, ⁴The Mosaic Group, Baltimore, MD, ⁵College of Global Public Health, New York University, New York, NY
- 39 *Key ingredients for conducting daily or weekly IVR/SMS surveys*
L. Massey¹, M. A. Walton¹, R. M. Cunningham², J. Cranford¹, A. Buu³, ¹Psychiatry, University of Michigan, Ann Arbor, MI, ²Emergency Medicine, University of Michigan, Ann Arbor, MI, ³School of Nursing, University of Michigan, Ann Arbor, MI

- 40 *E-cigarette expectancies: Initial qualitative assessment for measure development*
P. T. Harrell¹, G. Quinn², B. Vesely¹, T. Brandon², ¹Pediatrics, Eastern Virginia Medical School, Norfolk, VA, ²Health Outcomes & Behavior, Moffitt Cancer Center, Tampa, FL

41 *WITHDRAWN*

POLYDRUG

- 42 *Psychedelic-associated addiction remission: An online survey*
A. Garcia-Romeu, R. R. Griffiths, M. W. Johnson, Psychiatry, Johns Hopkins, Baltimore, MD
- 43 *A pilot study of the feasibility and potential effectiveness of using smartphones to provide recovery support*
C. K. Scott¹, M. L. Dennis¹, D. Gustafson², K. Johnson², ¹Lighthouse Institute, Chestnut Health Systems, Chicago, IL, ²CHESS, University of Wisconsin, Madison, WI
- 44 *Healthcall on smartphone: A brief intervention to reduce concurrent drug and alcohol use*
E. Aharonovich^{1,2}, E. Greenstein², A. Le², D. S. Hasin^{1,2}, ¹Psychiatry, Columbia University Medical Center, New York, NY, ²NYSPI, New York, NY
- 45 *Clinician involvement with internet-delivered treatment and association to outcomes*
A. Campbell¹, E. V. Nunes¹, M. Pavlicova², ¹Department of Psychiatry, Columbia University Medical Center, New York, NY, ²Columbia University, New York, NY
- 46 *Comparing predictors of treatment completion and length of stay for outpatient treatment*
G. Stahler, J. Mennis, Temple University, Philadelphia, PA
- 47 *Housing status, psychiatric distress, and substance use among sober living house residents*
D. L. Polcin, R. Korcha, A. Mericle, S. Gupta, J. Witbrodt, Alcohol Research Group, Public Health Institute, Emeryville, CA
- 48 *Intrinsic and extrinsic motivation predict treatment outcome in a sample of HIV+ drug users*
D. Cannizzaro¹, M. Stohl¹, D. Hasin^{1,2}, E. Aharonovich^{1,2}, ¹New York State Psychiatric Institute, New York, NY, ²Psychiatry, Columbia University, New York, NY
- 49 *Methadone maintenance therapy and comorbid substance use: A brief qualitative report*
N. Puri, R. McNeil, W. Small, Urban Health Research Institute, BC Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada
- 50 *Performance of the TAPS-I brief screening tool in primary care*
J. Gryczynski², J. McNeely⁴, L. T. Wu¹, G. Subramaniam³, G. Sharma⁵, C. Nordeck², A. Sharma², L. A. Cathers⁶, C. Cushing³, D. Svikis⁶, E. Jelstrom⁵, K. O'Grady⁷, R. P. Schwartz², ¹Duke University, Durham, NC, ²Friends Research Institute, Baltimore, MD, ³NIDA, Rockville, MD, ⁴NYU, New York, NY, ⁵The EMMES Corporation, Rockville, MD, ⁶VCU, Richmond, VA, ⁷Univ. of Maryland, College Park, MD
- 51 *Prevalence and correlates of recovery from drug dependence*
J. A. Cranford², C. J. Boyd¹, S. McCabe³, ¹Health Behavior and Behavioral Science, University of Michigan, Ann Arbor, MI, ²Psychiatry, University of Michigan, Ann Arbor, MI, ³Institute for Research on Women & Gender, University of Michigan, Ann Arbor, MI

COMORBIDITY

- 52 *Feasibility and satisfaction of the women's recovery group for patients with co-occurring substance use and eating disorders*
S. F. Greenfield^{1,2,3}, D. E. Sugarman^{1,2,3}, B. Iles², E. Dechant³, T. Weigel³, P. Tarbox³, ¹Harvard Medical School, Boston, MA, ²Division of Alcohol and Drug Abuse, McLean Hospital, Belmont, MA, ³Division of Women's Mental Health, McLean Hospital, Belmont, MA

- 53 *Smartphone-enhanced behavioral activation treatment for substance use and depression*
Y. Chen², J. A. De Leo², L. Matalenas¹, A. C. McLaughlin¹, A. Petruzzella², E. Jones²,
S. B. Daughters², ¹Department of Psychology, North Carolina State University, Raleigh, NC,
²Department of Psychology and Neuroscience, University of North Carolina at Chapel Hill,
Chapel Hill, NC
- 54 *Nicotine metabolite ratio and associations with smoking topography in a population with
affective disorders*
D. Gaalema², J. W. Tidey¹, R. Tyndale³, S. Higgins², ¹Center for Alcohol & Addictions
Studies, Brown University, Providence, RI, ²University of Vermont, Burlington, VT,
³University of Toronto, Toronto, ON, Canada
- 55 *OCD symptom severity and tobacco withdrawal symptomatology among African American
smokers*
M. S. Bello, J. F. McBeth, R. Pang, A. Leventhal, Preventive Medicine, University of
Southern California, Los Angeles, CA
- 56 *Emotion dysregulation in adult smokers with and without ADHD: Baseline differences and
abstinence-induced effects*
J. T. Mitchell², C. W. Lejuez⁶, F. McClernon², J. Beckham^{2,5}, R. A. Brown⁷, S. H. Kollins¹,
¹Psychiatry, Duke University Medical Center, Durham, NC, ²Psychiatry & Behavioral
Sciences, Duke University Medical Center, Durham, NC, ⁵Veterans Affairs Medical Center,
Durham, NC, ⁶University of Maryland, College Park, MD, ⁷University of Texas at Austin,
Austin, TX
- 57 *Facets of mindfulness mediate the relationship between depressive symptoms and smoking
expectancies*
C. Vinci¹, C. A. Spears³, M. R. Peltier¹, A. Copeland¹, ¹UT MD Anderson Cancer Center,
Houston, TX, ³The Catholic University of America, Washington, DC
- 58 *High prevalence of major depression among treatment-seeking ketamine-dependent patients*
L. Chen¹, K. Xu², C. Chen⁴, M. Huang³, ¹General Psychiatry, Taipei City Psychiatric
Center, Taipei City Hospital, Songde Branch, Taipei, Taiwan, ²Yale School of Medicine,
New Haven, CT, ³Taipei City Psychiatric Center, Taipei, Taiwan, ⁴Department of Psychiatry,
Chang Gung Memorial Hospital, Keelung, Taiwan
- 59 *Major depressive disorder and family history of alcoholism in two treatment samples: Does
gender matter?*
K. M. Polak¹, A. Edwards², K. S. Kendler², D. Svikis¹, E. Ngjelina¹, S. Spicer¹, ¹Psychology,
Virginia Commonwealth University, Henrico, VA, ²Psychiatry, Virginia Commonwealth
University, Richmond, VA
- 60 *Substance use disorder and home neighborhood disorder do not predict posttraumatic stress
symptoms*
S. K. Hertz, L. Moran, W. J. Kowalczyk, D. H. Epstein, K. L. Preston, K. A. Phillips,
Treatment Section, NIDA IRP, Baltimore, MD
- 61 *Predictors of barriers to mental healthcare service utilization in returning veterans*
M. B. Benz¹, B. Borsari^{1,2}, J. Metrik^{1,3}, ¹Center for Alcohol and Addiction Studies, Brown
University, Providence, RI, ²San Francisco VAMC, San Francisco, CA, ³Providence VAMC,
Providence, RI
- 62 *Greater psychiatric morbidity among youth with synthetic cannabinoid use in residential
treatment*
V. L. Selby^{2,1}, C. Storr², M. Fishman^{3,1}, ¹Maryland Treatment Centers, Baltimore, MD,
²University of Maryland School of Nursing, Baltimore, MD, ³Johns Hopkins School of
Medicine, Baltimore, MD

- 63 *Improvement in psychiatric symptoms during Interim buprenorphine treatment*
J. M. Streck¹, T. A. Ochalek¹, B. Hruska³, J. D. Pusey³, S. C. Sigmon³, ¹Psychological Science, University of Vermont, Burlington, VT, ³Psychiatry, University of Vermont, Burlington, VT
- 64 *The impact of addiction medications on outcomes for persons with co-occurring PTSD and opioid use disorders*
E. Saunders¹, M. P. McGovern⁴, C. Lambert-Harris², A. Meier⁴, B. McLeman³, ¹The Dartmouth Institute, Lebanon, NH, ²Psychiatry, Dartmouth Geisel School of Medicine, Lebanon, NH, ³Dartmouth Psychiatric Research Center, Lebanon, NH, ⁴Psychiatry, Dartmouth Geisel School of Medicine, Lebanon, NH
- 65 *Development and pilot test of integrated cognitive behavioral therapy for anxiety and opioid use disorder*
K. McHugh, S. F. Greenfield, R. Weiss, McLean Hospital/Harvard Medical School, Belmont, MA
- 66 *Life in the barrio: Stress, depression and drug use*
Y. Villarreal¹, M. R. Klawans¹, L. Torres², P. Bordnick², A. Stotts¹, ¹McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, ²Graduate College of Social Work, University of Houston, Houston, TX
- 67 *Anxiety disorders as a risk factor for needle sharing among cocaine users: Results from the COSMO study*
A. Levesque^{2,3}, E. Roy¹, D. Jutras-Aswad^{2,5}, G. Zang², A. Arteni^{2,3}, J. Bruneau^{2,4}, ¹Community Health Sciences, Université de Sherbrooke, Longueuil, QC, Canada, ²Research Center, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ³Family Medicine, McGill University, Montreal, QC, Canada, ⁴Family and Emergency Medicine, Université de Montréal, Montreal, QC, Canada, ⁵Psychiatry, Université de Montréal, Montréal, QC, Canada
- 68 *Acute tryptophan depletion in cocaine dependent subjects with comorbid-depression*
M. Torrens^{2,1,3}, J. I. Mestre-Pintó¹, C. Pérez-Mañà^{1,3}, E. Papaseit^{1,3}, F. Fonseca^{2,1,3}, M. Farré^{4,1,3}, ¹Institut Hospital del Mar d'Investigacions Mèdiques, PSMAR, Barcelona, Spain, ²Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Barcelona, Spain, ³Universitat Autònoma de Barcelona, Barcelona, Spain, ⁴Hospital Universitari Germans Trias i Pujol-IGTP, Badalona, Spain
- 69 *Effect of vasopressin and oxytocin on ACTH secretion in cocaine-dependent patients*
M. S. Heller, F. R. Levin, E. V. Nunes, W. N. Raby, Psychiatry, Columbia University, New York, NY
- 70 *Effects of plasma pregnanolone levels on stress response, mood and drug craving in cocaine-dependent men and women*
V. Milivojevic¹, H. C. Fox¹, J. Covault², R. Sinha¹, ¹Psychiatry, Yale University School of Medicine, New Haven, CT, ²Psychiatry, University of Connecticut School of Medicine, Farmington, CT

IMPULSIVITY

- 71 *Self-reported impulsivity is related to age at first methamphetamine use*
A. Cservenka², L. Ray^{1,2,3}, ¹Psychology, University of California, Los Angeles, Los Angeles, CA, ²Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, ³Brain Research Institute, University of California, Los Angeles, Los Angeles, CA
- 72 *Differences in clinical presentation between high and low impulsive methamphetamine users*
E. E. Hartwell^{2,3}, L. Ray^{2,1}, ¹Psychiatry, UCLA, Los Angeles, CA, ²Psychology, UCLA, Los Angeles, CA, ³Integrated Substance Abuse Programs, UCLA, Los Angeles, CA

- 73 *Behavioral impulsivity as a predictor of success in a smoking cessation in adolescents*
S. M. Dowd¹, S. Fields¹, B. Reynolds², ¹Psychology, Texas A&M University, College Station, TX, ²University of Kentucky, Lexington, KY
- 74 *Impulsivity, sensation seeking and substance use among adolescents: A longitudinal research study*
L. Carla, V. Martinez-Loredo, S. Fernández Artamendi, J. Fernández-Hermida, I. Pericot-Valverde, W. Sara, R. Secades-Villa, University of Oviedo, Spain, Oviedo, Spain
- 75 *Assessing naturalistic risk-taking in nondaily smokers using a novel momentary balloon analogue risk task*
R. R. MacLean^{3,1,2}, J. M. Smyth³, C. F. Geier³, S. J. Wilson³, ¹VA Connecticut Healthcare System, West Haven, CT, ²Yale University, New Haven, CT, ³Pennsylvania State University, University Park, PA
- 76 *Psychopathological symptoms, impulsivity and decision making in HIV patients with and without tobacco smoking*
A. Lim, E. Lau, L. Chang, Department of Medicine, University of Hawaii, John A. Burns School of Medicine, Honolulu, HI

STIMULANTS: HUMAN STUDIES

- 77 *History of cocaine sensitization in humans is associated with lipidomic changes similar to those in cocaine-sensitized rats*
K. L. Preston², K. A. Phillips⁴, J. J. Wagner³, B. Cummings³, D. H. Epstein¹, ¹Treatment Section, NIDA IRP, Baltimore, MD, ²Clinical Pharmacology and Therapeutics Research Branch, NIDA Intramural Research Program, Baltimore, MD, ³Univ. of Georgia, Athens, GA, ⁴Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD
- 78 *Regional and network-based alterations in D₂/D₃ receptor availability in cocaine use disorder*
P. D. Worhunsky^{1,2}, D. Matuskey^{1,2}, J. Gallezot¹, N. Nabulsi¹, G. A. Angarita², V. D. Calhoun^{3,4,2}, R. T. Malison², M. N. Potenza^{1,5}, R. E. Carson¹, ¹Radiology & Biomedical Imaging, Yale School of Medicine, New Haven, CT, ²Psychiatry, Yale School of Medicine, New Haven, CT, ³Electrical & Computer Engineering, University of New Mexico, Albuquerque, NM, ⁴The Mind Research Network, Albuquerque, NM, ⁵Neuroscience, Yale School of Medicine, New Haven, CT
- 79 *A careful assessment of cognitive functioning in individuals with cocaine use disorder*
K. M. Frazer¹, J. J. Manly², G. Downey^{1,3,4}, C. L. Hart^{1,3,4}, ¹Psychology, Columbia University, New York, NY, ²Neurology, Columbia University College of Physicians and Surgeons, New York, NY, ³Division on Substance Abuse and Department of Psychiatry, New York State Psychiatric Institute, New York, NY, ⁴Columbia University College of Physicians and Surgeons, New York, NY
- 80 *Executive functioning and outpatient treatment adherence after intensive inpatient care in cocaine dependence: A six-month follow-up study*
P. D. Goncalves³, M. Ometto², A. Malbergier², P. Martins², L. Beraldo², B. Santos⁴, S. Nicastrì², A. Andrade², P. J. Cunha¹, ¹Department of Psychiatry, Laboratory of Psychiatric Neuroimaging (LIM 21), São Paulo, Brazil, ²Psychiatry, University of São Paulo, São Paulo, Brazil, ³Psychiatry, University of California San Diego, San Diego, CA, ⁴University of Sao Paulo, Sao Paulo, Brazil

- 81 *Acute inhibitory control training in cocaine users*
J. L. Alcorn², E. Pike^{1,2}, J. A. Lile^{1,2,3}, W. W. Stoops^{1,2,3}, C. R. Rush^{1,2,3}, ¹Psychology, University of Kentucky, Lexington, KY, ²Behavioral Science, University of Kentucky, Lexington, KY, ³Psychiatry, University of Kentucky, Lexington, KY
- 82 *Effects of mixed amphetamine salts dose and belief about drug assignment on cognitive performance in college students*
K. Cropsey, M. Froelich, P. Hendricks, R. Fargason, University of Alabama at Birmingham, Birmingham, AL
- 83 *Cocaine decreases preference for condom use as function of delayed condom availability and STI risk*
M. W. Johnson¹, E. S. Herrmann², P. S. Johnson³, M. M. Sweeney¹, ¹Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, ²New York State Psychiatric Institute, New York, NY, ³Psychology, California State University, Chico, Chico, CA
- 84 *The influence of buspirone maintenance on the pharmacodynamic effects of methamphetamine*
A. R. Reynolds¹, W. W. Stoops^{1,2,3}, J. A. Lile^{1,2,3}, C. R. Rush^{1,2,3}, ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Psychology, University of Kentucky, Lexington, KY, ³Psychiatry, University of Kentucky, Lexington, KY
- 85 *Impact of lisdexamfetamine on retention of methamphetamine-dependent patients in a residential facility*
M. J. Mancino², J. D. Thostenson³, J. B. Guise², J. McGaugh², A. Oliveto², ²Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR, ³Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR
- 86 *Cue-induced cocaine craving increases with aripiprazole treatment in methadone-maintenance patients*
L. Moran¹, K. A. Phillips¹, W. J. Kowalczyk¹, U. Ghitza², D. H. Epstein¹, K. L. Preston¹, ¹NIDA-IRP, Baltimore, MD, ²NIDA, Baltimore, MD
- 87 *A novel approach to naltrexone injections may reduce complications and increase adherence*
J. Walker¹, D. Santos³, C. Rowe¹, G. Santos^{1,2}, S. Jung¹, P. Coffin^{1,4}, ¹Substance Use Research Unit, San Francisco Department of Public Health, San Francisco, CA, ²Community Health Systems, University of California San Francisco, San Francisco, CA, ³Housing and Urban Health, San Francisco Department of Public Health, San Francisco, CA, ⁴Division of HIV/AIDS, University of California, San Francisco, San Francisco, CA
- 88 *Changes in quality of life in cocaine-dependent participants provided treatment with buprenorphine and naloxone and extended-release naltrexone*
D. Blumberg¹, F. Carrizales², W. Kazanis², M. P. Hillhouse³, A. G. Matthews⁴, J. S. Potter², ¹NIDA Clinical Coordinating Center, The Emmes Corporation, Rockville, MD, ²Psychiatry, UT Health Science Center, San Antonio, TX, ³Integrated Substance Abuse Programs, University of California, Los Angeles, CA, ⁴The Emmes Corporation, Rockville, MD
- 89 *Participant treatment assignment perceptions in the NIDA CTN cocaine use reduction with buprenorphine study*
A. G. Matthews², M. P. Hillhouse¹, C. Thomas¹, W. Ling¹, D. Blumberg², ¹UCLA, Los Angeles, CA, ²Emmes, Rockville, MD
- 90 *Use of contingency management for crack cocaine dependence in South America: Preliminary results from a randomized clinical trial*
A. Q. Miguel¹, C. S. Madruga², S. McPherson³, M. G. McDonell³, J. M. Roll³, R. Laranjeira², ¹Psychiatry, Federal University of São Paulo, Sao Paulo, Brazil, ²Psychiatry, Universidade Federal de São Paulo, Sao Paulo, Brazil, ³Washington State University, Spokane, WA

PRESCRIPTION DRUGS

- 91 *Early exposure to prescription drugs and substance use disorder symptoms in adulthood*
P. T. Veliz¹, J. Schulenberg², S. McCabe¹, ¹Institute for Research on Women & Gender, University of Michigan, Ann Arbor, MI, ²Institute for Social Research, University of Michigan, Ann Arbor, MI
- 92 *Reasons for prescription opioid misuse while playing in the NFL associated with current use and misuse among retired players*
E. M. Dunne¹, C. W. Striley², N. E. Whitehead¹, L. Cottler², ¹Clinical and Health Psychology, University of Florida, Gainesville, FL, ²Epidemiology, University of Florida, Gainesville, FL
- 93 *Physical health of women recovering from prescription opioid abuse*
K. R. Marks, M. Delaney, C. Leukefeld, Behavioral Science, University of Kentucky, Lexington, KY
- 94 *Association between lifetime heroin use and perceived risk of heroin among nonmedical prescription opioid users*
V. R. Votaw¹, K. McHugh^{1,3}, ¹McLean Hospital, Belmont, MA, ³Harvard Medical School, Boston, MA
- 95 *Patient perspectives of transitioning from prescription opioids to heroin and the role of route of administration*
L. Monico, S. G. Mitchell, Friends Research Institute, Baltimore, MD
- 96 *Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic non-cancer pain: Different measures, same patients?*
G. Campbell⁵, R. Bruno², M. Cohen³, W. Hall⁴, S. Nielsen⁵, N. Lintzeris¹, B. Larance⁵, R. P. Mattick⁵, M. Farrell⁵, L. Degenhardt⁵, ¹Langton Centre, Sydney, NSW, Australia, ²School of Medicine, University of Tasmania, Hobart, TAS, Australia, ³Clinical School, St. Vincents, Sydney, NSW, Australia, ⁴Centre for Youth Substance Abuse Research, University of Queensland, Brisbane, QLD, Australia, ⁵National Drug and Alcohol Research Centre, UNSW, Sydney, NSW, Australia
- 97 *A fully automated algorithm for identifying patients with problem prescription opioid use using electronic health record data*
D. Carrell¹, J. Mardekian², D. Cronkite¹, A. Ramaprasan¹, K. Hansen¹, D. E. Gross², R. E. Palmer², E. Masters², M. Von Korff¹, ¹Group Health Research Institute, Seattle, WA, ²Pfizer Inc., New York, NY
- 98 *Prescribing opioids safely in the emergency department study: Predictors of emergency department discharge with high morphine milligram equivalent prescription*
K. Hawk¹, S. Weiner², J. Dziura¹, D. A. Fiellin³, D. DaEun⁴, L. Nelson⁵, J. Hoppe⁶, J. Perrone⁷, G. D'Onofrio¹, ¹Emergency Medicine, Yale University, New Haven, CT, ²Emergency Medicine, Brigham & Women's Hospital, Boston, MA, ³Internal Medicine, Yale University, New Haven, CT, ⁴Harvard Medical School, Boston, MA, ⁵Emergency Medicine, NYU, New York, NY, ⁶Emergency Medicine, University of Colorado, Denver, CO, ⁷Emergency Medicine, University of Pennsylvania, Philadelphia, PA

- 99 *Patterns of prescription drug use in Spain: The European opioid treatment patient survey*
F. Fonseca^{2,4,5}, M. Torrens^{2,4,5}, M. Farré^{6,4,5}, J. L. Green¹, I. Maremmanni^{7,8}, M. Guareschi⁸,
M. Auriacombe³, N. Scherbaum⁹, T. Clausen¹⁰, D. Hill¹¹, R. C. Dart¹, ¹RADARS System, Denver
Health, Denver, CO, ²Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Barcelona,
Spain, ³Addiction Psychiatry (CNRS USR 3413), Université Bordeaux, Bordeaux, France, ⁴Institut
Hospital del Mar d'Investigacions Mèdiques, PSMAR, Barcelona, Spain, ⁵Universitat Autònoma
de Barcelona, Barcelona, Spain, ⁶Hospital Universitari Germans Trias i Pujol-IGTP, Badalona,
Spain, ⁷Department of Neurosciences, Santa Chiara University Hospital, Pisa, Italy, ⁸Associazione
per l'Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali, Pietrasanta, Italy, ⁹Department
of Psychiatry, LVR Clinic, Essen, Germany, ¹⁰Norwegian Centre for Addiction Research, Oslo,
Norway, ¹¹NHS Lanarkshire, Motherwell, United Kingdom
- 100 *Alcohol, cannabis, and cigarette use and non-medical prescription drug use stages*
B. J. Arterberry², S. R. Horbal¹, H. Lin¹, A. Buu², ¹Indiana University, Bloomington, IN,
²University of Michigan, Ann Arbor, MI
- 101 *Collaborative care for injured patients with prescription drug misuse: A feasibility study*
L. K. Whiteside¹, D. Darnell², K. Jackson¹, D. Donovan^{2,3}, D. Zatzick², ¹Division of
Emergency Medicine, University of Washington, Seattle, WA, ²Psychiatry and Behavioral
Sciences, University of Washington, Seattle, WA, ³Alcohol and Drug Abuse Institute,
University of Washington, Seattle, WA
- 102 *Acceptability and feasibility of an intervention for overdose and HIV risk during addictions
treatment for patients with prescription opioid misuse*
A. S. Bohnert, M. Walton, F. Blow, L. Thomas, M. Ilgen, Psychiatry, University of Michigan,
Ann Arbor, MI
- 103 *Change in overdose/poisoning diagnoses in patients prescribed oxycontin after its reformulation
with abuse-deterrent properties*
P. Coplan¹, A. Kadakia³, R. Singh³, A. DeVeugh-Geiss¹, ¹Risk Management and
Epidemiology, Purdue Pharma, Stamford, CT, ³Purdue, Stamford, CT
- 104 *Timing of sexual abuse, sexual risk behaviors and substance use among U.S. women*
M. Cook, Integrated Substance Abuse Programs, University of California, Los Angeles, CA

Symposium XV

Fiesta 10/14

10:00 - 12:00 PM

RISKY BUSINESS: NEUROBIOLOGICAL MECHANISMS OF RISKY DECISION MAKING IN DRUG ABUSE AND ADDICTION

Chairs: Shelley Su and Carlos Blanco

- 10:00 *Dopaminergic modulation of frontal-amygdalar-striatal circuits subserving risk/reward
decision making*
Stan Floresco, University of British Columbia, Vancouver, BC, Canada
- 10:25 *Risky decision making, cocaine self-administration, and dopamine signaling*
Barry Setlow, University of Florida, Gainesville, FL
- 10:50 *Linking neural networks to markers of dopamine signaling and risky decision-making in
methamphetamine dependence*
Milky Kohno, University of California, Los Angeles, CA
- 11:15 *The danger of inadequate risk and reward processing in drug addiction*
Martin P Paulus, Laureate Institute for Brain Research, Tulsa, OK
- 11:40 *DISCUSSANT: Risky decision making: towards integrating basic and clinical perspectives*
Carlos Blanco, NIH/NIDA/DESPR, Bethesda, MD

Oral Communications 20

Fiesta 4

10:00 - 12:00 PM

TRADING PLACES: RACE/SOCIO-ECONOMIC STATUS

Chairs: Debra Furr-Holden and Raymond L. Moody

- 10:00 *Alcohol use among Native Americans compared to whites: Examining the veracity of the 'Native American elevated alcohol consumption' belief*
J. K. Cunningham^{2,1}, T. A. Solomon¹, M. L. Muramoto², ¹Native American Research and Training Center, University of Arizona, Tucson, AZ, ²Family and Community Medicine, University of Arizona, Tucson, AZ
- 10:15 *Racial, ethnic and gender disparities in substance use at discharge*
E. Guerrero¹, K. Fenwick¹, Y. Kong¹, H. Amaro², ¹School of Social Work, University of Southern California, Los Angeles, CA, ²Social Work and Preventive Medicine, University of Southern California, Los Angeles, CA
- 10:30 *Emotion regulation moderates the relationship between perceived discrimination and risk behaviors in African American college students*
A. M. Heads¹, L. G. Castillo², A. Glover², J. Schmitz¹, ¹University of Texas HSC Houston, Houston, TX, ²Texas A&M University, College Station, TX
- 10:45 *The impact of discrimination on drug dependence among gay and bisexual men: A look at the role of emotion dysregulation*
R. L. Moody^{1,2}, J. T. Parsons^{1,2}, C. Grov², ¹Psychology, Graduate Center, City University of New York, New York, NY, ²Center for HIV Educational Studies and Training (CHEST), New York, NY
- 11:00 *Association between any major discrimination and current cigarette smoking among adult African American men*
L. J. Parker¹, B. Kinlock¹, D. Chisolm³, D. Furr-Holden², R. Thorpe¹, ¹Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Sociology, Morgan State University, Baltimore, MD
- 11:15 *Environmental smoke exposure among daily smokers with low v.s. high educational attainment*
J. W. Tidey², R. Denlinger¹, D. Hatsukami⁴, E. Donny³, ¹Behavioral and Social Sciences, Brown University, Providence, RI, ²Center for Alcohol & Addictions Studies, Brown University, Providence, RI, ³Psychology, University of Pittsburgh, Pittsburgh, PA, ⁴Masonic Cancer Center, University of Minnesota Medical School, Minneapolis, MN
- 11:30 *Diminished alternative reinforcement mediates socioeconomic disparities in adolescent substance use: A longitudinal study*
N. Andrabi¹, A. Leventhal¹, R. Khoddam², ¹Institute for Preventive Medicine, University of Southern California, Los Angeles, CA, ²Psychology, University of Southern California, Los Angeles, CA
- 11:45 *Perceived social support and socioeconomic status predict maternal delay discounting behavior and neural function in healthy postpartum women*
L. K. Brents, J. Young, B. Knight, J. L. Coker, S. L. Ray-Griffith, Z. Stowe, G. A. James, C. Kilts, University of Arkansas for Medical Sciences, Little Rock, AR

Oral Communications 21

Fiesta 6/8
10:00 - 12:00 PM

TRAINSPOTTING: OVERDOSE

Chairs: Alexander Y. Walley and Amy Peacock

- 10:00 *Use of a prescription opioid registry to examine opioid misuse and overdose*
C. Campbell¹, A. Bahorik³, C. Weisner^{1,3}, P. VanVeldhuisen², A. Rubinstein⁴, T. Ray¹,
¹Division of Research, Kaiser Permanente Northern California, Oakland, CA, ²The EMMES Corporation, Rockville, MD, ³Psychiatry, UCSF, San Francisco, CA, ⁴Anesthesiology, Kaiser Permanente, Santa Rosa Medical Center, Santa Rosa, CA
- 10:15 *Polypharmacy and non-fatal overdose in patients with HIV infection and substance dependence*
T. W. Kim, A. Y. Walley, A. S. Ventura, G. Lerner, G. Patts, T. Heeren, R. Saitz, Boston University Schools of Medicine and Public Health, Boston, MA
- 10:30 *Same-day use of opioids and depressants: A retrospective diary study*
A. Peacock^{5,3}, R. Bruno⁵, B. Larance⁴, N. Lintzeris¹, R. Ali², D. Oen³, O. Sotade³, N. White², L. Degenhardt³, ¹Langton Centre, Sydney, NSW, Australia, ²University of Adelaide, Adelaide, SA, Australia, ³National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW, Australia, ⁴University of New South Wales, Sydney, NSW, Australia, ⁵School of Medicine, University of Tasmania, Hobart, TAS, Australia
- 10:45 *Factors associated with nonfatal overdose among young opioid users: Heroin and benzodiazepine use, prescription opioid and heroin injection and HCV status*
P. Mateu-Gelabert¹, H. Guarino¹, D. Frank¹, K. Ruggles³, C. Syckes¹, E. Goodbody¹, S. R. Friedman¹, ¹NDRI, New York, NY, ³NYU, New York, NY
- 11:00 *Overdose risk behaviors during the period preceding non-fatal overdose events among veterans*
A. S. Bennett¹, E. R. Pouget², L. Elliott², A. Golub², A. Rosenblum², P. Britton³, ¹National Development and Research Institutes, New York City, NY, ²NDRI, New York, NY, ³Medical Center, University of Rochester, Rochester, NY
- 11:15 *Integrating opioid overdose prevention in the emergency department*
R. McCormack, MD², C. Koziatek, MD², A. Rubin¹, L. O'Donnell², L. Nelson¹, ¹NYU School of Medicine, New York, NY, ²Ronald O. Perelman Department of Emergency Medicine, NYU School of Medicine, New York, NY
- 11:30 *Effect of local health department leadership on community overdose prevention coalitions*
A. A. Alexandridis, N. Dasgupta, C. Ringwalt, C. Sanford, A. McCort, Injury Prevention Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 11:45 *Help-seeking among community responders trained in overdose prevention and naloxone administration*
A. Y. Walley¹, J. Sisti⁴, L. Forman², S. Ruiz³, Z. Xuan², ¹BU School of Med, Boston, MA, ²BU School of Public Health, Boston, MA, ³Mass Dept of Public Health, Boston, MA, ⁴Harvard School of Public Health, Boston, MA

Oral Communications 22

Fiesta 12

10:00 - 11:00 AM

COCAINE COWBOYS: CLINICAL STUDIES

Chairs: William W. Stoops and Margaret Haney

- 10:00 *Changes in brain white matter integrity after PPAR-gamma agonist treatment for cocaine use disorder*
S. D. Lane¹, K. M. Hasan⁵, B. Mwangi¹, P. A. Narayana⁵, J. Vincent¹, F. Moeller⁴, J. Steinberg⁴, K. Dineley³, K. A. Cunningham², J. Schmitz¹, ¹Psychiatry & Behavioral Sciences, University of Texas Health Science Center - Houston, Houston, TX, ²Center for Addiction Research, University of Texas Medical Branch, Galveston, TX, ³Neurology, University of Texas Medical Branch, Galveston, TX, ⁴Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA, ⁵Diagnostic and Interventional Imaging, University of Texas Health Science Center - Houston, Houston, TX
- 10:15 *Modafinil reduces cocaine self-administration in humans: Effects vary as a function of cocaine 'priming' and cost*
M. Haney¹, E. Rubin², R. Foltin¹, ¹Psychiatry, Columbia University Medical Center, New York, NY, ²Psychiatry, Harlem Hospital, New York, NY
- 10:30 *Safety and tolerability of cocaine during phendimetrazine maintenance*
W. W. Stoops^{1,2,3}, J. A. Lile^{1,2,3}, L. R. Hays³, A. O. Rayapati³, C. R. Rush^{1,2,3}, ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Psychology, University of Kentucky, Lexington, KY, ³Psychiatry, University of Kentucky, Lexington, KY
- 10:45 *Effect of a glucocorticoid receptor antagonist - mifepristone - on relapse risk in cocaine-dependent men*
W. N. Raby^{1,2}, F. R. Levin¹, E. V. Nunes¹, ¹Psychiatry, Columbia University, New York City, NY, ²Psychiatry, Albert Einstein College of Medicine, Bronx, NY

Oral Communications 23

Fiesta 12

11:15 - 12:15 PM

BUFFALO SOLDIERS: OPIOID PRECLINICAL STUDIES

Chair: Hsiao-Ying Wey

- 11:15 *Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as toll-like receptor 4 antagonists*
X. Wang, Chemical Biology Laboratory, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, China
- 11:30 *Simultaneous PET/MRI of static and dynamic functional connectivity to opioids*
H. Wey, B. R. Rosen, J. B. Mandeville, Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
- 11:45 *Individual differences in heroin reward perception in C57BL/6 mice*
C. Wincott, B. Reed, V. Yuferov, M. Kreek, Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY
- 12:00 *Remifentanyl vs. food choice under a dependent schedule*
J. J. Chow, J. S. Beckmann, Psychology, University of Kentucky, Lexington, KY

BRUNCH WITH CHAMPIONS (PRE-REGISTRATION ONLY)

CAPRA
12:00 - 1:15 PM

Oral Communications 24

Fiesta 10/14
1:15 - 3:15 PM

REEFER MADNESS: CANNABIS AND CANNABINOIDS

Chairs: Jan Copeland and Staci Gruber

- 1:15 *Serotonergic responsiveness after repeated exposure to the synthetic cannabinoid JWH-018*
J. S. Elmore, M. H. Baumann, IRP, NIDA, NIH, Baltimore, MD
- 1:30 *Cannabidiol attenuates a spatial working memory impairment caused by THC in monkey*
M. A. Taffe¹, C. Glavis-Bloom², J. D. Nguyen¹, ¹CNAD, The Scripps Research Institute, La Jolla, CA, ²SRI, International, Menlo Park, CA
- 1:45 *Splendor in the Grass? A pilot study assessing the impact of medical marijuana on cognition*
S. Gruber^{1,2}, M. Dahlgren^{1,3}, K. Sagar¹, A. Gonenc^{1,2}, M. Racine¹, R. Smith¹, S. E. Lukas^{2,4},
¹Cognitive & Clinical Neuroimaging Core, McLean Hospital - Imaging Center, Belmont, MA, ²Department of Psychiatry, Harvard Medical School, Belmont, MA, ³Department of Psychology, Tufts University, Medford, MA, ⁴Behavioral Pharmacology Research Lab, McLean Hospital, Belmont, MA
- 2:00 *Sleep-related problems in adults receiving medical cannabis*
M. Ilgen^{2,1}, K. Bohnert^{2,1}, ¹Psychiatry, University of Michigan, Ann Arbor, MI, ²VA Center for Clinical Management Research (CCMR), Ann Arbor, MI
- 2:15 *Reductions in traffic fatalities rates across states with operational dispensaries of marijuana*
J. Santaella¹, C. Mauro², M. M. Wall², J. H. Kim¹, S. S. Martins¹, ¹Epidemiology, Columbia University, New York City, NY, ²Biostatistics, Columbia University, New York, NY
- 2:30 *Illicit drug use among young adult marijuana users in Los Angeles: Implications for medical use*
E. V. Fedorova, S. E. Lankenau, Community Health and Prevention, Drexel University, Philadelphia, PA
- 2:45 *The relationship of age to cannabis use and motives for use among medical cannabis dispensary patients*
J. E. Sottile¹, N. A. Haug¹, C. B. Padula², A. Heinz^{2,3}, M. O. Bonn-Miller^{2,3}, ¹Palo Alto University, Palo Alto, CA, ²Psychiatry, VA Palo Alto Health Care System, Palo Alto, CA, ³Center of Excellence in Substance Abuse Treatment and Education, VA Palo Alto Health Care System, Menlo Park, CA
- 3:00 *Comparison of brief versus extended feedback in an online intervention for cannabis users: A randomised controlled trial*
J. Copeland², S. Rooke¹, L. Gibson², ¹Nil, Sydney, NSW, Australia, ²National Cannabis Prevention and Information Centre, University of NSW, Sydney, NSW, Australia

Oral Communications 25

Fiesta 4
1:15 - 3:15 PM

200 CIGARETTES: NICOTINE

Chairs: Yasmin Mashhoon and Elias M. Klemperer

- 1:15 *Increased nicotine exposure decreases sensitivity to the nicotine-like effects of AChE inhibitors in monkeys discriminating nicotine*
M. J. Moerke, L. McMahon, Pharmacology, University of Texas Health Science Center, San Antonio, TX
- 1:30 *Effects of chronic nicotine treatment and discontinuation on nicotine self-administration*
S. Kohut, C. Barkin, J. Bergman, McLean Hospital/Harvard Medical School, Belmont, MA
- 1:45 *Repetitive transcranial magnetic stimulation of the dorsal lateral prefrontal cortex inhibits medial orbitofrontal activity in smokers*
X. Li¹, G. Sahlem¹, C. A. Hanlon¹, K. J. Hartwell¹, B. Badran¹, S. Henderson¹, M. George^{1,2},
¹Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, ²Psychiatry, Ralph H. Johnson VA Medical Center, Charleston, SC
- 2:00 *A behavioral and neurophysiological examination of the impact of smoking abstinence on drug and non-drug reinforcement*
N. Schlienz^{1,2}, L. Hawk², ¹Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Psychology, State University of New York at Buffalo, Amherst, NY
- 2:15 *Nicotine withdrawal induces neural and behavioral deficits in reward processing*
J. Oliver¹, D. E. Evans², M. Addicott¹, T. Brandon², D. J. Drobes², ¹Psychiatry and Behavioral Sciences, Duke University, Durham, NC, ²Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL
- 2:30 *The effects of nicotine administration and drug cue on impulsivity*
S. Martinez^{1,2,3}, J. D. Jones¹, A. Bisaga¹, S. D. Comer¹, ¹Division on Substance Abuse, New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, ²Derner Institute of Advanced Psychological Studies, Adelphi University, Garden City, NY, ³Translational Research Training Program in Addiction, City College of New York, New York, NY
- 2:45 *Reduction in cigarettes per day prospectively predicts quit attempts and cessation in smokers who are not ready to quit*
E. M. Klemperer, J. Hughes, Psychiatry and Psychological Sciences, University of Vermont, Burlington, VT
- 3:00 *Early age of cigarette smoking onset is associated with greater P300 smoking cue reactivity*
Y. Mashhoon¹, J. Betts², S. L. Farmer², S. E. Lukas¹, ¹McLean Imaging Center, Harvard Medical School | McLean Hospital, Belmont, MA, ²McLean Imaging Center, McLean Hospital, Belmont, MA

Thursday, June 16, 2016

SWEEPSTAKES DRAWING

**Fiesta 6/8
3:15 - 3:45 PM**

***YOU MUST BE SEATED IN ONE OF THE SESSIONS
STARTING AT 1:15 PM IN ORDER TO HAVE YOUR
BADGE COLLECTED***

HAVE A SAFE TRIP HOME!

SEE YOU IN MONTREAL, CANADA, JUNE 17-22, 2017

AUTHOR INDEX

- Aarde, S. M. 14
 Abatemarco, D. J. 69
 Abdolahi, A. 11
 Abel, J. 3
 Abraham, A. 78
 Acheampong, A. 19, 62
 Achtmeyer, C. 94
 Acri, Jane B. 51
 Addicott, M. 12, 106
 Addis, M. 94
 Addison, T. 87
 Adebowale, T. 10
 Ades, P. 86
 Afifi, R. 93
 Aguirre, C. G. 87
 Ahamad, K. 4, 59
 Aharonovich, Efrat 9, 57, 95
 Ahmed, M. S. 69, 85
 Aiken, A. 60
 Aklin, Will 65
 Akpara, U. 88
 Akutagava-Martins, G. C. 79
 al'Absi, M. 85
 Albizu, C. 62
 Alcorn, J. L. 99
 Alcover, K. C. 20, 56
 Aldrich, Jane 73
 Alexander, A. 85
 Alexandre, J. 63, 91
 Alexandridis, A. A. 103
 Alford, D. 77
 Ali, R. 103
 Alia-Klein, N. 56
 Alicata, D. 69
 Alicea-Rodríguez, A. 62
 Allen, A. M. 85
 Allen, L. 22
 Allen, S. 85
 Allen, S. T. 58
 Allende-labastida, J. 67
 Almeida, R. 65
 Alshaarawy, O. 20, 68
 Altarifi, A. 12
 Altice, F. L. 94
 Altshuler, R. 3
 Alving, C. 12
 Amador, C. 80
 Amaral, R. 21
 Amaro, H. 102
 Ananthan, S. 66
 Anastasio, Noelle C 52, 65, 80
 Andersen, M. L. 64
 Andersen, R. 17, 56
 Anderson Goodell, E. M. 57, 83
 Anderson, B. J. 11
 Anderson, K. 75
 Anderson-Carpenter, K. D. 82
 Andrabi, N. 102
 Andrade, A. 21, 98
 Andreuccetti, G. 84
 Andrews, A. M. 80
 Andrews, P. 91
 Angarita, G. A. 98
 Anglin, D. M. 18
 Anthony, James C. 6, 7, 19, 20, 56, 60, 61, 63, 68, 91, 93
 Antoline, J. 12
 Apata, J. 87
 Areesantichai, C. 83, 92
 Arfken, C. L. 12
 Arger, C. A. 53
 Armendariz, A. 12
 Arout, Caroline A. 69
 Arria, A. M. 20, 55
 Arroyo Currás, N. 14
 Artenie, A. 97
 Arterberry, B. J. 101
 Artigiani, Erin 26
 Aston, E. R. 53
 Aubé, Jeff 73
 Auriacombe, Marc 63, 74, 89, 91, 101
 Austad, C. 14
 Ayo, S. 10
 Babbin, S. F. 60
 Babson, K. 21
 Bacciardi, S. 11
 Back, S. 90
 Badger, G. J. 86
 Badran, B. 106
 Bagley, J. R. 80
 Bagley, S. M. 77
 Bahorik, A. L. 4, 103
 Bailey, S. R. 21
 Baker, N. 10, 54, 55, 59, 93
 Baladi, Michelle 53
 Balodis, I. 61, 88
 Balster, Robert 71
 Banducci, A. N. 60
 Bangel, S. 57
 Banich, M. T. 15, 88
 Banks, Matt 51
 Banta-Green, C. J. 22
 Banu, L. 76
 Bara, J. 58
 Barbieri, V. A. 78
 Barbosa, C. 21
 Barbosa-Leiker, Celestina 63, 71
 Bardo, M. T. 3, 10, 66, 75, 89
 Bares, Cristina B 5
 Barkin, C. 106
 Barluenga, E. 83
 Barondess, D. 91
 Barr, P. B. 55
 Barrett, F. S. 14
 Barska, J. 94
 Bart, Gavin 51
 Bastos, F. I. 63
 Bates, M. 76
 Batki, S. L. 57
 Batten, S. R. 80
 Bau, G. 84
 Baumann, M. H. 24, 105
 Baumeister, S. 17
 Bauza, L. N. 22
 Bazzi, A. R. 58
 Beadnell, B. 58
 Bear, S. A. 91
 Beardsley, Patrick 6
 Bebarta, V. 93
 Bechara, A. 15
 Bechler, L. 91
 Beck, J. G. 90
 Becker, W. 77, 78, 83
 Beckham, J. 96
 Beckmann, J. S. 80, 104
 Bedi, G. 55, 70

AUTHOR INDEX

- Beebe, K. 77
 Behling, M. 86, 92
 Behrends, C. N. 94
 Beiter, R. M. 3
 Belkoff, A. 75
 Bell, R. P. 15, 16, 25
 Bell, S. 16
 Bello, M. S. 96
 Belohlavek, A. 87
 Benesch, C. 11
 Benner, M. 18
 Bennett, A. S. 103
 Benny, C. 83
 Benz, M. B. 96
 Beraldo, L. 98
 Berens, P. 68
 Bergeria, C. L. 85
 Bergman, Jack 51, 53, 106
 Berkenblit, G. 94
 Berkowitz, J. 69
 Berro, L. F. 64, 89
 Bertz, J. W. 76
 Besharat, A. C. 17
 Betts, J. 70, 106
 Beuttel, L. A. 52
 Bianco, A. 53
 Bickel, Warren Kurt 1, 2, 53, 61, 75, 76, 81
 Bierut, L. 87
 Bigelow, G. 10, 54, 78
 Bisaga, A. 78, 106
 Bjork, J. 15, 55
 Black, A. C. 82
 Black, J. 53
 Black, K. 85
 Black, R. A. 83, 86
 Blackstock, O. 94
 Blaker, A. 13
 Blanco, Carlos 73, 101
 Blanken, P. 79
 Blevins, E. 75
 Block, R. 11
 Blokhina, E. 9, 11, 56, 59
 Blough, B. 12, 64
 Blow, F. 101
 Blumberg, D. 99
 Boak, A. 61
 Bobashev, G. 21, 60
 Boggs, D. 21
 Bohnert, Amy S. 21, 87, 101
 Bohnert, K. 54, 105
 Bold, K. 60
 Bonadonna, J. 3
 Bonar, E. E. 54
 Bonci, Antonello 2
 Bone, C. W. 56
 Bonn-Miller, Marcel O. 21, 60, 67, 105
 Bonson, K. 63
 Bordnick, P. 17, 97
 Borodovsky, J. 19, 76
 Borsari, B. 96
 Boyd, C. J. 95
 Boyd, M. L. 94
 Bozinoff, N. 58
 Bozzo, J. 69
 Bradley, C. A. 13, 25, 52
 Bradley, K. A. 94
 Brady, Kathleen T. 65
 Brandon, T. 95, 106
 Brands, B. 19
 Brandt, C. 83
 Brandt, L. 75
 Brecht, L. 82
 Breiter, H. C. 20
 Brents, L. K. 102
 Bresani, Elena 70, 79
 Brett, B. 91
 Bridden, C. 11, 59, 91
 Brimijoin, S. 3
 Brincks, A. M. 61
 Britton, P. 103
 Brooks, A. C. 4, 92
 Brooks, D. J. 54
 Brooks, S. J. 14
 Brown, B. 94
 Brown, D. 93
 Brown, L. S. 91
 Brown, Qiana 5, 18, 19, 55, 68, 85
 Brown, R. A. 96
 Brown, R. W. 13, 52, 81
 Brown, Sandra A 5
 Browne, Felicia 27
 Bruijnzeel, Adriaan 2
 Bruneau, J. 97
 Bruno, Raimondo 6, 60, 100, 103
 Bucceri, J. 87
 Bucher Bartelson, B. 84
 Bucholz, K. K. 89
 Buchthal, S. 69
 Buckman, J. 76
 Budman, S. H. 83
 Budney, Alan J. 19, 60, 67
 Bugbee, B. A. 20, 55
 Buono, F. D. 76, 89
 Burdick, T. 19, 21
 Burgos, J. 84
 Burlew, K. 57
 Burmeister, M. 52
 Burnett, J. 17
 Burns, L. 63
 Burris, S. 22
 Burt, C. I. 94
 Butelman, Eduardo 10, 12
 Butler, R. 68
 Butler, S. F. 83, 86, 92
 Buttram, M. E. 21, 24, 56
 Buu, A. 94, 101
 Byrne, E. 4
 Cahanap, T. 64
 Cahill, Larry 73
 Cai, X. 69
 Calabrese, S. 94
 Caldeira, K. M. 20, 55
 Caldeiro, R. 94
 Calderon, S. N. 63
 Calhoun, V. D. 98
 Callaghan, R. 82, 83
 Camenga, D. R. 60
 Campbell, A. 55, 56, 95
 Campbell, C. 4, 103
 Campbell, G. 100
 Campollo, O. 92
 Cannella, L. 17
 Cannizzaro, D. 95
 Canterbury, M. 10

AUTHOR INDEX

- Cao, V. 78
 Cao, Z. 3
 Carbonaro, T. M. 64
 Carla, L. 98
 Carliner, H. 18, 19, 55, 57
 Carlson, A. K. 3
 Carlson, E. 68
 Carnahan, D. 93
 Carpenedo, C. M. 4
 Carpenter, C. A. 3
 Carrell, D. 100
 Carrico, Adam 11, 74
 Carrizales, F. 99
 Carroll, Ivy 73
 Carroll, Kathleen 9, 14, 16, 61
 Carroll, Marilyn E. 3, 73
 Carson, R. E. 98
 Carter, L. P. 17, 53
 Carvalho, H. B. 84
 Cassidy, R. 16
 Cassidy, T. A. 83
 Castillo, L. G. 102
 Cathers, L. A. 95
 Caudarella, A. 11
 Cavallo, D. A. 60
 Cercone Heavey, S. 57, 83, 90
 Cerda, M. 18
 Chairs, Co- 6
 Chaisson, C. 11, 59
 Chalk, M. 78
 Chambers, J. E. 92
 Chandra, M. 82
 Chandrasekar, P. 76
 Chaney, L. 82
 Chang, J. S. 77
 Chang, K. 84
 Chang, L. 11, 55, 69, 98
 Chang, W. 11
 Chaudhry, T. S. 94
 Chauhan, K. 10, 88
 Chen, C. 9, 96
 Chen, J. 81
 Chen, L. 63, 96
 Chen, M. 77
 Chen, Rong 23
 Chen, Y. 13, 25, 59, 91, 96
 Cheng, C. 95
 Cheng, D. M. 11, 56, 59, 77
 Cheng, H. G. 58, 60
 Cherifi, B. 89
 Cherpitel, C. J. 84
 Chiapperino, D. 63
 Chilcoat, H. 17, 83
 Childress, Anna Rose 8, 15, 16
 Chisolm, D. 102
 Chiu, J. 77
 Choi, J. 54
 Chorlian, D. 89
 Chow, J. J. 104
 Chow, L. 13
 Chung, S. 60
 Ciciurkaite, G. 62
 Cisewski, J. A. 21
 Claborn, K. 58
 Clair, V. 4
 Clare, P. 60
 Clark, S. 69
 Clark, Westley 51
 Clausen, T. 101
 Cloherty, G. 59
 Coelho Pinguello, A. 59
 Coffin, Phillip 26, 57, 99
 Cohen, D. J. 21
 Cohen, M. 100
 Cohn, J. A. 12
 Coker, J. L. 85, 102
 Cole, A. 88
 Cole, J. 69
 Cole, M. 14
 Coleman-Cowger, V. H. 86
 Collaborative Study on the
 Genetics of Alcoholism
 Collaborators, *. 89
 Collins, G. T. 53, 64, 66
 Collins, R. L. 54
 Collombat, J. 89
 Comer, Sandra 1, 17, 53, 59, 70,
 78, 106
 Comfort, M. L. 58
 Cone, E. 63
 Connelly, K. L. 64
 Conniff, J. 68
 Connor, J. 81
 Conrod, Patrica 65
 Cook, J. E. 13
 Cook, J. M. 68
 Cook, M. 54
 Coop, Andrew 8
 Cooper, Ziva D. 53, 70
 Cope, L. M. 88, 89
 Copeland, A. 96
 Copeland, Jan 6, 105
 Copenhaver, M. 57, 94
 Copersino, M. L. 70
 Coplan, P. 17, 22, 83, 101
 Cordero, D. 12
 Cornelius, J. 90
 Corsi, Karen F 27
 Cosgrove, Kelly 65
 Cottler, Linda 19, 20, 22, 26, 55,
 56, 62, 83, 84, 100
 Courtney, K. E. 15
 Covault, J. 97
 Cox, B. 92
 Crane, H. M. 58
 Cranford, J. A. 54, 94, 95
 Croff, R. 78
 Crofton, E. 64, 81
 Cronkite, D. 100
 Crooke, H. R. 19, 83
 Crooks, P. A. 3, 66
 Cropsey, K. L. 62, 99
 Crosier, B. S. 19, 76
 Crouch, P. 11
 Crowell, S. E. 95
 Crowley, Thomas J 65, 88
 Crystal, S. 78
 Csernansky, J. G. 20
 Cservenka, A. 97
 Culver, J. P. 66
 Culverhouse, A. 3
 Cummings, B. 98
 Cummins, E. D. 13, 81
 Cunha, P. J. 21, 98
 Cunningham, C. 94
 Cunningham, E. 69
 Cunningham, J. K. 87, 102

AUTHOR INDEX

- Cunningham, K. A. 15, 65, 67, 80, 104
 Cunningham, R. M. 54, 76, 94
 Curry, D. 75
 Curtis, Brenda L 70
 Cushing, C. 95
 Cutter, C. J. 89
 Czoty, Paul W. 23
- D'Aunno, T. 76, 94
 D'Onofrio, G. 100
 DaEun, D. 100
 Dager, A. D. 14
 Dahlgren, M. 105
 Dailey, T. M. 86, 92
 Dale, Anders 5
 Dalwani, M. 15, 88
 Daniulaityte, Raminta 27
 Darnell, D. 101
 Darnley, S. 15
 Darst-Campbell, M. 11
 Dart, R. C. 84, 101
 Dasgupta, N. 103
 Daughters, S. B. 16, 25, 75, 96
 Davenport, P. 15
 David, T. 85
 Davidson, T. 79
 Davis, D. R. 92
 Day, C. 85
 de Jong, Y. 59
 de la Torre, R. F. 17
 De Leo, J. A. 96
 de Souza Fernandes, E. 17
 Dean, S. A. 52
 DeBeck, K. 22, 58
 Dechant, E. 95
 DeCicco-Skinner, K. 81
 DeFulio, A. 78
 Degenhardt, L. 77, 84, 100, 103
 DeGeorge, D. 75
 DeHovitz, J. 94
 del Franco, A. 13
 del Rio, C. 61
 Delaney, M. 100
 Delucchi, K. 61, 87
 DeMartini, A. 57
- Denehy, E. D. 3
 Denis, Cecile M. 88, 89
 Denlinger, R. 20, 86, 102
 Denner, L. 80
 Dennis, Michael L 20, 21, 26, 95
 Denton, A. R. 81
 Derri, J. 57
 Desai, A. 59
 Desarno, M. 53
 DeVeagh-Geiss, A. 17, 22, 101
 DeVito, E. E. 16
 DeVoe, J. E. 21
 Devonish, J. 83, 90
 DeVries, W. 10, 81
 Dewey, William L. 51
 Dias, N. 16, 70
 Dickson, M. F. 61, 62
 Dillon-Carter, O. 24
 Dimet, A. 80
 Dineen, R. 92
 Dineley, K. 67, 80, 104
 Ditre, J. 69
 Dolan, S. 64
 Dombrowski, J. C. 58
 Domingo, C. 52
 Dong, G. 16
 Dong, H. 11, 58, 59, 84
 Dongo, V. 21
 Donny, E. 16, 20, 25, 86, 102
 Donovan, D. 58, 101
 Dose, J. M. 81
 Douet, V. 55
 Dowd, S. M. 98
 Dowd, W. 21
 Dowdle, L. T. 10, 81
 Dowling, Gaya 5
 Downey, G. 98
 Doyle, E. 83
 Drainoni, M. 58, 61
 Drobes, D. J. 106
 Du, H. C. 65
 Dubernet, J. 91
 Ducat, E. 11
 Dugosh, K. L. 61, 66
 Dumchev, K. 94
 Dunn, A. 12
- Dunn, Kelly E. 9, 10, 26
 Dunn, T. 67
 Dunne, E. M. 100
 Duplessy-Garcon, C. 58
 Durand, H. 53, 85
 Dusek, K. 94
 Dwoskin, Linda P 3, 36, 73
 Dziura, J. 100
- Eans, S. 12
 Eddy, C. 61
 Edelman, E. J. 78, 94
 Edlund, Mark 87
 Edwards, A. 96
 Edwards, R. R. 54
 Eggleston, B. 21
 Eichberg, C. 16
 El Salibi, N. J. 93
 El-Bassel, N. 67
 Elhauge, T. 17
 Elkoussi, A. A. 24
 Ellen, J. M. 60
 Elliott, A. 22
 Elliott, L. 103
 Elliott, R. 86
 Elmore, J. S. 105
 Elzanie, A. 10, 88
 Emurian, C. E. 14
 Epstein, D. H. 57, 76, 96, 98, 99
 Epstein-Ngo, Q. 76
 Erensen, J. G. 22
 Ernst, T. 55, 69
 Eron, J. J. 58
 Espinoza, I. 18
 Euren, J. 57
 Evans, D. E. 106
 Evans, E. 55, 59, 62
 Evans, S. 54
 Even-Sapir, E. 14
- Fairman, B. J. 20
 Fallahi, C. 14
 Fant, R. V. 63
 Fargason, R. 99
 Farmer, S. L. 106
 Farokhnia, Mehdi 52, 53

AUTHOR INDEX

- Farré, M. 17, 97, 101
 Farrell, M. 66, 78, 100
 Farrell-Moore, D. 92
 Fatseas, M. 63, 74, 89, 91
 Favor, K. 4
 Feaster, Daniel J. 61, 71
 Fedorova, E. V. 105
 Fedota, J. 70
 Feeney, G. 81
 Felton, J. W. 18, 60
 Fenton, B. 83
 Fenwick, K. 102
 Fernández-Artamendi, S. 86, 98
 Fernández-Hermida, J. 98
 Ferrato, D. 68
 Ferré, S. 55
 Ferrell, A. *WITHDRAWN*
 Festinger, David S. 61, 66
 Fields, S. 89, 98
 Fiellin, David A 77, 78, 87, 94, 100
 Fiestas, F. 21
 Figueiro, M. G. 76
 Filbey, Francesca 8
 Fingerhood, M. 68, 78
 Finley, E. 93
 Finnegan, Loretta 68
 Fischer, B. D. 88
 Fischer, G. 75
 Fishman, M. 96
 Fitzmaurice, G. 9
 Flagel, S. 80
 Flannery, M. 10, 81
 Flax, S. M. 81
 Fleischer, L. M. 12
 Flores, D. V. 17
 Floresco, Stan 101
 Fokina, V. M. 69, 85
 Foltin, R. 70, 104
 Fonseca, F. 17, 18, 94, 97, 101
 Ford, J. A. 18
 Ford, J. H. 78
 Forman, L. 56, 103
 Forray, A. 69
 Forster, M. J. 13, 64
 Fortmann, S. P. 21
 Fox, E. A. 76
 Fox, H. C. 97
 Fox, R. G. 65
 France, C. P. 51, 64
 Francis, J. 83
 Franck, C. 61, 76
 Frank, D. 103
 Frank, E. 4
 Franklin, T. 15, 16
 Franklin, Teresa 5
 Frazer, K. M. 98
 Freedman, Andrew 27
 Freeman, K. 13, 25, 67
 Freisthler, Bridget 27
 Friedman, S. R. 84, 103
 Friedmann, P. 76, 94
 Frimpong, J. A. 61, 76, 94
 Frisch, O. 14
 Froelich, M. 99
 Froeliger, B. 16
 Funada, M. 13
 Furr-Holden, Debra 76, 82, 102
 Fuster, D. 83
 Gaalema, Diann 26, 53, 86, 96
 Gaines, T. 58
 Gaither, J. R. 78
 Galea, S. 20
 Galindo, K. 66
 Gallezot, J. 98
 Gan, G. 56
 Gandhi, D. 77
 Gannon, B. M. 53, 66
 Gao, J. 67
 Garcia, A. A. 93
 Garcia-Romeu, A. 95
 Gargano, S. 91
 Garment, A. 10
 Gastfriend, David R 66, 71, 92
 Gatch, M. B. 13, 64
 Gatley, J. 82, 83
 Gawrysiak, M. 15
 Gbedemah, M. 20
 Gearhardt, A. 89
 Gehlert, D. R. 81
 Geier, C. F. 98
 Gelberg, L. 17, 56
 Geng, E. H. 58
 Gentile, D. 89
 George, M. 81, 106
 Gerak, L. R. 64
 Ghadban, R. 92
 Ghahremani, D. 15
 Ghandour, L. A. 93
 Ghee, S. M. 10
 Ghitza, U. 92, 99
 Gibson, L. 105
 Gibson, S. 11
 Gifford, A. 59
 Gilbertson, S. 65
 Gildred, T. 94
 Gilmore, K. 92
 Gipson-Reichardt, C. 13
 Glanton Holzhauer, Cathryn 74
 Glavis-Bloom, C. 105
 Glennon, R. A. 24
 Glick, S. N. 22, 84
 Glover, A. 102
 Gnatenko, N. 11, 56, 59
 Gnegy, Margaret 3, 23
 Gobel, D. 91
 Goeders, N. E. 82
 Goenaga, J. 13
 Golbeck, Jennifer 26
 Goldenson, N. 61, 87
 Goldfeld, K. 10
 Goldman, M. 16
 Goldstein, N. D. 68
 Goldstein, R. 56
 Goldstick, J. E. 76
 Golub, A. 103
 Gomez Luna, S. E. 60
 Gomez-Pinilla, F. 88
 Goncalves, P. D. 21, 98
 Gonenc, A. 105
 González-Roz, A. 56, 62, 68, 86
 Gonzalez-Zuniga, P. 58
 Goodbody, E. 84, 103
 Gooden, L. 61
 Goodwin, R. 19, 20
 Gopinath, K. 24
 Gordon, A. R. 57

AUTHOR INDEX

- Gordon, K. S. 78
 Gorodetzky, Charles 9, 10
 Gosden, J. 66
 Goswami, D. 79
 Goulet, J. 78
 Gourevitch, M. 10, 81
 Gowing, L. 77
 Grant, A. C. 67
 Grant, B. F. 19
 Grant, Y. 14
 Grasing, K. 52
 Gray, K. M. 16, 59
 Grazioli, F. 59
 Greco, P. 59
 Greemland, M. 14
 Green, J. L. 17, 84, 101
 Green, Thomas 23, 64, 81
 Greene, M. 74, 82
 Greenfield, S. F. 95, 97
 Greenstein, E. 95
 Greenwald, Mark 12, 18, 52, 65, 78
 Gregoire, A. 89
 Grella, C. E. 55
 Griffin, M. L. 9, 25
 Griffiths, Paul 6
 Griffiths, R. R. 14, 64, 95
 Gringer Richards, J. 91
 Grishina, O. 78
 Gross, D. E. 100
 Grossman, E. 10
 Grov, C. 102
 Gruber, Staci 105
 Gruber, V. 77
 Gryczynski, G. 77
 Gryczynski, J. 63, 77, 94, 95
 Gu, H. 70
 Guareschi, M. 101
 Guariglia, C. 12
 Guarino, H. 76, 84, 103
 Gudjonsson, G. 62
 Guerrero, E. 102
 Guillot, C. 86
 Guimaraes, L. S. 65
 Guise, J. B. 77, 99
 Gullo, K. 10
 Gunning, M. 87
 Gunter, B. W. 13
 Gupta, S. 95
 Gustafson, D. 95
 Gutierrez, K. M. 60
 Ha, D. 59
 Haddad, L. 92
 Haddox, J. D. 22
 Hager, N. 16
 Hahn, J. 57
 Haile, C. N. 68
 Hall, S. m. 87
 Hall, W. 100
 Hallyburton, M. 75
 Hamilton, H. 19, 61
 Han, B. 87
 Hand, A. 10
 Hand, D. J. 69
 Haney, M. 53, 70, 104
 Haney, Margaret 104
 Haney, Meg 70
 Hankins, G. 69, 85
 Hanlon, C. A. 10, 81, 106
 Hanlon, Colleen A 2
 Hanlon, Colleen A. 2
 Hanrahan, M. 22
 Hansen, K. 100
 Hardee, J. 89
 Hardee, J. E. 88
 Harding, M. H. 52
 Hardy, D. 56
 Hargrave, S. 79
 Harikrishnan, V. 17, 83
 Harrell, P. T. 95
 Harrris, D. 88
 Hart, C. L. 92, 98
 Hartwell, E. E. 97
 Hartwell, K. J. 55, 87, 106
 Hartz, S. 87
 Hartzler, B. 58
 Harvanko, A. 88
 Hasan, K. M. 104
 Hasin, D. S. 18, 19, 20, 55, 57, 68, 95
 Hasson, A. 77
 Hatsukami, D. 16, 20, 86, 102
 Haug, N. A. 21, 105
 Havens, J. R. 61, 62, 83
 Hawk, K. 100
 Hawk, L. 106
 Hayama, S. 69
 Hayashi, K. 11, 22, 59, 84
 Haynes, L. 61
 Hays, L. R. 104
 Heads, A. M. 102
 Heal, David John 66, 72
 Heeren, T. 103
 Heffernan, J. 88
 Heidenfelder, B. 92
 Heil, Sarah Hughes 10, 52, 53, 56, 77, 85, 86
 Heilig, M. 81
 Heintzman, J. 21
 Heinz, A. 105
 Heinze, J. 76
 Heitzeg, M. 88, 89
 Heller, M. S. 97
 Henderson, S. 106
 Hendricks, P. 62, 99
 Henningfield, Jack 17, 63, 72
 Henry, M. 89
 Hernandez-Casner, C. 88
 Herrmann, E. S. 70, 99
 Hertz, S. K. 57, 96
 Hicks, C. 80
 Hien, D. 55, 62, 90
 Higgins, S. T. 10, 20, 53, 77, 85, 86, 92, 96
 Hill, D. 101
 Hill, M. 92
 Hillhouse, M. P. 99
 Hine, C. 69
 Hlaing, W. 19
 Hoang, V. 78
 Hobkirk, A. L. 12, 15
 Hodgkinson, C. 53
 Hoffman, K. 19, 21
 Hoffman, M. K. 68
 Hoffer, R. S. 89
 Holtyn, A. 68, 78
 Homish, D. 57, 83, 90

AUTHOR INDEX

- Homish, G. G. 57, 83, 90
Honce, J. 15
Hoopes, M. J. 21
Hoover, D. 13
Hoppe, J. 100
Hopyan, T. 63
Horbal, S. R. 101
Horton, T. L. 91
Horwood, L. J. 82
Horyniak, D. 84
Hosler, C. 94
Hosseini, M. 94
Howell, Leonard 24, 51, 64, 75, 80, 89
Howell, R. 4
Hruska, B. 10, 77, 97
Hser, Y. 62, 84
Hsieh, H. 76
Hu, L. 4, 77
Hu, M. 20, 56
Huang, D. Y. 62
Huang, E. 13
Huang, M. 96
Huang, T. 13
Huang, Y. 64
Hudson, J. I. 14
Hudzik, T. J. 53
Huedo-Medina, T. B. 57
Huentelman, M. 80
Huffaker, S. 57
Hughes, J. 85, 106
Huh, J. 87
Hui, D. 77
Hunkele, K. 14
Hutchinson, D. 60
Hymel, K. 12
- Ialomiteanu, A. 19
Ialongo, N. 60
Ibrahim, J. 22
Idrisov, B. 11
Iguchi, Martin Y. 51
Iles, B. 95
Ilgen, M. 54, 105
Ilika, I. 94
Ilyuk, R. 78
- Iniguez, S. D. 24
Ironson, G. 82
Irvine, J. 21
Irving, T. 88
Iverson, E. 54
Iwamoto, D. 18
- Jaafar, M. 18
Jackson, K. 101
Jackson, N. 75
Jacobson, A. E. 12
Jaffe, J. H. 63, 77
Jagannathan, K. 15, 16
Jain, J. P. 11
Jalah, R. 12
James, G. A. 102
Jamshidimanesh, M. 94
Janes, A. 16, 70
Janganati, V. 66
Jarlais, Don Des 74
Jarvis, B. 68, 78
Jefee-Bahloul, H. 18
Jelstrom, E. 95
Jernigan, Terry 5
Jiang, C. 69
Jiang, I. 25
John, W. S. *WITHDRAWN*
Johnson, A. 3
Johnson, J. Aaron A. 4
Johnson, K. A. 25, 75, 78, 95
Johnson, L. 87
Johnson, Matthew W. 14, 24, 64, 88, 95, 99
Johnson, P. S. 99
Johnson, S. K. 22
Johnston, L. A. 18
Jones, Hendree E. 52, 66, 96
Jones, J. D. 17, 59, 78, 106
Jones, M. 82
Jones, S. A. 13
Jordans, M. J. 74
Joseph, J. 14
Jung, S. 99
Jurkovitz, c. 91
Justice, A. 78
Justinova, Zuzana 51
- Jutkiewicz, E. M. 3
Jutras-Aswad, D. 97
- Kadakia, A. 22, 101
Kahana, Shoshana 74
Kalayasiri, R. 81
Kaltenbach, Karol 52, 69
Kaminer, Y. 59
Kampman, K. M. 15, 16
Kanayama, G. 14
Kane, J. C. 74
Kaphalia, B. 67
Kaplan, L. M. *WITHDRAWN*
Karakula, S. L. 9, 25
Karolak, S. 58
Katz, Elizabeth C. 88, 89
Kaufman, M. J. 12, 14
Kazanis, W. 93, 99
Kazankov, K. 78
Kearney-Ramos, T. 81
Kearns, D. 79
Keith, D. R. 85
Kelly, S. M. 63, 77
Kelly, T. H. 14
Kelpin, S. S. 4, 85
Kelsh, D. 17
Kendler, K. S. 96
Kennedy, R. 3
Kenny, Paul 8
Kermack, A. 10, 81
Kerns, R. 78, 83
Kerr, T. 11, 58, 59, 84
Kerridge, B. T. 82
Kerrigan, D. 63
Kervran, C. 89
Kessler, F. H. 65, 79
Keyes, K. 18
Keyser-Marcus, L. 55
Khoddam, R. 61, 75, 102
Kibitov, A. 9
Kieschnick, D. 21
Kiguchi, N. 64
Kilts, C. 102
Kim, H. 77
Kim, J. H. 21, 105
Kim, J. K. 3

AUTHOR INDEX

- Kim, Jae K. 1, 3
 Kim, S. 75, 77
 Kim, S. J. 86
 Kim, T. W. 103
 Kimmel, Heather 23
 King, H. E. 81
 Kinlock, B. 102
 Kioumars, A. 21
 Kippin, T. E. 14, 80
 Kirby, Kimberly C. 4, 70, 71, 79
 Kirby, S. 52, 81
 Kiriazova, T. 62
 Kirk, A. 94
 Kirkpatrick, M. 25, 69, 75, 86, 87
 Kirschmann, E. 88
 Kirschner, J. 92
 Kish, S. J. 82
 Kishioka, S. 64
 Kivell, B. M. 3
 Klawans, M. R. 59, 68, 97
 Klein, Michael 63, 72
 Klemperer, Elias M. 20, 106
 Klimas, J. 84
 Kline-Simon, A. H. 4
 Knight, B. 102
 Knight, E. 22
 Knopik, V. 53
 Knudsen, H. K. 61, 83
 Ko, M. 64
 Kober, H. 16
 Koffarnus, M. N. 53, 61, 76
 Kohn, R. 11
 Kohno, Milky 101
 Kohrt, B. A. 74
 Kohut, S. 106
 Kollins, S. H. 75, 96
 Kong, F. 81
 Kong, G. 60
 Kong, Y. 102
 Koocher, G. P. 54
 Korcha, R. 95
 Korthuis, T. 19, 59
 Kosheleff, A. 88
 Koshy, S. 64
 Kosten, T. 9, 15, 52, 67, 68
 Koszowski, B. 86
 Koustova, Elena 8
 Kowalczyk, W. J. 76, 96, 99
 Koziatsek, MD, C. 103
 Kozink, R. 75
 Kral, A. 58
 Krawczyk, N. 63
 Krebs, C. A. 52
 Krebs, E. 22, 62
 Kreek, M. 11, 12, 79, 104
 Kreiner, P. 83
 Kreisler, A. 80
 Krishnan-Sarin, S. 60, 61
 Kroll, C. 88
 Krupitsky, E. 9, 11, 59, 78
 Kubicki, M. 14
 Kuhar, Michael 71
 Kunkel, L. 19, 59
 Kunoe, N. 9
 Kurti, A. N. 20, 85
 Kurtz, S. P. 21, 24, 56
 Kushnir, V. 87
 Kuypers, K. 17
 Kwiatkowski, E. 19, 55, 56
 Kypri, K. 60
 L. Huskinson, Sally 13, 25
 Labelle, C. 77
 Lacadie, C. 88
 LaConte, S. M. 81
 Lacy, R. 75
 LaLiberte, B. V. 78
 Lamb, K. 87
 Lambdin, B. 58
 Lambert-Harris, C. 79, 97
 Lanaway, D. 18
 Lane, S. D. 15, 80, 104
 Langleben, D. 15, 78
 Lanier, R. K. 63
 Lankenau, S. E. 21, 54, 105
 Lanyon, M. 91
 Lapham, G. 94
 Lappan, S. 62
 Larance, B. 77, 100, 103
 Laranjeira, R. 82, 99
 Larney, S. 84
 LaRowe, S. 87
 Lasopa, S. O. 20, 84
 Latif, Z. 9
 Latypov, A. 57
 Lau, E. 98
 Lauby, J. 4
 Le, A. 57, 95
 Le, C. 16
 Leake, B. 17
 Leatherdale, S. 87
 Ledgerwood, D. M. 18, 78
 Lee, A. K. 94
 Lee, Dustin C. 19, 67
 Lee, J. D. 10, 59, 81
 Lee, M. J. 22
 Lee, N. 3, 66
 Leed, R. 19
 Lefever, T. 64
 Leggio, Lorenzo 2, 53
 Leickly, E. 68
 Lejuez, C. W. 18, 60, 94, 96
 Lemieux, A. 85
 Lemos, N. P. 84
 Leong, K. 10
 Lerman, H. 14
 Lerner, Alicja 72
 Lerner, G. 103
 Leukefeld, C. 61, 62, 66, 100
 Leventhal, Adam 18, 25, 61, 67, 69, 70, 75, 86, 87, 96, 102
 Levesque, A. 97
 Levi Minzi, M. A. 56
 Levi, Y. 58
 Levin, F. R. 54, 62, 97, 104
 Levit, A. 78
 Levran, O. 79
 Levy-Cooperman, N. 54
 Lewis, C. 89
 Leyton, V. 84
 Li, Jun-Xu 1, 23
 Li, X. 106
 Li, Z. 94
 Liang, R. 10, 88
 Liang, Y. 79
 Liao, D. 75
 Liautaud, M. M. 18
 Lichti, C. F. 81

AUTHOR INDEX

- Liebschutz, J. M. 11
 Lile, J. A. 14, 99, 104
 Lim, A. 98
 Lim, J. 56
 Lima, D. R. 21
 Lin, H. 101
 Lin, J. 76
 Lin, L. A. 21
 Lin, Lewei Allison 87
 Lindblad, R. 4, 59, 77
 Lindhardt, K. 17
 Ling, P. 87
 Ling, W. 77, 99
 Lintzeris, N. 77, 100, 103
 Lioznov, D. 56, 59
 Lisieski, M. J. 65, 89
 Lister, J. J. 18, 65, 78
 Little, A. Roger 73
 llgen, M. 21, 101
 Lloyd, D. P. 76, 89
 Lofwall, M. R. 77, 83
 London, E. 81
 Long, Ed 51
 Lopez, A. 58
 Lopez, Marsha 7, 27
 Lopez-Castro, T. 55, 62
 Lopez-Gamundi, P. 80
 López-Núñez, C. 86
 Lopez-Quintero, C. 19, 20, 60
 Lorvick, J. 58
 Loscalzo, E. 78
 Lounsbury, D. 94
 Lozano, P. 94
 Lu, L. 77
 Lu, Y. 17
 Luba, R. 59
 Ludman, E. 94
 Luedtke, R. R. 3
 Luitel, N. 74
 Lukas, Scott E. 70, 105, 106
 Lum, P. J. 59
 Lundahl, L. H. 12, 52, 65
 Lunze, K. 11
 Luo, Sean 71
 Luo, X. 16
 Lupulescu-Mann, N. 78
 Lutton, E. 80
 Luxon, B. 81
 Lyall, A. E. 14
 Lynch, Minda 1, 2
 Lynch, Wendy J. 3
 Lyvers, M. 81
 Ma, L. 15, 55
 MacAfee, L. 85
 Mach, R. H. 3
 MacKillop, J. 53
 MacLean, R. R. 98
 MacPherson, L. 18, 60
 Madras, Bertha 8, 71
 Madruga, C. S. 11, 82, 99
 Magee, C. P. 75
 Magura, S. 22
 Mahaffey, Carlos C. 66
 Maher, L. 85
 Mahony, A. 54
 Maidment, N. 80, 88
 Maki, P. 56
 Makris, N. 14
 Malbergier, A. 21, 98
 Malcolm, R. J. 54
 Maldonado, A. 60
 Malison, R. T. 98
 Mallet-Lambert, I. 62
 Maltbie, E. A. 24
 Mamey, M. 63
 Mancino, M. J. 77, 85, 99
 Mandeville, J. B. 104
 Mandler, R. 59, 61
 Manhapra, A. 77
 Manly, J. J. 98
 Mann, R. 19, 61, 63
 Manser, K. 86
 Manubay, J. M. 17
 Marchi, N. 65
 Mardekian, J. 100
 Maremmanni, A. G. 11
 Maremmanni, I. 101
 Mariani, J. J. 54
 Marino, M. 21
 Marks, K. R. 61, 100
 Marotta, P. 67
 Marsch, L. A. 86
 Marsden, J. 66
 Martin, C. 14
 Martin, E. 56
 Martin, R. 69
 Martinez, S. 106
 Martínez-Loredo, V. 86, 98
 Martins, P. 98
 Martins, S. S. 18, 19, 21, 55, 60, 68, 85, 105
 Marusich, J. A. 64
 Marx, L. 94
 Mashhoon, Yasmin 16, 106
 Mason, Walter 27
 Masri, D. N. 92
 Massey, L. 94
 Masters, E. 100
 Matalenas, L. 96
 Mateu-Gelabert, P. 76, 84, 103
 Mateus, J. F. 17
 Mathers, B. M. 84
 Matheson, T. 57
 Matous, A. L. 70
 Matson, P. A. 60
 Matsumoto, T. 64
 Matsuzaki, S. 64
 Matthews, A. G. 99
 Matthews, W. C. 58
 Mattick, R. P. 60, 82, 100
 Matusiewicz, A. K. 56, 86
 Matuskey, D. 98
 Matveev, N. 9
 Matyas, G. R. 12
 Mauro, C. 21, 105
 Mauro, P. M. 18, 19, 21, 55
 Maxwell, Jane C. 6
 May, A. C. 15, 25
 May, J. 92
 Mayer, K. H. 58
 Mayes, L. C. 88
 Mayfield, S. M. 3
 Mbonu, T. 18
 McBeth, J. F. 69, 96
 McBride, N. 60
 McCabe, Sean 23, 95, 100
 McCaffrey, S. 86

AUTHOR INDEX

- McCarty, Dennis 19, 21, 51, 59, 78
 McClernon, F. J. 16, 20, 75, 96
 McClure, Erin A 6, 59
 McConnell, P. 16
 McCormack, MD, R. 103
 McCort, A. 103
 McCuistian, C. L. 57
 McCutcheon, V. V. 89
 McDermott, K. 9
 McDonald, R. D. 81, 93
 McDonell, M. G. 11, 68, 82, 99
 McGaugh, J. 77, 99
 McGear, D. 93
 McGear, J. 53
 McGinty, J. F. 90
 McGovern, M. P. 79, 97
 McGrath, Erica 67
 McHugh, K. 9, 25, 97, 100
 McKay, J. R. 92
 McKelvey, K. 61
 McLaughlin, A. C. 96
 McLaughlin, J. P. 12
 McLeman, B. 79, 97
 McLeod, A. 91
 McLeod, C. 85
 McMahan, L. 106
 McMahan, T. 82
 McNaughton, E. C. 86, 92
 McNeely, J. 4, 10, 95
 McNeil, R. 95
 McPherson, Sterling M. 11, 63, 68, 71, 82, 99
 McRae-Clark, A. 10, 54, 55, 93
 McWilliams, S. K. 88
 Meacham, M. C. 58
 Meade, C. S. 12, 15
 Meade, Christina S. 74
 Means, S. 22
 Meda, S. 14
 Medina, J. 12
 Meier, A. 79, 97
 Melbostad, H. S. 56, 86
 Mellis, A. 61
 Mendez, I. A. 80
 Mendoza, R. 3
 Mennis, J. 95
 Menzaghi, F. 66
 Mercincavage, M. 20, 86
 Merghati-khoei, E. 94
 Mericle, A. 95
 Merkel, S. 17, 80
 Merry, B. 69
 Messiah, S. 19
 Mestre-Pintó, J. I. 97
 Mété, D. 63
 Metrik, J. 53, 96
 Metsch, L. R. 61
 Metz, V. 17, 59
 Metzger, D. 4
 Meyerhoff, Dieter 23
 Meyers, Jacquelyn L. 89
 Meyers, Kathleen 70, 79
 Mezghanni, M. 76
 Miech, R. 18
 Miguel, A. Q. 11, 82, 99
 Mikhailov, A. 78
 Mikulich-Gilbertson, Susan Kay 71, 88
 Milam, A. J. 76
 Milani, S. A. 83
 Milivojevic, V. 97
 Miller, G. M. 12
 Miller, R. 80
 Milloy, M. 11, 22, 69, 84
 Minerva, A. R. 24
 Mintzopoulos, D. 12
 Mishlen, K. 78
 Mitchell, J. T. 96
 Mitchell, S. G. 63, 77, 94, 100
 Mithoefer, O. 81
 Miziara, I. D. 84
 Moeller, F. 15, 55, 104
 Moeller, S. 56
 Moerke, M. J. 106
 Mogali, S. 17
 Monge, Z. 15
 Monico, L. 100
 Montgomery, L. 57
 Moody, L. 81
 Moody, Raymond L. 102
 Mooney, L. 77
 Moore, A. 75
 Moore, B. A. 10, 76, 77, 83, 89, 94
 Moore, R. D. 58
 Moore, T. 92
 Moran, L. 57, 96, 99
 Morean, M. E. 60
 Moreland, A. 93
 Morford, Z. H. 86
 Morie, K. P. 14
 Morris, R. J. 21
 Morrison, M. F. 92
 Moskowitz, A. L. 55
 Moss, Howard 23
 Muench, J. 19
 Muga, R. 83
 Mugavero, M. 58
 Muller, D. 79
 Muller, M. 81
 Mullins, C. 81
 Munayco, G. M. 94
 Munoz, D. R. 84
 Muqueeth, S. 92
 Muramoto, M. L. 102
 Muritala, M. 10
 Murphy, N. 80, 88
 Murray, Margaret 5
 Musau, A. 4
 Mutch, L. 62
 Mutiso, V. 4
 Mwangi, B. 104
 Myers, B. 64
 Nabulsi, N. 98
 Nader, M. 53
 Nagarajan, R. M. 69
 Nagarajan, V. 88
 Najman, J. 60, 82
 Nanovskaya, T. 69, 85
 Napravnik, S. 58
 Narayana, P. A. 15, 104
 Narayanan, S. L. 85
 Nardone, N. 20
 Nazarian, Arbi 2, 12
 Ndeti, D. 4
 Neelakantan, H. 80
 Nefau, T. 58
 Negus, S. S. 3, 12

AUTHOR INDEX

- Neisewander, J. L. 3
 Nelson, L. 100, 103
 Ngjelina, E. 96
 Nguyen, J. D. 14, 105
 Nguyen, P. 84
 Nicastrì, S. 21, 98
 Nich, C. 14
 Nickell, J. R. 3, 66
 Niculete, M. E. 21
 Nielsen, D. A. 9, 52
 Nielsen, E. M. 52
 Nielsen, S. 77, 100
 Nieto, S. J. 67
 Nijhawan, A. 61
 Nolan, S. 4
 Nordeck, C. 95
 Norman, I. 93
 Norman, W. 69
 Northrup, T. 59, 68
 Nosyk, Bohdan 22, 62, 71
 Novak, S. P. 54
 Nunes, E. V. 95, 97, 104
 Nunes, Edward V. 5, 6
- O'Brien, Bess 1
 O'Brien, C. P. 15, 16
 O'Brien, Moira 26
 O'Connor, P. 91
 O'Donnell, L. 103
 O'Grady, K. E. 20, 55, 63, 77, 95
 O'Malley, P. 18
 Obi, R. 81
 Oblak, J. 91
 Ochalek, T. A. 10, 77, 97
 Oden, N. 4, 59, 82
 Oen, D. 103
 Oishi, K. 69
 Ojeda, V. 84
 Olding, M. 22
 Olesti, E. 17
 Oliver, E. B. 24
 Oliver, J. 75, 106
 Oliveto, A. 77, 99
 Olonoff, M. 54
 Olsen, Y. 77
 Ometto, M. 21, 98
- Ompad, D. C. 94
 Oncken, C. 69, 85
 Ondersma, Steven J. 4, 6
 Opheim, A. 9
 Oros, M. 94
 Osborne, V. 84
 Oser, C. B. 61, 62
 Osiowy, M. 82
 Ostlund, S. 80, 88
 Otiashvili, D. 57
 Ott, J. 79
 Øvergård, M. J. 17
- Pacek, L. 20
 Pachado, M. P. 65
 Padula, C. B. 105
 Pagano, M. 21, 24
 Pagni, B. 13
 Palmatier, M. I. 13, 25, 52
 Palmer, R. E. 100
 Pan, X. 13
 Pandey, A. 89
 Panee, J. 11
 Pang, R. 18, 70, 75, 86, 96
 Paniagua, S. M. 84, 93
 Papaseit, E. 17, 97
 Papini, S. 55, 62
 Park, Tae Woo 87
 Parker, L. J. 102
 Parker, M. A. 61
 Parks, C. 63
 Parks, R. 3
 Parra-Cardona, J. R. 93
 Parry, C. D. 93
 Parsons, J. T. 102
 Parsons, L. 14
 Partilla, J. S. 24
 Parvaz, Muhammad A. 9, 56
 Patel, D. N. 55
 Patel, V. 94
 Pater, H. 16
 Paterson, B. 81
 Patterson Bhatraju, E. 10
 Patton, G. 82
 Patts, G. J. 11, 58, 103
 Paulus, Martin P. 15, 25, 101
- Pavlicova, M. 54, 95
 Payment, M. 19
 Paz, A. L. 68
 Peachman, K. K. 12
 Peacock, Amy 84, 103
 Pearlson, G. 14
 Pechansky, F. P. 65, 79
 Peckham, A. 21
 Peechatka, A. L. 16
 Peiper, N. 54
 Peltier, M. R. 96
 Penetar, D. 70
 Peralta, R. L. 55
 Perez Diaz, M. 64, 80
 Perez, P. 78
 Pérez-Mañà, C. 17, 97
 Pericot-Valverde, I. 86, 98
 Perngparn, U. 83, 92
 Perrine, Shane A. 65, 89
 Perrone, J. 100
 Perry, E. 53
 Pester, M. 25
 Peteet, B. 57, 62
 Peterson, A. B. 3
 Peterson, D. J. 13, 81
 Petro, J. 13
 Petruzzella, A. 25, 96
 Petry, N. 25
 Peyser, Deena 75, 76
 Pfefferbaum, Adolf 8
 Phelps, C. L. 84
 Phillips, K. A. 57, 76, 94, 96, 98, 99
 Phillips, K. T. 11
 Philogene, H. 24
 Pickover, A. M. *WITHDRAWN*
 Pike, E. 99
 Pinedo, M. 84
 PING Consortium, T. 55
 Pitts, E. G. 24
 Platt, D. 13, 67
 Platt, E. 22
 Platt, J. 19
 Plaxco, K. 14
 Ploense, K. 14
 Polak, K. M. 96

AUTHOR INDEX

- Polcin, D. L. 95
 Pollack, H. 76, 94
 Polli, J. R. 13
 Pollock, M. 88
 Ponce-Terashima, J. 19, 21
 Pope, Jr., H. G. 14
 Porjesz, B. 89
 Potenza, M. N. 14, 16, 61, 82, 88, 98
 Potter, Jennifer Sharpe 84, 87, 93, 99
 Pouget, E. R. 103
 Powell, Claudia 27
 Powell, G. 3, 13
 Powers, C. 58
 Prado, G. 19
 Pravetoni, Marco 8
 Prendergast, M. A. 89
 Preston, K. L. 57, 76, 96, 98, 99
 Preston-Campbell, R. N. 56
 Price, A. E. 15, 80
 Price, C. *WITHDRAWN*
 Priest, J. 20, 85
 Pringle, J. L. 91
 Printz, D. M. 76, 89
 Prisinzano, Thomas 3, 73
 Prochaska, J. 87
 Pugh, M. 93
 Pugh, T. 61
 Puri, N. 95
 Puro, J. 21
 Purpura, M. 10
 Pusey, J. D. 77, 97

 Quinn, E. 59, 77
 Quinn, G. 95
 Quisenberry, A. 53, 76

 Rabinovitz, S. 22
 Raby, W. N. 97, 104
 Racine, M. 105
 Rahim-Juwel, R. 18, 19, 55
 Raj, A. 56, 59
 Ramaekers, J. 17
 Ramaprasan, A. 100
 Ramchand, Rajeev 7

 Ramesh, D. 70
 Ramirez, S. 17, 80
 Ramirez-Coombs, E. 15
 Ramo, D. 61, 87
 Ramo, Danielle 6
 Ramos, J. 88
 Randall-Thompson, J. 63
 Randesi, M. 79
 Rao, H. 16
 Rao, M. 12
 Rappeneau, V. 13
 Raskin, S. 14
 Ratcliffe, Sian 72
 Rawls, S. 3, 17, 24, 80
 Ray, B. M. 11
 Ray, L. 15, 69, 97
 Ray, T. 103
 Rayapati, A. O. 104
 Ray-Griffith, S. L. 102
 Raymond, K. 88
 Razmpour, R. 17
 Rea, M. 76
 Redner, R. 20, 85
 Reed, B. 12, 104
 Reed, M. 21
 Reed, S. C. 70
 Reese, E. D. 16, 25
 Regier, P. S. 15, 16
 Regner, M. F. 15
 Reichel, C. M. 10
 Reichin, S. 76
 Reitz, A. 24
 Reske, M. 25
 Reynolds, A. R. 99
 Reynolds, B. 88, 98
 Reynolds, M. D. 91
 Rhodes, A. 92
 Ribeiro, A. 11
 Rice, Kenner 1, 12, 24, 53, 66
 Rich, M. T. 64
 Richards, J. 94
 Richardson, J. 26
 Richardson, L. 22, 58
 Rickard-Aasen, S. 91
 Rico, M. 17
 Ridenour, T. 93

 Rieb, Launette M. 69
 Ries, R. 68
 Rigg, K. 18
 Riggs, L. M. 24
 Riley, A. L. 79, 81
 Rimland, D. 78
 Ringwalt, C. 103
 Risco, C. M. 18, 94
 Ritchie, J. 85
 Ritter, A. 78
 Rivas, I. 83
 Roberts, J. D. 69
 Robinson, A. M. 75
 Rocha, Beatriz 8
 Rock, A. 12
 Rodriguez, B. 58
 Roesch, S. 58
 Rogers, S. 91
 Roll, J. M. 68, 99
 Rollier, S. 94
 Roman, T. 79
 Rooke, S. 105
 Rorick-Kehn, L. 81
 Rosa, C. 4
 Rosa, M. C. 89
 Rose, G. 10, 77
 Rosello, R. 15
 Rosen, B. R. 104
 Rosen, K. D. 84, 93
 Rosen, M. I. 82
 Rosenblum, A. 103
 Rosenheck, R. A. 69
 Rosenthal, R. 77
 Ross, T. 16, 70
 Rosselli, M. 68
 Rotrosen, J. 81
 Rowe, A. 18
 Rowe, C. 57, 99
 Rowlett, J. K. 13, 25, 67, 79
 Roy, E. 97
 Rubin, A. 103
 Rubin, E. 104
 Rubin, L. 56
 Rubinstein, A. 103
 Rubinstein, M. 61
 Ruby, J. 9

AUTHOR INDEX

- Ruggieri, E. 53
 Ruggles, K. 84, 103
 Ruglass, L. 55, 90
 Ruiz, M. 58
 Ruiz, S. 103
 Rupprecht, L. E. 25
 Rush, C. R. 25, 99, 104
 Rybakova, K. 78
- Sacco, P. 75
 Saddleson, M. L. 86
 Sadicario, J. S. 85
 Sagar, K. 105
 Sahlem, Gregory 2, 54, 106
 Saika, F. 64
 Saint-Fleur, A. 18
 Saitz, R. 58, 103
 Sakai, J. 15, 88
 Sakloth, F. 24
 Salas-Ramirez, K. Y. 10, 88
 Salas-Ramirez, Kaliris Y. 88
 Salmeron, B. 70
 Salvatore, J. 89
 Salyuk, T. 94
 Samet, J. H. 11, 56, 59, 77, 91
 Samko, M. 94
 Sanches, M. 83
 Sanchez, K. 75
 Sanders, E. M. 25
 Sanford, C. 103
 Santa Ana, E. J. 87
 Santaella, J. 21, 60, 105
 Santiago Rivera, O. J. 56
 Santos, B. 98
 Santos, D. 57, 99
 Santos, G. 11, 57, 99
 Sanvisens, A. 83
 Sara, W. 98
 Saraiya, T. 56
 Sareedenchai, P. 81
 Sarvet, A. L. 18, 19, 55, 57
 Satre, D. 4, 57
 Saunders, E. 79, 97
 Sawyer, A. 85
 Saxon, A. 77, 84
 Schackman, B. 94
- Scheer, S. 11
 Scherbaum, N. 101
 Scherer, J. N. 65
 Schindler, C. W. 24
 Schlienz, N. 106
 Schmidt, Heath 2
 Schmidt, L. 78
 Schmitz, J. 15, 102, 104
 Schuch, J. B. 79
 Schulenberg, J. 18, 100
 Schutzman, C. 87
 Schwandt, M. 53
 Schwartz, R. P. 4, 61, 63, 77, 94, 95
 Scofield, M. 13
 Scott, B. 11
 Scott, C. K. 20, 21, 95
 Seale, P. 4
 Secades-Villa, R. 86, 98
 Segura, L. E. 60
 Seitz, J. 14
 Seitz-Brown, C. 75
 Selby, P. 87
 Selby, V. L. 96
 Sellers, E. 17
 Serafine, Katherine M. 88
 Serdarevic, M. 83
 Sereda, Y. 62
 Serre, F. 74, 89
 Sessler, N. 83
 Setlow, Barry 101
 Setnik, Beatrice 72
 Severtson, S. G. 84
 Sferra, M. S. 89
 Shah, M. 94
 Shanahan, M. 78
 Sharma, A. 95
 Sharma, G. 4, 82, 95
 Sharma-Haase, K. 9
 Shaw, J. 66
 Sheikhattari, P. 87
 Sherman, B. J. 10
 Sherman, S. 58
 Shimamoto, A. 13
 Shimane, T. 64
 Shinday, N. M. 79
 Shiu, K. 61, 76
- Shmulewitz, D. 18, 19, 55, 68
 Short, V. 69
 Shorter, D. 52
 Showalter, H. 3
 Shram, M. 54
 Shrestha, R. 57, 94
 Shukla, N. 78
 Sierka, C. 66
 Sigmon, S. C. 10, 53, 77, 85, 97
 Silins, E. *WITHDRAWN*
 Silverberg, M. 57
 Silverman, K. 68, 78
 Simon, P. 60
 Singh, R. 22, 101
 Singh, S. 10
 Sinha, R. 88, 97
 Sirikantraporn, S. 84
 Sisti, J. 103
 Skak, N. 17
 Skalisky, J. 68
 Skanderson, M. 78
 Skelly, J. M. 85
 Skinstad, A. H. 91
 Skranes, J. 69
 Slater, K. 70
 Slater, N. 66
 Small, W. 95
 Smethells, John R. 3, 73
 Smith, M. A. 75
 Smith, M. D. 17
 Smith, M. T. 54
 Smith, R. 105
 Smith, T. T. 16, 25
 Smits, J. 55
 Smyth, J. M. 98
 Snider, S. E. 81
 Sofuoglu, Mehmet 9, 69
 Sokolowska, M. 93
 Solli, K. 9
 Solomon, L. J. 92
 Solomon, T. A. 102
 Somerson, J. 14
 Song, K. 93
 Sorensen, J. 59, 61, 77
 Sorenson, R. 3
 Sorsdahl, K. 64

AUTHOR INDEX

- Sotade, O. 103
 Soto, C. 65
 Sottile, J. E. 21, 105
 Sparenborg, S. 77
 Spears, C. A. 96
 Spencer, R. H. 66
 Spicer, S. 96
 Spilman, S. 75
 Spitzer, E. 11
 spodick, j. 69
 Spratt, H. 81
 Spratt, S. 92
 Sprong, M. E. 89
 Sproule, B. 83, 87
 Squeglia, L. M. 59
 Srebnik, D. 68
 Sripada, C. S. 88
 Stahler, G. 95
 Stanger, C. 60
 Staton-Tindall, M. 57, 61, 62
 Stein, D. J. 14, 64
 Stein, Elliot 8, 16, 70
 Stein, Jack 71
 Stein, M. 11
 Steinberg, H. 21
 Steinberg, J. 15, 55, 104
 Steketee, J. D. 80
 Sterling, R. 78
 Stevens, Sally 26
 Stevens-Watkins, D. 66
 Stewart, J. L. 15, 25
 Stillwell, G. 66
 Stitzer, M. 53
 Stohl, M. 95
 Stolf, A. R. 79
 Stoltman, Jonathan J. 5
 Stone, M. 75
 Stoops, William W. 25, 99, 104
 Storholm, E. D. 57
 Storr, C. 60, 96
 Stotts, A. 59, 68, 92, 97
 Stouffer, D. G. 14
 Stowe, Z. 85, 102
 Stoytcheva, B. 55
 Strain, E. C. 10, 54
 Strang, J. 93
 Strasser, A. 20, 86
 Strathdee, S. 58
 Streck, J. M. 97
 Strickland, Justin C 5, 25, 75, 88
 Striley, C. W. 19, 20, 22, 55, 56, 62, 83, 84, 100
 Stringfellow, E. 63
 Stutz, S. J. 80
 Su, Shelley 101
 Subramaniam, G. 4, 95
 Sugarman, D. E. 95
 Suh, J. 15, 16
 Sullivan, M. A. 58, 59, 78
 Summers, K. C. 80
 Sun, W. 66
 Suzuki, M. 24
 Sved, A. F. 25
 Svikis, D. 4, 85, 92, 95, 96
 Swalve, N. 3
 Sweeney, M. M. 88, 99
 Sweitzer, M. 16, 75
 Swendsen, J. 74
 Syckes, C. 84, 103
 Sykes, J. 82
 Sylvester, C. 59, 91
 Szobot, C. 79
 Tabit, Mary 71, 79
 Taffe, M. A. 14, 105
 Tai, B. 92
 Talal, A. 59, 91
 Tallarida, C. S. 17
 Tamashunas, N. 12
 Tanabe, Jody 15, 65, 88
 Tanguy, J. 91
 Tanum, L. H. 9
 Tapert, Susan 5, 15, 25
 Tarbox, P. 95
 Tartarini, W. 70
 Tarter, R. E. 93
 Techer, L. 63
 Teixeira, P. 61
 Tennen, H. 14
 Terplan, Mishka 52, 85, 86, 92
 Tetrault, J. 94
 Theunisen, E. 17
 Thibault, V. 58
 Thiede, H. 22, 84
 Thomas, A. 59
 Thomas, B. F. 6, 64
 Thomas, C. 77, 99
 Thomas, L. 101
 Thompson, E. 95
 Thompson, L. E. 91
 Thorberg, F. A. 81
 Thorndike, E. 24
 Thorpe, R. 102
 Thorsell, A. 81
 Thostenson, J. D. 77, 99
 Thrul, J. 87
 Tidey, J. W. 16, 53, 86, 96, 102
 Tiruveedhulaand, V.V.N.P.B. 68
 Todhunter, B. 78
 Todtenkopf, Mark S. 73
 Tofighi, B. 10, 59, 81
 Tol, W. A. 74, 82
 Tomiyama, K. 13
 Tompkins, D. A. 10, 54
 Tor, J. 83
 Torregrossa, M. M. 64, 88
 Torrents, M. 17, 97, 101
 Torres, C. A. 92
 Torres, L. 17, 97
 Torres, O. 12, 92
 Toumbourou, J. 82
 Toussova, O. 56, 59
 Towe, S. L. 12
 Townsend, D. 67
 Trachtenberg, A. 63
 Traynor, John 23
 Tross, S. 61
 Tsan, L. 88
 Tsui, J. I. 22, 34, 56, 84, 91
 Tyburski, M. 76
 Tyndale, R. 87, 96
 Tyssen, R. 81
 Umbricht, A. 78
 Unterwald, E. M. 64
 Upchurch, D. 55
 Urada, D. 56, 62
 Utevsky, A. V. 15

AUTHOR INDEX

- Vaddiparti, K. 19, 20
 Vahabzadeh, M. 76
 Vahidi, M. 17, 56
 Vallender, E. J. 79
 van den Brink, W. 79
 van Hout, M. 93
 Van Nunen, L. 14
 van Ree, J. M. 79
 van Wijngaarden, E. 11
 Vandewater, S. 14
 Vandrey, Ryan 20, 21, 67
 VanVeldhuisen, P. 4, 77, 82, 103
 Varetska, O. 94
 Vasquez, C. 88
 Vassileva, J. 55, 56
 Vazquez Sanroman, D. B. 10
 Vélez Pastrana, M. 62
 Veliz, P. T. 100
 Ventura, A. S. 58, 103
 Verbitskaya, E. 9
 Vergara-Rodriguez, P. 59
 Vesely, B. 95
 Vidot, Denise C. 5, 19, 62
 Vieira, P. 14
 Viera, P. 10
 Villa-Gonzalez, A. 88
 Villarreal, Y. 59, 68, 97
 Vince, B. 17
 Vincent, J. 104
 Vincent, K. B. 20, 55
 Vinci, C. 96
 Vittinghoff, E. 57
 Vlahov, D. 57
 Vocci, F. 77
 Vogelmann, J. 59
 Volkow, Nora 8
 Von Korff, M. 100
 Vosburg, S. 93
 Votaw, V. R. 100
 Vsevolozhskaya, O. A. 56, 63

 Wadolowski, M. 60
 Wagman, J. A. 56
 Wagner, F. A. 56, 63, 87
 Wagner, J. J. 98

 Wakim, P. 4
 Walker, J. R. 55, 99
 Wall, M. M. 18, 19, 20, 21, 55, 105
 Wallace, J. 18
 Walley, Alexander Y. 58, 59, 77, 103
 Walsh, S. L. 10, 83
 Walters, H. M. 24
 Walton, M. A. 54, 76, 94, 101
 Wang, G. 17
 Wang, H. 11
 Wang, J. 84, 94
 Wang, L. 22
 Wang, M. 12
 Wang, X. 104
 Ward, G. 76
 Ward, K. 85
 Wardle, M. 80
 Washio, Y. 68, 91
 Watchko, S. M. 85
 Waters, Andrew 9
 Watson-Thompson, J. 82
 Webster, L. R. 17, 54
 Webster, M. 61, 62
 Wechsberg, Wendee 57, 74
 Weerts, Elise M. 67, 68
 Weglicki, L. 92
 Wehmeyer, K. 78
 Weidberg, S. E. 86
 Weigel, T. 95
 Weinberger, A. H. 19
 Weiner, S. 100
 Weinstein, A. M. 14
 Weinstein, S. 78
 Weinstein, Z. M. 77
 Weiser, S. D. 11
 Weisner, C. 4, 103
 Weiss, R. 9, 25, 97
 Weiss, Susan 5
 Weiss, V. G. 75
 Wesley, M. J. 14
 West, H. 69, 85
 Westmoreland, S. 79
 Wetherill, R. 15, 16
 Wetherington, Cora Lee 65

 Wetzell, B. B. 81
 Wey, H. 104
 Wey, Hsiao-Ying 104
 Wherry, J. 13, 52
 White, B. 85
 White, N. 103
 Whitehead, N. E. 100
 Whiteside, L. K. 101
 Wickens, C. 63
 Wiersema, J. 61
 Wiley, J. 54, 64
 Williams, E. A. 13, 25
 Williams, G. 11
 Wilson, A. G. 61, 66
 Wilson, B. L. 91
 Wilson, M. 80
 Wilson, S. J. 98
 Wincott, C. 104
 Windisch, K. 12
 Winoske, K. J. 67
 Winter, M. R. 77
 Wish, Eric 26
 Witbrodt, J. 95
 Wolff, K. 62
 Wong, C. F. 54
 Wong, S. 81
 Wood, E. 4, 11, 58, 59, 69, 84
 Wood, R. 14
 Woodcock, E. A. 52, 65
 Woody, G. E. 78, 84
 Worhunsky, P. D. 98
 Wu, L. T. 4, 92, 95
 Wu, P. 67
 Wulfert, E. 74

 Xenitidis, K. 62
 Xia, J. 55
 Xia, R. 17
 Xu, H. 52
 Xu, J. 16
 Xu, K. 96
 Xuan, S. 18
 Xuan, Z. 103

 Yamakawa, R. 69
 Yamamoto, Bryan K 13, 23

AUTHOR INDEX

- Yamamoto, D. 15
Yang, Yihong 8
Yao, W. D. 79
Yassin, N. 93
Yates, J. R. 75
Yeh, H. H. 93
Yerkes, L. 92
Yi, J. Y. 16, 25
Yi, R. 94
Yip, S. W. 14, 61, 88
Yonkers, K. A. 69
Yoon, Jin H. 6
Young, D. 3
Young, J. 102
Young, K. A. 15
Young, M. 89
Young, R. M. 81
Young, S. 59, 62
Young-Wolff, K. C. 4
Yuferov, V. 79, 104
- Zacharoff, K. L. 83
Zadzielski, E. 91
Zah, V. 9
Zakiniaev, Y. 88
Zang, G. 97
Zaplatkin, I. 78
Zaslav, D. 79
Zatzick, D. 101
Zavala, A. R. 24
Zavala, R. 59
Zawertailo, L. 87
Zentgraf, K. 79
Zeremski, M. 59, 91
Zestos, A. 3
Zeziulin, O. 94
Zhai, Z. 93
Zhan, C. 66
Zhang, M. 83
Zhang, Y. 64, 79, 81
Zhao, S. 87
Zheng, G. 3, 66
Zhu, J. 66
Zhu, M. 52
Zhuang, Y. 88
Zilverstand, A. 56
- Zimmerman, M. 76
Zorrilla, E. 80
Zucker, R. A. 88, 89
Zule, W. 57
Zulich, A. 22
Zuluaga, P. 83
Zuo, C. 70
Zvartau, E. 9
Zvolensky, M. J. 20
Zvorsky, I. A. 20, 85

SYMPOSIA

Sunday, June 12

President's Symposium

TITLE: Where There's Smoke: U.S., Australasian, and European Cannabis Policies and Use

AUTHOR: Deborah Hasin^{1,2}

INSTITUTIONS: ¹Columbia University; ²New York State Psychiatric Institute

Americans increasingly see marijuana as a harmless substance and favor its legalization; changes in state laws regarding marijuana reflect these changing attitudes. Time trends in adolescent marijuana use are reviewed, and the strength of evidence examined for a relationship between medical marijuana laws and adolescent use. Increases over time in adult marijuana use, marijuana use disorders and other marijuana-related consequences are also reviewed, for the population as a whole and within major population subgroups.

AUTHOR: Alison Ritter³

INSTITUTION: ³University of New South Wales

Cannabis use in Australia has been one of the highest in the world, yet cannabis policies in Australia have not substantially changed and there is little appetite for a less prohibitionist approach (for example, as of 2013, only 26% of the population supported cannabis legalisation). Given policy stasis in Australia, it is interesting to reflect on possible drivers for changing cannabis prevalence (which has decreased from 18% last year use in 1998 to 10% last year use in 2013). Factors such as attitudes to smoking, and/or awareness of health effects, may be more important than formal drug policies in driving changes in cannabis prevalence rates.

AUTHOR: Marc Auriacombe^{4,5,6}

INSTITUTIONS: ⁴University of Bordeaux (France); ⁵CH Ch. Perrens and CHU Bordeaux, France;

⁶University of Pennsylvania

Marijuana regulations across European countries vary wildly regarding both what is permitted and what is not. There are also significant differences across countries in enforcement of cannabis laws. This gives us an opportunity to examine data available in the different countries in relation to each country's specific regulations. Prevalence of overall use in adolescents and adults, as well as estimates of problem use will be reviewed in this perspective.

SYMPOSIA

Sunday, June 12

I. *Developing innovative brain stimulation treatment options for substance-dependent individuals: Translating basic science knowledge of neural circuits to our clinics*

Chairs: Colleen Hanlon and Antonello Bonci

In the last decade we have become increasingly aware of the role that frontal- striatal circuits have on drug-taking behavior and relapse. Using elegant molecular techniques, we are able to change drug-taking behavior by modulating these circuits. Until recently, however, there were no techniques available to modulate these circuits in our patients. Developing brain stimulation as a treatment option for addiction is one of the goals of NIDA's new strategic plan. SPECIFIC AIMS: We will introduce transcranial magnetic stimulation (TMS), provide a theoretical model for approaching addiction treatment, and highlight current TMS research in a diverse population of patients with substance use disorders (SUD). APPROACH: First, we will describe a theoretical framework for selecting neural circuit based targets likely to be fruitful candidates for SUD treatment. This will be followed by presentations from several laboratories that are evaluating the efficacy of TMS as a tool to decrease craving and/or increase cognitive control in alcoholics, nicotine smokers, prescription opiate users, and cocaine users. Each of these presentations will highlight both the successes and the challenges they faced when applying these techniques to patients. Finally, we will return to the theoretical model and describe links to both basic science research as well as pragmatic issues required to bring TMS to outpatients.

II. *Influence of metabolic hormones on reward processing and addiction*

Chairs: Arbi Nazarian and Minda Lynch

Peripherally based metabolic hormones play significant roles in regulation of homeostatic feeding and satiation systems, with their dysregulation leading to conditions such as obesity and diabetes. More recent examinations have revealed that metabolic hormones are also active modulators of natural hedonic processing for food, as well as modulators of reward processing to drugs of abuse by acting within the mesocorticolimbic system. Understanding the neurobiological mechanisms of metabolic hormones can shed light on the contribution of these hormones on reward signaling in the brain and facilitate development of novel therapeutic approaches for the treatment of drug and food addiction. In this symposium, findings will be presented demonstrating the modulatory role of metabolic hormones in alcoholism in humans, rodent models of nicotine and cocaine abuse, as well as food intake. The aim of this symposium is to 1) introduce the audience to metabolic hormones, as modulators of reward processing; 2) develop an understanding of the intricate interaction of the peripheral endocrine system with reward signaling; and 3) encourage consideration and investigation of the influence of metabolic hormones in studies of addiction.

SYMPOSIA

Monday, June 13

III. Identifying system-level biomarkers of substance abuse using functional connectivity of the brain

Chairs: Yihong Yang and Elliot Stein

Substance abuse is a complex neuropsychiatric disorder manifested as dysregulations of multiple cognitive and affective constructs. Recent advances in neuroimaging have shown promise in identifying system-level biomarkers that are closely associated with the behavioral phenotype and may be potentially useful for individualized treatment and predicting therapeutic outcome. In particular, brain functional connectivity, derived from the synchronized fluctuations of the resting-state functional MRI signal between brain regions, has undergone rapid technological developments and consequently as a noninvasive imaging tool to assess neuroplasticity of brain circuits and networks in various neuropsychiatric disorders. In this symposium, we will present the latest developments in identifying imaging biomarkers of substance use disorders using functional connectivity. The four speakers will present recent data from their labs using a number of analytical approaches to understand the circuitry underlying the abuse profile of cocaine, marijuana, alcohol and nicotine. Finally, these recent developments will be discussed in view of emerging theory related to drug-induced imbalance of neuronal circuits. We will also discuss the potential value of these imaging biomarkers 1) as therapeutic targets; 2) in the prediction of group or subgroup membership and monitoring of treatment outcomes; and 3) in translational and “back-translational” studies using preclinical models.

IV. Cognitive function as a novel treatment target for drug addiction

Chairs: Mehmet Sofuoglu and Kathleen Carroll

The aim of this symposium is to review the promise of cognitive function as a novel target for behavioral and pharmacological treatments for drug addiction. Results will be presented showing that oral methylphenidate enhances performance and underlying fronto-striatal function on tasks of inhibitory control and drive, and resting-state functional connectivity, in cocaine addiction. Data will be shown from randomized trials designed to determine whether engagement in daily technological enhancements (interactive voice response or smartphone app), as a cognitive-enhancement strategy, and brief interventions to reduce drug use were more effective than brief interventions alone among drug users treated in HIV comprehensive care settings. Following a brief overview of the potential utility of attentional retraining interventions for addictions that aims to reverse attentional bias to drug cues, and therefore cue-provoked craving and drug use, recent data in which cognitive biases for cigarette smoking are assessed and modified on mobile devices will be presented. Findings will be presented from a recently completed clinical trial that tested efficacy of a cognitive enhancer, galantamine (a cholinesterase inhibitor) and computerized cognitive behavioral therapy (CBT4CBT), alone and in combination, on treatment outcome and cognitive functioning among cocaine users. A discussion of the implications of these findings for developing novel treatment approaches for drug addiction and providing future research directions will conclude the symposium.

SYMPOSIA

Monday, June 13

V. *Identifying system-level biomarkers of substance abuse using functional connectivity of the brain*

Chairs: Margaret Gnegy and John Traynor

Substance abuse is a complex neuropsychiatric disorder manifested as dysregulations of multiple cognitive and affective constructs. Recent advances in neuroimaging have shown promise in identifying system-level biomarkers that are closely associated with the behavioral phenotype and may be potentially useful for individualized treatment and predicting therapeutic outcome. In particular, brain functional connectivity, derived from the synchronized fluctuations of the resting-state functional MRI signal between brain regions, has undergone rapid technological developments and consequently as a noninvasive imaging tool to assess neuroplasticity of brain circuits and networks in various neuropsychiatric disorders. This symposium will present the latest developments in identifying imaging biomarkers of substance use disorders using functional connectivity. Recent data will be presented using a number of analytical approaches to understand the circuitry underlying the abuse profile of cocaine, marijuana, alcohol and nicotine. These developments will be reviewed in light of emerging theory related to drug-induced imbalance of neuronal circuits. In addition, the potential value of imaging biomarkers will be discussed as therapeutic targets; in the prediction of group or subgroup membership and monitoring of treatment outcomes; and in translational and “back-translational” studies in preclinical models.

VI. *Intracellular signaling molecules as targets for stimulant abuse treatment*

Chairs: Heather Kimmel and Paul W. Czoty

Epidemiological data suggests that poly-substance use, the use of more than one drug over a period of time, is common; yet basic and clinical research typically examine the consequences of a single drug at a time. Polysubstance users have an increased risk of developing comorbid psychiatric and other health conditions. Current prevention and treatment approaches are under-developed, indicating a need to understand the antecedent and consequential circumstances surrounding polysubstance use. This symposium will showcase current epidemiological, clinical, and basic research findings describing current polysubstance use trends and subsequent health outcomes. We will describe recent polysubstance use findings from two different nationally representative cross-sectional studies of youth and adults. Building upon these cross-sectional data, we will discuss novel longitudinal research tracking polysubstance use from adolescence through young adulthood. A clinical perspective will be provided, presenting neuroimaging and neurocognitive data to demonstrate differing cognitive outcomes in alcohol dependent individuals who also use stimulants compared to alcoholics that do not use stimulants. Data will demonstrate that serial alcohol and methamphetamine administration in rodents exacerbates the neurotoxic effects of either drug alone. The discussion will integrate these data to discuss how these findings inform each other. Bringing these diverse perspectives together will facilitate discussions of how epidemiological data can inform basic animal and clinical research and, conversely, how findings from basic and clinical research can guide epidemiological research.

SYMPOSIA

Tuesday, June 14

VII. *5HT2A and 5HT2C ligands as potential therapeutics for substance use disorders*

Chairs: Jane B. Acri and Leonard Howell

We will present and discuss data relevant to the clinical advancement of 5HT2 ligands as substance use treatment medications. There are no approved medications for cocaine, methamphetamine, or THC use disorders, and these results may suggest clinical efficacy for substance use disorders. The 5HT system can influence the abuse-related effects of cocaine and other drugs of abuse through its direct and indirect interactions with dopaminergic systems in key brain areas. The regional distribution of 5HT2A and 5HT2C involve the prefrontal cortex, the nucleus accumbens and the ventral tegmental area. The two receptor systems can functionally oppose each other in terms of their regulation of the dopaminergic signaling. Several selective ligands have recently been developed by pharma for different indications; lorcaserin a 5HT2C agonist is in clinical use for weight reduction, and pimavanserin, a 5HT2A antagonist may soon be approved for the treatment of psychosis in Parkinson's Disease. Clinical availability of selective ligands will greatly enhance our ability to translate these findings in human clinical trials. These compounds have recently been evaluated in drug self-administration models using non-human primates trained to self-administer cocaine, methamphetamine, or THC, using FR, PR, or choice models. These results will be presented and discussed in terms of relevance to the treatment of substance use disorders.

VIII. *Neonatal Abstinence Syndrome: Context and consequences in 2016*

Chairs: Karol Kaltenbach and Hendree Jones

Under the banner of fetal protection, judges and prosecutors have implemented punitive approaches against women who use prescribed and non-prescribed opioids during pregnancy. Policy makers mirror such punitive approaches in laws passed that focus on women who use drugs while pregnant. The symposium will review the current situation for women who use substances during pregnancy and their NAS-diagnosed babies. These actions in the judicial-political sphere suggest that the science of NAS is well understood. While there are numerous reports in the empirical literature documenting efforts to assess and treat NAS over the past 50 years, rigorous studies testing the best ways to assess and treat these infants are relatively recent as are studies that identify factors that exacerbate or mitigate the severity of NAS. The state of the science in assessment; efficacy of medication used to treat NAS; and protocols for initiation of treatment and weaning will be described. Factors that have been recently been identified that exacerbate the severity and length of treatment as well as changes in hospital policies and practices that been shown to be effective in reducing NAS severity will be discussed. These presentations will outline how a diagnosis of NAS is not a diagnosis of maternal substance use disorder; an indication of a negative relationship between substance use and fetal outcome

SYMPOSIA

Tuesday, June 14

IX: *Translational markers of substance use vulnerability: Receptors, risk-processing, and psychopathology*

Chairs: Noelle C. Anastasio and Thomas Crowley

Among human children and adolescents, externalizing behaviors, including impulsivity and risk-taking, predict adolescent and adult substance use disorders. Our translational studies of substance-naïve human and non-human subjects suggest that aberrant brain function underlies aberrant early behaviors and reflects a neural vulnerability to substance use disorders. An imbalance in the cortical glutamatergic system as an underpinning of inherent impulsivity in rodents may be driven by dysregulation of N-methyl-D-aspartate receptor signaling and selective NMDAR potentiation may reduce high inherent impulsivity. Earlier work demonstrating that in a risky-decision game, adolescents with substance and conduct problems (SCP) had widespread brain hypoactivity will be extended to the same game-stimulated neural activity in numerous brain regions of drug-naïve 9-11 year-olds. Correlation with participants' parent-rated externalizing scores suggests that aberrant brain function antedates, and may contribute to, SCP in many adolescents. Data from the IMAGEN study, a longitudinal cohort of 2200 adolescents who underwent genetic, neuroimaging and behavioral assessments, will be presented. Correlates of factors of psychopathology within a hierarchical structural model associated with psychiatric conditions, including substance use disorder, will be shown. This panel will emphasize that a greater understanding of the vulnerability to the development of substance use disorders requires the cross-talk and contribution of cross-discipline, cross-species studies.

X: *Imaging the male & female addicted brain: Structural and functional differences and implications for precision medicine*

Chairs: Cora Lee Wetherington and Will M. Aklin

The Precision Medicine Initiative was announced by President Obama in the 2015 State of the Union address, and was subsequently described by Francis Collins & Harold Varmus (NEJM, 2015) as “prevention and treatment strategies that take individual variability into account.” Because biological sex is the most fundamental difference among individuals, studying differences in outcomes between men and women is low-hanging fruit in achieving precision medicine. Speakers in this symposium will present sex differences in neuroimaging data that are providing a window on potential targets, both behavioral and pharmacologic, to enhance precision medicine, from both prevention and treatment perspectives. A brief review of sexual dimorphism in brain structure and connectivity in healthy people will precede discussion of sex-specific differences in cortical and subcortical gray-matter volume and correlated drug use and behavioral measures in long-term abstinent stimulant users. Data from the PET image analysis, lp-ntPET, will be shown, which can provide real-time ‘movies’ and quantification of dopamine release during smoking, and has revealed sex differences in dopamine release in the ventral striatum and dorsal putamen and its relationships to mood and reward in smokers. Also presented will be data from males and females with substance use disorders, with and without trauma histories, comparing their resting-state functional connectivity, their response to pharmacologic probes of neural systems, and their response to drug-related cues.

SYMPOSIA

Tuesday, June 14

XI. *Not your average joint: Alternative methods of cannabis consumption*

Chairs: Adam Leventhal and Marcel O. Bonn-Miller

With increasing legalization of cannabis, there has been a proliferation of the number and types of cannabis preparations and drug delivery devices available on the market. Consequently, smoking cannabis is no longer the exclusive route of cannabinoid consumption prominent in the population. Oral consumption of edible cannabis products, transdermal application of topical cannabinoid ointments, and vaporization of cannabis plant, oils, and liquid extracts via e-cigarettes and other electronic devices are becoming increasingly popular. Unfortunately, many drug dependence researchers, clinicians, and policy makers are unaware of this trend and the emerging science on alternative routes of cannabis administration. This symposium synthesizes laboratory, clinical, and population-based research on the pharmacology, clinical correlates, and epidemiology of cannabis consumption via alternative routes. Human laboratory research on the acute pharmacokinetic and pharmacodynamic dose-effects of oral cannabis will be presented and contrasted to prototypical drug effect profiles of cannabis smoking. Clinical research pertaining to use of various cannabis preparations among cannabis-dependent individuals and patients using for therapeutic and recreational purposes will be discussed. Survey data characterizing cannabis vaping in adolescent and adult cannabis users will be presented. Also discussed will be the epidemiology of cannabis use by route of consumption and novel data on the prevalence and mental health correlates of adolescent cannabis vaping and use of edible cannabis products. The session will close with a discussion of translation across basic, clinical, and epidemiologic perspectives, and implications for regulation.

Wednesday, June 15

XII: *Medicinal chemistry of novel kappa opioid receptor ligands*

Chairs: F.I. Carroll and Thomas Prisinzano

Every since the discovery of the potent and selective kappa opioid receptor antagonists nor-BNI and kappa opioid receptor agonist such as U69,593 as well as other antagonists and agonists of this receptor system there has been continuing interest in basic medicinal chemistry studies that this receptor plays in numerous biological processes. Animal behavioral studies have shown that both antagonists and agonists have high potential for treating substance abuse (nicotine, alcohol, cocaine, methamphetamine and opiates) as well as other CNS disorders (depression, anxiety, attention deficit hyperactivity disorder, pain, and others). This symposium will provide information concerning newer kappa opioid receptor ligands for treating substance abuse. The presentations will include studies directed towards 1) the effect of substitution for the tryptophan residue in the natural product CJ-15,208; 2) a better understanding of the medicinal chemistry properties of salvinorin A and analogs; 3) the optimization of biased kappa opioid receptor ligands; and 4) the effect of changing the 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine part of JDTic on its medicinal chemistry properties. The basic medicinal chemistry research information presented in these four presentations will provide a better understanding of how the kappa opioid receptor target will lead to potential pharmacotherapies for treatment of various substance abuse problems and other CNS disorders.

SYMPOSIA

Wednesday, June 15

XIII: *Bio-behavioral research on HIV among people who use drugs*

Chairs: Christina S. Meade and Adam W. Carrico

Since the beginning of the HIV/AIDS epidemic, drug users have been at increased risk for HIV infection and transmission, both through risky injection drug practices and risky sexual behaviors. As the epidemic has evolved, drug users have faced increasing disparities related to HIV testing treatment, and retention in care— with correspondingly poorer clinical and psychosocial outcomes. Moreover, drug addiction can interfere with HIV treatment outcomes, both directly through biological processes and indirectly through difficulties with HIV disease management. With the goal of an AIDS-free generation, funding priorities now emphasize biomedical approaches. However, behavioral research remains critical to ensure that all individuals - no matter how difficult to reach - can derive the maximum benefits from new biomedical treatments to reduce the transmission of HIV and effectively manage HIV-associated comorbidities. This symposium highlights major advances from interdisciplinary research teams led by behavioral scientists. The presentations cover bio-behavioral approaches to identifying behavioral risks among high-risk groups, neurocognitive impacts on decision-making processes relevant to HIV risk, and multi-component interventions to reduce risk of HIV transmission and improve HIV-related outcomes. The discussant will review the results of these studies in light of new NIH priorities for HIV/AIDS research among persons who use and abuse drugs.

XIV: *Reducing the harms of opioid analgesic use in health systems*

Chairs: Amy Bohnert and Tae Woo Park

Reducing the harms of opioid medications used in the treatment of pain has become a major priority of health systems, public health agencies, and policymakers. Because opioid prescribing has been linked to overdose and misuse on a population and individual level, improving treatment practices is a major focus of efforts to address this problem. We will report emerging evidence related to efforts to reduce the harms of opioids in treatment settings. Patients in addiction treatment settings will represent a group of particular attention for several of the studies reported. One avenue of health system-based prevention is to use information readily in electronic medical records to identify those patients receiving opioids at greatest risk for harm. We will present on patient and treatment characteristics associated with opioid misuse in a military population as well as overdose specifically among addiction treatment clients. We will seek to further elucidate risk reduction strategies through qualitative interviews with health care providers. This will include examining the feasibility of a military prescription drug monitoring program. Additionally, a series of interviews with primary care providers and pharmacists will explore their decision-making processes when balancing the benefits and risks of prescribing and dispensing opioids for chronic non-cancer pain. We will also report on use of non-pharmacological pain management strategies among individuals with comorbid chronic pain and substance use disorders to explore avenues for reducing reliance on opioids for analgesia. The discussion will focus on the translation of these findings to patient-, provider-, and system-level interventions.

SYMPOSIA

Thursday, June 16

XV: *Risky business: Neurobiological mechanisms of risky decision making in drug abuse and addiction*

Chairs: Shelly Su and Carlos Blanco

Individuals with substance use disorders exhibit deficits in executive function, including the inability to think flexibly, to update and manipulate information, and to inhibit choices and actions that are irrelevant to the current goals. New and exciting findings indicate a relationship between drug abuse vulnerability and risk preference, or the preference for an uncertain delivery of a large reward over certain delivery of a small reward. The purpose of this symposium is to showcase this emerging area of research and highlight the neural circuitry subserving drug-induced risky decision making in basic animal and human-based laboratory research. The symposium will begin with data characterizing the neural systems that integrate information regarding cost/benefit analysis in a probabilistic discounting task in healthy, drug-naïve rodents. Building upon this neural circuitry, evidence will be presented for a bi-directional relationship between risky decision making and cocaine self-administration in rodents and the contributions of dopamine signaling to this association. Behavioral and neuroimaging data from healthy and methamphetamine-dependent participants engaging in the Balloon Analog Risk Task, which parallels the same cognitive deficits and neural networks observed in rodent models, will be presented. A translational perspective and data on altered risk perceptions and changes in neural patterns of activity in drug-dependent individuals will be discussed.

WORKSHOPS

Sunday, June 12

I. Navigating key stages of a career in addiction science: Graduate school, post-doc and early-career

Chairs: Teresa Franklin and Denise Vidot

You are a budding addictions-focused Investigator with new ideas, new techniques and new approaches and— you are presenting a poster or a talk at CPDD— maybe this is your first, or your third, but it is an important moment in your career— Congratulations! In addition to presenting your work, the opportunities to learn and network at CPDD are monumental! For example, this workshop, which will focus on issues specific to 3 key stages in your early career, Pre-Doctoral, Post-Doctoral, and Early Career/Faculty, could be helpful to you. Three of your colleagues, who have ‘Been There, Done That’ want to share their experiences with you. Each presentation will outline steps that can be taken to maximize your career stage-specific experience and make you a competitive job applicant for the next stage of your career. Examples of topics that will be covered include how to choose your mentors; striking a balance between executing your mentor’s vision and growing as an independent scientist; how to narrow down an innovative and significant research question; publishing amidst other responsibilities; obtaining grant-writing experience; applying for awards; establishing your niche and conveying its importance to potential employers; collaborating and networking; deciding whether to teach; life-work balance; finding the NIH funding mechanisms that are most appropriate for you; how to begin writing your grant; and crucial to it all - time management strategies.

II. The landmark Adolescent Brain Cognitive Development Study (ABCD): A detailed discussion of the study goals, methodologies, and project start-up

Chairs: Susan R.B. Weiss and Margaret M. Murray

Adolescence, a time of dramatic physical, emotional, and intellectual growth, is a developmental period that sets the foundation for an individual’s life trajectory. While advances in brain imaging and cognitive neuroscience are providing insights into the developing brain, to date, few studies have been able to capture the factors that influence this development over time in large and diverse populations. Children and adolescents are exposed to myriad internal and external influences that interact with their changing biology and genetic and environmental vulnerabilities that affect their development. To gain better understanding of brain, cognitive, social, and emotional development trajectories from childhood through adolescence; the NIH launched the landmark ABCD in the fall of 2015. This unparalleled prospective, longitudinal, multi-site study will combine developmental psychology, neuroimaging, cognitive neuroscience, genetics, and epidemiology with advanced techniques in bioassays, bioinformatics, and mobile assessment to follow 10,000 9-10-year-olds recruited at 19 sites around the country. This workshop brings together representatives from the ABCD Research Consortium leadership to present the goals of the study, assessments and technologies being used to address these goals, and sampling methodology designed to recruit and retain subjects with multiple dimensions of diversity (i.e., race, ethnicity, education, urban and rural environments). Project start-up information will also be shared. Findings from ABCD are expected to increase the ability to distinguish environmental, sociocultural, and genetic factors relevant to substance use and brain development and to inform prevention, treatment, and public health strategies.

WORKSHOPS

Sunday, June 12

III. *Emerging technology for human subjects research* Chairs: Jonathan JK Stoltman and Edward Nunes

The College on Problems of Drug Dependence Committee on Human Research presents a practical workshop that includes human researchers of both junior and senior status with diverse interests within the substance abuse field. The workshop is positioned to benefit both junior and senior investigators in the audience by exposure to new technology. In addition, roughly a third of the time will be a question-and-answer session with discussion regarding ethical and legal issues facilitated by an expert senior discussant. The workshop will provide all attendees with different perspectives and best practices at other universities, thereby enhancing translation from the workshop to real world implementation. The basic workshop design includes brief description of new technology, the opportunities they hold, and the challenges we might face implementing them. Summaries will be provided for popular and novel technologies for human subject research. The workshop is designed to cover technology throughout the research stages of reaching IRB approval; recruiting; and data collection. Specifically, two popular methods of online recruitment and data collection will be discussed (Amazon Mechanical Turk and Facebook), HIPAA, technology to deliver interventions, and technology monitoring in ecological environments. A variety of technology and substance-using populations will be covered.

IV. *International emergence and abuse of new psychotropic substances (NPS), their toxicity and the current regulatory response* Chairs: Patrick Beardsley and Jane C. Maxwell

New psychotropic substances (NPS) of abuse continue to emerge and cause harm worldwide. Commonly associated NPS drug classes have been the synthetic cannabinoids and cathinones, but newly emerging benzodiazepines, dissociative anesthetics and opioid and opioid-mimicking drugs have recently added to this onslaught. Not only is their number and diversity a challenge, but also their transience, detection and geographical heterogeneity, which provide special issues to health practitioners and regulatory authorities relative to more established abused drugs. The fact that their availability and supply are often mediated through the diffuseness of the Internet compounds the problems of their control. The specific aims of this workshop are to illuminate the international diversity of the NPS problem, the harm they cause, and how regulatory authorities are responding to their challenge. Hopefully, this information will better alert and inform those practitioners confronting NPS health issues, and enkindle interest in their research by scientists. The workshop will address forensic challenges associated with NPSs and their toxicology, present an international canvas of the NPS problem, focusing on the NPS story in Australasia, Europe and the United States. It will conclude with a summary of the presented topics and a focus on the international regulatory response in its attempt to control the NPS problem.

WORKSHOPS

Sunday, June 12

V. *Epidemiology and public health research methods*
Chairs: James Anthony and Jan Copeland

This workshop will begin with an overview of high priority program announcements for the NIDA Division of Epidemiology, Service, and Prevention Research (DESPR), DESPR funding opportunities, and DESPR-initiated data archives for public and restricted use epidemiological datasets. Then, we turn to some innovations in statistical estimation and inference for prevention, health services, and treatment research when randomization is not possible (e.g., estimation of the effects of childhood-onset cannabis use in relation to brain imaging outcomes). The final segment of the workshop will be a chair-organized and chair-led but generally open discussion about the promise and pitfalls of using data from Google Trends, Facebook, Twitter, and other social media in NIDA, NIAAA, NCI, and FDA epidemiology and public health research on nicotine products, cannabis products, and related topics.

Monday, June 13

VI. *21st Annual Contingency Management Working Group*
Chairs: Diann Gaalema and Kelly Dunn

The Contingency Management (CM) Working Group, held annually during the CPDD convention, is an opportunity for the dissemination and discussion of current research regarding the use of CM interventions to promote behavior change and reduce drug use. CM is a behavioral treatment strategy that has demonstrated consistent success in promoting abstinence from a wide-range of drugs and across many different treatment populations. It is also being used to promote change in behaviors impacting the course of other chronic diseases (e.g., obesity, diabetes). At the 21st Annual Meeting of the CM Working Group, junior and senior researchers will present preliminary data from ongoing studies involving CM. The goal for this working group is to provide an informal outlet for discussion of ongoing CM research, with an emphasis on developing or improving research strategies by seeking audience input, and providing opportunities for junior and senior researchers to interact.

WORKSHOPS

Monday, June 13

VII. Introducing the National Drug Early Warning System (NDEWS)

Chairs: Eric D. Wish and Moira O'Brien

In 2014, the National Institute on Drug Abuse (NIDA) funded the Center for Substance Abuse Research (CESAR) at the University of Maryland, College Park, to serve as the Coordinating Center for its new National Drug Early Warning System (NDEWS). NDEWS builds on the infrastructure of a successful earlier NIDA project, the Community Epidemiology Workgroup (CEWG). NDEWS supports the cross-disciplinary collection and exchange of information on the availability of drugs, consumption of drugs, and consequences of drug use. NDEWS-coordinated activities include early detection and communication by the NDEWS virtual network, social media scans, and a partnership with the American Association of Poison Control Centers. NDEWS also monitors emerging local drug trends in 12 Sentinel Community Sites (SCS) and through targeted Hot Spot Studies. This workshop will present the methods and findings generated by NDEWS during its first two years. The presenters will 1) introduce NDEWS and review its components; 2) highlight NDEWS advancements; 3) discuss emerging drug use patterns and trends in the SCSs; 4) highlight emerging drug use trends and patterns in San Francisco (a SCS); 5) review the results of recent ethnographic interviews conducted as part of a Hot Spot study on the use of synthetic cannabinoids; and 6) describe new techniques for scanning and interpreting drug-related tweets.

VIII. A gender lens to addressing adolescent substance use disorders and trauma with systems level approach / SASATE Business Meeting

Chairs: Michael Dennis and Sally Stevens

Adolescents who have experienced trauma report more substance use, criminal activity, homelessness, and mental and physical health challenges. These youth are in need of trauma-informed integrated services — including girls and lesbian, gay, bisexual, transgender (LGBT) youth. The effectiveness of treatment can be improved if services incorporate a systems-integration approach specifically tailored to these high-risk groups. The specific aims of the workshop are to (1) provide an overview of adolescent substance use disorders and trauma by sex and gender identity; and (2) present outcome data on the effectiveness of systems-integrated, trauma informed, gender- and LGBT-targeted interventions for substance-involved adolescents who present with histories of trauma. Reports will include information on substance use disorders and trauma symptoms in national data from adolescents entering substance abuse treatment by sex and sexual identity; substance use, trauma, sexual behaviors, and outcomes of a trauma-informed and systems-integrated intervention effective in reducing substance use, trauma symptoms, and risky sexual behaviors among adolescent girls; trauma-responsive system of care for LGBT youth and how this system of care improved outcomes with regard to substance use, mental health and homelessness for this population; a clustered randomized pilot trial that reached female adolescent dropouts who use drugs in a South African study and have been traumatized and live in violent poor townships, their response to a pilot study and the government response.

WORKSHOPS

Monday, June 13

IX. Marijuana laws: the changing legal landscape and its consequences

Chairs: Marsha Lopez Andrew Freedman

Marijuana is still illegal under federal law, but over half the states in the US have decriminalized or legalized it in some form. The effects of these changes are highly controversial. Public opinion about marijuana use is rapidly becoming more permissive, while proliferating marijuana dispensaries for medical or recreational use are providing ways to consume marijuana not previously seen at this scale, including marijuana-infused food and beverage products, electronic delivery devices, and emerging marijuana tourism in states with legalized recreational use. Many questions remain unanswered about the impact of these developments on the risk for marijuana use and related problems, questions that are the focus of intense public and scientific debate as the public considers and votes on medical and recreational marijuana laws, and as clinicians and policy-makers seek guidance from research findings. This workshop brings together important new findings from studies of these issues, including information on how adolescent attitudes and behaviors have been influenced by the law changes in Washington; how patterns of medical marijuana use in California correspond to health outcomes; how trends in hospital and poison center usage have been impacted by medical and recreational legalization policies in Colorado; and how social media is being used to track emerging cannabis trends.

Tuesday, June 14

X. Research and emerging strategies for parents of substance-involved adolescents and youth: Results from NIDA's Parents' Translational Research Center

Chairs: Kimberly C. Kirby and Elena Bresani

Use of illicit drugs, binge drinking, and heavy alcohol are highest among adolescents and young adults (16-29 years old), and heroin use and overdose has increased over the past 5 years among young adults (21-29 years). As their children begin to deteriorate in the face of increasing drug use severity, parents are often desperate and unsure how to help. An abundance of advice is available, but much of it is conflicting and very little has a basis of empirical support. The goal of this workshop is to present the translational research that has been completed during the past 5 years by the first NIDA-funded center focused on the needs of parents of drug-involved adolescents and young adults. Speakers will present findings from research addressing parental responses to substance use at a broad continuum of severity, beginning with factors influencing parents' initial detection and response to substance use (N=1,102), through guidelines for selecting and evaluating treatment options (N=208) and changes in adolescent service provision (N=435), to methods for facilitating treatment entry of treatment resistant adolescents and young adults (N=59). Future research and the importance of providing parents with information and practical tools for addressing substance use of their adolescents and young adults will be discussed, highlighting parent needs and quality of services.

WORKSHOPS

Tuesday, June 14

XI. Annual CPDD design and analysis workshop

Chairs: Sterling McPherson and Susan Mikulich-Gilbertson

Since the beginning of the HIV/AIDS epidemic, drug users have been at increased risk for HIV infection and transmission, both through risky injection drug practices and risky sexual behaviors. As the epidemic has evolved, drug users have faced increasing disparities related to HIV testing treatment, and retention in care— with correspondingly poorer clinical and psychosocial outcomes. Moreover, drug addiction can interfere with HIV treatment outcomes, both directly through biological processes and indirectly through difficulties with HIV disease management. With the goal of an AIDS-free generation, funding priorities now emphasize biomedical approaches. However, behavioral research remains critical to ensure that all individuals— no matter how difficult to reach— can derive the maximum benefits from new biomedical treatments to reduce the transmission of HIV and effectively manage HIV-associated comorbidities. This workshop highlights major advances from interdisciplinary research teams led by behavioral scientists. The presentations cover bio-behavioral approaches to identifying behavioral risks among high-risk groups, neurocognitive impacts on decision-making processes relevant to HIV risk, and multi-component interventions to reduce risk of HIV transmission and improve HIV-related outcomes. Our discussant will review the results of these studies in light of new NIH priorities for HIV/AIDS research among persons who use and abuse drugs.

XII. Education in drug abuse

Chairs: Michael Kuhar and Jack Stein

How do you respond when a student, fellow, collaborator, visitor or layman wants to know more about drug abuse? Often laymen, faculty and trainees are exposed to a narrow area of training, but then may seek more information or even a broader overview of the field. It is to everyone's advantage to expand their knowledge about drug abuse, and the availability of educational resources is very important. Education is central to prevention, treatment and research. It facilitates collaborative efforts and communication among colleagues. This workshop will describe what educational resources are available, and how to access them. The recent expansion of Internet resources can be overwhelming, but this workshop will describe them as well. It will cover online (and other) degree programs; the body of available knowledge and teaching; various online programs such as MOOCs (massive open online courses that can be taken anywhere at the learners convenience); and discovering NIDA's research portfolio.

WORKSHOPS

Tuesday, June 14

XIII. Regulatory and methodological considerations in the evaluation of drug dependence in the preclinical and clinical setting
Chairs: Beatrice Setnik and Michael Klein

Evaluating drug withdrawal effects is an integral component of dependence potential, which informs the overall safety, appropriate dosing, and scheduling of a drug. The methodological approaches to assess dependence continue to evolve and require careful evaluation of both preclinical and clinical data. Physical dependence can manifest from various drug classes including classes of drugs that are and are not associated with substance use disorder (e.g. beta blockers, corticosteroids). Preliminary approaches often include animal models to evaluate psychological dependence and the physical manifestation of withdrawal type symptoms. Translation of animal pharmacokinetics to human can be challenging and needs to be carefully evaluated to determine the translatability of animal to human data. In the clinical setting, evaluation of withdrawal requires characterization of a drug's pharmacology to determine what type of symptoms may manifest upon abrupt discontinuation. Study populations must be carefully considered, particularly in patient populations that cannot be safely withdrawn from study drug. Clinical trials must determine what population, duration of maintenance and endpoints are relevant for a given drug. Commonly adverse events and drug-specific withdrawal scales are included to evaluate withdrawal symptoms, however other pharmacodynamics measures may also be considered. The administration of endpoints and safety monitoring requires also practical considerations in the context of larger patient trials, where confined stays may not be possible following abrupt discontinuation. This workshop will address the regulatory and methodological considerations that are rapidly evolving in this active area of research and will cover case examples of studies examining drug withdrawal and dependence.

Acknowledgements

The following organizations and individuals have financially supported
the work of the CPDD organization during the past year

Apt Foundation	Dr. & Mrs. Donald Mess, Jr.
George Bigelow, PhD, Johns Hopkins Behavioral Pharmacology Research Unit	Michigan State
Alan Budney and Dartmouth College	Mrs. Regina Hurley Nash
Cerecore	Dr. John B. Neeld, Jr.
Howard Chilcoat	NIDA (National Institute on Drug Abuse)
Theodore Cicero	Charles O'Keeffe
Sandra Comer	James Sorensen
William Dewey	UCLA Integrated Substance Abuse Programs
Linda Dwoskin	University of Arkansas for Medical Sciences
Loretta Finnegan	University of Kentucky T32 Training Grant Dr. Linda Dwoskin
Charles Gorodetzky	
Sarah Heil & Andrew Goodwin IV	University of Miami, Miller School of Medicine
Mr. Thomas C. Grissom	Vince & Associates Clinical Research
Leonard Howell	
Lewis Katz School of Medicine at Temple University	Washington University School of Medicine
Marc J. Kaufman	

Funding for this conference was made possible (in part) by
Grant Agreement # 5 R13 DA13192-12 from the
National Institute on Drug Abuse

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government

